nct_id,study_title,phase_clean,status,intervention_name,intervention_type,mechanism_class,sponsor,conditions,start_date,primary_completion_date,source_link
NCT04215328,Facilitated Release of Endogenous Enterokines,Unknown,COMPLETED,"Mixed-Meal, Electrolyte Solution","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Southern California,"['Diabetes Mellitus, Type 2']",2014-11-01,2019-02-28,https://clinicaltrials.gov/study/NCT04215328
NCT06498063,The Underlying Mechanisms Regarding the Effect of Glucagon on the Kidneys Will be Investigated in Healthy Males.,Unknown,RECRUITING,"Glucagon, Placebo, Glucagon and exendin 9-39","OTHER, OTHER, OTHER",Other,Ali Asmar,['Kidney Diseases'],2024-02-20,2025-03-28,https://clinicaltrials.gov/study/NCT06498063
NCT07187830,Visceral Adipose Tissue and Liver Changes Associated With Semaglutide in CKD,Unknown,NOT_YET_RECRUITING,,,Unknown,University of Alberta,"['Chronic Kidney Disease in Type 2 Diabetes', 'Obesity & Overweight']",2025-12-15,2027-12-15,https://clinicaltrials.gov/study/NCT07187830
NCT00211536,Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration,Unknown,COMPLETED,"Medtronic MiniMed Implantable Pump Human Recombinant Insulin, Medtronic MiniMed Implantable Pump System, Aventis HOE21PH U400","DRUG, DEVICE, DRUG",Other,Medtronic Diabetes,['Type 1 Diabetes'],2002-06,2004-08,https://clinicaltrials.gov/study/NCT00211536
NCT02284009,Albiglutide Versus Placebo in Insulin-treated Subjects With New-onset Type 1 Diabetes Mellitus,Unknown,COMPLETED,"Albiglutide weekly injection, Placebo weekly injection, Insulin","BIOLOGICAL, BIOLOGICAL, BIOLOGICAL",Other,GlaxoSmithKline,"['Diabetes Mellitus, Type 1']",2014-10-10,2017-10-18,https://clinicaltrials.gov/study/NCT02284009
NCT03108521,SNP Study of DPP-4 and GLP-1R in Chinese People (Including Diabetes Patients),Unknown,COMPLETED,Sitagliptin,DRUG,Other,Sichuan Provincial People's Hospital,['Diabetes Mellitus'],2016-04-21,2018-01-04,https://clinicaltrials.gov/study/NCT03108521
NCT01972152,"Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of G-Pen(TM) (Glucagon Injection) to Treat Severe Hypoglycemia",Unknown,COMPLETED,"G-Pen(TM) 1 mg, Lilly Glucagon(TM) 1 mg, G-Pen(TM) 0.5 mg","DRUG, DRUG, DRUG",Other,Xeris Pharmaceuticals,['Hypoglycemia'],2013-10,2014-02,https://clinicaltrials.gov/study/NCT01972152
NCT06700538,Study of ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus,Unknown,RECRUITING,"ARO-INHBE, Placebo, Tirzepatide","DRUG, DRUG, DRUG",Other,Arrowhead Pharmaceuticals,['Obesity'],2024-12-04,2026-02,https://clinicaltrials.gov/study/NCT06700538
NCT01176708,Intact Liver Innervation and Glucose and Glucagon-like Peptide-1 (GLP-1) Induced Insulin Secretion,Unknown,UNKNOWN,"dipeptidyl peptidase 4 (DPP4) inhibitor, oral glucose, intravenous glucose","DRUG, OTHER, OTHER",Other,"University Hospital, Gentofte, Copenhagen",['Liver Transplantation'],2009-07,2012-08,https://clinicaltrials.gov/study/NCT01176708
NCT01664624,Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes,Unknown,COMPLETED,"Roflumilast, Alogliptin, Exenatide, Placebo to roflumilast, Placebo to alogliptin","DRUG, DRUG, DRUG, DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes'],2012-07,2012-11,https://clinicaltrials.gov/study/NCT01664624
NCT07059988,Endogenous Energy Production in Critically Ill Patients,Unknown,NOT_YET_RECRUITING,"Stable isotope tracers, Parenteral nutrition","OTHER, DIETARY_SUPPLEMENT",Other,Karolinska University Hospital,"['Critical Illness', 'Metabolism and Nutrition Disorder']",2025-07,2026-12,https://clinicaltrials.gov/study/NCT07059988
NCT02637388,Effects of Beta-glucan on Energy Intake and Satiety,Unknown,UNKNOWN,"Oatwell28 Oatwell Original Powder, Control Breakfast","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,Queen Margaret University,['Obesity'],2016-03,2016-12,https://clinicaltrials.gov/study/NCT02637388
NCT01157780,Parenteral Nutrition Associated Liver Disease: Early Markers and Therapy Wih Enteral Omega-3 Supplementation,Unknown,UNKNOWN,Lovaza (fish oil),DRUG,Other,University of Tennessee,['Parenteral Nutrition Associated Liver Disease'],2008-10,2014-06,https://clinicaltrials.gov/study/NCT01157780
NCT02883127,Motivational Interviewing With Focus on Diet and Weight Gain in Pregnant Women With Type 2 Diabetes,Unknown,COMPLETED,Motivational interviewing,BEHAVIORAL,Other,"Rigshospitalet, Denmark","['Type 2 Diabetes', 'Pregnancy']",2015-08-01,2018-02-28,https://clinicaltrials.gov/study/NCT02883127
NCT06854861,Premixed Glucagon/Insulin Solution for Faster Insulin Absorption in Type 1 Diabetes,Unknown,SUSPENDED,"Lyumjev 100 UNT/ML Injectable Solution, Premixed Lyumjev","DRUG, DRUG",Other,St. Olavs Hospital,['Type 1 Diabetes'],2025-04-01,2025-11-30,https://clinicaltrials.gov/study/NCT06854861
NCT00155376,Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography,Unknown,UNKNOWN,morphine and glucagon,DRUG,Other,National Taiwan University Hospital,['Liver Disease'],2005-09,,https://clinicaltrials.gov/study/NCT00155376
NCT04348617,Effect of Acute Exercise on Food Intake and Energy Expenditure Following a Gastric Bypass,Unknown,UNKNOWN,"Moderate exercise, Rest","OTHER, OTHER",Other,Universite du Quebec en Outaouais,['Obesity'],2021-05-15,2023-03-31,https://clinicaltrials.gov/study/NCT04348617
NCT02274740,Effect of Lixisenatide on Postprandial Lipid Profile in Obese Type 2 Diabetic Patients,Unknown,TERMINATED,"LIXISENATIDE AVE0010, metformin","DRUG, DRUG",Other,Sanofi,['Type II Diabetes Mellitus'],2015-04,2015-08,https://clinicaltrials.gov/study/NCT02274740
NCT05541991,Study on the Effect of Rhubarb Extract on Stool Frequency and Biological Markers of Intestinal Function in Seniors With Low Defecation,Unknown,COMPLETED,"single dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract, placebo coated tablet, double dose coated tablet Fruits & Fibres Rhubarbe with standardised rhubarb extract","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,ortis,['Constipation - Functional'],2017-02-10,2018-03-14,https://clinicaltrials.gov/study/NCT05541991
NCT02847091,Study of Ipragliflozin in Patients With Type 2 Diabetes Mellitus Receiving Insulin Therapy,Unknown,COMPLETED,"Ipragliflozin, Insulin","DRUG, DRUG",Other,Astellas Pharma Inc,['Type 2 Diabetes Mellitus'],2016-07-29,2017-11-09,https://clinicaltrials.gov/study/NCT02847091
NCT02891525,"The Influence of Sweet Substrates on Hunger, Gastrointestinal Hormones and the Migrating Motor Complex",Unknown,COMPLETED,"50g glucose, 25g fructose, 220mg acesulfame-K, 250mL tap water","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,Universitaire Ziekenhuizen KU Leuven,['Healthy'],2015-03,2016-02,https://clinicaltrials.gov/study/NCT02891525
NCT02689791,Effect of Resistant Wheat Starch on Subjective Appetite and Food Intake in Healthy Adults,Unknown,COMPLETED,Resistant Starch Type 4,DIETARY_SUPPLEMENT,Other,Iowa State University,['Feeding Behavior'],2012-01,2013-01,https://clinicaltrials.gov/study/NCT02689791
NCT04345120,Multiple Ascending Doses of SY-008 in Type 2 Diabetes Mellitus,Unknown,COMPLETED,"SY-008, SY-008 matching placebo","DRUG, DRUG",Other,"Suzhou Yabao Pharmaceutical R&D Co., Ltd.",['Type 2 Diabetes Mellitus'],2020-06-15,2021-12-15,https://clinicaltrials.gov/study/NCT04345120
NCT00588380,GLP1R Polymorphisms and Response to GLP1,Unknown,COMPLETED,GLP-1,DRUG,GLP-1 agonist,Mayo Clinic,['Diabetes'],2007-11,2010-09,https://clinicaltrials.gov/study/NCT00588380
NCT01422590,Pharmacodynamics of Mitiglinide/Sitagliptin Compared to Mitiglinide and Sitagliptin,Unknown,COMPLETED,"Sitagliptin, Mitiglinide, Sitagliptin, Mitiglinide","DRUG, DRUG, DRUG",Other,Samsung Medical Center,['Type 2 Diabetes Mellitus'],2010-05,2011-04,https://clinicaltrials.gov/study/NCT01422590
NCT04615910,A GLP-1 Receptor PET Imaging Substudy Within the VER-A-T1D Trial Investigating the Effects on Beta Cell Mass,Unknown,RECRUITING,68Ga-NODAGA-exendin-4 PET/CT,RADIATION,Other,Radboud University Medical Center,['Diabetes Mellitus'],2021-07-01,2025-04-01,https://clinicaltrials.gov/study/NCT04615910
NCT06295913,Hydroxytyrosol Dietary Supplement and Prevention of Age-Related Diseases,Unknown,COMPLETED,"Group 1, hydroxytyrosol-rich extract capsule, Group 2, capsule of placebo","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,"National Research Council, Spain","['Overweight', 'PreDiabetes']",2023-12-01,2024-09-30,https://clinicaltrials.gov/study/NCT06295913
NCT01666223,Effect of Bile Acids on GLP-1 Secretion,Unknown,COMPLETED,"Colesevelam, Chenodeoxycholic Acid, saline, Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg","DRUG, DRUG, OTHER, DRUG",Other,"University Hospital, Gentofte, Copenhagen","['Type 2 Diabetes', 'Obesity']",2012-11,2013-06,https://clinicaltrials.gov/study/NCT01666223
NCT03761186,"Comparison of Low, Moderate and High Carbohydrate Diet on Insulin Requirements and Metabolic Control in Type 1 Diabetes",Unknown,UNKNOWN,"traditional diabetes diet, moderately low carbohydrate diet, strictly low carbohydrate diet","BEHAVIORAL, BEHAVIORAL, BEHAVIORAL",Other,Anneli Björklund,['Type1diabetes'],2018-12-12,2024-03,https://clinicaltrials.gov/study/NCT03761186
NCT03216226,A Trial to Evaluate the Immunogenicity of Dasiglucagon and GlucaGen in Patients With Type 1 Diabetes Mellitus,Unknown,COMPLETED,"dasiglucagon, GlucaGen","DRUG, DRUG",Other,Zealand Pharma,"['Hypoglycemia', 'Diabetes Mellitus, Type 1']",2017-06-28,2018-02-13,https://clinicaltrials.gov/study/NCT03216226
NCT01761318,Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients,Unknown,COMPLETED,"Liraglutide, Liraglutide - Placebo","DRUG, DRUG",Other,Leiden University Medical Center,"['Diabetes Mellitus Type 2', 'Metabolic Syndrome', 'Cardiovascular Disease', 'Diastolic Dysfunction', 'Fatty Liver']",2013-11,2016-03,https://clinicaltrials.gov/study/NCT01761318
NCT04590690,Gut Microbiome and Sex as Risk Factors for Kidney Stones After Bariatric Surgery,Unknown,RECRUITING,Special diet,OTHER,Other,University of Chicago,['Bariatric Surgery Candidate'],2020-11-01,2026-02-01,https://clinicaltrials.gov/study/NCT04590690
NCT03921580,Enriched Canned Tuna With Fibre or Polyphenols on Satiety,Unknown,COMPLETED,"Control Canned Tuna, Enriched Canned Tuna Variety 1, Enriched Canned Tuna Variety 2","OTHER, OTHER, OTHER",Other,Instituto de Investigación Hospital Universitario La Paz,['Overweight'],2018-06-22,2018-07-06,https://clinicaltrials.gov/study/NCT03921580
NCT02810691,The Effect of Soluble Fiber to Reduce Post-prandial Glycemic Excursion in Adults With Cystic Fibrosis,Unknown,COMPLETED,"Soluble fiber supplementation, Placebo (for fiber supplementation)","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,Institut de Recherches Cliniques de Montreal,"['Cystic Fibrosis-related Diabetes', 'Cystic Fibrosis']",2016-07,2018-04,https://clinicaltrials.gov/study/NCT02810691
NCT02512523,Exploratory Study to Compare the Effects of Tenelia® or Januvia® on Glucose Variability in add-on to Metformin (CGMS Study),Unknown,COMPLETED,"Teneligliptin, Sitagliptin","DRUG, DRUG",Other,Handok Inc.,['Type 2 Diabetes Mellitus'],2015-08-27,2016-09-26,https://clinicaltrials.gov/study/NCT02512523
NCT03573258,Dietary Fibers and Satiety in Bariatric Patients,Unknown,COMPLETED,Fiber or Placebo (depending on the randomization),DIETARY_SUPPLEMENT,Other,University of Zurich,['Bariatric Surgery Candidate'],2018-06-01,2021-05-04,https://clinicaltrials.gov/study/NCT03573258
NCT03324776,Initiating Mealtime Ultra-Rapid Acting Insulin (Afrezza) in Uncontrolled Type 2 Diabetes Patients,Unknown,COMPLETED,Afrezza Inhalant Product,DRUG,Other,Model Clinical Research LLC,['Type2 Diabetes'],2017-10-16,2020-06-10,https://clinicaltrials.gov/study/NCT03324776
NCT02168491,Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin,Unknown,COMPLETED,"Lixisenatide, Insulin glargine","DRUG, DRUG",Other,Medical University of Vienna,['Type 2 Diabetes Mellitus'],2014-11,2015-07,https://clinicaltrials.gov/study/NCT02168491
NCT02229240,Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus,Unknown,WITHDRAWN,"Albiglutide, Matching albiglutide placebo","DRUG, DRUG",Other,GlaxoSmithKline,"['Diabetes Mellitus, Type 2']",2015-08,2015-12,https://clinicaltrials.gov/study/NCT02229240
NCT01156779,Study to Evaluate Safety and PK/PD of DA-3091 in Healthy Male Subjects,Unknown,COMPLETED,SR-exenatide,DRUG,Other,"Dong-A Pharmaceutical Co., Ltd.",['Diabetes Mellitus'],2010-07,2012-04,https://clinicaltrials.gov/study/NCT01156779
NCT03384303,"Changes in Incretines, Gut Hormones and Bile Acids After Roux-en-Y Gastric Bypass",Unknown,COMPLETED,Standardized meal test,OTHER,Other,Rijnstate Hospital,['Morbid Obesity'],2015-10-01,2016-05-01,https://clinicaltrials.gov/study/NCT03384303
NCT05268627,Endoscopic Ultrasound Guided Gastric Botulinum Toxin Injections Versus Glucagon Like Peptide 1 Receptor Agonist in Weight Loss,Unknown,UNKNOWN,Liraglutide,DRUG,Other,Mansoura University,['Obesity'],2022-01-27,2023-01-27,https://clinicaltrials.gov/study/NCT05268627
NCT05920889,Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke Treated by Reperfusion Therapies,Unknown,COMPLETED,Semaglutide,DRUG,Other,Chinese University of Hong Kong,"['Stroke', 'Stroke, Acute', 'Stroke, Ischemic', 'Brain Diseases']",2023-08-01,2024-10-25,https://clinicaltrials.gov/study/NCT05920889
NCT01664247,The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification,Unknown,COMPLETED,"insulin degludec, placebo, liraglutide","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2012-10-01,2013-12-31,https://clinicaltrials.gov/study/NCT01664247
NCT06925997,Metabolic Effects of Endogenous Bile Acids After Gastric Bypass Surgery,Phase 1,RECRUITING,Colesevelam,DRUG,Other,Hvidovre University Hospital,"['Bariatric Surgery Candidate', 'Bile Acid, Elevated Serum', 'Glucose Metabolism Disorders']",2024-05-02,2027-12,https://clinicaltrials.gov/study/NCT06925997
NCT05903482,Gastric Volume in Patients on GLP-1 Medications,Unknown,COMPLETED,None - observational,OTHER,Other,Children's Hospital of Philadelphia,['Diabetes'],2023-06-06,2024-12-31,https://clinicaltrials.gov/study/NCT05903482
NCT06976658,Glucokinase Activator in Monogenic Diabetes,Unknown,NOT_YET_RECRUITING,"Dorzagliatin, matched placebo","DRUG, DRUG",Other,Chinese University of Hong Kong,"['Diabetes Mellitus', 'Monogenic Diabetes']",2025-05-28,2026-12-31,https://clinicaltrials.gov/study/NCT06976658
NCT03254368,Study to Assess the Effects and Safety of ZGN-1061 in Overweight and Obese Participants With Type 2 Diabetes,Unknown,COMPLETED,"ZGN-1061, Placebo","DRUG, DRUG",Other,"Zafgen, Inc.","['Type 2 Diabetes Mellitus', 'Overweight and Obesity']",2017-09-12,2018-11-12,https://clinicaltrials.gov/study/NCT03254368
NCT03017352,Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetic Cases,Unknown,COMPLETED,"Exenatide, Placebos","DRUG, DRUG",Other,Filip Krag Knop,"['Diabetes Mellitus, Type 1']",2016-12,2019-06,https://clinicaltrials.gov/study/NCT03017352
NCT03989817,"The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) on Headache, Cranial Hemodynamic and Autonomic Symptoms in Healthy Volunteers",Unknown,COMPLETED,Vasoactive Intestinal Peptide (VIP) and Saline,DRUG,Other,Danish Headache Center,['Headache Disorders'],2019-06-14,2020-06-30,https://clinicaltrials.gov/study/NCT03989817
NCT01865760,"Etiology, Assessment and Treatment of Post-gastric Bypass Severe Hypoglycemia",Unknown,COMPLETED,"Oral Glucose tolerance test (OGGT), Liquid mixed meal, Octreotide","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DRUG",Other,University of Aarhus,"['Obesity', 'Hypoglycemia', 'Surgery']",2013-06,2016-03,https://clinicaltrials.gov/study/NCT01865760
NCT06182891,Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy,Unknown,COMPLETED,Dulaglutide Injection,DRUG,Other,The Affiliated Hospital of Xuzhou Medical University,['Type 2 Diabetic Nephropathy'],2021-10-30,2023-06-30,https://clinicaltrials.gov/study/NCT06182891
NCT02898506,Incretin-based Therapy in Late Preclinical Type 1 Diabetes,Unknown,COMPLETED,"Victoza®, Placebo","DRUG, DRUG",Other,University of Oulu,['Type 1 Diabetes'],2016-03,2021-06,https://clinicaltrials.gov/study/NCT02898506
NCT04352738,Role of the Liver in Glucose Homeostasis Using Metabolic Imaging,Unknown,COMPLETED,"Multiparametric, multinuclear MR (DMI/ 13C-MRS/ GlycoCEST/GlycoNOE)",DIAGNOSTIC_TEST,Other,"Insel Gruppe AG, University Hospital Bern","['Type 1 Diabetes', 'Bariatric Surgery Candidate']",2021-04-15,2022-04-21,https://clinicaltrials.gov/study/NCT04352738
NCT07227948,Repurposing Semaglutide for the Treatment of Cocaine Use Disorder,Unknown,NOT_YET_RECRUITING,"Semaglutide, Placebo, cognitive behavioral therapy (CBT).","DRUG, DRUG, BEHAVIORAL",Other,"The University of Texas Health Science Center, Houston",['Cocaine Use Disorder'],2025-11-17,2029-01-28,https://clinicaltrials.gov/study/NCT07227948
NCT06501326,Efficacy and Safety of Liraglutide in the Treatment of Obesity Combined With Metabolism Associated Fatty Liver Disease,Unknown,UNKNOWN,"Liraglutide, Orlistat","DRUG, DRUG",Other,Affiliated Hospital of Nantong University,"['Non-alcoholic Fatty Liver Disease', 'Obesity']",2023-11-01,2024-10-31,https://clinicaltrials.gov/study/NCT06501326
NCT00959426,"A Multiple Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers",Unknown,COMPLETED,"PF-04620110, Placebo","DRUG, DRUG",Other,Pfizer,"['Obesity', 'Overweight', 'Healthy']",2009-08,2010-05,https://clinicaltrials.gov/study/NCT00959426
NCT06588218,Effect of Watermelon on Gut and Cardiometabolic Health,Unknown,RECRUITING,"Watermelon, Belvita Breakfast Sandwich + 12 oz Water","OTHER, OTHER",Other,Florida State University,"['Obesity and Overweight', 'Dysbiosis']",2024-10-13,2026-08,https://clinicaltrials.gov/study/NCT06588218
NCT05786443,Safety and Efficacy of Empagliflozin in Hemodialysis,Unknown,RECRUITING,"Empagliflozin 10 MG, Placebo","DRUG, DRUG",Other,NYU Langone Health,['End Stage Renal Disease'],2024-01-31,2026-12-30,https://clinicaltrials.gov/study/NCT05786443
NCT04365517,The Effect of Sitagliptin Treatment in COVID-19 Positive Diabetic Patients,Unknown,UNKNOWN,Sitagliptin,DRUG,Other,University of Milan,"['Covid19', 'Diabetes Mellitus, Type 2', 'CKD']",2021-12-29,2022-03-30,https://clinicaltrials.gov/study/NCT04365517
NCT01967589,"Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects",Unknown,COMPLETED,"NNC0113-0987, placebo","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Healthy']",2013-10,2014-05,https://clinicaltrials.gov/study/NCT01967589
NCT03235050,A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes,Unknown,COMPLETED,"MEDI0382 low dose, MEDI0382 mid dose, MEDI0382 high dose, Placebo, Liraglutide","DRUG, DRUG, DRUG, DRUG, DRUG",Other,AstraZeneca,"['Diabetes Mellitus, Type 2']",2017-08-02,2018-05-03,https://clinicaltrials.gov/study/NCT03235050
NCT03990090,A Study of TG103 in Chinese Healthy Adult Subjects,Unknown,COMPLETED,"TG103, Placebo","DRUG, DRUG",Other,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",['Healthy'],2019-07-29,2020-11-11,https://clinicaltrials.gov/study/NCT03990090
NCT06064084,Incretin Effect in Patients With Psoriasis and Controls,Unknown,COMPLETED,"Oral glucose tolerance test, Intravenous isoglycaemic glucose clamp, Liquid Mixed meal test","DIAGNOSTIC_TEST, OTHER, OTHER",Other,"University Hospital, Gentofte, Copenhagen",['Psoriasis Vulgaris'],2011-09-11,2015-09-11,https://clinicaltrials.gov/study/NCT06064084
NCT04280549,Platelet PAR-1 Activation in Health and Diabetes,Unknown,COMPLETED,,,Unknown,Vanderbilt University Medical Center,"['Type 2 Diabetes', 'Healthy']",2018-06-01,2021-02-02,https://clinicaltrials.gov/study/NCT04280549
NCT00866658,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)",Unknown,COMPLETED,"Lixisenatide (AVE0010), Placebo, Pen auto-injector, Sulfonylurea, Basal Insulin","DRUG, DRUG, DEVICE, DRUG, DRUG",Other,Sanofi,"['Diabetes Mellitus, Type 2']",2009-03,2010-06,https://clinicaltrials.gov/study/NCT00866658
NCT01162876,A Clinical Pharmacology Study of Saxagliptin in Patients With Type 2 Diabetes Mellitus,Unknown,COMPLETED,saxaglipitin,DRUG,Other,"Kyowa Kirin Co., Ltd.",['Diabetes'],2010-07,2010-11,https://clinicaltrials.gov/study/NCT01162876
NCT06647368,Development of a Non-invasive Method for Quantifying Cerebral Glucose Metabolism for Studying the Effect of Glucagon in Humans,Unknown,RECRUITING,PET with 18-FDG,OTHER,Other,Nicolai Jacob Wewer Albrechtsen,['Cerebral Glucose Metabolism'],2024-10-22,2024-12-17,https://clinicaltrials.gov/study/NCT06647368
NCT06142006,The Diabetes Staging System in Patient Aligned Care Teams,Unknown,RECRUITING,Diabetes Staging System (DSS) use among Primary Care Teams,OTHER,Other,Durham VA Medical Center,"['Diabetes Mellitus', 'Type 2 Diabetes']",2023-09-01,2024-09-01,https://clinicaltrials.gov/study/NCT06142006
NCT04186026,Co-infusion of Neurotensin and GLP-1 Effects on Appetite and Food Intake.,Unknown,UNKNOWN,"Saline + saline, Neurotensin + saline, GLP-1 + saline, GLP-1 + Neurotensin","OTHER, OTHER, OTHER, OTHER",GLP-1 agonist,University of Copenhagen,['Obesity'],2019-10-01,2024-06-10,https://clinicaltrials.gov/study/NCT04186026
NCT04860869,"Endocrine, Metabolic and Microbiome Influence on the Post-acute Sequelae SARS-CoV-2 (PASC)",Unknown,COMPLETED,,,Unknown,"The University of Texas Medical Branch, Galveston",['Covid19'],2021-05-12,2022-05-31,https://clinicaltrials.gov/study/NCT04860869
NCT01718457,Endobarrier Treatment in Obese Subjects With T2DM,Unknown,UNKNOWN,Endobarrier,DEVICE,Other,Sheba Medical Center,"['Type 2 Diabetes', 'Obesity']",2012-12,2016-12,https://clinicaltrials.gov/study/NCT01718457
NCT01121783,The Effect of Lactisole on the Responses to Glucose Solution,Unknown,UNKNOWN,"Lactisole, Lactisole, Lactisole, Lactisole","OTHER, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,Northern Care Alliance NHS Foundation Trust,"['Blood Glucose', 'Appetite', 'Therapeutic Uses', 'Hormones']",2010-05,2011-05,https://clinicaltrials.gov/study/NCT01121783
NCT04712266,A Trial to Investigate Hyperglycemic and Hypoglycemic Excursions in Subjects With Type 1 Diabetes,Phase 1,COMPLETED,"Glucagon, Insulin","DRUG, DRUG",Other,Abvance Therapeutics,['Type 1 Diabetes Mellitus With Hypoglycemia'],2020-09-15,2020-12-15,https://clinicaltrials.gov/study/NCT04712266
NCT06222775,"Multicomponent Intervention on Lifestyle, Anthropometric Measurements, Glycemic Control and Quality of Life in Patients Obese People With Type II Diabetes",Unknown,RECRUITING,"Group session 1, Group session 2, Group session 3, Group session 4, Group session 5, Group session 6, Group session 7 to 8, Group session 9, Control Intervention 1, Control Intervention 2, Control Intervention 3, Control Intervention 4","BEHAVIORAL, BEHAVIORAL, BEHAVIORAL, BEHAVIORAL, BEHAVIORAL, BEHAVIORAL, BEHAVIORAL, BEHAVIORAL, BEHAVIORAL, BEHAVIORAL, BEHAVIORAL, BEHAVIORAL",Other,Castilla-La Mancha Health Service,"['Obesity', 'Diabetes Mellitus, Type 2']",2023-12-04,2025-12-31,https://clinicaltrials.gov/study/NCT06222775
NCT06208475,Different Menstrual Cycle in Eating Behavior Following Resistance Exercise,Unknown,COMPLETED,Resistance exercise,OTHER,Other,National Taiwan Normal University,"['Menstruation', 'Energy Balance', 'Appetitive Behavior', 'Food Reward']",2023-08-01,2024-06-06,https://clinicaltrials.gov/study/NCT06208475
NCT02863419,Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"semaglutide, liraglutide, placebo","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2016-08-10,2017-08-19,https://clinicaltrials.gov/study/NCT02863419
NCT06640972,Effects of RDX-002 on Postprandial Triglycerides in Patients Discontinuing GLP-1 Agonists,Unknown,ACTIVE_NOT_RECRUITING,"RDX-002, Placebo","DRUG, DRUG",Other,Response Pharmaceuticals,"['Triglycerides', 'Weight Gain Trajectory', 'Cholesterol, Elevated']",2024-09-27,2025-01-04,https://clinicaltrials.gov/study/NCT06640972
NCT03648112,"Effects of Beta-glucan From Barley and Oats on Glucose and Lipid Metabolism, and Satiety",Unknown,COMPLETED,"Intervention 1, Intervention 2, Intervention 3, Intervention 4, Control","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Jena,"['Lipid Metabolism', 'Glucose Metabolism', 'Satiety']",2018-05-02,2018-05-31,https://clinicaltrials.gov/study/NCT03648112
NCT03406312,Validation of a Diagnostic Tool for Postprandial Hypoglycaemia in Patients After Roux en Y Gastric Bypass Surgery,Unknown,COMPLETED,Post Prandial Hypoglycemia test,DIAGNOSTIC_TEST,Other,University Ghent,['Post Prandial Hypoglycemia'],2017-06-01,2020-05-05,https://clinicaltrials.gov/study/NCT03406312
NCT00318461,To Compare the Effect of Liraglutide When Given Together With Metformin With the Effect of Metformin Given Alone and With the Effect of Glimepiride and Metformin Given Together,Unknown,COMPLETED,"liraglutide, metformin, glimepiride, placebo, placebo, liraglutide, liraglutide","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2006-05,2007-05,https://clinicaltrials.gov/study/NCT00318461
NCT06932666,Why Calories Are Not the Same - a Gut Explanation?,Unknown,RECRUITING,"Diet A group, Diet B group","OTHER, OTHER",Other,University of Copenhagen,"['Diet, Healthy', 'Breath Analysis']",2025-05-15,2026-12-31,https://clinicaltrials.gov/study/NCT06932666
NCT01814137,A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily,Unknown,COMPLETED,"insulin degludec/insulin aspart, insulin degludec, insulin aspart, insulin aspart","DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2013-03,2014-03,https://clinicaltrials.gov/study/NCT01814137
NCT03046186,Physiological Effects of Gastric Sleeve Operation,Unknown,COMPLETED,Mixed meal test with double tracer technique,DIAGNOSTIC_TEST,Other,Hvidovre University Hospital,"['Obesity, Morbid', 'Bariatric Surgery']",2016-06,2017-06,https://clinicaltrials.gov/study/NCT03046186
NCT04788069,"Effect of Sourdough Breads Consumption on Postprandial Responses, Satiety and Food Intake at Subsequent Meal",Unknown,COMPLETED,"Wholemeal bread, Sourdough bread, Bread with sourdough","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,KU Leuven,"['Energy Intake', 'Appetite Regulation']",2021-06-01,2024-02-05,https://clinicaltrials.gov/study/NCT04788069
NCT02408705,Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects,Unknown,COMPLETED,"Liraglutide, Placebo, Mixed Meal Tolerance Test with paracetamol","DRUG, DRUG, DRUG",Other,Medical University of Graz,['Type 1 Diabetes Mellitus'],2015-01,2016-05,https://clinicaltrials.gov/study/NCT02408705
NCT03625245,Enriched Yogurts With Soluble Fibre or Vegetable Protein on Satiety,Unknown,COMPLETED,"Control Yogurt, Yogurt Variety 1, Yogurt Variety 2","OTHER, OTHER, OTHER",Other,Instituto de Investigación Hospital Universitario La Paz,['Overweight'],2018-05-10,2018-05-24,https://clinicaltrials.gov/study/NCT03625245
NCT06131437,A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight,Unknown,ACTIVE_NOT_RECRUITING,"Cagrilintide, Semaglutide, Tirzepatide","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,['Obesity'],2023-11-27,2025-12-02,https://clinicaltrials.gov/study/NCT06131437
NCT01593137,"A Long-term Trial to Compare the Effects of Liraglutide and Sulphonylurea (Glimepiride) Both in Combination With Metformin on Clinical, Endothelial and Image Markers of Cardiovascular Risk in Patients With Type 2 Diabetes",Unknown,WITHDRAWN,"Liraglutide + metformin, Glimepiride + metformin","DRUG, DRUG",Other,Fundación Fernández-Cruz,['Type 2 Diabetes'],2012-05,2013-12,https://clinicaltrials.gov/study/NCT01593137
NCT06035081,CIRcadian Rhythms and CortisoL. Effects on Substrate Metabolism and Clock Gene Expression and Functioning,Unknown,COMPLETED,"Prednisolone, Placebo","DRUG, OTHER",Other,University of Aarhus,['Healthy'],2023-09-15,2024-04-13,https://clinicaltrials.gov/study/NCT06035081
NCT01408628,The I-KAN Study: Internet Insulin Education for Kansans,Unknown,COMPLETED,Internet Insulin Education,BEHAVIORAL,Other,"David Robbins, MD",['Type 2 Diabetes'],2011-08,2014-09,https://clinicaltrials.gov/study/NCT01408628
NCT04205045,Identification of Physiological Biomarkers of Gastro-intestinal Discomforts Induced by Milk Consumption,Unknown,COMPLETED,"Lactose Breath Test, Gut permeability test, Milk Test","DIAGNOSTIC_TEST, OTHER, OTHER",Other,Paola Vitaglione,['Healthy Subjects'],2018-10-01,2020-01-24,https://clinicaltrials.gov/study/NCT04205045
NCT06143956,A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight,Unknown,RECRUITING,"LY3305677, LY3841136, Tirzepatide, Placebo, LY3549492","DRUG, DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Obesity', 'Overweight']",2023-11-17,2026-06,https://clinicaltrials.gov/study/NCT06143956
NCT01846702,A Study of LY3084077 in Healthy Participants,Unknown,COMPLETED,"Placebo, LY3084077","DRUG, DRUG",Other,Eli Lilly and Company,['Healthy Volunteers'],2013-05,2013-12,https://clinicaltrials.gov/study/NCT01846702
NCT07042672,"Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity",Unknown,RECRUITING,"GLP-1, CBTe Group Therapy","DRUG, BEHAVIORAL",GLP-1 agonist,Haukeland University Hospital,"['Binge Eating Disorder Associated With Obesity', 'Binge Eating Disorder', 'Eating Disorder Binge', 'Eating Disorders', 'GLP-1', 'CBT', 'Obesity &Amp; Overweight']",2025-07-01,2027-11-05,https://clinicaltrials.gov/study/NCT07042672
NCT01508806,Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function,Unknown,COMPLETED,liraglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2005-08,2006-03,https://clinicaltrials.gov/study/NCT01508806
NCT07158385,Effect of High Fat High Protein Meal in Type 1 Diabetes,Unknown,COMPLETED,"Standard test meal (SM), High fat high protein meal-carbohydrate counting (HFHP), High fat high protein meal-fat counting (HFHP-a), High fat high protein meal-fat and protein counting (HFHP-b)","OTHER, OTHER, OTHER, OTHER",Other,Cumhuriyet University,"['Type 1 Diabetes Mellitus', 'Adolescent']",2019-01-01,2019-10-30,https://clinicaltrials.gov/study/NCT07158385
NCT02838589,The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Non-stroke Volunteers,Unknown,COMPLETED,"Byetta, Isotonic saline","DRUG, DRUG",Other,Christina Kruuse,['Stroke'],2016-08,2017-02,https://clinicaltrials.gov/study/NCT02838589
NCT00713830,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea",Unknown,COMPLETED,"Lixisenatide (AVE0010), Placebo, Pen auto-injector, Sulfonylurea, Metformin","DRUG, DRUG, DEVICE, DRUG, DRUG",Other,Sanofi,"['Diabetes Mellitus, Type 2']",2008-07,2011-01,https://clinicaltrials.gov/study/NCT00713830
NCT03066830,Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin,Unknown,COMPLETED,"Sotagliflozin (SAR439954), Placebo, Metformin, Sulfonylurea","DRUG, DRUG, DRUG, DRUG",Other,Lexicon Pharmaceuticals,['Type 2 Diabetes Mellitus'],2017-02-24,2019-04-17,https://clinicaltrials.gov/study/NCT03066830
NCT03680248,Monitoring of Hepatic Fat Metabolism Using Magnetic Resonance Methods,Unknown,COMPLETED,"Fat, Fasting, Fat+Glucose, Glucose, Fat+Fructose, Fructose","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,Institute for Clinical and Experimental Medicine,['Hepatic Fat Content'],2016-04-26,2019-12,https://clinicaltrials.gov/study/NCT03680248
NCT00510952,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes on Anti-Hyperglycemic Medications (IOPE),Unknown,COMPLETED,"Insulin Lispro Protamine Suspension, Insulin Glargine","DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2007-08,2008-10,https://clinicaltrials.gov/study/NCT00510952
NCT03048578,Clinical Efficacy and Safety of Using 3.0mg Liraglutide to Treat Weight Regain After Roux-en-Y Gastric Bypass Surgery,Unknown,COMPLETED,"Saxenda, Placebo","DRUG, DRUG",Other,NYU Langone Health,['Obesity'],2017-05-22,2021-03-02,https://clinicaltrials.gov/study/NCT03048578
NCT01158417,Resveratrol in Type2 Diabetes and Obesity,Unknown,TERMINATED,"Placebo, Resveratrol 40 mg oral three times a day, Resveratrol 500 mg oral once daily.","DRUG, DRUG, DRUG",Other,University at Buffalo,"['Type 2 Diabetes', 'Obesity', 'Insulin Resistance']",2008-12,2012-07-08,https://clinicaltrials.gov/study/NCT01158417
NCT05260021,A Study to Evaluate Tirzepatide (LY3298176) in Pediatric and Adolescent Participants With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin or Basal Insulin or Both,Unknown,COMPLETED,"Tirzepatide Dose 1, Tirzepatide Dose 2, Placebo","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Type2 Diabetes', 'Diabetes Mellitus', 'Diabetes Mellitus, Type 2', 'T2D', 'T2DM (Type 2 Diabetes Mellitus)', 'Glucose Metabolism Disorders', 'Endocrine System Diseases', 'Metabolic Disease']",2022-04-13,2024-07-30,https://clinicaltrials.gov/study/NCT05260021
NCT01155206,Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon,Unknown,COMPLETED,glucagon,DRUG,Other,"University Health Network, Toronto",['Diabetes'],2009-06,2010-01,https://clinicaltrials.gov/study/NCT01155206
NCT01801540,The Effects of L-arabinose in a Meal in Healthy Men,Unknown,COMPLETED,L-arabinose - effect on glucose metabolism,DIETARY_SUPPLEMENT,Other,University of Copenhagen,['Glucose Metabolism'],2010-12,2011-03,https://clinicaltrials.gov/study/NCT01801540
NCT05548647,"Semaglutide Treatment, Appetite, and Eating Behavior: Long-term Effects",Unknown,COMPLETED,"Behavioral Treatment, Placebo, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]","BEHAVIORAL, DRUG, DRUG",Other,University of Pennsylvania,['Obesity'],2022-07-26,2025-05-12,https://clinicaltrials.gov/study/NCT05548647
NCT04375449,Investigation of Milk Peptides (Pep2Dia®) on Postprandial Blood Glucose Profile in Prediabetic Subjects,Unknown,COMPLETED,"Pep2dia, maltodextrin","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,Ingredia S.A.,['Prediabetic State'],2020-05-04,2020-07-25,https://clinicaltrials.gov/study/NCT04375449
NCT06884449,A Placebo-Controlled Study Evaluating the Effects of Arrabina P on Satiety in Healthy Adults,Unknown,COMPLETED,"Arrabina P Prebiotic 5.0 g, Arrabina P Prebiotic 3.5 g, Placebo","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, OTHER",Other,Comet Bio Inc.,"['Satiety', 'Appetite Regulation', 'Weight Control']",2025-04-15,2025-10-28,https://clinicaltrials.gov/study/NCT06884449
NCT00834938,Comparison Between Patients With or Without Diabetes Recovery After Bariatric Surgery,Unknown,COMPLETED,No intervention,OTHER,Other,"University of Campinas, Brazil","['Diabetes', 'Bariatric Surgery', 'Obesity']",2007-07,2008-07,https://clinicaltrials.gov/study/NCT00834938
NCT06908655,Diffusion Endometriosis MRI to Detect and Quantify Symptomatic Neurological Impairment in Pelvic Endometriosis,Unknown,NOT_YET_RECRUITING,MRI,OTHER,Other,Assistance Publique - Hôpitaux de Paris,['Endometriosis'],2025-04-01,2027-04-30,https://clinicaltrials.gov/study/NCT06908655
NCT03373435,Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia,Unknown,COMPLETED,"exendin 9-39, Placebo","DRUG, OTHER",Other,Eiger BioPharmaceuticals,['Postbariatric Hypoglycemia'],2018-03-19,2019-01-30,https://clinicaltrials.gov/study/NCT03373435
NCT06797869,A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy,Unknown,ACTIVE_NOT_RECRUITING,"CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2', 'Diabetic Peripheral Neuropathy']",2025-01-29,2026-08-21,https://clinicaltrials.gov/study/NCT06797869
NCT02364869,Prebiotic in Chronic Kidney Disease Patients,Unknown,COMPLETED,"Fructooligosaccharide, Maltodextrin","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,Federal University of São Paulo,['Chronic Kidney Disease'],2015-05,2016-12,https://clinicaltrials.gov/study/NCT02364869
NCT02946983,Influence of Intragastric Fructose Infusion on Behavioural and Neural Responses to Negative Emotion Induction,Unknown,COMPLETED,"Fructose, Control","OTHER, OTHER",Other,Universitaire Ziekenhuizen KU Leuven,['Healthy Volunteers'],2015-09,2016-06,https://clinicaltrials.gov/study/NCT02946983
NCT00641056,Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (DURATION - 3),Unknown,COMPLETED,"Exenatide Once Weekly, Insulin Glargine","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2008-04,2009-05,https://clinicaltrials.gov/study/NCT00641056
NCT02250222,Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus,Unknown,COMPLETED,"LGD-6972, Placebo (Captisol ®)","DRUG, DRUG",Other,Ligand Pharmaceuticals,['Type 2 Diabetes Mellitus'],2014-10,2015-05,https://clinicaltrials.gov/study/NCT02250222
NCT02057172,Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes,Unknown,COMPLETED,"HM11260C, liraglutide, Placebo","DRUG, DRUG, DRUG",Other,Hanmi Pharmaceutical Company Limited,['Type 2 Diabetes'],2014-01,2014-10,https://clinicaltrials.gov/study/NCT02057172
NCT02322112,The Alberta FYBER (Feed Your Gut Bacteria morE fibeR) Study,Unknown,COMPLETED,"Microcrystalline Cellulose Supplementation, Acacia Gum Supplementation, Resistant Starch Type 4 Supplementation","OTHER, OTHER, OTHER",Other,University of Alberta,['Overweight and Obesity'],2015-08,2020-04,https://clinicaltrials.gov/study/NCT02322112
NCT03500900,Vildagliptin on Gastric Accommodation,Unknown,COMPLETED,"Vildagliptin 50 mg, Placebo Oral Tablet","DRUG, DRUG",Other,Universitaire Ziekenhuizen KU Leuven,['Healthy'],2016-03-01,2017-01-01,https://clinicaltrials.gov/study/NCT03500900
NCT01507337,Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy Volunteers,Unknown,COMPLETED,liraglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes', 'Healthy']",2004-04,2004-06,https://clinicaltrials.gov/study/NCT01507337
NCT00881530,"Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension",Unknown,COMPLETED,"BI 10773, Metformin, BI 10773, Sitagliptin","DRUG, DRUG, DRUG, DRUG",Other,Boehringer Ingelheim,"['Diabetes Mellitus, Type 2']",2009-03,2011-05,https://clinicaltrials.gov/study/NCT00881530
NCT05390307,Obesity Treatment to Improve Diabetes,Unknown,COMPLETED,"Liraglutide / Semaglutide, Dapagliflozin, Liraglutide or Semaglutide / Dapagliflozin, Liraglutide or Semaglutide / Dapagliflozin plus intensive weight loss nutrition, Usual care","DRUG, DRUG, DRUG, DRUG, OTHER",Other,Dasman Diabetes Institute,['Type 1 Diabetes'],2023-04-01,2024-01-01,https://clinicaltrials.gov/study/NCT05390307
NCT04575844,Effects of Exercise and GLP-1 Agonism on Muscle Microvascular Perfusion and Insulin Action in Adults With Metabolic Syndrome,Unknown,RECRUITING,"Liraglutide, Exercise training, Liraglutide + Exercise training","DRUG, OTHER, DRUG",Other,University of Virginia,['Metabolic Syndrome'],2020-11-01,2026-04-30,https://clinicaltrials.gov/study/NCT04575844
NCT03322631,A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes,Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes Mellitus'],2017-11-15,2018-05-29,https://clinicaltrials.gov/study/NCT03322631
NCT06620666,NEUROmuscular Training for Enhanced AGE Longevity,Unknown,ACTIVE_NOT_RECRUITING,"Water-based power resistance training + Dietary supplement I (WPowDSI), Water-based power resistance training + Placebo (WPowPl), Elastic band-based power resistance training + Dietary supplement I (EBPowDSI), Elastic band-based power resistance training + Placebo (EBPowPl), Elastic band-based eccentric resistance training + Dietary supplement II (EBEccDSII), Elastic band-based eccentric resistance training + Placebo (EBEccPl), Elastic band-based maximum strength resistance training + Dietary supplement II (EBMaxDSII), Elastic band-based maximum strength resistance training + Placebo (EBMaxPl), Control + Placebo (CPl), Control + Dietary supplement I (CDSI), Control + Dietary supplement (CDSII), Active Comparator: Aerobic training + Placebo (AerPl)","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Valencia,"['Aging', 'Physical Activity', 'Training']",2024-01-24,2027-07-15,https://clinicaltrials.gov/study/NCT06620666
NCT02607865,Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes,Unknown,COMPLETED,"semaglutide, sitagliptin, placebo","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2016-02-15,2017-02-14,https://clinicaltrials.gov/study/NCT02607865
NCT02128022,Cardioprotective Effects of GLP-1 and Their Mechanisms,Unknown,COMPLETED,"GLP-1 (7-36) amide, Glibenclamide","DRUG, DRUG",GLP-1 agonist,Papworth Hospital NHS Foundation Trust,['Angina Pectoris'],2014-07,2016-03,https://clinicaltrials.gov/study/NCT02128022
NCT01135472,Plasm Gastrin Concentrations in Response to Nexium Administration in Healthy Volunteers,Unknown,COMPLETED,Esomeprazole Magnesium,DRUG,Other,City of Hope Medical Center,['Healthy'],2010-03,2012-04,https://clinicaltrials.gov/study/NCT01135472
NCT02971228,Feasibility Trial Testing the Bionic Pancreas With ZP4207,Unknown,COMPLETED,"Insulin Lispro, ZP4207 (dasiglucagon), Glucagon, iPhone-based bionic pancreas, iLet-based bionic pancreas","DRUG, DRUG, DRUG, DEVICE, DEVICE",Other,Zealand Pharma,"['Diabetes Mellitus, Type 1']",2016-11,2017-05-24,https://clinicaltrials.gov/study/NCT02971228
NCT05957185,Effects of Microbial Protease Supplementation on Postprandial Plasma Amino Acid Concentrations and Appetite,Unknown,COMPLETED,"OPTIZIOME® P³ HYDROLYZER® - WHEY, Placebo","DIETARY_SUPPLEMENT, OTHER",Other,"BIO-CAT, Inc.","['Digestive Health', 'Gastrointestinal Health', 'Appetitive Behavior']",2023-08-07,2024-01-18,https://clinicaltrials.gov/study/NCT05957185
NCT02550548,Incretin Action in Physiology and Diabetes,Unknown,COMPLETED,"GIP infusion, GLP-1 infusion, Ex-9 infusion","DRUG, DRUG, DRUG",Dual agonist,"David D'Alessio, M.D.",['Insulin Secretion'],2016-04-21,2021-04-16,https://clinicaltrials.gov/study/NCT02550548
NCT03588000,The Effect of Remote SMBG Combined With the Application of APP on the Improvement of T2DM Management in the Community,Unknown,COMPLETED,Strengthen self-monitoring of blood glucose,OTHER,Other,Yuwen Zhang,"['Diabetes Mellitus, Type 2']",2018-11-23,2021-02-28,https://clinicaltrials.gov/study/NCT03588000
NCT03232112,Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?,Unknown,COMPLETED,"Exenatide 2 MG Injection, BD PosiFlush (saline)","DRUG, DRUG",Other,"Anders Fink-Jensen, MD, DMSci","['Alcohol Dependence, in Remission', 'Addiction, Alcohol']",2017-08-07,2020-03-15,https://clinicaltrials.gov/study/NCT03232112
NCT02625636,"A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients",Unknown,COMPLETED,"SAR438544, placebo, r-glucagon","DRUG, DRUG, DRUG",Other,Sanofi,['Type 1 Diabetes Mellitus'],2015-12,2016-02,https://clinicaltrials.gov/study/NCT02625636
NCT06243536,The Effect of Semaglutide on Disordered Eating Behaviour in Type 2 Diabetic Patients,Unknown,NOT_YET_RECRUITING,"Semaglutide, standard of care","DRUG, DRUG",Other,University Hospital Sestre Milosrdnice,"['Type 2 Diabetes', 'Overweight', 'Disordered Eating Behaviors']",2024-02-01,2024-12-31,https://clinicaltrials.gov/study/NCT06243536
NCT03688711,Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM,Unknown,COMPLETED,"Dasiglucagon, Placebo","DRUG, DRUG",Other,Zealand Pharma,"['Hypoglycemia', 'Diabetes Mellitus, Type 1']",2018-11-01,2019-03-11,https://clinicaltrials.gov/study/NCT03688711
NCT06270901,Acute Effects of Legume-enriched Meals Compared to Western Diet Meals on Postprandial Metabolism in Participants with Increased Cardiometabolic Risk,Unknown,COMPLETED,"High Protein Planetary Health Diet, Low Protein Planetary Health Diet, High Protein Western Diet, Low Protein Western Diet","OTHER, OTHER, OTHER, OTHER",Other,University of Bonn,"['Cardiovascular Diseases', 'Metabolic Syndrome']",2024-05-02,2024-09-11,https://clinicaltrials.gov/study/NCT06270901
NCT05671965,Effects of Oral Xylitol on Subsequent Energy Intake,Unknown,COMPLETED,"Xylitol, Sucrose, Acesulfame Potassium, Water","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,"University Hospital, Basel, Switzerland","['Energy Intake', 'Gastrointestinal Hormones', 'Glycemic Control', 'Appetite', 'Satiation']",2023-01-27,2024-01-31,https://clinicaltrials.gov/study/NCT05671965
NCT03444467,"First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People.",Unknown,COMPLETED,"NNC9204-1513, Glucagon, Placebo","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 1', 'Diabetes Mellitus, Type 2']",2018-02-05,2018-05-24,https://clinicaltrials.gov/study/NCT03444467
NCT03738865,G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes,Unknown,COMPLETED,"G-Pen, Novo Glucagon","DRUG, DRUG",Other,Xeris Pharmaceuticals,"['Insulin Hypoglycemia', 'Type 1 Diabetes Mellitus', 'Severe Hypoglycemia']",2018-09-27,2019-03-29,https://clinicaltrials.gov/study/NCT03738865
NCT02380833,"Effectiveness of a Paleolithic Based Diet Compared to MyPlate Guidelines, With and Without Exercise, in Women.",Unknown,COMPLETED,"MyPlate, MyPlate + Exercise, Paleolithic, Paleolithic + Exercise","BEHAVIORAL, BEHAVIORAL, BEHAVIORAL, BEHAVIORAL",Other,Clemson University,['Healthy'],2015-04,2016-05,https://clinicaltrials.gov/study/NCT02380833
NCT02563847,Effect of Amino Acids and Sugar Alcohols on Gastric Emptying and Release of Satiation Peptides in Humans,Unknown,COMPLETED,"0.52 g L-Tryptophan, 1.56 g L-Tryptophan, 1.56 g L-Leucine, 50 g Xylitol, 75 g Erythritol, 75 g Glucose, 300 mL tap water, 50 mg 13C-sodium acetate","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, OTHER",Other,"University Hospital, Basel, Switzerland",['Endocrine System Diseases'],2014-05,2015-03,https://clinicaltrials.gov/study/NCT02563847
NCT06350149,A Pilot and Feasibility Study to Evaluate High vs Low Glycemic Index Mixed Meal Tolerance Test in Adolescents and Young Adults With Cystic Fibrosis,Unknown,RECRUITING,"Sugar Sweetened Beverages (SSB), Hi GI, Lo GI","OTHER, OTHER, OTHER",Other,Emory University,['Cystic Fibrosis'],2024-03-22,2025-09,https://clinicaltrials.gov/study/NCT06350149
NCT04871204,Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer,Unknown,COMPLETED,Octreotide Injection,DRUG,Other,Fredrik Klevebro,"['Esophageal Cancer', 'Gastric Cancer']",2021-06-16,2024-02-21,https://clinicaltrials.gov/study/NCT04871204
NCT03454152,Ecg & Echo Changes in Children With DKA,Unknown,UNKNOWN,,,Unknown,Assiut University,['Pediatric Disorder'],2019-03,2020-03,https://clinicaltrials.gov/study/NCT03454152
NCT03064347,Targeted Enteral Nutrient Delivery: A Prospective Randomized Study,Unknown,COMPLETED,"Sucrose plus Whole Milk Powder in Enteric Coating, Non coated Sucrose plus Whole Milk, Sucrose in Enteric Coating, Sucrose with Separate Enteric Coating Materials, Whey Protein in Enteric Coating, Whey Protein with Separate Enteric Coating Materials, Pea Protein in Enteric Coating, Pea Protein with Separate Enteric Coating Materials","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Southern California,"['Diabetes Mellitus, Type 2']",2017-02-22,2018-06-20,https://clinicaltrials.gov/study/NCT03064347
NCT07136714,Does Semaglutide Improve Depressive Symptoms in Patients With Major Depressive Disorder and Overweight or Obesity,Unknown,RECRUITING,"Semaglutide Injectable Product, Placebo","DRUG, DRUG",Other,Maj Vinberg,['Major Depressive Disorder'],2025-09-11,2027-09,https://clinicaltrials.gov/study/NCT07136714
NCT02799849,Metabolism Characteristics in the Children With Narcolepsy,Unknown,UNKNOWN,Sleep and metabolism assessment,OTHER,Other,Hospices Civils de Lyon,['Narcolepsy'],2013-12-20,2019-11,https://clinicaltrials.gov/study/NCT02799849
NCT00518115,Out-Patient Study in Patients With Type 2 Diabetes Mellitus Who Are Taking no Diabetes Medication or Metformin Only,Unknown,COMPLETED,Albiglutide (GSK716155) or exenatide,DRUG,Other,GlaxoSmithKline,"['Diabetes Mellitus, Type 2']",2007-04,2008-05,https://clinicaltrials.gov/study/NCT00518115
NCT04122716,Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie Diet,Unknown,UNKNOWN,"Liraglutide, Exercise","DRUG, BEHAVIORAL",Other,Signe Torekov,['Obesity'],2016-09,2019-11,https://clinicaltrials.gov/study/NCT04122716
NCT02987348,Clinical Outcomes of Exenatide Versus Basal Insulin,Unknown,COMPLETED,"exenatide once weekly, exenatide twice daily, basal insulin","DRUG, DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes'],2015-06-30,2015-06-30,https://clinicaltrials.gov/study/NCT02987348
NCT01454232,Adaptation of Human Gut Microbiota to Energetic Restriction,Unknown,COMPLETED,"stools sampling, adipose tissue biopsy","OTHER, OTHER",Other,Assistance Publique - Hôpitaux de Paris,"['Obesity', 'Metabolic Diseases', 'Nutrition Disorders', 'Body Weight']",2011-06-07,2018-09-14,https://clinicaltrials.gov/study/NCT01454232
NCT02113332,Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections,Unknown,COMPLETED,"Liraglutide, Placebo","DRUG, DRUG",Other,Vastra Gotaland Region,['Type 2 Diabetes Mellitus'],2013-01,2014-08,https://clinicaltrials.gov/study/NCT02113332
NCT05136287,"SEMAGLUTIDE VERSUS GLP-1 RECEPTOR AGONISTS. EFFECTIVENESS , SAFETY AND QUALITY OF LIFE IN PATIENTS WITH DIABETES MELLITUS 2. OBSERVATIONAL, PROSPECTIVE AND MULTICENTER STUDY. SEVERAL STUDY.",Unknown,COMPLETED,GLP-1 receptor agonist,DRUG,GLP-1 agonist,Jose Seijas Amigo,"['Weight Loss', 'Diabetes Mellitus, Type 2', 'Quality of Life', 'Safety Issues']",2022-02-01,2023-11-15,https://clinicaltrials.gov/study/NCT05136287
NCT04656236,Metabolic Effects of Exogenous 3-hydroxybutyrate in Patients With Type 1 Diabetes and Healthy Controls,Unknown,COMPLETED,3-hydroxybutyrate,BIOLOGICAL,Other,University of Aarhus,"['Type 1 Diabetes Mellitus', 'Diabetic Ketoacidosis']",2021-01-01,2022-03-01,https://clinicaltrials.gov/study/NCT04656236
NCT04615871,Semaglutide to Reduce Myocardial Injury in PATIents With COVID-19,Unknown,UNKNOWN,semaglutide,DRUG,Other,Vladimír Džavík,"['Covid19', 'Myocardial Injury']",2021-09-10,2022-03-31,https://clinicaltrials.gov/study/NCT04615871
NCT04985240,Intervention Study on Molibdenum Biofortification Vegetables ( Nutri-Mo-Food ),Unknown,COMPLETED,"Lettuce with no biofortification, Intervention Molibdenum group","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Palermo,['Healthy Diet'],2021-04-01,2021-07-15,https://clinicaltrials.gov/study/NCT04985240
NCT01856790,Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes,Phase 1,COMPLETED,"ePID closed loop system, liraglutide","DEVICE, DRUG",Other,Jennifer Sherr,['Type 1 Diabetes'],2013-02,2015-11,https://clinicaltrials.gov/study/NCT01856790
NCT01507597,The Effect of GLP-1 on the Inhibition of Glucagon Secretion,Unknown,COMPLETED,"Native human Glucagon-like Peptide-1 ( GLP-1(7-36)), NaCl, Native human Glucagon-like Peptide-1 ( GLP-1(7-36)), Native human Glucagon-like Peptide-1 ( GLP-1(7-36))","DRUG, DRUG, DRUG, DRUG",GLP-1 agonist,"University Hospital, Gentofte, Copenhagen","['Type 2 Diabetes', 'Type 1 Diabetes']",2011-12,2013-08,https://clinicaltrials.gov/study/NCT01507597
NCT01513590,A Trial Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart and BIAsp 30 in Insulin naïve Subjects With Type 2 Diabetes,Unknown,COMPLETED,insulin degludec/insulin aspart,DRUG,Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2012-01-16,2012-11-19,https://clinicaltrials.gov/study/NCT01513590
NCT06000891,"A Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570",Unknown,TERMINATED,"ZP7570, Placebo","DRUG, DRUG",Other,Zealand Pharma,['Safety and Tolerability'],2023-09-15,2025-02-11,https://clinicaltrials.gov/study/NCT06000891
NCT01572090,Comparison of Weight Loss Induced by Bariatric Surgery vs Conventional Treatment,Unknown,UNKNOWN,"Lifestyle Changes, Adjustment of oral antidiabetics/insulin therapy, Laparoscopic sleeve gastrectomy, Laparoscopic Roux-en-Y gastric bypass","BEHAVIORAL, OTHER, PROCEDURE, PROCEDURE",Other,"Clinica Universidad de Navarra, Universidad de Navarra",['Obesity'],2006-01,2016-12,https://clinicaltrials.gov/study/NCT01572090
NCT02963935,Effect and Safety of Liraglutide 3.0 mg as an Adjunct to Intensive Behaviour Therapy for Obesity in a Non-specialist Setting,Unknown,COMPLETED,"liraglutide, placebo, CMS Intensive Behavior Therapy","DRUG, DRUG, BEHAVIORAL",Other,Novo Nordisk A/S,"['Metabolism and Nutrition Disorder', 'Obesity']",2017-02-06,2018-05-23,https://clinicaltrials.gov/study/NCT02963935
NCT02246543,Whey Protein Study - Identification of Sustainable Satiety,Unknown,COMPLETED,"Control, HPL, LPL, HPS, LPS","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Aberdeen,['Satiety'],2013-08,2015-10,https://clinicaltrials.gov/study/NCT02246543
NCT03236116,Almond Consumption and Glycemia,Unknown,COMPLETED,"Almonds, Control (no nuts)","OTHER, OTHER",Other,Purdue University,"['Glucose Intolerance', 'Appetite Disorders', 'Glucose Metabolism Disorders (Including Diabetes Mellitus)', 'Lipid Metabolism Disorder']",2017-08-01,2020-03-20,https://clinicaltrials.gov/study/NCT03236116
NCT01694004,Nutrient Sensing in the Duodenum,Unknown,COMPLETED,Benzocaine Infusion into Duodenum,DRUG,Other,Vanderbilt University Medical Center,['The Effect of LCFA on Nutrient Absorption'],2012-11,2014-10-27,https://clinicaltrials.gov/study/NCT01694004
NCT07014709,Impact of GLP-1 Receptor Agonists on Patients With IPMN,Unknown,NOT_YET_RECRUITING,GLP1 receptor agonist,DRUG,GLP-1 agonist,Hôpital Fribourgeois,"['IPMN', 'IPMN, Pancreatic', 'GLP-1', 'Intraductal Papillary Mucinous Neoplasm of Pancreas', 'Glucagon-Like Peptide-1 Receptor Agonists']",2025-05-31,2026-10-31,https://clinicaltrials.gov/study/NCT07014709
NCT01890993,Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe,Unknown,COMPLETED,liraglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2013-08,2014-06,https://clinicaltrials.gov/study/NCT01890993
NCT02722655,Cohort of Mexican Children With Diabetes Mellitus (CMC-DM),Unknown,RECRUITING,,,Unknown,Hospital Regional de Alta Especialidad del Bajio,['Diabetes Mellitus'],2008-03,2020-12,https://clinicaltrials.gov/study/NCT02722655
NCT03689608,Daily vs Intermittent Restriction of Energy: Controlled Trial to Reduce Diabetes Risk (DIRECT),Unknown,COMPLETED,"Intermittent Fasting (IF), Daily Restriction (DR), standard care (SC)","OTHER, OTHER, OTHER",Other,University of Adelaide,['Individuals at Risk of Developing Diabetes'],2018-09-26,2020-11-30,https://clinicaltrials.gov/study/NCT03689608
NCT02292433,A Phase 1 Study In Japanese Subjects With Type 2 Diabetes Mellitus As Monotherapy,Unknown,COMPLETED,"PF-04937319 high dose, PF-04937319 low dose, Placebo","DRUG, DRUG, DRUG",Other,Pfizer,['Type 2 Diabetes Mellitus'],2015-01,2015-03,https://clinicaltrials.gov/study/NCT02292433
NCT01511185,Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group,Unknown,COMPLETED,"liraglutide, placebo","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2001-02,2001-10,https://clinicaltrials.gov/study/NCT01511185
NCT06842433,The NUTRIOME Study - a Data-driven Precision Nutrition Intervention,Unknown,RECRUITING,"General healthy diet, Personalized diet","OTHER, OTHER",Other,Chalmers University of Technology,['Metabolic Control'],2025-03-14,2026-06-30,https://clinicaltrials.gov/study/NCT06842433
NCT02402933,Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents,Unknown,COMPLETED,Nasal Glucagon,DRUG,Other,Eli Lilly and Company,"['Hypoglycemia', 'Diabetes Mellitus']",2015-03,2015-08,https://clinicaltrials.gov/study/NCT02402933
NCT03994549,"A Single Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570",Phase 1,COMPLETED,Dual GLP-1/GLP-2 Receptor agonists,DRUG,Dual agonist,Zealand Pharma,['Healthy'],2019-06-14,2020-11-02,https://clinicaltrials.gov/study/NCT03994549
NCT04260035,The Effects of a Long-lasting Infusion of Vasoactive Intestinal Peptide (VIP) in Episodic Migraine Patients,Unknown,COMPLETED,"Vasoactive Intestinal Polypeptide (VIP), Sterile saline","DRUG, DRUG",Other,Danish Headache Center,"['Migraine', 'Pain', 'Neurologic Manifestations', 'Signs and Symptoms', 'Brain Diseases', 'Central Nervous System Diseases']",2020-05-19,2020-09-15,https://clinicaltrials.gov/study/NCT04260035
NCT01301833,Long-term Safety Study of MP-513 in Patients With Type 2 Diabetes,Unknown,COMPLETED,"teneligliptin, glinide, biguanide, alpha-glucosidase inhibitor","DRUG, DRUG, DRUG, DRUG",Other,Tanabe Pharma Corporation,['Type 2 Diabetes Mellitus'],2011-02,2012-09,https://clinicaltrials.gov/study/NCT01301833
NCT04086043,The MILESTONE Study,Unknown,UNKNOWN,Endovascular Denervation,DEVICE,Other,Zhongda Hospital,['Type 2 Diabetes Mellitus'],2019-09-10,2022-09-09,https://clinicaltrials.gov/study/NCT04086043
NCT05078255,The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes,Unknown,COMPLETED,"Semaglutide 1.34 MG/ML [Ozempic], Glucose-dependent insulinotropic polypeptide (GIP), Semaglutide 1.34 mg/ml placebo, GIP placebo","DRUG, DRUG, OTHER, OTHER",GIP agonist,"Asger Lund, MD","['Type 2 Diabetes', 'Obesity']",2022-01-27,2025-01-06,https://clinicaltrials.gov/study/NCT05078255
NCT05218915,Basal Plus GLP1-ra on Glycemic Variability in CKD,Unknown,COMPLETED,"Dulaglutide, Insulin Degludec, Continuous glucose monitor","DRUG, DRUG, DEVICE",Other,Elaine Chow,"['Diabetes Mellitus', 'Diabetic Kidney Disease']",2022-01-28,2024-10-30,https://clinicaltrials.gov/study/NCT05218915
NCT02087826,Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS,Unknown,ACTIVE_NOT_RECRUITING,"Mixed Meal Tolerance Test, Metformin","OTHER, DRUG",Other,Massachusetts General Hospital,"['Genetics', 'Metabolism', 'Type 2 Diabetes']",2014-04,2025-12,https://clinicaltrials.gov/study/NCT02087826
NCT05273073,Effects of Probiotics on Gut Microbiota Composition and Metabolic Outcomes in Post- Gestational Diabetes Women,Unknown,COMPLETED,"Probiotics, Placebo","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,National University of Malaysia,['Gestational Diabetes'],2018-03-01,2021-04-11,https://clinicaltrials.gov/study/NCT05273073
NCT07220473,Tirzepatide to Slow Biological Aging,Unknown,NOT_YET_RECRUITING,Zepbound,DRUG,Other,"The University of Texas Medical Branch, Galveston","['Aging', 'LONGEVITY 1']",2025-11,2027-11,https://clinicaltrials.gov/study/NCT07220473
NCT00631046,Essential Fatty Acids During Complementary Feeding,Unknown,COMPLETED,"Fish Oil, Sunflower Oil","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Copenhagen,"['Obesity', 'Growth', 'Metabolic Syndrome', 'Cardiovascular Disease']",2008-02,2009-05,https://clinicaltrials.gov/study/NCT00631046
NCT07182669,Blood Flow and Oxygenation in the Portal Vein in Subjects With Chronic Narrowing of the Blood Vessels to the Gut,Unknown,NOT_YET_RECRUITING,,,Unknown,"Rigshospitalet, Denmark",['Chronic Mesenteric Ischemia'],2025-10-01,2027-10-01,https://clinicaltrials.gov/study/NCT07182669
NCT01674283,Effect of Glucagon on Uterine Contractility at the Time of Embryo Transfer in in Vitro Fertilization,Unknown,WITHDRAWN,"Glucagon, placebo","DRUG, DRUG",Other,Clinique Ovo,['Women With Fertility Disorder'],2013-10,2013-10,https://clinicaltrials.gov/study/NCT01674283
NCT00589888,FFA-Induced Hypertension and Endothelial Dysfunction,Unknown,COMPLETED,"Intralipid 20% @ 20cc/hour, Intralipid 20%@ 40cc/hour, Normal Saline, 32-gram oral fat load, 64-gram oral fat load","DRUG, DRUG, DRUG, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,Emory University,"['Endothelial Dysfunction', 'Hypertension']",2006-08,2008-04,https://clinicaltrials.gov/study/NCT00589888
NCT05369390,A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity,Unknown,COMPLETED,"NNC0487-0111 A, NNC0487-0111 B, Placebo B (NNC0487-0111 B), Placebo A (NNC0487-0111 A)","DRUG, DRUG, OTHER, OTHER",Other,Novo Nordisk A/S,['Obesity'],2022-05-11,2024-01-09,https://clinicaltrials.gov/study/NCT05369390
NCT07030010,Effect of a Liquid Tonic Drink on Post-meal Glucose and Insulin Responses,Unknown,RECRUITING,"Breakfast meal challenge with tonic drink, Breakfast meal challenge with placebo drink","OTHER, OTHER",Other,Australian Catholic University,['Overweight or Obese Adults'],2025-07-08,2025-12-19,https://clinicaltrials.gov/study/NCT07030010
NCT02553213,Early Changes of Diabetes Parameters After Obesity Therapy,Unknown,UNKNOWN,"Laparoscopic sleeve gastrectomy, Laparoscopic Roux-en-Y gastric bypass, Caloric restriction diet, easy digestible diet","OTHER, OTHER, OTHER, OTHER",Other,University of Hohenheim,['Bariatric Surgery Candidate'],2015-07,2019-05,https://clinicaltrials.gov/study/NCT02553213
NCT01650324,A Single-dose Phase 1 Study of DBPR108 in Healthy Male Subjects,Unknown,COMPLETED,"DBPR108, matching placebo","DRUG, DRUG",Other,"National Health Research Institutes, Taiwan","['Diabetes Mellitus, Type 2']",2012-07,2012-12,https://clinicaltrials.gov/study/NCT01650324
NCT04027023,Evaluation of the Impact of Intensive Short-Term Drug Therapy in Patients With Type 2 Diabetes Mellitus,Unknown,UNKNOWN,Diabetes mellitus Type 2 De-escalation treatment (DET),DRUG,Other,Sciema UG,"['Diabetes Mellitus, Type 2']",2019-10-30,2021-04-30,https://clinicaltrials.gov/study/NCT04027023
NCT03013296,Delinieation of GIP's Effects During a Meal in Humans Using GIP Receptor Antagonisation (GA-4),Unknown,COMPLETED,"GIP-A, Placebo, GLP-1 receptor antagonist Exendin[9-39], GIP-A + Exendin[9-39]","OTHER, OTHER, OTHER, OTHER",Dual agonist,"University Hospital, Gentofte, Copenhagen",['Glucose Metabolism Disorders'],2016-10,2017-07,https://clinicaltrials.gov/study/NCT03013296
NCT02865486,Digestion of Biopolymer Based Lipid Emulsions,Unknown,COMPLETED,"Lipid emulsion, Lipid emulsion, Lipid emulsion","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Zurich,['Healthy'],2016-03,2016-10,https://clinicaltrials.gov/study/NCT02865486
NCT02635386,"EQW, DAPA, EQW/DAPA, DAPA/MET ER and PHEN/TPM ER in Obese Women With PolycysticOvary Syndrome (PCOS)",Unknown,COMPLETED,"Exenatide once weekly (EQW ), Dapagliflozin (DAPA), EQW plus DAPA, Dapagliflozin plus Glucophage (MET ER), Phentermine /Topiramate (PHEN/ TPM) ER","DRUG, DRUG, DRUG, DRUG, DRUG",Other,Woman's,"['Polycystic Ovary Syndrome', 'Obesity']",2016-03-22,2020-07-22,https://clinicaltrials.gov/study/NCT02635386
NCT01938469,"Effect of Meal Number, Frequency, and Form on Satiety and Metabolism After Weight Loss Surgery",Unknown,COMPLETED,"Liquid Meal, Solid Meal","OTHER, OTHER",Other,St. Luke's-Roosevelt Hospital Center,"['Gastric Bypass Surgery', 'Obesity']",2010-09,2014-07,https://clinicaltrials.gov/study/NCT01938469
NCT03305783,The Influence of Cholecystectomy on Secretion of Incretin Hormones,Unknown,COMPLETED,cholecystectomy,PROCEDURE,Other,"University Hospital, Gentofte, Copenhagen",['Glucose Metabolism Disorders'],2017-11-01,2022-03-11,https://clinicaltrials.gov/study/NCT03305783
NCT01074268,Comparison of NN1250 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes,Unknown,COMPLETED,"insulin degludec, insulin detemir, insulin aspart","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 1']",2010-02,2010-12,https://clinicaltrials.gov/study/NCT01074268
NCT06301191,The Effect of Semaglutide on Cardiovascular Markers and Liver Function,Unknown,RECRUITING,"Semaglutide, 1.0 mg/mL, Dipeptidyl Peptidase 4 inhibitor","DRUG, DRUG",Other,Attikon Hospital,['Diabetes Type 2'],2022-03-01,2023-03-01,https://clinicaltrials.gov/study/NCT06301191
NCT06422624,"A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human Subjects",Unknown,NOT_YET_RECRUITING,"Semaglutide Extended-release for Injectable Suspension, 1 mg, Semaglutide Extended-release for Injectable Suspension, 4 mg, Semaglutide Extended-release for Injectable Suspension, 8 mg","DRUG, DRUG, DRUG",Other,"Bostal Drug Delivery Co., Ltd","['Diabetes Mellitus, Type 2']",2024-08,2024-11,https://clinicaltrials.gov/study/NCT06422624
NCT05726227,A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight,Unknown,ACTIVE_NOT_RECRUITING,"Semaglutide, Placebo","DRUG, DRUG",Other,Novo Nordisk A/S,['Obesity'],2023-07-07,2025-10-15,https://clinicaltrials.gov/study/NCT05726227
NCT02014259,"Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function",Unknown,COMPLETED,semaglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2', 'Healthy']",2013-12-11,2014-10-24,https://clinicaltrials.gov/study/NCT02014259
NCT05227196,A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People,Unknown,COMPLETED,"Semaglutide D Dose 1, Semaglutide D Dose 2, Semaglutide D Dose 3, Semaglutide Dose 4, Semaglutide Dose 5, Semaglutide Dose 6","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Healthy Volunteers', 'Type 2 Diabetes']",2022-02-04,2023-06-28,https://clinicaltrials.gov/study/NCT05227196
NCT03929679,"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in The Netherlands, as Part of Local Clinical Practice (SURE NETHERLANDS)",Unknown,COMPLETED,semaglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2019-05-28,2020-11-24,https://clinicaltrials.gov/study/NCT03929679
NCT03574597,Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity,Unknown,COMPLETED,"Semaglutide, Placebo (semaglutide)","DRUG, DRUG",Other,Novo Nordisk A/S,"['Overweight', 'Obesity']",2018-10-24,2023-06-21,https://clinicaltrials.gov/study/NCT03574597
NCT04822181,Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH),Unknown,ACTIVE_NOT_RECRUITING,"Semaglutide, Placebo","DRUG, DRUG",Other,Novo Nordisk A/S,['Non-alcoholic Steatohepatitis'],2021-04-01,2029-04-25,https://clinicaltrials.gov/study/NCT04822181
NCT03596450,Long Term Comparative Effectiveness of Once Weekly Semaglutide Versus Standard of Care in a Real World Adult US Population With Type 2 Diabetes - a Randomized Pragmatic Trial,Unknown,COMPLETED,"Semaglutide, Standard of care","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2018-07-13,2022-06-09,https://clinicaltrials.gov/study/NCT03596450
NCT02016911,"Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment",Unknown,COMPLETED,semaglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2', 'Healthy']",2013-12-12,2015-01-12,https://clinicaltrials.gov/study/NCT02016911
NCT04940078,A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity,Unknown,COMPLETED,"Cagrilintide, semaglutide, Cagrilintide and semaglutide","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,['Obesity & Overweight'],2021-07-07,2022-01-19,https://clinicaltrials.gov/study/NCT04940078
NCT05877547,A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013),Unknown,ACTIVE_NOT_RECRUITING,"Efinopegdutide, Semaglutide, Placebo","DRUG, DRUG, DRUG",Other,Merck Sharp & Dohme LLC,"['Non-alcoholic Fatty Liver Disease', 'Fatty Liver, Nonalcoholic', 'NAFLD', 'Nonalcoholic Fatty Liver Disease', 'Nonalcoholic Steatohepatitis']",2023-06-23,2025-12-29,https://clinicaltrials.gov/study/NCT05877547
NCT06577090,Study to Evaluate the Effect on Obesity of Once Weekly Nimacimab Injection and Once Weekly Nimacimab Injection Co-administered With Semaglutide Injection Versus Placebo,Unknown,ACTIVE_NOT_RECRUITING,"Nimacimab injection, Nimacimab placebo injection, semaglutide injection","BIOLOGICAL, BIOLOGICAL, COMBINATION_PRODUCT",Other,"Skye Bioscience, Inc.",['Obesity'],2024-08-22,2025-08,https://clinicaltrials.gov/study/NCT06577090
NCT06716216,A Study of BGM0504 in Participants with Type 2 Diabetes,Unknown,RECRUITING,"Drug: 5 mg BGM0504 Administered SC, Drug:10 mg BGM0504 Administered SC, Drug: Semaglutide Administered SC","DRUG, DRUG, DRUG",Other,"BrightGene Bio-Medical Technology Co., Ltd.",['Type 2 Diabetes Mellitus (T2DM)'],2024-11-29,2026-03-20,https://clinicaltrials.gov/study/NCT06716216
NCT03707990,A Research Study of NNC0165-1875 Alone or Together With Semaglutide in People Who Are Overweight or Obese,Unknown,COMPLETED,"NNC0165-1875, Placebo (NNC0165-1875), Semaglutide","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,['Obesity and Overweight'],2018-10-15,2019-08-13,https://clinicaltrials.gov/study/NCT03707990
NCT06804603,A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use,Unknown,COMPLETED,"Tradipitant, Placebo","DRUG, DRUG",Other,Vanda Pharmaceuticals,['Obesity'],2025-02-25,2025-10-06,https://clinicaltrials.gov/study/NCT06804603
NCT07043361,"Efficacy of Semaglutide in Glycemic Control, Weight Loss, and Improving Lipidogram- Role of Baseline Vitamin D Levels",Unknown,COMPLETED,semaglutide,DRUG,Other,Hillel Yaffe Medical Center,['Metabolic Disease'],2023-12-18,2024-12-21,https://clinicaltrials.gov/study/NCT07043361
NCT06149260,Subcutaneous Semaglutide in Systemic Scleroderma,Unknown,RECRUITING,Semaglutide Pen Injector,DRUG,Other,Second Xiangya Hospital of Central South University,"['Scleroderma, Systemic', 'Fibrosis', 'Semaglutide']",2024-02-29,2024-08-29,https://clinicaltrials.gov/study/NCT06149260
NCT05502562,A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes in India,Unknown,COMPLETED,Oral semaglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2023-02-24,2024-06-03,https://clinicaltrials.gov/study/NCT05502562
NCT06411210,Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment,Unknown,RECRUITING,"Semaglutide Pen Injector, Placebo","DRUG, DRUG",Other,Yale University,"['Diabetes type1', 'Obesity']",2024-07-16,2028-04-30,https://clinicaltrials.gov/study/NCT06411210
NCT02172313,Effect of Food on the Pharmacokinetics of Oral Semaglutide in Healthy Subjects,Unknown,COMPLETED,semaglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes', 'Healthy']",2014-06,2014-10,https://clinicaltrials.gov/study/NCT02172313
NCT05442450,Efficacy of Oral Semaglutide in Overweight or Obesity,Unknown,UNKNOWN,oral semaglutide,DRUG,Other,"Asian Institute of Gastroenterology, India","['Obesity', 'Weight Loss']",2022-07-10,2023-06-30,https://clinicaltrials.gov/study/NCT05442450
NCT06548490,GLP-1R Agonist Treatment for Opioid Use Disorder,Unknown,RECRUITING,"Semaglutide Pen Injector, Placebo","DRUG, DRUG",Other,Milton S. Hershey Medical Center,"['Opioid Use Disorder', 'Opioid Abuse and Addiction', 'Narcotic-Related Disorders', 'Substance-Related Disorders', 'Chemically-Induced Disorders', 'Mental Disorder', 'Opioid']",2025-01-13,2026-11,https://clinicaltrials.gov/study/NCT06548490
NCT03987919,A Study of Tirzepatide (LY3298176) Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Participants With Type 2 Diabetes,Unknown,COMPLETED,"Tirzepatide, Semaglutide","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes'],2019-07-30,2021-01-28,https://clinicaltrials.gov/study/NCT03987919
NCT04873245,Lifestyle Counseling and Medication for Adolescent Weight Management,Unknown,ACTIVE_NOT_RECRUITING,"Intensive Behavioral Program, Semaglutide and Behavioral Program","BEHAVIORAL, DRUG",Other,University of Minnesota,"['Obesity, Childhood']",2022-03-15,2026-07-31,https://clinicaltrials.gov/study/NCT04873245
NCT05394519,A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight,Unknown,COMPLETED,"Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide","DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Overweight', 'Obesity', 'Type 2 Diabetes Mellitus']",2023-02-01,2025-01-28,https://clinicaltrials.gov/study/NCT05394519
NCT04074161,Research Study to Investigate How Well Semaglutide Works Compared to Liraglutide in People Living With Overweight or Obesity,Unknown,COMPLETED,"Semaglutide, Placebo (semaglutide), Liraglutide, Placebo (liraglutide)","DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Overweight', 'Obesity']",2019-09-11,2021-03-27,https://clinicaltrials.gov/study/NCT04074161
NCT05822830,A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities,Unknown,COMPLETED,"Tirzepatide, Semaglutide","DRUG, DRUG",Other,Eli Lilly and Company,"['Obesity', 'Overweight']",2023-04-21,2024-11-13,https://clinicaltrials.gov/study/NCT05822830
NCT06118008,A Study of HS-20094 in T2DM Participants,Unknown,COMPLETED,"HS-20094 5mg, HS-20094 10mg, HS-20094 15mg, HS-20094 20mg","DRUG, DRUG, DRUG, DRUG",Other,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",['Type 2 Diabetes'],2023-05-31,2024-01-04,https://clinicaltrials.gov/study/NCT06118008
NCT04469855,Post-Marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Ozempic®,Unknown,COMPLETED,semaglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2020-07-27,2025-05-12,https://clinicaltrials.gov/study/NCT04469855
NCT06691243,Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV,Unknown,RECRUITING,"Semaglutide, Placebo","DRUG, DRUG",Other,"University of Maryland, Baltimore","['Cocaine Use Disorder', 'HIV']",2025-08-07,2026-07,https://clinicaltrials.gov/study/NCT06691243
NCT06981936,This Randomized Trial Aims to Investigate the Efficacy of Balanced Nutritional Tablets-Comprehensive Multivitamin and Mineral Supplements- in Preventing Micronutrient Deficiencies Among Patients Utilizing GLP-1 RAs for Weight Loss in Comparison to a Placebo Control,Unknown,RECRUITING,"Balance Tablet, Control (placebo)","DRUG, DRUG",Other,"General Committee of Teaching Hospitals and Institutes, Egypt",['Micronutrient Deficiencies'],2025-05-15,2026-05,https://clinicaltrials.gov/study/NCT06981936
NCT06745284,A Study to Test Whether Survodutide Improves How the Body Uses Energy and Breaks Down Fat in People With Obesity,Unknown,RECRUITING,"Survodutide, Semaglutide","DRUG, DRUG",Other,Boehringer Ingelheim,['Obesity'],2025-03-26,2027-01-08,https://clinicaltrials.gov/study/NCT06745284
NCT07081178,A Non-interventional Study Investigating Semaglutide in Combination With Lifestyle-based Modifications for the Management of Obesity in Real-World Clinical Practice in Germany (WeGo Real Germany).,Unknown,ENROLLING_BY_INVITATION,Semaglutide,DRUG,Other,Novo Nordisk A/S,['Obesity'],2025-08-08,2027-10-21,https://clinicaltrials.gov/study/NCT07081178
NCT07017270,Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis,Unknown,NOT_YET_RECRUITING,Semaglutide Pen,DRUG,Other,Unity Health Toronto,"['Kidney Disease, Chronic', 'Diabetes', 'Dialysis', 'End Stage Kidney Disease (ESRD)']",2025-07,2027-07,https://clinicaltrials.gov/study/NCT07017270
NCT04998136,Research Study Investigating How Well Semaglutide Works in People From Thailand and South Korea Living With Obesity,Unknown,COMPLETED,"Semaglutide 2.4 mg, Placebo (semaglutide 2.4 mg)","DRUG, DRUG",Other,Novo Nordisk A/S,['Obesity'],2022-08-15,2023-10-16,https://clinicaltrials.gov/study/NCT04998136
NCT02845219,A Trial Investigating the Influence of Oral Semaglutide on Pharmacokinetics of Ethinylestradiol and Levonorgestrel in an Oral Contraceptive Combination Drug in Healthy Postmenopausal Females,Unknown,COMPLETED,"semaglutide, SNAC, Microgynon®","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2016-07,2016-12,https://clinicaltrials.gov/study/NCT02845219
NCT06050577,The Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Randomized Placebo-controlled Clinical Trial,Unknown,RECRUITING,"oral Semaglutide/Rybelsus, Placebo","DRUG, DRUG",Other,Odense University Hospital,"['Type 2 Diabetes', 'Osteopenia']",2024-06-07,2025-11,https://clinicaltrials.gov/study/NCT06050577
NCT05521256,A Research Study of a New Medicine NNC0113-6856 in Healthy Males,Unknown,COMPLETED,"NNC0113-6856, Placebo","DRUG, DRUG",Other,Novo Nordisk A/S,"['Healthy Volunteers', 'Type 2 Diabetes']",2022-08-26,2023-03-27,https://clinicaltrials.gov/study/NCT05521256
NCT05990374,Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 Years,Unknown,UNKNOWN,"Duragtide, Semaglutide, losenatide, tirzepatide, ebenatide, etc",DRUG,Other,"Nanjing First Hospital, Nanjing Medical University",['Diabetes'],2023-08-01,2024-01-01,https://clinicaltrials.gov/study/NCT05990374
NCT04083820,"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)",Unknown,COMPLETED,semaglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2019-09-16,2021-09-27,https://clinicaltrials.gov/study/NCT04083820
NCT04287179,SUSTAIN SWITCH: A Research Study to Compare Two Dose Schedules of Semaglutide Taken Once Weekly in People With Type 2 Diabetes,Unknown,WITHDRAWN,Semaglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2020-03-09,2020-11-16,https://clinicaltrials.gov/study/NCT04287179
NCT06500143,Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery,Unknown,NOT_YET_RECRUITING,Gastric ultrasound,DIAGNOSTIC_TEST,Other,Ciusss de L'Est de l'Île de Montréal,['Gastric Retention'],2024-09,2025-03,https://clinicaltrials.gov/study/NCT06500143
NCT06215196,Effectiveness and Safety of Semaglutide Combined With Dietary Fiber (Soloways) in Adults With Overweight or Obesity,Unknown,COMPLETED,"Fiber Supplement Group, placebo","DIETARY_SUPPLEMENT, OTHER",Other,S.LAB (SOLOWAYS),['Overweight and Obesity'],2023-04-14,2023-06-28,https://clinicaltrials.gov/study/NCT06215196
NCT02243098,Investigating the Influence of Semaglutide on the Pharmacokinetics of Single Doses of Atorvastatin and Digoxin in Healthy Subjects,Unknown,COMPLETED,"semaglutide, digoxin, atorvastatin","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Healthy']",2014-09-16,2015-04-07,https://clinicaltrials.gov/study/NCT02243098
NCT05574439,Young Adults With Early-onset Obesity Treated With Semaglutide,Unknown,RECRUITING,"TCOC treatment, Semaglutide 3 mg/ml, Placebo (Semaglutide 3 mg/ml)","BEHAVIORAL, DRUG, DRUG",Other,Signe Torekov,"['Obesity, Adolescent']",2022-06-01,2026-04-30,https://clinicaltrials.gov/study/NCT05574439
NCT07251556,GLP-1 Receptor Agonists in Non-diabetic Patients With Psoriatic Arthritis,Unknown,NOT_YET_RECRUITING,"Semaglutide 0.5 mg, Semaglutide 1.0 mg, Semaglutide 0.25 mg, No intervention","DRUG, DRUG, DRUG, OTHER",Other,Chinese University of Hong Kong,['Psoriasis Arthritis'],2025-12-01,2027-01-01,https://clinicaltrials.gov/study/NCT07251556
NCT02147431,A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes,Unknown,COMPLETED,"semaglutide, placebo","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2014-05-21,2015-05-20,https://clinicaltrials.gov/study/NCT02147431
NCT05333003,Semaglutide in Comorbid Schizophrenia Spectrum Disorder and Obesity,Unknown,RECRUITING,"Semaglutide, Placebo","DRUG, OTHER",Other,Centre for Addiction and Mental Health,['Schizophrenia Spectrum Disorders'],2022-05-25,2025-08,https://clinicaltrials.gov/study/NCT05333003
NCT05040971,Research Study Looking at How Well Semaglutide Works in People Living With Obesity and Prediabetes,Unknown,COMPLETED,"Semaglutide 2.4 mg, Placebo","DRUG, DRUG",Other,Novo Nordisk A/S,['Obesity'],2021-09-06,2023-01-06,https://clinicaltrials.gov/study/NCT05040971
NCT04126603,Impact of Semaglutide on CD34+ EPC and Fat Derived MSC,Unknown,COMPLETED,"Semaglutide, Placebos","DRUG, DRUG",Other,Sabyasachi Sen,"['Diabetes Mellitus, Type 2']",2019-08-01,2023-10-25,https://clinicaltrials.gov/study/NCT04126603
NCT05254314,"Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3)",Unknown,RECRUITING,"Semaglutide Pen Injector 2.4mg weekly, Placebo","DRUG, OTHER",Other,Vanderbilt University Medical Center,['Asthma'],2022-10-11,2026-02,https://clinicaltrials.gov/study/NCT05254314
NCT06082063,Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes,Unknown,RECRUITING,"Aspirin tablet, Semaglutide, Sotagliflozin, Finerenone","DRUG, DRUG, DRUG, DRUG",Other,Steno Diabetes Center Copenhagen,"['Cardiovascular Diseases', 'Heart Failure', 'Type 1 Diabetes', 'Kidney Failure']",2024-07-01,2029-07-01,https://clinicaltrials.gov/study/NCT06082063
NCT06884293,A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）,Unknown,RECRUITING,"IBI362, semaglutide","DRUG, DRUG",Other,Innovent Biologics (Suzhou) Co. Ltd.,"['Overweight', 'Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)']",2025-05-09,2026-12-31,https://clinicaltrials.gov/study/NCT06884293
NCT02648204,Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.,Unknown,COMPLETED,"semaglutide, Dulaglutide","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2016-01-06,2017-04-10,https://clinicaltrials.gov/study/NCT02648204
NCT02461589,Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes,Unknown,COMPLETED,"semaglutide, liraglutide, placebo","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2015-09-21,2016-10-13,https://clinicaltrials.gov/study/NCT02461589
NCT04016974,A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese,Unknown,COMPLETED,"Oral semaglutide, Placebo","DRUG, DRUG",Other,Novo Nordisk A/S,"['Healthy Volunteers', 'Diabetes Mellitus, Type 2']",2019-10-08,2021-01-23,https://clinicaltrials.gov/study/NCT04016974
NCT03292315,Once Weekly GLP-1 in Persons With Spinal Cord Injury,Unknown,COMPLETED,"Semaglutide 1MG Injection [Ozempic], No Intervention","DRUG, OTHER",Other,James J. Peters Veterans Affairs Medical Center,"['Spinal Cord Injuries', 'Insulin Resistance', 'Pre Diabetes', 'Obesity']",2018-10-16,2020-03-01,https://clinicaltrials.gov/study/NCT03292315
NCT02254291,A Trial Comparing the Safety and Efficacy of Semaglutide Once Weekly Versus Sitagliptin Once Daily in Japanese Subjects With Type 2 Diabetes,Unknown,COMPLETED,"semaglutide, semaglutide, sitagliptin","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2014-10-02,2015-11-11,https://clinicaltrials.gov/study/NCT02254291
NCT05857085,Novel Therapeutics and Endothelial Dysfunction in T1DM Patients,Unknown,COMPLETED,"Semaglutide Pen Injector [Ozempic], Empagliflozin 10 MG","DRUG, DRUG",Other,General and Teaching Hospital Celje,"['Endothelial Dysfunction', 'Diabetes Mellitus, Type 1', 'Biomarkers', 'Endothelial Progenitor Cells', 'SGLT 2 Inhibitors', 'Incretins', 'Glucose Excursions', 'FMD', 'FPF', 'Arterial Stiffness']",2021-12-15,2022-03-10,https://clinicaltrials.gov/study/NCT05857085
NCT04175665,Real-world Health Outcomes in Canadian Patients Using Semaglutide,Unknown,COMPLETED,Semaglutide,DRUG,Other,LMC Diabetes & Endocrinology Ltd.,['Type 2 Diabetes'],2020-01-06,2020-02-09,https://clinicaltrials.gov/study/NCT04175665
NCT06420739,The Semaglutide Study,Unknown,ACTIVE_NOT_RECRUITING,Gastric Ultrasound,DIAGNOSTIC_TEST,Other,"University Health Network, Toronto",['Fasting'],2024-03-25,2025-11-30,https://clinicaltrials.gov/study/NCT06420739
NCT01619345,Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects,Unknown,COMPLETED,semaglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes', 'Healthy']",2012-06,2012-08,https://clinicaltrials.gov/study/NCT01619345
NCT05424003,Randomized Double Blinded Placebo-Controlled w/Semaglutide to Prevent Weight Gain After Liver Transplant,Unknown,RECRUITING,"Semaglutide Pen Injector, Placebo","DRUG, DRUG",Other,Virginia Commonwealth University,['NAFLD'],2024-02-22,2026-02,https://clinicaltrials.gov/study/NCT05424003
NCT04916470,"Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes",Unknown,COMPLETED,"Semaglutide, Placebo (Semaglutide)","DRUG, DRUG",Other,Novo Nordisk A/S,"['Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2']",2021-06-15,2023-10-11,https://clinicaltrials.gov/study/NCT04916470
NCT04228354,A Research Study Looking at the Comparability (Bioequivalence) of Two Versions of Semaglutide,Unknown,COMPLETED,Semaglutide,DRUG,Other,Novo Nordisk A/S,"['Healthy Volunteers', 'Overweight', 'Obesity']",2020-01-29,2020-06-01,https://clinicaltrials.gov/study/NCT04228354
NCT05498610,A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Chinese Men,Unknown,COMPLETED,"NNC0480 0389, Semaglutide","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2022-08-11,2022-10-12,https://clinicaltrials.gov/study/NCT05498610
NCT07139405,TRIGLYTZA® VERSUS METFORMIN IN OBESE ADULT TYPE 2 DIABETES (T2DM) PATIENTS OVER 24 WEEKS OF TREATMENT,Unknown,NOT_YET_RECRUITING,"Metformin XR 1000mg, Valsartan 80mg Tablet, Valsartan 160mg tablet, Celecoxib (Celebrex®) 100mg, Celecoxib (Celebrex®) 200mg, Metformin XR 500 mg","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Myopharm Limited,['Type 2 Diabetes (T2DM)'],2026-02,2027-12,https://clinicaltrials.gov/study/NCT07139405
NCT07254572,Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetes,Unknown,RECRUITING,"Semaglutide 14 MG [Rybelsus], Dapagliflozin (Forxiga), Metformin, Optimal Medical Therapy (OMT) And Lifestyle Intervention","DRUG, DRUG, DRUG, BEHAVIORAL",Other,"National Institute of Cardiology, Warsaw, Poland","['Coronary Artery Disease', 'PreDiabetes']",2025-07-10,2029-08-01,https://clinicaltrials.gov/study/NCT07254572
NCT06778967,A Phase III Clinical Study to Evaluate the Efficacy and Safety of GZR18 Injection in Adult Type 2 Diabetes Mellitus,Unknown,ACTIVE_NOT_RECRUITING,"GZR18, semaglutide","DRUG, DRUG",Other,Gan & Lee Pharmaceuticals.,['Type 2 Diabetes Mellitus (T2DM)'],2025-02-13,2026-12-11,https://clinicaltrials.gov/study/NCT06778967
NCT07040592,Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide,Unknown,NOT_YET_RECRUITING,semaglutide,DRUG,Other,Yale University,"['Alcohol Use Disorder (AUD)', 'HIV']",2025-11-15,2027-06-30,https://clinicaltrials.gov/study/NCT07040592
NCT03457012,"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice",Unknown,COMPLETED,Semaglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2018-03-29,2019-12-19,https://clinicaltrials.gov/study/NCT03457012
NCT05205928,Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care,Unknown,COMPLETED,Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy,DRUG,Other,McGill University Health Centre/Research Institute of the McGill University Health Centre,"['Type 1 Diabetes', 'Diabetes Mellitus, Type 1']",2022-10-02,2024-04-15,https://clinicaltrials.gov/study/NCT05205928
NCT06449625,Semaglutide in Auto-HSCT,Unknown,NOT_YET_RECRUITING,"Semaglutide Pen Injector [Ozempic], Placebo","DRUG, DRUG",Other,Klaus Gottlob Müller,"['Intestinal Mucositis', 'Inflammation', 'Chemotherapeutic Toxicity']",2024-08-12,2026-12-31,https://clinicaltrials.gov/study/NCT06449625
NCT06487832,Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness,Unknown,RECRUITING,"Subcutaneous GLP1-RA, Subcutaneous placebo","OTHER, OTHER",GLP-1 agonist,University Hospital Tuebingen,"['Normal Weight', 'Overweight and Obesity', 'Insulin Sensitivity', 'Insulin Resistance']",2024-07-01,2027-07-31,https://clinicaltrials.gov/study/NCT06487832
NCT07207148,People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists,Unknown,NOT_YET_RECRUITING,"GLP-1, Ocrelizumab (US)","DRUG, DRUG",GLP-1 agonist,Northwestern University,['Multiple Sclerosis'],2025-10-15,2028-04-01,https://clinicaltrials.gov/study/NCT07207148
NCT06814938,A Study of a Novel Precision Medicine Approach for Obesity,Unknown,RECRUITING,"Semaglutide, Placebo","DRUG, DRUG",Other,Mayo Clinic,['Obesity'],2025-02-21,2027-12,https://clinicaltrials.gov/study/NCT06814938
NCT05429593,A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet,Unknown,COMPLETED,"Semaglutide, Dapagliflozin, Semaglutide/dapagliflozin","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,['Healthy Volunteers'],2022-06-22,2023-03-10,https://clinicaltrials.gov/study/NCT05429593
NCT06788626,Glucagon-like Peptide 1 Receptor Agonist in Acute Large Vessel Occlusion Stroke After Endovascular Treatment,Unknown,NOT_YET_RECRUITING,"Semaglutide 0.5 mg, Standard medical treatment","DRUG, OTHER",Other,Wei Hu,"['Acute Ischemic Stroke', 'Large Vessel Occlusion', 'Neuroprotective Drugs', 'Endovascular Treatment']",2025-02,2028-02,https://clinicaltrials.gov/study/NCT06788626
NCT04109547,A Research Study Comparing a New Medicine Oral Semaglutide to Placebo in People With Type 2 Diabetes,Unknown,COMPLETED,"Oral semaglutide, Placebo","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2019-10-01,2021-09-23,https://clinicaltrials.gov/study/NCT04109547
NCT04560998,A Research Study to Compare a Medicine Called Semaglutide Against Placebo in People With Peripheral Arterial Disease and Type 2 Diabetes,Unknown,COMPLETED,"Semaglutide, Placebo (semaglutide)","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2', 'Peripheral Arterial Disease']",2020-10-01,2024-06-05,https://clinicaltrials.gov/study/NCT04560998
NCT07055607,"A Two-year Prospective, Observational Study of Wegovy in Real-world Clinical Practice",Unknown,NOT_YET_RECRUITING,Semaglutide,DRUG,Other,Novo Nordisk A/S,['Obesity'],2025-10-01,2027-10-25,https://clinicaltrials.gov/study/NCT07055607
NCT07221214,GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV,Unknown,NOT_YET_RECRUITING,"Semaglutide (Rybelsus®), Placebo","DRUG, DRUG",Other,Vanderbilt University Medical Center,"['HIV', 'Alcohol', 'Smoking Cigarette', 'Cardiovascular Disease Prevention']",2026-02-06,2029-07-31,https://clinicaltrials.gov/study/NCT07221214
NCT06287307,Semaglutide 2.4mg for Low Responders After Bariatric Surgery,Unknown,NOT_YET_RECRUITING,"Placebo, Semaglutide 2.4 MG/0.75 ML Subcutaneous Solution [WEGOVY]","OTHER, DRUG",Other,Zuyderland Medisch Centrum,"['Obesity', 'Obesity, Morbid', 'Weight Gain']",2024-05,2026-02,https://clinicaltrials.gov/study/NCT06287307
NCT06699329,A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023),Unknown,COMPLETED,"Enlicitide Decanoate, Semaglutide","DRUG, DRUG",Other,Merck Sharp & Dohme LLC,['Healthy'],2024-01-22,2024-05-24,https://clinicaltrials.gov/study/NCT06699329
NCT05501483,Adipose Tissue Heterogeneity and Its Link to Type 2 Diabetes,Unknown,RECRUITING,"Pioglitazone 45 mg, Empagliflozin 25 MG, Semaglutide 7 MG","DRUG, DRUG, DRUG",Other,Karolinska Institutet,['Type 2 Diabetes'],2023-02-08,2026-09-01,https://clinicaltrials.gov/study/NCT05501483
NCT06908694,Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy,Unknown,RECRUITING,Semaglutide Pen Injector,DRUG,Other,Hamilton Health Sciences Corporation,['Prostate Cancer'],2025-07-02,2026-07-31,https://clinicaltrials.gov/study/NCT06908694
NCT06097390,A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation III,Unknown,COMPLETED,Semaglutide,DRUG,Other,Novo Nordisk A/S,['Healthy Participants'],2023-09-28,2024-02-22,https://clinicaltrials.gov/study/NCT06097390
NCT05371496,Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction,Unknown,ENROLLING_BY_INVITATION,"Semaglutide, Placebo, Counselling on healthy lifestyle intervention","DRUG, DRUG, BEHAVIORAL",Other,Mayo Clinic,"['Cardiomyopathy', 'Heart Failure With Preserved Ejection Fraction (HFpEF)', 'Obesity']",2022-09-06,2026-08,https://clinicaltrials.gov/study/NCT05371496
NCT06820047,Sleeve Gastrectomy vs. Lifestyle & Medications: Impact on BMI Trajectory and Target Attainment in a Matched Cohort Study,Unknown,COMPLETED,"Laparoscopic sleeve gastrectomy, Obesity pharmacotherapy","PROCEDURE, OTHER",Other,University of Roma La Sapienza,['Obesity and Obesity-related Medical Conditions'],2022-05-01,2023-07-01,https://clinicaltrials.gov/study/NCT06820047
NCT06959784,Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study),Unknown,ENROLLING_BY_INVITATION,"semaglutide, Metformin","DRUG, DRUG",Other,China-Japan Friendship Hospital,"['Diabetes Mellitus', 'Cardiovascular Diseases', 'Cerebrovascular Disease']",2024-01-01,2026-12-31,https://clinicaltrials.gov/study/NCT06959784
NCT04572165,Epidemiological Assessment of the Risk for Pancreatic Cancer Associated With the Use of Semaglutide in Patients With Type 2 Diabetes - A Cohort Study Based on Nordic Registry Data,Unknown,ENROLLING_BY_INVITATION,"Ozempic®, Active Comparator, Rybelsus®","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2021-01-26,2024-12-31,https://clinicaltrials.gov/study/NCT04572165
NCT05230615,"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice",Unknown,COMPLETED,Oral semaglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2022-04-01,2023-10-31,https://clinicaltrials.gov/study/NCT05230615
NCT07172867,"A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM",Unknown,NOT_YET_RECRUITING,"HT-6184, HT-6184 Matching Placebo, Semaglutide 1 mg","DRUG, DRUG, DRUG",Other,"Halia Therapeutics, Inc.","['Diabetes Mellitus, Type 2', 'Obesity']",2025-09,2026-06,https://clinicaltrials.gov/study/NCT07172867
NCT06120556,Efficacy of Glucagon-like Peptide-1 Receptor Agonists According to Type 2 Diabetes Subtypes,Unknown,COMPLETED,GLP-1 receptor agonist,DRUG,GLP-1 agonist,Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari,"['Diabetes Mellitus, Type 2']",2023-06-10,2023-10-31,https://clinicaltrials.gov/study/NCT06120556
NCT07216651,WeDosify Real World Evidence (RWE) Study: Personalized Semaglutide Dosing in U.S. Adults,Unknown,RECRUITING,,,Unknown,Closed Loop Medicine,['Obesity & Overweight'],2025-09-23,2026-01-31,https://clinicaltrials.gov/study/NCT07216651
NCT04865744,The Effect of Semaglutide on Pituitary Function,Unknown,COMPLETED,"Semaglutide 7 MG Oral Tablet, Placebo, Semaglutide 14 MG Oral Tablet","DRUG, DRUG, DRUG",Other,University of Tartu,['Healthy'],2021-05-19,2021-09-23,https://clinicaltrials.gov/study/NCT04865744
NCT03648281,"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Denmark and Sweden, as Part of Local Clinical Practice (SURE DENMARK/SWEDEN)",Unknown,COMPLETED,Semaglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2018-08-24,2020-01-10,https://clinicaltrials.gov/study/NCT03648281
NCT06005012,Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM,Unknown,UNKNOWN,"Semaglutide, Placebo","DRUG, DRUG",Other,"University of California, San Diego","['Fibrosis, Liver', 'Type 2 Diabetes Mellitus in Obese', 'Non-Alcoholic Fatty Liver Disease']",2023-07-25,2025-03,https://clinicaltrials.gov/study/NCT06005012
NCT02064348,A Thorough QTc Evaluation of the Effect of Semaglutide on Cardiac Repolarisation in Healthy Subjects,Unknown,COMPLETED,"semaglutide, placebo, moxifloxacin","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Healthy']",2014-02-26,2015-04-23,https://clinicaltrials.gov/study/NCT02064348
NCT04263415,"The Effects of Semaglutide on Taste, Tongue Tissue Transcriptome, Gastric Emptying and Central Neural Response in Women With PCOS and Obesity",Unknown,COMPLETED,"Semaglutide, Placebo","DRUG, OTHER",Other,University Medical Centre Ljubljana,"['PCOS', 'Semaglutide', 'Taste, Altered', 'Tongue Tissue Transcriptome', 'Gastric Emptying', 'Central Neural Response']",2019-11-02,2020-05-08,https://clinicaltrials.gov/study/NCT04263415
NCT06762314,Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes,Unknown,RECRUITING,"Insulin, Semaglutide, Empagliflozin","DRUG, DRUG, DRUG",Other,Mostafa Bahaa,['Diabetes'],2025-01-20,2027-09-20,https://clinicaltrials.gov/study/NCT06762314
NCT06830343,"The Safety, Tolerability, and Pharmacokinetics of of SYH9017 in Chinese Participants With Overweight and Obesity",Unknown,RECRUITING,"SYH9017, Placebo, Wegovy ®","DRUG, DRUG, DRUG",Other,"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.",['Overweight or Obesity'],2025-02-27,2026-08-01,https://clinicaltrials.gov/study/NCT06830343
NCT06060392,Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus,Unknown,RECRUITING,Semaglutide Pill,DRUG,Other,"Medanta, The Medicity, India","['Liver Transplant; Complications', 'Diabete Mellitus']",2023-10-30,2025-09-02,https://clinicaltrials.gov/study/NCT06060392
NCT04261933,"A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Germany, as Part of Local Clinical Practice (SURE GERMANY)",Unknown,COMPLETED,semaglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2020-02-13,2021-05-25,https://clinicaltrials.gov/study/NCT04261933
NCT06575738,Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in Adolescents,Unknown,RECRUITING,"Injectable semaglutide, Standard postoperative care","DRUG, BEHAVIORAL",Other,"University of Colorado, Denver","['Obesity', 'Adolescent Obesity', 'Body-Weight Trajectory', 'Weight Loss Trajectory', 'Bariatric Surgery', 'Anti-obesity Agents']",2024-10-11,2027-09,https://clinicaltrials.gov/study/NCT06575738
NCT04383197,Exercise and GLP-1 RA on Insulin Secretion,Unknown,UNKNOWN,"Endurance exercise training, Semaglutide","BEHAVIORAL, DRUG",Other,University of Copenhagen,['Type 2 Diabetes'],2019-12-10,2021-08,https://clinicaltrials.gov/study/NCT04383197
NCT06986993,Impact of Semaglutide on Tobacco Use and Related Health Behaviors,Unknown,RECRUITING,"Semaglutide, Placebo","DRUG, DRUG",Other,University of Oklahoma,['Tobacco Use'],2024-07-01,2028-05-30,https://clinicaltrials.gov/study/NCT06986993
NCT07225816,"Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)",Unknown,RECRUITING,"Liraglutide, Oral Semaglutide, Semaglutide","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,['Obesity'],2025-11-07,2026-06-19,https://clinicaltrials.gov/study/NCT07225816
NCT05564104,A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body,Unknown,COMPLETED,Cagrilintide,DRUG,Other,Novo Nordisk A/S,"['Hepatic Impairment', 'Healthy Volunteers']",2023-04-05,2024-09-06,https://clinicaltrials.gov/study/NCT05564104
NCT06634927,"Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.",Unknown,COMPLETED,"Ozempic®, HDG1901","DRUG, DRUG",Other,"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.",['Type 2 Diabetes'],2024-09-22,2024-11-14,https://clinicaltrials.gov/study/NCT06634927
NCT03811561,A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes,Unknown,ACTIVE_NOT_RECRUITING,"Semaglutide, Placebo (semaglutide)","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2019-05-08,2026-12-25,https://clinicaltrials.gov/study/NCT03811561
NCT03693430,Two-year Research Study Investigating How Well Semaglutide Works in People Suffering From Overweight or Obesity,Unknown,COMPLETED,"Semaglutide, Placebo (Semaglutide)","DRUG, DRUG",Other,Novo Nordisk A/S,"['Overweight', 'Obesity']",2018-10-05,2021-01-29,https://clinicaltrials.gov/study/NCT03693430
NCT06292065,Gastric Ultrasound To Assess Gastric Contents In Patients On Semaglutide Therapy,Unknown,COMPLETED,Point-of-care gastric ultrasound,DIAGNOSTIC_TEST,Other,Nils Vlaeminck,['Gastroparesis'],2024-04-16,2025-05-31,https://clinicaltrials.gov/study/NCT06292065
NCT02128932,Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as add-on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes,Unknown,COMPLETED,"semaglutide, insulin glargine","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2014-08-04,2015-09-03,https://clinicaltrials.gov/study/NCT02128932
NCT04639414,Combined Active Treatment in Type 2 Diabetes with NASH,Unknown,ACTIVE_NOT_RECRUITING,"Empagliflozin 10mg oral tablet / Semaglutide 1mg pen injector, Empagliflozin 10mg oral tablet and placebo pen injector matching semaglutide, Placebo matching empagliflozin and placebo pen injector matching semaglutide","DRUG, DRUG, DRUG",Other,German Diabetes Center,"['Type 2 Diabetes', 'Non-alcoholic Steatohepatitis (NASH)', 'Non-alcoholic Fatty Liver Disease (NAFLD)']",2021-03-26,2025-01-31,https://clinicaltrials.gov/study/NCT04639414
NCT06065540,"A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor",Unknown,ACTIVE_NOT_RECRUITING,"Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide","DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,['Type 2 Diabetes Mellitus'],2023-09-27,2025-11-17,https://clinicaltrials.gov/study/NCT06065540
NCT06987669,Gastric Emptying in Healthy Volunteers and GLP-1 Agonist Users,Unknown,NOT_YET_RECRUITING,Gastric Ultrasound,DIAGNOSTIC_TEST,Other,Clinica Alemana de Santiago,"['Diabetes Type 2', 'Obesity and Overweight']",2025-05-17,2026-12-31,https://clinicaltrials.gov/study/NCT06987669
NCT05303857,Analyse the Effect of Semaglutide on Vascular Structure and Function in Patients With Early Type 2 Diabetes,Unknown,COMPLETED,"Semaglutide Pen Injector, Placebo","DRUG, DRUG",Other,University of Erlangen-Nürnberg Medical School,"['Diabetes Mellitus, Type 2']",2022-03-03,2023-12-15,https://clinicaltrials.gov/study/NCT05303857
NCT05622045,"Does Personality Predict Patient Adherence, Health Behaviors, and Weight Loss Outcomes During the Latino Crossover Semaglutide Study (LCSS)? (Story-LCSS Project)",Unknown,ACTIVE_NOT_RECRUITING,Voice data,BEHAVIORAL,Other,Loma Linda University,"['Obesity', 'Body Weight Changes']",2023-02-01,2024-05-29,https://clinicaltrials.gov/study/NCT05622045
NCT06015893,Semaglutide Therapy for Alcohol Reduction (STAR),Unknown,RECRUITING,"Take Control, Semaglutide","BEHAVIORAL, DRUG",Other,National Institute on Drug Abuse (NIDA),"['Addiction', 'Alcohol Use Disorder']",2023-10-17,2030-12-31,https://clinicaltrials.gov/study/NCT06015893
NCT04885634,Semaglutide for the Reduction of Arrhythmia Burden in Overweight AF Patients,Unknown,WITHDRAWN,"Semaglutide Injectable Product, Placebo","DRUG, DRUG",Other,Axel Brandes,"['Atrial Fibrillation', 'Overweight and Obesity']",2022-10,2024-01,https://clinicaltrials.gov/study/NCT04885634
NCT05756764,Anti-obesity Pharmacotherapy and Inflammation,Unknown,ACTIVE_NOT_RECRUITING,"Semaglutide, Phentermine-Topiramate combination, Phentermine, Tirzepatide, Topiramate, Diethylpropion, Naltrexone/Bupropion, Liraglutide","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Louisiana State University Health Sciences Center in New Orleans,['Obesity'],2023-06-01,2026-01-30,https://clinicaltrials.gov/study/NCT05756764
NCT05071898,Pharmacogenetics of Response to GLP1R Agonists,Unknown,RECRUITING,Semaglutide Pen Injector [Ozempic],DRUG,Other,"University of Maryland, Baltimore","['Obesity', 'Diabetes Type 2']",2022-04-11,2026-11-30,https://clinicaltrials.gov/study/NCT05071898
NCT07171723,Studying the Influence of LEAP2 on Integrated Endocrine Control of Eating During Semaglutide Treatment,Unknown,RECRUITING,"Liver-Expressed Antimicrobial Peptide 2 (LEAP2), Placebo (saline)","BIOLOGICAL, OTHER",Other,"University Hospital, Gentofte, Copenhagen",['Obesity &Amp; Overweight'],2025-09-01,2025-12-14,https://clinicaltrials.gov/study/NCT07171723
NCT03611582,Research Study to Look at How Well Semaglutide is at Lowering Weight When Taken Together With an Intensive Lifestyle Program,Unknown,COMPLETED,"Semaglutide, Placebo (semaglutide)","DRUG, DRUG",Other,Novo Nordisk A/S,"['Overweight', 'Obesity']",2018-08-01,2020-03-18,https://clinicaltrials.gov/study/NCT03611582
NCT06659718,Emulation of the SOUL Diabetes Trial in Healthcare Claims,Unknown,COMPLETED,"Oral semaglutide, Sitagliptin","DRUG, DRUG",Other,Brigham and Women's Hospital,"['Diabetes Mellitus, Type 2']",2024-10-24,2025-02-13,https://clinicaltrials.gov/study/NCT06659718
NCT02849080,Efficacy and Safety of Oral Semaglutide Using a Flexible Dose Adjustment Based on Clinical Evaluation Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus.,Unknown,COMPLETED,"semaglutide, sitagliptin","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2016-09-20,2018-02-28,https://clinicaltrials.gov/study/NCT02849080
NCT05087342,Latino Semaglutide Study,Unknown,COMPLETED,"Semaglutide 2.4mg, Placebo","DRUG, DRUG",Other,Loma Linda University,"['Obesity', 'Obesity; Drug', 'Overweight or Obesity', 'Weight Loss', 'Weight Loss Trajectory', 'Weight, Body']",2022-12-13,2024-05-29,https://clinicaltrials.gov/study/NCT05087342
NCT04559815,"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Canada, as Part of Local Clinical Practice",Unknown,COMPLETED,Oral Semaglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2020-10-21,2022-09-14,https://clinicaltrials.gov/study/NCT04559815
NCT05220917,Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study,Unknown,UNKNOWN,"SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU","DRUG, DRUG, DRUG, DRUG",GLP-1 agonist,Brigham and Women's Hospital,"['Cardiovascular Events', 'Type2 Diabetes', 'Renal Disease']",2021-08-01,2024-07-31,https://clinicaltrials.gov/study/NCT05220917
NCT06400615,Study That Tests AD109 in Patients Taking GLP-1 Drugs,Unknown,COMPLETED,AD109,DRUG,Other,Apnimed,['OSA'],2024-05-20,2024-12-26,https://clinicaltrials.gov/study/NCT06400615
NCT07018544,"A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea",Unknown,ENROLLING_BY_INVITATION,semaglutide,OTHER,Other,Novo Nordisk A/S,['Obesity and Overweight'],2024-11-19,2027-02-28,https://clinicaltrials.gov/study/NCT07018544
NCT05751226,A Study in People With Overweight or Obesity to Test How Well Different Doses of BI 1820237 Are Tolerated When Given Alone or in Combination With Either Semaglutide or BI 456906,Unknown,COMPLETED,"BI 1820237, semaglutide, Placebo, BI 456906","DRUG, DRUG, DRUG, DRUG",Other,Boehringer Ingelheim,"['Healthy', 'Obesity']",2023-04-11,2024-08-01,https://clinicaltrials.gov/study/NCT05751226
NCT06771115,Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity,Unknown,COMPLETED,"VTX3232 Dose A, Placebo, VTX3232 Dose A in combination with semaglutide, Placebo in combination with semaglutide","DRUG, DRUG, DRUG, DRUG",Other,Zomagen Biosciences Ltd.,['Obesity'],2025-01-07,2025-09-10,https://clinicaltrials.gov/study/NCT06771115
NCT07226947,Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment,Unknown,RECRUITING,"Smartwatch activity and body composition monitor, General guidance on recommended exercise","DEVICE, BEHAVIORAL",Other,Massachusetts General Hospital,"['Obesity', 'Body Composition']",2025-11,2027-06,https://clinicaltrials.gov/study/NCT07226947
NCT04515849,A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"Cotadutide 100 micrograms, Cotadutide 300 micrograms, Cotadutide 600 micrograms, Semaglutide, Placebo","DRUG, DRUG, DRUG, DRUG, DRUG",Other,AstraZeneca,"['Type 2 Diabetes Mellitus', 'Chronic Kidney Diseases']",2020-08-31,2022-03-08,https://clinicaltrials.gov/study/NCT04515849
NCT05892432,Clinical Trial of Rybelsus (Semaglutide) Among Adults With Alcohol Use Disorder (AUD),Unknown,ACTIVE_NOT_RECRUITING,"Semaglutide 3 MG [Rybelsus], Semaglutide 7 MG [Rybelsus], Placebo","DRUG, DRUG, DRUG",Other,"University of Colorado, Denver",['Alcohol Use Disorder'],2024-01-11,2025-10-30,https://clinicaltrials.gov/study/NCT05892432
NCT06715514,"Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes",Unknown,RECRUITING,"GLP-1 Receptor Agonist, Menopausal Hormone Therapy","DRUG, DRUG",GLP-1 agonist,Lia Bally,"['Menopause', 'Type 2 Diabetes']",2025-02-18,2026-08-31,https://clinicaltrials.gov/study/NCT06715514
NCT03086330,Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to SGLT-2i in Subjects With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"Semaglutide, Placebo","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2017-03-15,2018-07-04,https://clinicaltrials.gov/study/NCT03086330
NCT05067621,Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease,Unknown,RECRUITING,"Semaglutide Pen Injector, Placebo","DRUG, DRUG",Other,Yale University,"['Type 2 Diabetes Mellitus', 'Impaired Glucose Tolerance', 'Non-Alcoholic Fatty Liver Disease', 'Obesity, Childhood']",2023-07-17,2026-12,https://clinicaltrials.gov/study/NCT05067621
NCT06863363,PEG-rhGH and Semaglutide Combination Therapy in Non-Diabetic Obese Adults,Unknown,NOT_YET_RECRUITING,"PEG-rhGH Injection + Semaglutide Injection, Semaglutide Injection","DRUG, DRUG",Other,Shanghai Zhongshan Hospital,['Non-diabetic Obesity'],,,https://clinicaltrials.gov/study/NCT06863363
NCT06410352,Effectiveness of Weight Loss Methods on Lifespan for Metabolic Syndrome,Unknown,RECRUITING,"Semaglutide, Empagliflozin, Minigastric bypass, Analimentary detoxication, Ramadan fast's weight loss","DRUG, PROCEDURE, DIETARY_SUPPLEMENT, BEHAVIORAL",Other,"University Medical Center, Kazakhstan",['Metabolic Syndrome'],2024-03-01,2025-09-30,https://clinicaltrials.gov/study/NCT06410352
NCT07139548,A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes,Unknown,NOT_YET_RECRUITING,"RAY1225, Semaglutide","DRUG, DRUG",Other,"Guangdong Raynovent Biotech Co., Ltd",['T2DM'],2025-08-31,2026-12-01,https://clinicaltrials.gov/study/NCT07139548
NCT07253285,A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight,Unknown,NOT_YET_RECRUITING,"Cagrilintide, Semaglutide, Placebo cagrilintide, Placebo semaglutide","DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Overweight', 'Obesity']",2026-01-08,2030-03-20,https://clinicaltrials.gov/study/NCT07253285
NCT06323161,A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Once-daily Basal Insulin With or Without Metformin,Unknown,COMPLETED,"Cagrilintide, Semaglutide, Placebo","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,['Type 2 Diabetes'],2024-03-26,2025-09-09,https://clinicaltrials.gov/study/NCT06323161
NCT06914141,Comparative Effectiveness of Tirzepatide Versus Semaglutide in Individuals With Heart Failure With Preserved Ejection Fraction,Unknown,ACTIVE_NOT_RECRUITING,"Tirzepatide, Semaglutide","DRUG, DRUG",Other,Brigham and Women's Hospital,"['Diabetes Mellitus, Type 2', 'HFpEF - Heart Failure With Preserved Ejection Fraction']",2025-01-14,2025-05,https://clinicaltrials.gov/study/NCT06914141
NCT02070510,A Trial Investigating the Influence of Oral Semaglutide on the Pharmacokinetics of Lisinopril and Warfarin in Healthy Subjects,Unknown,COMPLETED,"semaglutide, lisinopril, warfarin, placebo","DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Healthy']",2014-02-27,2014-08-20,https://clinicaltrials.gov/study/NCT02070510
NCT05984238,"A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2)",Unknown,UNKNOWN,"ReCET, Semaglutide, 1.0 mg/mL, Sham procedure","DEVICE, DRUG, OTHER",Other,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),"['Diabetes Mellitus, Type 2']",2023-08-03,2025-01,https://clinicaltrials.gov/study/NCT05984238
NCT07090343,Semaglutide in Patients Undergoing Transcatether Aortic Valve Replacement,Unknown,NOT_YET_RECRUITING,"Wegovy ®, Placebo","DRUG, DRUG",Other,Leiden University Medical Center,"['Aortic Stenosis', 'Heart Failure']",2026-04-01,2030-09-01,https://clinicaltrials.gov/study/NCT07090343
NCT06738979,A Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects,Unknown,NOT_YET_RECRUITING,"TQF3510 (Semaglutide Injection), Wegovy®","DRUG, DRUG",Other,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",['Obesity'],2025-03,2026-07,https://clinicaltrials.gov/study/NCT06738979
NCT05232708,A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide,Unknown,COMPLETED,"Semaglutide B, 1.34 mg/mL, Semaglutide D, 1.0 mg/mL, Semaglutide D, 1.0 mg/mL, Semaglutide B, 1.34 mg/mL","DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Healthy Volunteers (Diabetes Mellitus, Type 2)']",2022-01-19,2022-08-30,https://clinicaltrials.gov/study/NCT05232708
NCT05064735,Research Study Looking at How Well Semaglutide Works in People Suffering From Obesity and Knee Osteoarthritis,Unknown,COMPLETED,"semaglutide 2.4 mg, semaglutide 2.4 mg (placebo)","DRUG, DRUG",Other,Novo Nordisk A/S,['Obesity'],2021-10-01,2023-07-24,https://clinicaltrials.gov/study/NCT05064735
NCT04447859,16-week Flexible vs. 8-week Semaglutide Titration,Unknown,UNKNOWN,"Semaglutide, label recommended titration","DRUG, OTHER",Other,Tel-Aviv Sourasky Medical Center,['Diabetes type2'],2020-02-23,2022-05-10,https://clinicaltrials.gov/study/NCT04447859
NCT05230589,"A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Saudi Arabia, as Part of Local Clinical Practice",Unknown,COMPLETED,Oral semaglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2022-04-25,2023-03-13,https://clinicaltrials.gov/study/NCT05230589
NCT06409130,"Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease",Unknown,ACTIVE_NOT_RECRUITING,"NNC0194-0499, Semaglutide, NNC0194-0499 placebo, Semaglutide placebo (Group A), Cagrilintide + semaglutide, Cagrilintide, Cagrilintide placebo, Semaglutide placebo (Group B)","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,['Alcohol-related Liver Disease'],2024-05-20,2025-11-13,https://clinicaltrials.gov/study/NCT06409130
NCT04889183,SeMaglutide and Albuminuria Reduction Trial in Obese Individuals Without Diabetes,Unknown,COMPLETED,"Semaglutide, Placebo","DRUG, DRUG",Other,University Medical Center Groningen,"['Obesity', 'Albuminuria']",2022-03-14,2024-05-28,https://clinicaltrials.gov/study/NCT04889183
NCT03842202,A Research Study to Look at How Semaglutide Affects Gastric Emptying in People With Obesity,Unknown,COMPLETED,"Semaglutide, Placebo","DRUG, DRUG",Other,Novo Nordisk A/S,"['Overweight', 'Obesity']",2019-02-15,2019-11-04,https://clinicaltrials.gov/study/NCT03842202
NCT03951753,A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus (T2DM),Unknown,COMPLETED,"Tirzepatide, Semaglutide, Placebo","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2019-06-28,2021-04-08,https://clinicaltrials.gov/study/NCT03951753
NCT06083675,Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes,Unknown,WITHDRAWN,"Semaglutide, Empagliflozin, Metformin","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2024-01-26,2025-01-24,https://clinicaltrials.gov/study/NCT06083675
NCT07041983,24-h Energy Expenditure and Anti-obesity Medication,Unknown,NOT_YET_RECRUITING,anti obesity medication,DRUG,Other,University of Pisa,['Obesity'],2025-07-01,2026-06-01,https://clinicaltrials.gov/study/NCT07041983
NCT05013229,"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)",Unknown,COMPLETED,"IcoSema, Insulin glargine, insulin aspart","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2021-11-30,2023-11-14,https://clinicaltrials.gov/study/NCT05013229
NCT03600480,A Research Study of How NNC0174-0833 Taken With Semaglutide Works in People Who Are Overweight or Obese,Unknown,COMPLETED,"NNC0174-0833, Semaglutide, Placebo (NNC0174-0833)","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Obesity', 'Overweight']",2018-07-25,2020-06-12,https://clinicaltrials.gov/study/NCT03600480
NCT04251156,Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.,Unknown,COMPLETED,"Semaglutide, Placebo (semaglutide)","DRUG, DRUG",Other,Novo Nordisk A/S,"['Overweight', 'Obesity', 'Diabetes Mellitus, Type 2']",2020-12-08,2022-08-23,https://clinicaltrials.gov/study/NCT04251156
NCT05779644,"Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes Mellitus",Unknown,UNKNOWN,"Liraglutide, Semaglutide, Metformin","DRUG, DRUG, DRUG",Other,RenJi Hospital,"['Metformin', 'Obesity, Abdominal', 'Diabetes Mellitus, Type 2', 'Abdominal Fat', 'Non-Alcoholic Fatty Liver Disease', 'Metabolism Disorder, Glucose', 'Metabolism Disorder, Lipid']",2023-02-23,2025-02-23,https://clinicaltrials.gov/study/NCT05779644
NCT06739044,Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes,Unknown,COMPLETED,"Ozempic®, HDG1901","DRUG, DRUG",Other,"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.",['Type 2 Diabetes'],2023-09-20,2024-10-11,https://clinicaltrials.gov/study/NCT06739044
NCT03884075,"Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)",Unknown,RECRUITING,Semaglutide,DRUG,Other,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),"['Non-Alcoholic Steatohepatitis', 'Non-Alcoholic Fatty Liver Disease']",2019-07-24,2026-08-31,https://clinicaltrials.gov/study/NCT03884075
NCT05788965,Semaglutide in CFRD,Unknown,COMPLETED,Semaglutide,DRUG,Other,University of Minnesota,"['Cystic Fibrosis', 'Cystic Fibrosis-related Diabetes']",2023-04-30,2024-12-31,https://clinicaltrials.gov/study/NCT05788965
NCT05891587,Semaglutide Therapy for Alcohol Reduction - Tulsa,Unknown,RECRUITING,"Semaglutide, Placebo","DRUG, DRUG",Other,Oklahoma State University Center for Health Sciences,['Alcohol Use Disorder'],2023-07-07,2025-07,https://clinicaltrials.gov/study/NCT05891587
NCT05616013,Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese,Unknown,COMPLETED,"Bimagrumab, Semaglutide, Placebo","BIOLOGICAL, DRUG, OTHER",Other,Eli Lilly and Company,"['Obesity', 'Obese', 'Overweight or Obesity']",2022-11-16,2024-05-16,https://clinicaltrials.gov/study/NCT05616013
NCT06431308,Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events,Unknown,RECRUITING,nutritional intervention,BEHAVIORAL,Other,Ariel University,['Obesity; Drug'],2025-01-30,2026-02-01,https://clinicaltrials.gov/study/NCT06431308
NCT05569772,Semaglutide for the Treatment of Glucose Intolerance in Women with Prior Gestational Diabetes,Unknown,RECRUITING,"Semaglutide Pen Injector, Semaglutide placebo","DRUG, DRUG",Other,Universitaire Ziekenhuizen KU Leuven,['Glucose Intolerance After a Recent History of Gestational Diabetes'],2023-09-14,2028-07,https://clinicaltrials.gov/study/NCT05569772
NCT04880005,Digital Individualized and Collaborative Treatment of T2D in General Practice Based on Decision Aid,Unknown,RECRUITING,"Clinical decision support, Digital Lifestyle Coaching, Integration to Standard Electronic Health Record","BEHAVIORAL, BEHAVIORAL, BEHAVIORAL",Other,University of Southern Denmark,['Diabetes type2'],2021-06-01,2025-08-31,https://clinicaltrials.gov/study/NCT04880005
NCT05816057,A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus,Unknown,COMPLETED,semaglutide injection,BIOLOGICAL,Other,"Hangzhou Jiuyuan Gene Engineering Co. Ltd.,","['Diabetes Mellitus, Type 2']",2022-07-25,2023-07-25,https://clinicaltrials.gov/study/NCT05816057
NCT00851773,"Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian Subjects",Unknown,COMPLETED,"semaglutide, semaglutide, semaglutide, semaglutide, semaglutide, placebo, placebo, placebo, placebo, placebo","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Healthy']",2009-02,2009-10,https://clinicaltrials.gov/study/NCT00851773
NCT04624672,Treatment of GLP-1 for Diabetic Bariatric Patients,Unknown,TERMINATED,"Semaglutide (1 Mg Dose), Placebo","DRUG, DRUG",Other,Geisinger Clinic,"['Diabetes Mellitus, Type 2']",2021-08-25,2022-07-18,https://clinicaltrials.gov/study/NCT04624672
NCT04777396,A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE),Unknown,ACTIVE_NOT_RECRUITING,"Semagludtide, Placebo (semaglutide)","DRUG, DRUG",Other,Novo Nordisk A/S,"[""Early Alzheimer's Disease""]",2021-05-18,2025-09-16,https://clinicaltrials.gov/study/NCT04777396
NCT05132088,Research Study to Investigate How Well Semaglutide Tablets Taken Once Daily Work in East Asian People Who Are Overweight or Living With Obesity,Unknown,COMPLETED,"semaglutide 50 mg, placebo (semaglutide)","DRUG, DRUG",Other,Novo Nordisk A/S,['Overweight and Obesity'],2021-11-16,2023-07-11,https://clinicaltrials.gov/study/NCT05132088
NCT06648031,"Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants",Unknown,ACTIVE_NOT_RECRUITING,"Arm 1 - DehydraTECH-CBD alone, Arm 2 - DehydraTECH-semaglutide alone, Arm 3 - DehydraTECH-CBD in combination with DehydraTECH-semaglutide, Arm 4 - Rybelsus medication (semaglutide) alone, Arm 5- Tirzepatide","DRUG, DRUG, DRUG, DRUG, DRUG",Other,Lexaria Bioscience Corp.,['Type2diabetes'],2024-12-04,2025-06-30,https://clinicaltrials.gov/study/NCT06648031
NCT05819853,Role of Semaglutide in Restoring Ovulation in Youth and Adults With Polycystic Ovary Syndrome,Unknown,RECRUITING,Semaglutide Injectable Product (Wegovy and/or Ozempic),DRUG,Other,"University of Colorado, Denver","['PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries', 'Obese']",2023-11-03,2028-02-01,https://clinicaltrials.gov/study/NCT05819853
NCT06154486,Evaluation of Gastric Content of Volunteers Fasting and Using Semaglutide: an Observational and Cross-sectional Study,Unknown,COMPLETED,semaglutide use,DRUG,Other,Hospital Israelita Albert Einstein,"['Pneumonia, Aspiration', 'Anesthesia']",2023-06-19,2023-06-19,https://clinicaltrials.gov/study/NCT06154486
NCT00696657,A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide,Unknown,COMPLETED,"semaglutide, semaglutide, semaglutide, semaglutide, semaglutide, semaglutide, placebo, placebo, placebo, placebo, placebo, liraglutide, liraglutide","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2008-06-03,2009-02-05,https://clinicaltrials.gov/study/NCT00696657
NCT06221969,A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor,Unknown,ACTIVE_NOT_RECRUITING,"Cagrilintide, Semaglutide, Tirzepatide","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,['Type 2 Diabetes'],2024-01-16,2026-02-20,https://clinicaltrials.gov/study/NCT06221969
NCT06937060,Effect of Semaglutide in Patients With Psoriasis and Obesity,Unknown,RECRUITING,semaglutide,BIOLOGICAL,Other,The University of Hong Kong,"['Psoriasis (PsO)', 'Obesity and Overweight']",2025-03-20,2026-07-31,https://clinicaltrials.gov/study/NCT06937060
NCT07094568,Tirzepatide vs Liraglutide in Bone,Unknown,RECRUITING,,,Unknown,National and Kapodistrian University of Athens,['Obesity (Disorder)'],2025-05-23,2026-07-30,https://clinicaltrials.gov/study/NCT07094568
NCT07203677,Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT),Unknown,COMPLETED,"Initiation of tirzepatide, Initiation of sitagliptin","DRUG, DRUG",Other,Brigham and Women's Hospital,"['Type2 Diabetes Mellitus', 'Atherosclerotic Cardiovascular Disease']",2025-09-19,2025-10-15,https://clinicaltrials.gov/study/NCT07203677
NCT06515418,Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over,Unknown,TERMINATED,"Oral Azelaprag (BGE-105), Oral Placebo for Azelaprag (BGE-105), Tirzepatide, Tirzepatide Placebo","DRUG, DRUG, DRUG, DRUG",Other,"BioAge Labs, Inc.",['Obesity'],2024-06-27,2025-02-06,https://clinicaltrials.gov/study/NCT06515418
NCT07046819,Tirzepatide in MetALD,Unknown,NOT_YET_RECRUITING,"Tirzepatide, Placebo","DRUG, OTHER",Other,National Institute on Alcohol Abuse and Alcoholism (NIAAA),"['Metabolic Alcohol-associated Liver Disease', 'Alcohol Use Disorder']",2025-12-10,2026-07-30,https://clinicaltrials.gov/study/NCT07046819
NCT04847557,A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial,Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, OTHER",Other,Eli Lilly and Company,"['Obesity', 'Heart Failure With Preserved Ejection Fraction (HFpEF)']",2021-04-20,2024-07-02,https://clinicaltrials.gov/study/NCT04847557
NCT06857942,A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO),Unknown,RECRUITING,Tirzepatide,DRUG,Other,Eli Lilly and Company,"['Psoriasis', 'Overweight or Obesity']",2025-03-19,2028-05,https://clinicaltrials.gov/study/NCT06857942
NCT03311724,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes,Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes'],2017-10-19,2018-04-24,https://clinicaltrials.gov/study/NCT03311724
NCT03861039,A Long-term Safety Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes,Unknown,COMPLETED,"Tirzepatide, Oral antihyperglycemic medication (OAM)","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes Mellitus'],2019-03-30,2021-01-26,https://clinicaltrials.gov/study/NCT03861039
NCT07228741,Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity,Unknown,NOT_YET_RECRUITING,"Tirzepatide, Resistance Exercise, Lifestyle Counseling","DRUG, BEHAVIORAL, BEHAVIORAL",Other,St. Jude Children's Research Hospital,"['Acute Lymphoblastic Leukemia', 'Obesity']",2026-01,2027-11,https://clinicaltrials.gov/study/NCT07228741
NCT06759701,Pre-Surgical Tirzepatide-Assisted Weight Loss in Overweight and Obese Men With Intermediate Risk Prostate Cancer: A Pilot Feasibility Study,Phase 1,RECRUITING,Tirzepatide,DRUG,Other,M.D. Anderson Cancer Center,"['Diabetes', 'Prostate Cancer']",2025-07-02,2026-12-31,https://clinicaltrials.gov/study/NCT06759701
NCT04407234,A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide,Unknown,COMPLETED,"Tirzepatide, Acetaminophen","DRUG, DRUG",Other,Eli Lilly and Company,"['Overweight', 'Obesity', 'Diabetes Mellitus, Type 2']",2020-09-15,2021-01-07,https://clinicaltrials.gov/study/NCT04407234
NCT03482024,A Study of Tirzepatide (LY3298176) in Participants With Impaired Kidney Function,Unknown,COMPLETED,Tirzepatide,DRUG,Other,Eli Lilly and Company,"['Renal Insufficiency', 'End Stage Renal Disease']",2018-03-30,2019-08-19,https://clinicaltrials.gov/study/NCT03482024
NCT07096908,Tirzepatide Use in People With Obesity and Type 1 Diabetes,Unknown,NOT_YET_RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,Dasman Diabetes Institute,"['Type1diabetes', 'Obesity']",2025-07-31,2028-02-25,https://clinicaltrials.gov/study/NCT07096908
NCT02759107,A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM),Unknown,COMPLETED,"Tirzepatide, Placebo, Dulaglutide","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Healthy', 'Type 2 Diabetes Mellitus (T2DM)']",2016-05-11,2017-06-26,https://clinicaltrials.gov/study/NCT02759107
NCT06937099,Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight,Unknown,RECRUITING,"Mirikizumab, Mirikizumab, Tirzepatide, Placebo","DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"[""Crohn's Disease"", 'Obesity or Overweight']",2025-06-26,2028-05,https://clinicaltrials.gov/study/NCT06937099
NCT05433584,A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes,Unknown,ACTIVE_NOT_RECRUITING,"Tirzepatide, Antihyperglycemic medication","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes'],2022-08-01,2025-10,https://clinicaltrials.gov/study/NCT05433584
NCT05766358,Role Of Metabolic Adaptation In Weight Regain,Unknown,COMPLETED,"Intensive lifestyle change therapy, Tirzepatide","BEHAVIORAL, DRUG",Other,Pennington Biomedical Research Center,"['Weight Loss', 'Weight Gain', 'Obesity']",2022-10-06,2024-05-24,https://clinicaltrials.gov/study/NCT05766358
NCT06864026,A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA),Unknown,RECRUITING,Tirzepatide,DRUG,Other,Eli Lilly and Company,"['Psoriatic Arthritis', 'Overweight or Obesity']",2025-03-06,2027-11,https://clinicaltrials.gov/study/NCT06864026
NCT03940742,A Study of Tirzepatide in Participants With Impaired Liver Function,Unknown,COMPLETED,Tirzepatide,DRUG,Other,Eli Lilly and Company,['Hepatic Insufficiency'],2019-07-22,2020-09-22,https://clinicaltrials.gov/study/NCT03940742
NCT04660643,A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss,Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, OTHER",Other,Eli Lilly and Company,"['Obesity', 'Overweight']",2021-03-29,2023-04-25,https://clinicaltrials.gov/study/NCT04660643
NCT04657003,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight,Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, OTHER",Other,Eli Lilly and Company,"['Type 2 Diabetes', 'Overweight', 'Obesity']",2021-03-29,2023-03-16,https://clinicaltrials.gov/study/NCT04657003
NCT06916065,A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity,Unknown,ACTIVE_NOT_RECRUITING,"Eloralintide and Tirzepatide, Eloralintide","DRUG, DRUG",Other,Eli Lilly and Company,"['Overweight', 'Obesity']",2025-04-09,2025-12,https://clinicaltrials.gov/study/NCT06916065
NCT06657209,Normal-weight Diabetes: Adipocyte-directed Therapy with Pioglitazone or Tirzepatide,Unknown,NOT_YET_RECRUITING,"Insulin resistance testing, OGTT, Fat biopsy, DXA scan, MRI, 1H-MRS, Tirzepatide, Pioglitazone","PROCEDURE, PROCEDURE, PROCEDURE, RADIATION, PROCEDURE, PROCEDURE, DRUG, DRUG",Other,Stanford University,"['Diabetes Mellitus, Type 2']",2024-12-15,2027-12-15,https://clinicaltrials.gov/study/NCT06657209
NCT04311411,A Study of Tirzepatide in Overweight and Very Overweight Participants,Unknown,COMPLETED,"Tirzepatide, Placebo, Liraglutide","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Obesity', 'Overweight']",2020-08-24,2022-12-16,https://clinicaltrials.gov/study/NCT04311411
NCT07257484,Tirzepatide's Role in Postmenopausal HR+ Breast Cancer Survivors,Unknown,NOT_YET_RECRUITING,Tirzepatide,DRUG,Other,Weill Medical College of Cornell University,"['Obesity (Disorder)', 'Breast Cancer']",2026-01-05,2027-07-06,https://clinicaltrials.gov/study/NCT07257484
NCT07247084,A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK),Unknown,NOT_YET_RECRUITING,"Tirzepatide, Standard of Care","DRUG, OTHER",Other,Eli Lilly and Company,['Obesity'],2025-12,2029-07,https://clinicaltrials.gov/study/NCT07247084
NCT07065552,Tirzepatide in Obesity-Driven Endometrial Cancer,Phase 1,NOT_YET_RECRUITING,Tirzepatide,DRUG,Other,UNC Lineberger Comprehensive Cancer Center,"['Endometrial Cancer', 'Obesity']",2025-12,2028-07,https://clinicaltrials.gov/study/NCT07065552
NCT06451458,ECHO for Diabetes and Multiple Chronic Conditions Study,Unknown,ENROLLING_BY_INVITATION,"ECHO program for DMMC, Usual care","BEHAVIORAL, BEHAVIORAL",Other,University of New Mexico,"['Diabetes Mellitus', 'Chronic Disease']",2024-10-16,2026-09-30,https://clinicaltrials.gov/study/NCT06451458
NCT07265752,Tirzepatide for the Treatment of Cannabis Use Disorder,Unknown,NOT_YET_RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,Brigham and Women's Hospital,['Cannabis Use Disorder'],2026-07-01,2028-06-30,https://clinicaltrials.gov/study/NCT07265752
NCT06901349,"A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes",Unknown,WITHDRAWN,"Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo","DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Obesity', 'Overweight']",2025-05-23,2025-06-10,https://clinicaltrials.gov/study/NCT06901349
NCT06737042,Efficacy and Safety of GZR18 Every 2 Weeks Versus Tirzepatide and Placebo in Obese or Overweight Participants,Unknown,NOT_YET_RECRUITING,"GZR18, Tirzepatide","DRUG, DRUG",Other,"Gan and Lee Pharmaceuticals, USA",['Obesity and Overweight'],2025-02-12,2026-02-09,https://clinicaltrials.gov/study/NCT06737042
NCT06635057,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan,Unknown,RECRUITING,Tirzepatide,DRUG,Other,Eli Lilly and Company,['Type 2 Diabetes'],2024-10-11,2026-04,https://clinicaltrials.gov/study/NCT06635057
NCT06914895,A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight,Unknown,RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Type 1 Diabetes', 'Obesity', 'Overweight']",2025-04-25,2027-05,https://clinicaltrials.gov/study/NCT06914895
NCT06582875,Glucagon-Like Peptide-1 Receptor Agonist in ADPKD,Unknown,RECRUITING,"Tirzepatide, Placebo","DRUG, OTHER",Other,"University of Colorado, Denver","['Autosomal Dominant Polycystic Kidney', 'Obesity']",2025-03-06,2029-06-30,https://clinicaltrials.gov/study/NCT06582875
NCT06565611,A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity,Unknown,ACTIVE_NOT_RECRUITING,"bremelanotide, tirzepatide","DRUG, DRUG",Other,"Palatin Technologies, Inc",['Obesity'],2024-08-05,2025-02-05,https://clinicaltrials.gov/study/NCT06565611
NCT06180616,Tirzepatide for the Treatment of Concurrent Type 1 Diabetes and Overweight or Obesity,Unknown,NOT_YET_RECRUITING,Tirzepatide,DRUG,Other,Royal North Shore Hospital,"['Type 1 Diabetes Mellitus', 'Overweight and Obesity']",2026-12,2028-12,https://clinicaltrials.gov/study/NCT06180616
NCT06162715,GLP-1 Receptor Agonists Post-Bariatric Surgery (GRABS) Pilot Trial,Unknown,ENROLLING_BY_INVITATION,"Tirzepatide, Standard of Care post-gastric bypass","DRUG, OTHER",Other,Vanderbilt University Medical Center,"['Severe Obesity', 'Obesity', 'BMI Greater Than 30']",2024-10-30,2027-01,https://clinicaltrials.gov/study/NCT06162715
NCT06721507,2024 Tirzepatide-Bariatric Surgery,Unknown,RECRUITING,"tirzepatide, Standard of Care","DRUG, BEHAVIORAL",Other,Marlene Starr,"['Obesity and Obesity-related Medical Conditions', 'Bariatric Surgery']",2025-03-27,2026-12-31,https://clinicaltrials.gov/study/NCT06721507
NCT06603571,"A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes",Unknown,ACTIVE_NOT_RECRUITING,"LY3841136, Tirzepatide, Placebo","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Obesity', 'Overweight']",2024-09-20,2026-06,https://clinicaltrials.gov/study/NCT06603571
NCT07165028,A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes),Unknown,RECRUITING,"Tirzepatide, Retatrutide, Placebo","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,['Metabolic Dysfunction-Associated Steatotic Liver Disease'],2025-10-15,2030-08,https://clinicaltrials.gov/study/NCT07165028
NCT05706506,A Study of Tirzepatide (LY3298176) in Adults With Type 2 Diabetes Switching From a GLP-1 RA (SURPASS-SWITCH-2),Unknown,COMPLETED,Tirzepatide,DRUG,Other,Eli Lilly and Company,"['Type 2 Diabetes', 'Diabetes Mellitus, Type 2']",2023-03-08,2023-10-31,https://clinicaltrials.gov/study/NCT05706506
NCT07088718,Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data,Unknown,COMPLETED,"Tirzepatide, Dulaglutide","DRUG, DRUG",Other,Brigham and Women's Hospital,"['Type 2 Diabetes', 'Major Adverse Cardiac Events', 'Cardiovascular (CV) Risk']",2024-10-01,2025-07-30,https://clinicaltrials.gov/study/NCT07088718
NCT04039503,A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin,Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes'],2019-08-30,2020-12-22,https://clinicaltrials.gov/study/NCT04039503
NCT05556512,A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity,Unknown,ACTIVE_NOT_RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Obesity', 'Overweight']",2022-10-11,2027-10,https://clinicaltrials.gov/study/NCT05556512
NCT07191873,Tirzepatide in Idiopathic Intracranial Hypertension Trial,Unknown,NOT_YET_RECRUITING,"Tirzepatide, Tirzepatide Placebo","DRUG, DRUG",Other,Duke University,['Idiopathic Intracranial Hypertension (IIH)'],2026-02,2027-02,https://clinicaltrials.gov/study/NCT07191873
NCT06517212,Tirzepatide Weight Loss for MRD+ Early Breast Cancer,Unknown,RECRUITING,Tirzepatide,DRUG,Other,Baylor Research Institute,"['Breast Cancer', 'Breast Neoplasms', 'Breast Cancers']",2024-11-26,2029-08-31,https://clinicaltrials.gov/study/NCT06517212
NCT06533527,Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy,Unknown,COMPLETED,GLP-1 medication,DRUG,GLP-1 agonist,The Cleveland Clinic,"['Diabetes Mellitus, Type 2', 'Obesity', 'Gastroparesis']",2024-07-31,2025-05-20,https://clinicaltrials.gov/study/NCT06533527
NCT07107334,A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial Neoplasia,Unknown,NOT_YET_RECRUITING,Glucagon-like peptide 1 receptor agonist,DRUG,Other,University of Florida,['Endometrioid Endometrial Adenocarcinoma'],2025-11,2028-11,https://clinicaltrials.gov/study/NCT07107334
NCT07095517,"Pathways, Risk Factors, and mOleculeS to Prevent Early-onset Colorectal Tumors",Unknown,NOT_YET_RECRUITING,Tirzepatide,DRUG,Other,Massachusetts General Hospital,"['Colorectal Cancer Prevention', 'Colorectal Adenoma']",2025-12-01,2026-08-31,https://clinicaltrials.gov/study/NCT07095517
NCT06374875,Fibrosis Lessens After Metabolic Surgery,Unknown,RECRUITING,"Metabolic surgery, Incretin-Based Therapy","PROCEDURE, DRUG",Other,Ali Aminian,"['Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)', 'Non-Alcoholic Fatty Liver Disease', 'Metabolic Dysfunction-Associated Steatohepatitis (MASH)', 'Liver Fibrosis', 'Obesity']",2024-07-11,2029-05-31,https://clinicaltrials.gov/study/NCT06374875
NCT06301256,Evaluate the Efficacy of TIRZEPATIDE for the Treatment of Moderate to Severe HS Hidradenitis Suppurativa,Unknown,NOT_YET_RECRUITING,TIRZEPATIDE,DRUG,Other,"Florida Academic Centers Research and Education, LLC",['Hidradenitis Suppurativa'],2024-03-11,2025-03-11,https://clinicaltrials.gov/study/NCT06301256
NCT06439277,A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2),Unknown,RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Obesity', 'Weight Gain']",2024-06-03,2027-10,https://clinicaltrials.gov/study/NCT06439277
NCT06727331,Study of Tirzepatide for Recovery and Alcohol Use Management,Unknown,RECRUITING,"Tirzepatide, Saline Placebo","DRUG, OTHER",Other,Brigham and Women's Hospital,['Alcohol Use Disorder (AUD)'],2025-09-15,2026-05,https://clinicaltrials.gov/study/NCT06727331
NCT06901245,"Tirzepatide in PWS, HO and GNSO",Unknown,RECRUITING,Tirzepatide,DRUG,Other,Grace Kim,"['Prader-Willi Syndrome', 'Hypothalamic Obesity', 'Obesity/Therapy']",2025-05-01,2026-06,https://clinicaltrials.gov/study/NCT06901245
NCT06885736,LEAN Mass Preservation With Resistance Exercise and Protein During Semaglutide/Tirzepatide Therapy,Unknown,NOT_YET_RECRUITING,"Resistance exercise, Protein Intake, Resistance exercise + protein intake","BEHAVIORAL, DIETARY_SUPPLEMENT, COMBINATION_PRODUCT",Other,Dasman Diabetes Institute,['Obesity'],2025-08-10,2029-08-30,https://clinicaltrials.gov/study/NCT06885736
NCT06861439,GLP-1s to Enhance Lasting Optimal Weight,Unknown,ACTIVE_NOT_RECRUITING,Tirzepatide,DRUG,Other,Wake Forest University Health Sciences,['Obesity'],2025-07-07,2026-09-30,https://clinicaltrials.gov/study/NCT06861439
NCT06779929,Emulation of the Study of Tirzepatide Compared with Dulaglutide on Major Cardiovascular Events in Participants with Type 2 Diabetes (SURPASS-CVOT),Unknown,ACTIVE_NOT_RECRUITING,"Tirzepatide, Dulaglutide","DRUG, DRUG",Other,Brigham and Women's Hospital,['Type 2 Diabetes'],2024-11-01,2025-01-30,https://clinicaltrials.gov/study/NCT06779929
NCT05822544,"Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes",Unknown,RECRUITING,"TLC-6740 Oral Solution, Placebo Oral Solution, TLC-6740 Tablet, Drug Metabolizing Enzyme, Tirzepatide, Placebo Tablet","DRUG, OTHER, DRUG, DRUG, DRUG, OTHER",Other,"OrsoBio, Inc","['Healthy Subjects', 'Obesity', 'Type 2 Diabetes']",2023-04-22,2025-10,https://clinicaltrials.gov/study/NCT05822544
NCT07179120,Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health,Unknown,NOT_YET_RECRUITING,"Semaglutide (Rybelsus®), Tirzepatide, Standardized Lifestyle Intervention","DRUG, DRUG, BEHAVIORAL",Other,First Affiliated Hospital of Wenzhou Medical University,['Obesity-related Male Infertility'],2026-05-01,2026-08-12,https://clinicaltrials.gov/study/NCT07179120
NCT06934642,Effect of Tirzepatide on Markers of MASLD in Patients With Obesity,Phase 1,RECRUITING,Tirzepatide,DRUG,Other,University of New Mexico,"['MASLD', 'Obesity']",2025-06-30,2026-08,https://clinicaltrials.gov/study/NCT06934642
NCT05582096,A Study of LY3457263 in Obese Participants,Unknown,COMPLETED,"LY3457263, Tirzepatide, Placebo","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Overweight', 'Obesity']",2022-11-11,2023-06-08,https://clinicaltrials.gov/study/NCT05582096
NCT04537923,A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin,Unknown,COMPLETED,"Tirzepatide, Insulin Lispro (U100)","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes'],2020-10-19,2022-10-11,https://clinicaltrials.gov/study/NCT04537923
NCT06976853,Moving Beyond Inflammation as a Therapeutic Target for Crohn's Disease,Unknown,RECRUITING,"Tirzepatide, Standard of care treatment","DRUG, DRUG",Other,Washington University School of Medicine,['Crohn Disease (CD)'],2025-05-13,2028-05,https://clinicaltrials.gov/study/NCT06976853
NCT06751589,A Study of a Weight Loss Intervention in People With Endometrial Cancer,Phase 1,RECRUITING,Tirzepatide,DRUG,Other,Memorial Sloan Kettering Cancer Center,['Endometrial Cancer'],2024-12-19,2026-12,https://clinicaltrials.gov/study/NCT06751589
NCT07229170,Changes in Taste and Eating Habits Associated With GLP-1 Agonists in Weight Loss Patients,Unknown,NOT_YET_RECRUITING,,,Unknown,San Raffaele Telematic University,"['Obesity & Overweight', 'Taste Alterations', 'Weight Loss', 'Eating Behavior Changes']",2025-12-01,2027-01-01,https://clinicaltrials.gov/study/NCT07229170
NCT04166773,A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH),Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Nonalcoholic Steatohepatitis'],2019-11-19,2023-12-11,https://clinicaltrials.gov/study/NCT04166773
NCT06893211,Effect of Tirzepatide on Brown Adipose Tissue in Obesity,Unknown,ACTIVE_NOT_RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,University Medical Centre Ljubljana,['Obesity'],2025-03-18,2025-11,https://clinicaltrials.gov/study/NCT06893211
NCT03375463,A Study of Tirzepatide (LY3298176) in Healthy Participants,Unknown,COMPLETED,"Tirzepatide, Tirzepatide, Placebo, Tirzepatide","DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,['Healthy'],2017-12-19,2018-12-27,https://clinicaltrials.gov/study/NCT03375463
NCT07096063,Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk,Unknown,COMPLETED,"Tirzepatide, Dulaglutide, Semaglutide, Sitagliptin","DRUG, DRUG, DRUG, DRUG",Other,Brigham and Women's Hospital,"['Type 2 Diabetes', 'Overweight', 'Cardiovascular (CV) Risk']",2024-10-01,2025-07-15,https://clinicaltrials.gov/study/NCT07096063
NCT07091734,Tirzepatide for Partial Lipodystrophy Treatment: A New Horizon in 2024,Unknown,RECRUITING,"Tirzepatide, Usual care medications","DRUG, DRUG",Other,University of Michigan,"['Lipodystrophy, Partial']",2025-09-08,2029-09,https://clinicaltrials.gov/study/NCT07091734
NCT04235959,A Study of Tirzepatide in Chinese Participants With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2020-10-21,2021-08-17,https://clinicaltrials.gov/study/NCT04235959
NCT06605703,A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial),Unknown,RECRUITING,"WW Clinic, Bupropion-Naltrexone, Bupropion-Naltrexone-Metformin","BEHAVIORAL, DRUG, DRUG",Other,"Michelle Cardel, PhD, MS, RD","['Obesity', 'Overweight']",2024-09-18,2025-05,https://clinicaltrials.gov/study/NCT06605703
NCT06965413,"A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity",Unknown,ACTIVE_NOT_RECRUITING,"RO7204239, RO7204239 Matching Placebo, Tirzepatide","DRUG, DRUG, DRUG",Other,Hoffmann-La Roche,"['Obesity', 'Overweight', 'Overweight With One Weight Related Comorbidity']",2025-05-05,2026-08-21,https://clinicaltrials.gov/study/NCT06965413
NCT07128082,The Long COVID Treatment Trial,Unknown,RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,Scripps Translational Science Institute,['Long COVID'],2025-10-30,2026-11,https://clinicaltrials.gov/study/NCT07128082
NCT06734273,Randomized Control Trial of Sleeve Gastrectomy with Tirzepatide in Maximizing Weight Loss,Phase 1,RECRUITING,"Mounjaro, Sleeve Gastrectomy","DRUG, PROCEDURE",Other,Nicholas Skertich,['Obesity and Obesity-related Medical Conditions'],2025-03-10,2027-03,https://clinicaltrials.gov/study/NCT06734273
NCT06732245,Safety and Efficacy of NA-931 and Tirzepatide in Adults Who Are Overweight or Obese,Unknown,NOT_YET_RECRUITING,"NA-931, Tirzepatide, Tirzepatide, NA-931, NA-931, NA-931, NA-931 150 mg + no Tirzepatide, NA-931, NA-931","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,"Biomed Industries, Inc.",['Obesity and Overweight'],2025-03-15,2026-08-15,https://clinicaltrials.gov/study/NCT06732245
NCT06534411,"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both",Unknown,ACTIVE_NOT_RECRUITING,"Cagrilintide, Semaglutide, Tirzepatide","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2024-11-05,2026-06-02,https://clinicaltrials.gov/study/NCT06534411
NCT05564039,A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH),Unknown,COMPLETED,"Tirzepatide, Dulaglutide","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes'],2022-11-30,2024-07-15,https://clinicaltrials.gov/study/NCT05564039
NCT07176663,Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure,Unknown,NOT_YET_RECRUITING,Tirzepatide,DRUG,Other,Shahid Beheshti University of Medical Sciences,['Obesity'],2025-11-01,2026-04-01,https://clinicaltrials.gov/study/NCT07176663
NCT04657016,A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program,Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, OTHER",Other,Eli Lilly and Company,"['Obesity', 'Overweight']",2021-03-29,2023-04-20,https://clinicaltrials.gov/study/NCT04657016
NCT06297616,A Study of LY3841136 in Japanese Participants With Obesity or Overweight,Unknown,ACTIVE_NOT_RECRUITING,"LY3841136, LY3841136-Placebo, Tirzepatide, Tirzepatide-Placebo","DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Obesity', 'Overweight']",2024-04-15,2025-11,https://clinicaltrials.gov/study/NCT06297616
NCT06854614,Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial),Unknown,RECRUITING,"Comprehensive weight loss, Enhanced lifestyle changes, Phentermine-Topiramate, Naltrexone-Bupropion Combination, Orlistat","OTHER, OTHER, DRUG, DRUG, DRUG",Other,The Cleveland Clinic,['Obesity'],2025-03-01,2025-12-31,https://clinicaltrials.gov/study/NCT06854614
NCT07244445,Pistachio Intake and Nutrition-Related Outcomes in Individuals on GLP-1 Therapy,Unknown,NOT_YET_RECRUITING,"Pistachios, Dual-energy X-ray absorptiometry (DEXA) scans","DIETARY_SUPPLEMENT, PROCEDURE",Dual agonist,"Ian J. Neeland, MD","['Dietary Change', 'Obesity & Overweight', 'Food Acceptance']",2026-01-02,2027-12,https://clinicaltrials.gov/study/NCT07244445
NCT07154719,GLP-1R Actions on Muscle and the Skeleton,Unknown,NOT_YET_RECRUITING,"Tirzepatide, Lifestyle toolkit","DRUG, BEHAVIORAL",Other,Pennington Biomedical Research Center,"['Musculoskeletal Abnormalities', 'Obesity', 'Sarcopenic Obesity', 'Osteoporosis', 'Drug Effect']",2025-09-01,2026-03-01,https://clinicaltrials.gov/study/NCT07154719
NCT06856928,Impact of Antiobesity Medications on Appetite and Appetite-related Hormones and Metabolites.,Unknown,NOT_YET_RECRUITING,Meal Challenge,OTHER,Other,"University of Colorado, Denver",['Obesity; Drug'],2025-03,2026-12,https://clinicaltrials.gov/study/NCT06856928
NCT05412004,Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea,Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Obstructive Sleep Apnea', 'Obesity']",2022-06-21,2024-03-12,https://clinicaltrials.gov/study/NCT05412004
NCT06373146,A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity,Unknown,ACTIVE_NOT_RECRUITING,"Tirzepatide, Mibavademab, Tirzepatide-Placebo, Mibavademab-Placebo","DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,['Obesity'],2024-04-24,2025-12,https://clinicaltrials.gov/study/NCT06373146
NCT06914154,Emulation of the SUMMIT Heart Failure Trial in Healthcare Claims Data,Unknown,ACTIVE_NOT_RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,Brigham and Women's Hospital,"['Diabetes Mellitus, Type 2', 'Heart Failure With Preserved Ejection Fraction (HFPEF)']",2025-01-14,2025-05,https://clinicaltrials.gov/study/NCT06914154
NCT06073184,Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the Endometrium,Unknown,NOT_YET_RECRUITING,"Mounjaro, Mirena","DRUG, DRUG",Other,"University Health Network, Toronto","['Endometrial Cancer', 'Atypical Hyperplasia']",2025-08,2027-02,https://clinicaltrials.gov/study/NCT06073184
NCT06847399,Efficacy and Safety of Tirzepatide Versus Placebo or Lisdexamfetamine Dimesylate for Binge-Eating Disorder,Unknown,RECRUITING,"Tirzepatide, Lisdexamfetamine Dimesylate, Guided self-help cognitive behavioral therapy, Placebo (oral), Placebo (injection)","DRUG, DRUG, BEHAVIORAL, DRUG, DRUG",Other,Johns Hopkins University,"['Obesity and Overweight', 'Binge Eating Disorder']",2025-09-17,2027-12-01,https://clinicaltrials.gov/study/NCT06847399
NCT07000955,Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity,Unknown,RECRUITING,"Tirzepatide, Placebo, IBI362","DRUG, DRUG, DRUG",Other,Innovent Biologics (Suzhou) Co. Ltd.,['Obesity'],2025-06-17,2026-12-01,https://clinicaltrials.gov/study/NCT07000955
NCT05812183,Gastric Sleeve-Induced Weight Loss on Shortness of Breath in Obesity,Unknown,WITHDRAWN,"Bariatric surgery, Medical weight loss","DEVICE, DRUG",Other,"University of California, Los Angeles","['Dyspnea', 'Quality of Life']",2023-07-09,2025-02-12,https://clinicaltrials.gov/study/NCT05812183
NCT06897475,A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide,Unknown,RECRUITING,"LY3457263, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes'],2025-03-28,2026-12,https://clinicaltrials.gov/study/NCT06897475
NCT06745128,Tirzepatide for Obesity and Meth Use Disorder,Unknown,ACTIVE_NOT_RECRUITING,Tirzepatide,DRUG,Other,University of Texas Southwestern Medical Center,"['Obesity', 'Methamphetamine Use Disorder']",2025-02-03,2026-03-31,https://clinicaltrials.gov/study/NCT06745128
NCT04311424,Study of Tirzepatide in Healthy Participants,Unknown,COMPLETED,14C Tirzepatide,DRUG,Other,Eli Lilly and Company,['Healthy'],2020-07-28,2020-10-02,https://clinicaltrials.gov/study/NCT04311424
NCT07156331,Research on Effects of Drugs on Body Composition and Function With Imaging in Diabetes,Unknown,NOT_YET_RECRUITING,,,Unknown,Kristin Clemens,['Type 2 Diabetes'],2025-10-01,2027-10-01,https://clinicaltrials.gov/study/NCT07156331
NCT06774079,Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients,Unknown,RECRUITING,"Tirzepatide, Mediterranean diet","DRUG, BEHAVIORAL",Other,University of Miami,['Crohn Disease'],2025-03-05,2026-03-05,https://clinicaltrials.gov/study/NCT06774079
NCT06811324,Effects of Tirzepatide on Muscle and Vascular Health in Obese Older Adults,Unknown,NOT_YET_RECRUITING,Tirzepatide,DRUG,Other,The University of Texas Health Science Center at San Antonio,"['Obesity Prevention', 'Sarcopenia in Elderly', 'Cardiovascular Function', 'GLP - 1', 'Weight Loss']",2025-09-15,2026-01-01,https://clinicaltrials.gov/study/NCT06811324
NCT05024032,A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN),Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Obesity', 'Overweight', 'Metabolism and Nutrition Disorder']",2021-09-01,2022-12-27,https://clinicaltrials.gov/study/NCT05024032
NCT06467604,CRAVE Study: Comparing Craving Responses and Diet Quality of GLP1 Receptor Agonist Users,Unknown,ACTIVE_NOT_RECRUITING,"Surveys, Indirect Calorimetry, Body composition, Anthropometrics","BEHAVIORAL, OTHER, OTHER, OTHER",Other,"University of California, Davis",['Obesity'],2024-11-01,2025-09-12,https://clinicaltrials.gov/study/NCT06467604
NCT04844918,A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease,Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, OTHER",Other,Eli Lilly and Company,['Obesity'],2021-05-10,2023-06-24,https://clinicaltrials.gov/study/NCT04844918
NCT06761703,A Study to Determine the Feasibility of Online Recruitment of People Using an Anti-Obesity Medication for Weight Loss,Unknown,COMPLETED,TAP® Micro Select Device (Touch Activated Phlebotomy),DEVICE,Other,Amgen,['Obesity'],2024-11-14,2025-01-06,https://clinicaltrials.gov/study/NCT06761703
NCT07244458,Dietary Peanuts and Nutrition-Related Outcomes,Unknown,NOT_YET_RECRUITING,"Peanuts, Dual-energy X-ray absorptiometry (DEXA) scans","DIETARY_SUPPLEMENT, PROCEDURE",Dual agonist,"Ian J. Neeland, MD","['Dietary Change', 'Obesity & Overweight', 'Food Acceptance']",2026-01,2027-12,https://clinicaltrials.gov/study/NCT07244458
NCT03882970,A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes,Unknown,COMPLETED,"Tirzepatide, Insulin Degludec","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes Mellitus'],2019-04-01,2020-12-11,https://clinicaltrials.gov/study/NCT03882970
NCT06445075,Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese,Unknown,COMPLETED,"Apitegromab, Placebo, Tirzepatide","DRUG, DRUG, DRUG",Other,"Scholar Rock, Inc.",['Overweight and Obesity'],2024-05-21,2025-03-04,https://clinicaltrials.gov/study/NCT06445075
NCT04004988,A Study of Tirzepatide Administered by Two Different Devices in Healthy Participants,Unknown,COMPLETED,"Tirzepatide, Prefilled syringe (PFS), Auto-injector (AI)","DRUG, DEVICE, DEVICE",Other,Eli Lilly and Company,['Healthy'],2019-08-19,2019-12-16,https://clinicaltrials.gov/study/NCT04004988
NCT07057310,Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal Women,Unknown,ENROLLING_BY_INVITATION,"semaglutide or tirzepatide, Lifestyle modification intervention","DRUG, BEHAVIORAL",Other,Mayo Clinic,"['Obesity', 'Menopause']",2025-05-01,2026-12-31,https://clinicaltrials.gov/study/NCT07057310
NCT05751720,Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 Analogue,Unknown,RECRUITING,GIP/GLP-1a,DRUG,Dual agonist,Dr Adnan Agha,"['Non-Alcoholic Fatty Liver Disease', 'Non-alcoholic Steatohepatitis', 'Type 2 Diabetes', 'Liver Fat']",2023-10-01,2024-10,https://clinicaltrials.gov/study/NCT05751720
NCT06962280,A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight,Unknown,RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Type 1 Diabetes', 'Obesity', 'Overweight']",2025-05-12,2027-04,https://clinicaltrials.gov/study/NCT06962280
NCT07027969,Metabolic Surgery for Atrial Fibrillation Elimination,Unknown,NOT_YET_RECRUITING,"Roux-en-Y Gastric Bypass or Sleeve Gastrectomy, Anti-Obesity Medication (AOM) treatment","PROCEDURE, DRUG",Other,Ali Aminian,"['Atrial Fibrillation', 'Obesity and Obesity-related Medical Conditions']",2026-02-01,2029-12-31,https://clinicaltrials.gov/study/NCT07027969
NCT07213323,Probiotic Intervention for Digestive Health in Obese Patients Initiating GLP-RA Treatment,Unknown,NOT_YET_RECRUITING,"Probiotics (Natural product), Placebo","DIETARY_SUPPLEMENT, OTHER",Other,Hospices Civils de Lyon,"['Obesity &Amp; Overweight', 'Digestive Disorders']",2025-12-15,2027-04-15,https://clinicaltrials.gov/study/NCT07213323
NCT04050670,A Study of Tirzepatide at Different Injection Sites in Participants With Different Body Sizes,Unknown,COMPLETED,Tirzepatide,DRUG,Other,Eli Lilly and Company,['Healthy'],2019-09-13,2020-04-03,https://clinicaltrials.gov/study/NCT04050670
NCT05810597,A Research Study Looking at Similarity Between Tirzepatide Versions for Different Injection Devices,Unknown,COMPLETED,"Tirzepatide, Single Dose Pen, Multi-use Prefilled Pen","DRUG, DEVICE, DEVICE",Other,Eli Lilly and Company,['Healthy'],2023-04-03,2023-07-17,https://clinicaltrials.gov/study/NCT05810597
NCT06606821,The Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease,Unknown,RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,Tina Vilsbøll,"['Coronary Artery Disease', 'Coronary Microvascular Dysfunction', 'Overweight or Obesity', 'Stable Angina Pectoris', 'Chronic Coronary Artery Disease', 'Atherosclerosis Cardiovascular Disease']",2024-10-01,2027-03-20,https://clinicaltrials.gov/study/NCT06606821
NCT06790225,Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA),Unknown,NOT_YET_RECRUITING,Glucose-dependent Insulinotropic Polypeptide (GIP),OTHER,GIP agonist,Esbjerg Hospital - University Hospital of Southern Denmark,"['Bone Disease, Metabolic', 'Diabetes Mellitus, Type 2', 'Obesity and Obesity-related Medical Conditions']",2025-04-01,2026-04-01,https://clinicaltrials.gov/study/NCT06790225
NCT05696847,A Study of Tirzepatide (LY3298176) in Pediatric Participants With Obesity,Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Obesity'],2023-02-07,2025-01-16,https://clinicaltrials.gov/study/NCT05696847
NCT06994338,Tirzepatide for Alcohol Use Disorder,Unknown,RECRUITING,"Tirzepatide, Placebo injections","DRUG, DRUG",Other,University of Southern California,"['Alcohol Use Disorder', 'Obesity and Overweight', 'Alcohol']",2025-10-06,2026-08-31,https://clinicaltrials.gov/study/NCT06994338
NCT07194317,A Feasibility Study to Determine the Most Appropriate Digital Dietary Assessment Tool in Patients With Obesity Initiating GLP-1 Receptor Agonist Treatment,Unknown,ENROLLING_BY_INVITATION,"Testing 3 different digital dietary assessment tools in a random order (Nutritics-Libro, MyFood24 and Intake24)",DEVICE,Other,King's College London,['Obese Patients'],2025-09-01,2026-03-01,https://clinicaltrials.gov/study/NCT07194317
NCT07058155,Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease,Unknown,RECRUITING,"Transjugular Intrahepatic Portosystemic Shunt (TIPS), Sleeve Gastrectomy, Anti-Obesity Pharmacotherapy (Class Effect), Lifestyle Counseling - Diet & Physical-Activity Program","PROCEDURE, PROCEDURE, DRUG, BEHAVIORAL",Other,The Cleveland Clinic,"['Liver Cirrhoses', 'Portal Hypertension Related to Cirrhosis', 'Severe Obesity', 'TIPS']",2025-12,2029-02-01,https://clinicaltrials.gov/study/NCT07058155
NCT06630585,GIP/GLP-1RA as Adjunctive to Automated Insulin Delivery in Adults With Type 1 Diabetes,Unknown,RECRUITING,Tirzepatide,DRUG,Other,University of Bern,['Type 1 Diabetes (T1D)'],2025-02-14,2026-06,https://clinicaltrials.gov/study/NCT06630585
NCT04172987,A Study of the Effect of Tirzepatide on How the Body Handles Birth Control Pills in Healthy Female Participants,Unknown,COMPLETED,"Tirzepatide, EE/NGM","DRUG, DRUG",Other,Eli Lilly and Company,['Healthy'],2020-02-26,2021-02-09,https://clinicaltrials.gov/study/NCT04172987
NCT06890611,A Study of Bimagrumab Alone (LY3985863) and Bimagrumab With Tirzepatide (LY900042) in Healthy Participants,Unknown,COMPLETED,"Bimagrumab, Tirzepatide, Bimagrumab + Tirzepatide Coformulation","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,['Healthy'],2025-03-25,2025-09-26,https://clinicaltrials.gov/study/NCT06890611
NCT06246799,Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes,Unknown,RECRUITING,"Tirzepatide, Pioglitazone, Sitagliptin, Metformin HCI XR","DRUG, DRUG, DRUG, DRUG",Other,The University of Texas Health Science Center at San Antonio,['Type 2 Diabetes (Adult Onset)'],2024-11-07,2029-04-30,https://clinicaltrials.gov/study/NCT06246799
NCT05978713,A Study of Tirzepatide (LY3298176) in Healthy Lactating Females,Unknown,COMPLETED,Tirzepatide,DRUG,Other,Eli Lilly and Company,['Healthy'],2023-07-31,2024-03-12,https://clinicaltrials.gov/study/NCT05978713
NCT06895408,Separate and Combined Extrapancreatic Effects of GIP and GLP-1,Unknown,COMPLETED,"Intravenous Infusion, Intravenous Infusion, Intravenous Infusion, Intravenous Infusion","OTHER, OTHER, OTHER, OTHER",Other,"University Hospital, Gentofte, Copenhagen",['Pancreatectomy; Hyperglycemia'],2025-02-19,2025-07-14,https://clinicaltrials.gov/study/NCT06895408
NCT03730662,A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk,Unknown,COMPLETED,"Tirzepatide, Insulin Glargine","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes Mellitus'],2018-11-20,2021-01-22,https://clinicaltrials.gov/study/NCT03730662
NCT06518837,Tirzepatide for Weight Loss Intervention in Early-Stage Hormone Receptor Positive/HER2 Negative Breast Cancer,Unknown,RECRUITING,Tirzepatide,DRUG,Other,"Rutgers, The State University of New Jersey","['Hormone Receptor-Positive Breast Cancer', 'HER2-Negative Breast Cancer']",2024-10-30,2027-09-30,https://clinicaltrials.gov/study/NCT06518837
NCT06047548,A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities,Unknown,ACTIVE_NOT_RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Overweight', 'Obesity']",2023-09-20,2026-05,https://clinicaltrials.gov/study/NCT06047548
NCT07115069,Comparison of Body Composition Changes With Weight Loss Interventions,Unknown,RECRUITING,"GLP-1 receptor agonist, Gastric Bypass Surgery (laparoscopic), Gastric Bypass Surgery (robotic)","DRUG, PROCEDURE, PROCEDURE",GLP-1 agonist,Vanderbilt University Medical Center,['Obesity'],2025-08-09,2026-09,https://clinicaltrials.gov/study/NCT07115069
NCT05708859,Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT,Unknown,RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,Matthew J. Budoff,"['Type II Diabetes', 'Atherosclerosis']",2024-01-02,2025-12,https://clinicaltrials.gov/study/NCT05708859
NCT06937086,Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study,Unknown,RECRUITING,"Mirikizumab, Mirikizumab, Tirzepatide, Placebo","DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Ulcerative Colitis', 'Obesity or Overweight']",2025-06-26,2028-04,https://clinicaltrials.gov/study/NCT06937086
NCT07223242,Tailored Exercise Training Study Among Adults With HFpEF,Unknown,RECRUITING,"Moderate-intensity continuous training (MCT), Resistance training, Weight loss","BEHAVIORAL, BEHAVIORAL, DRUG",Other,University of Texas Southwestern Medical Center,"['HFpEF - Heart Failure With Preserved Ejection Fraction', 'Diabetic Cardiomyopathies']",2025-02-18,2026-12-30,https://clinicaltrials.gov/study/NCT07223242
NCT07251803,GLP1 Fasting Status and Gastric Retention Using Gastric Ultrasound,Unknown,NOT_YET_RECRUITING,Gastric Ultrasound,DIAGNOSTIC_TEST,Other,Medical University of South Carolina,['Gastric Retention'],2025-12-31,2026-12-31,https://clinicaltrials.gov/study/NCT07251803
NCT05933499,"Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity",Unknown,NOT_YET_RECRUITING,"Bimagrumab, Tirzepatide, Calcium/Vitamin D, Lifestyle and nutrition counseling","DRUG, DRUG, DIETARY_SUPPLEMENT, BEHAVIORAL",Other,Massachusetts General Hospital,['Obesity'],2025-12-15,2028-12-31,https://clinicaltrials.gov/study/NCT05933499
NCT05553093,Effects of Tirzepatide and Insulin Glargine on Glucolipid Metabolism and Brain Function in Patients With Type 2 Diabetes,Unknown,RECRUITING,"Tirzepatide, Insulin Glargine","DRUG, DRUG",Other,"Nanjing First Hospital, Nanjing Medical University",['Type 2 Diabetes Mellitus'],2022-03-15,2023-12-31,https://clinicaltrials.gov/study/NCT05553093
NCT05691712,A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes,Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Type 2', 'Diabetes Mellitus', 'Glucose Metabolism Disorders', 'Metabolic Disease', 'Endocrine System Diseases']",2023-02-05,2024-07-01,https://clinicaltrials.gov/study/NCT05691712
NCT04093752,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes on Metformin With or Without Sulfonylurea (SURPASS-AP-Combo),Unknown,COMPLETED,"Tirzepatide, Insulin Glargine","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes'],2019-12-09,2021-11-01,https://clinicaltrials.gov/study/NCT04093752
NCT03131687,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"tirzepatide, Dulaglutide, Placebo","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes Mellitus'],2017-05-24,2018-08-01,https://clinicaltrials.gov/study/NCT03131687
NCT06790160,Study of Patients Being Treated With Anti-obesity Medication,Unknown,RECRUITING,,,Unknown,Texas Tech University,['Obesity and Overweight'],2025-01-31,2027-02,https://clinicaltrials.gov/study/NCT06790160
NCT06939088,Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder,Unknown,RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,"Anders Fink-Jensen, MD, DMSci","['Alcohol Use Disorder', 'Alcohol Abuse/Dependence', 'Alcohol Dependence', 'Alcoholism', 'Schizophrenia Disorders', 'Schizophrenia and Disorders With Psychotic Features', 'Schizophrenia and Schizophrenia Spectrum Psychosis', 'Schizophrenia']",2025-05-05,2028-08-01,https://clinicaltrials.gov/study/NCT06939088
NCT07202247,"Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial",Unknown,RECRUITING,"Antiandrogen Therapy, Behavioral Intervention, Biospecimen Collection, Cardiac Computerized Tomographic Angiography, Computed Tomography, Electronic Health Record Review, Internet-Based Intervention, Lifestyle Counseling, Medical Device Usage and Evaluation, Nutritional Intervention, Nutritional Intervention, Questionnaire Administration, Radiation Therapy, Referral, Semaglutide, Short-Term Fasting, Tirzepatide","DRUG, BEHAVIORAL, PROCEDURE, PROCEDURE, PROCEDURE, OTHER, OTHER, BEHAVIORAL, OTHER, OTHER, OTHER, OTHER, RADIATION, OTHER, DRUG, OTHER, DRUG",Other,City of Hope Medical Center,"['Prostate Carcinoma', 'Recurrent Prostate Carcinoma']",2025-12-08,2028-04-09,https://clinicaltrials.gov/study/NCT07202247
NCT06803888,Bariatric Surgery vs. Semaglutide vs. Tirzepatide,Unknown,RECRUITING,"Bariatric Surgery, Semaglutide, Tirzepatide","PROCEDURE, DRUG, DRUG",Other,Ali Aminian,['Obesity and Obesity-related Medical Conditions'],2025-01-29,2027-07-01,https://clinicaltrials.gov/study/NCT06803888
NCT06009653,Effects of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity,Unknown,WITHDRAWN,"Standard Care, Culturally-tailored dietary and behavioral intensive lifestyle intervention, Placebo, Tirzepatide","BEHAVIORAL, BEHAVIORAL, DRUG, DRUG",Other,Washington University School of Medicine,"['Obesity', 'Metabolic Disease']",2023-09-13,2024-05-29,https://clinicaltrials.gov/study/NCT06009653
NCT07262762,Spartina® (Tirzepatide) Effectiveness and Safety Evaluation,Unknown,RECRUITING,,,Unknown,Cinnagen,['Obesity & Overweight'],2025-11-11,2025-12,https://clinicaltrials.gov/study/NCT07262762
NCT07188545,Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH),Unknown,ACTIVE_NOT_RECRUITING,"Intervention, Active Comparator","DRUG, DRUG",Other,Ohio State University,['Cardiovascular Kidney Metabolic Syndrome'],2025-09-15,2029-06-30,https://clinicaltrials.gov/study/NCT07188545
NCT06354101,"The Purpose of This Registry Study is to Learn More About Metabolic Health: Approximately 15,000 Participants Who Are Overweight or Have Obesity With or Without Metabolic Diseases Are Expected to Participate in This Registry Study.",Unknown,WITHDRAWN,"Tirzepatide, Semaglutide","DRUG, DRUG",Other,CorEvitas,['Metabolic Health'],2023-07-01,2023-07-01,https://clinicaltrials.gov/study/NCT06354101
NCT05659368,Tirzepatide Monotherapy in Patients With Wolfram Syndrome Type 1,Unknown,RECRUITING,Tirzepatide,DRUG,Other,Ospedale San Raffaele,['Wolfram Syndrome'],2024-01-01,2024-10,https://clinicaltrials.gov/study/NCT05659368
NCT04255433,A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes,Unknown,COMPLETED,"Tirzepatide, Dulaglutide","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes Mellitus'],2020-05-29,2025-06-12,https://clinicaltrials.gov/study/NCT04255433
NCT06191848,Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA),Unknown,RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,University of Melbourne,"['Obesity', 'Knee Osteoarthritis', 'Osteoarthritis, Knee']",2024-11-19,2027-05,https://clinicaltrials.gov/study/NCT06191848
NCT06935838,Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV,Unknown,RECRUITING,Tirzepatide,DRUG,Other,University of Hawaii,"['Obesity and Overweight', 'HIV', 'Chronic Inflammation']",2025-11-12,2026-07-31,https://clinicaltrials.gov/study/NCT06935838
NCT06326047,A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes,Unknown,COMPLETED,"NNC0519-0130, Placebo, Trizepatide","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2024-03-18,2025-09-19,https://clinicaltrials.gov/study/NCT06326047
NCT07078838,Tirzepatide in Women With Obesity and Endometrial Intra-epithelial Neoplasia or Grade 1 Endometrial Cancer,Unknown,NOT_YET_RECRUITING,Tirzepatide,DRUG,Other,UNC Lineberger Comprehensive Cancer Center,"['Endometrial Cancer', 'Endometrial Intraepithelial Neoplasia', 'Grade 1 Endometrial Endometrioid Carcinoma']",2025-12,2029-03,https://clinicaltrials.gov/study/NCT07078838
NCT04184622,A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight,Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Overweight', 'Obesity']",2019-12-04,2022-04-01,https://clinicaltrials.gov/study/NCT04184622
NCT06801015,Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor Functions,Unknown,RECRUITING,"Semaglutide, Tirzepatide, Placebo","DRUG, DRUG, DRUG",Other,Mayo Clinic,['Obesity'],2025-10-01,2028-01-31,https://clinicaltrials.gov/study/NCT06801015
NCT06485089,"Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers",Unknown,ACTIVE_NOT_RECRUITING,tirzepatide,DRUG,Other,University of Kansas Medical Center,"['Obesity', 'Breast Cancer Risk']",2024-09-14,2026-02,https://clinicaltrials.gov/study/NCT06485089
NCT06980623,Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction,Unknown,ACTIVE_NOT_RECRUITING,"Tirzepatide, Semaglutide","DRUG, DRUG",Other,Brigham and Women's Hospital,"['Type 2 Diabetes', 'Heart Failure']",2025-01-01,2025-06-01,https://clinicaltrials.gov/study/NCT06980623
NCT07099742,Effectiveness and Safety of Tirzepatide Among Participants With Obesity With or Without Type 2 Diabetes Mellitus (T2DM),Unknown,NOT_YET_RECRUITING,"Tirzepatide, Life Style Modification","DRUG, BEHAVIORAL",Other,Dr. Md. Alimur Reza,['Obesity'],2025-09,2026-04,https://clinicaltrials.gov/study/NCT07099742
NCT05912621,Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity,Unknown,RECRUITING,Tirzepatide,DRUG,Other,Stanford University,"['Obesity', 'Overweight and Obesity', 'Overweight']",2023-11-09,2028-06,https://clinicaltrials.gov/study/NCT05912621
NCT05536804,A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes,Unknown,ACTIVE_NOT_RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Overweight', 'Obesity', 'Chronic Kidney Disease', 'Type 2 Diabetes', 'T2D']",2023-02-08,2026-09,https://clinicaltrials.gov/study/NCT05536804
NCT06484114,Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide,Unknown,ACTIVE_NOT_RECRUITING,"Revita Duodenal Mucosal Resurfacing (DMR), Sham","DEVICE, DEVICE",Other,Fractyl Health Inc.,"['Obesity', 'Weight Change Trajectory', 'Weight Change, Body']",2024-09-01,2026-09-30,https://clinicaltrials.gov/study/NCT06484114
NCT05177653,Separate and Combined Extrapancreatic Effects of the Incretin Hormones,Unknown,COMPLETED,"Intravenous infusion, Intravenous infusion, Intravenous infusion, Intravenous infusion","OTHER, OTHER, OTHER, OTHER",Other,"University Hospital, Gentofte, Copenhagen",['Pancreatectomy; Hyperglycemia'],2022-04-07,2023-03-03,https://clinicaltrials.gov/study/NCT05177653
NCT06937203,Study of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus,Unknown,RECRUITING,"ARO-ALK7, Placebo","DRUG, DRUG",Other,Arrowhead Pharmaceuticals,"['Obesity', 'Diabetes Mellitus, Type 2']",2025-05-07,2026-07,https://clinicaltrials.gov/study/NCT06937203
NCT07218445,The Effect of Tirzepatide on Menopausal Vasomotor Symptoms and Biological Aging in Post-menopausal Women With Obesity,Unknown,ACTIVE_NOT_RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,Mayo Clinic,"['Obesity', 'Menopause Hot Flashes']",2025-09-16,2027-09-18,https://clinicaltrials.gov/study/NCT07218445
NCT06918405,Efficacy and Safety of Tirzepatide for Weight Management,Unknown,ACTIVE_NOT_RECRUITING,Tirzepatide,DRUG,Other,Chittagong Medical College,['Obesity and Obesity-related Medical Conditions'],2025-01-01,2026-06-30,https://clinicaltrials.gov/study/NCT06918405
NCT06588283,Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight,Unknown,ACTIVE_NOT_RECRUITING,"Ixekizumab, Tirzepatide","DRUG, DRUG",Other,Eli Lilly and Company,"['Psoriasis', 'Obesity']",2024-09-30,2025-12,https://clinicaltrials.gov/study/NCT06588283
NCT03861052,A Study of Tirzepatide (LY3298176) Compared to Dulaglutide in Participants With Type 2 Diabetes,Unknown,COMPLETED,"Tirzepatide, Dulaglutide","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes'],2019-05-07,2021-03-10,https://clinicaltrials.gov/study/NCT03861052
NCT04050553,A Study of Tirzepatide in Participants With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2', 'Hypoglycemia']",2020-02-24,2022-01-25,https://clinicaltrials.gov/study/NCT04050553
NCT06588296,Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight,Unknown,ACTIVE_NOT_RECRUITING,"Ixekizumab, Tirzepatide","DRUG, DRUG",Other,Eli Lilly and Company,"['Psoriatic Arthritis', 'Obesity']",2024-09-24,2025-11,https://clinicaltrials.gov/study/NCT06588296
NCT06820281,Acute Metabolic Effects of Tirzepatide in Type 1 Diabetes,Unknown,NOT_YET_RECRUITING,"Tirzepatide 2.5mg weekly, Placebo injection (normal saline)","DRUG, DRUG",Other,Garvan Institute of Medical Research,['Type 1 Diabetes Mellitus'],2025-12-01,2027-12-31,https://clinicaltrials.gov/study/NCT06820281
NCT06651177,Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder,Unknown,NOT_YET_RECRUITING,"Tirzepatide, Placebo","DRUG, OTHER",Other,"T. John Winhusen, PhD","['Opioid Use Disorder', 'Opioid Use Disorder, Moderate', 'Opioid Use Disorder, Severe']",2025-11-19,2027-06-30,https://clinicaltrials.gov/study/NCT06651177
NCT03954834,A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone,Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes Mellitus'],2019-06-03,2020-10-05,https://clinicaltrials.gov/study/NCT03954834
NCT06662383,A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity,Unknown,ACTIVE_NOT_RECRUITING,"Retatrutide, Tirzepatide","DRUG, DRUG",Other,Eli Lilly and Company,['Obesity'],2024-11-01,2026-12,https://clinicaltrials.gov/study/NCT06662383
NCT05963022,A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO),Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes'],2023-08-21,2024-10-09,https://clinicaltrials.gov/study/NCT05963022
NCT06911203,A Study of BGM0504 in Participants With Obesity,Unknown,RECRUITING,"BGM0504, Tirzepatide","DRUG, DRUG",Other,"BrightGene Bio-Medical Technology Co., Ltd.",['Obesity'],2025-04-03,2026-01-11,https://clinicaltrials.gov/study/NCT06911203
NCT06037252,A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity,Unknown,ACTIVE_NOT_RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Type 2 Diabetes', 'Obesity']",2023-09-21,2026-01,https://clinicaltrials.gov/study/NCT06037252
NCT04081337,A Study to Measure Energy Expenditure and Food Intake in Participants With Obesity Using Tirzepatide,Unknown,COMPLETED,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Obesity'],2020-07-09,2022-05-26,https://clinicaltrials.gov/study/NCT04081337
NCT06345066,A Study of LY3841136 in Overweight and Obese Participants,Unknown,COMPLETED,"Tirzepatide, LY3841136, Placebo","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Obesity', 'Overweight']",2024-04-03,2025-09-29,https://clinicaltrials.gov/study/NCT06345066
NCT06075667,A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities,Unknown,ACTIVE_NOT_RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Obesity', 'Overweight']",2023-10-16,2026-05,https://clinicaltrials.gov/study/NCT06075667
NCT06802081,TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation,Unknown,RECRUITING,"Tirzepatide, Placebo","DRUG, DRUG",Other,The Cleveland Clinic,"['Atrial Fibrillation', 'Obesity']",2025-04-08,2026-06-01,https://clinicaltrials.gov/study/NCT06802081
NCT07245771,"Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effect on Body Weight of RN3161 as Monotherapy and in Combination With Tirzepatide in Adults With Overweight and Obesity",Unknown,RECRUITING,"RN3161, Placebo Control, Tirzepatide","DRUG, DRUG, DRUG",Other,Ikaria Bioscience Pty Ltd,['Obesity &Amp; Overweight'],2025-11-04,2027-02-15,https://clinicaltrials.gov/study/NCT07245771
NCT02608853,Estimation of Malignancy Rates Within Humedica Patient Populations Sampled to be Representative of Liraglutide Initiators and LEADER™ Trial Participants,Unknown,COMPLETED,No treatment given,OTHER,Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2015-01,2015-01,https://clinicaltrials.gov/study/NCT02608853
NCT06171152,Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues,Phase 1,RECRUITING,"Liraglutide Pen Injector [Saxenda], Medication Diary","DRUG, OTHER",Other,University of Chicago,"['Multiple Sclerosis', 'Long COVID', 'Long Covid19', 'Obese', 'Obesity', 'Obesity, Morbid', 'Acute Leukemia in Remission']",2024-01-26,2026-06-01,https://clinicaltrials.gov/study/NCT06171152
NCT04487743,Efficacy and Safety of Liraglutide on Body Weight in Obese Subjects or Overweight Subjects With Co-morbidities,Unknown,UNKNOWN,"Liraglutide, placebo","DRUG, DRUG",Other,Xiangya Hospital of Central South University,['Obesity'],2020-05-09,2022-06,https://clinicaltrials.gov/study/NCT04487743
NCT01319240,Safety and Tolerability of Insulin Degludec/Liraglutide (A3) in Healthy Subjects,Unknown,COMPLETED,"insulin degludec, insulin degludec/liraglutide, liraglutide","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Healthy']",2011-03,2011-05,https://clinicaltrials.gov/study/NCT01319240
NCT01722266,Liraglutide in the Treatment of Type 1 Diabetes Mellitus,Unknown,COMPLETED,"Liraglutide, Placebo","DRUG, DRUG",Other,University at Buffalo,['Type 1 Diabetes'],2012-11-01,2014-04-01,https://clinicaltrials.gov/study/NCT01722266
NCT02073929,LIPT - Liraglutide in Polycystic Ovary Syndrome,Unknown,COMPLETED,"Liraglutide for 26 weeks, placebo","DRUG, DRUG",Other,Jens Faber,"['Polycystic Ovary Syndrome', 'Cardiovascular Disease']",2014-03,2015-12,https://clinicaltrials.gov/study/NCT02073929
NCT02545738,Antiproteinuric Effects of Liraglutide Treatment,Unknown,COMPLETED,"Liraglutide, placebo","DRUG, DRUG",Other,Steno Diabetes Center Copenhagen,['Diabetic Kidney Disease'],2015-04,2016-05,https://clinicaltrials.gov/study/NCT02545738
NCT03038620,Impact of Liraglutide 3.0 on Body Fat Distribution,Unknown,COMPLETED,"Liraglutide, Placebo","DRUG, DRUG",Other,University of Texas Southwestern Medical Center,"['Obesity, Visceral', 'Cardiovascular Diseases', 'Fat Disorder']",2017-01,2020-10-13,https://clinicaltrials.gov/study/NCT03038620
NCT06217848,"The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study",Phase 1,RECRUITING,Saxenda,DRUG,Other,Seoul National University Hospital,"['Panhypopituitarism', 'Craniopharyngioma', 'Hypothalamic Obesity']",2022-11-28,2024-02-08,https://clinicaltrials.gov/study/NCT06217848
NCT03115099,A Study of LY3325656 in Healthy Participants and Participants With Type 2 Diabetes,Unknown,COMPLETED,"LY3325656, Placebo, Liraglutide, Sitagliptin","DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2017-05-31,2018-04-05,https://clinicaltrials.gov/study/NCT03115099
NCT02501850,The Effect of the GLP-1 Receptor Agonists on Blood Levels of Lipoprotein (a),Unknown,UNKNOWN,"Liraglutide, metformin","DRUG, DRUG",Other,Hospital Universitari Vall d'Hebron Research Institute,['Diabetes Mellitus Type 2'],2014-10,2015-07,https://clinicaltrials.gov/study/NCT02501850
NCT02299050,Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy,Unknown,COMPLETED,Cycloset,DRUG,Other,The University of Texas Health Science Center at San Antonio,['Type 2 Diabetes'],2014-06,2018-04-30,https://clinicaltrials.gov/study/NCT02299050
NCT05952882,"Liraglutide and Metformin Combination on Weight Loss, Metabolic - Endocrine Parameters and Pregnancy Rate in Women With PCOS, Obesity and Infertility",Unknown,NOT_YET_RECRUITING,"Liraglutide + Metformin, Metformin","DRUG, DRUG",Other,Mỹ Đức Hospital,"['Polycystic Ovary Syndrome', 'Obesity', 'Infertility, Female']",2023-11-01,2025-12-31,https://clinicaltrials.gov/study/NCT05952882
NCT04034524,Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin,Unknown,UNKNOWN,"GLP-1 receptor agonist, Insulin","DRUG, DRUG",GLP-1 agonist,Brigham and Women's Hospital,"['Diabetes Mellitus, Type 2']",2019-05-01,2020-12-31,https://clinicaltrials.gov/study/NCT04034524
NCT05467514,Effect of Liraglutide on Subclinical Atherosclerosis in Patients With Type 1 Diabetes Mellitus,Unknown,COMPLETED,Liraglutide,DRUG,Other,David Sanchez Garcia,"['Diabetes Mellitus, Type 1']",2022-07-01,2023-02-28,https://clinicaltrials.gov/study/NCT05467514
NCT04643301,Liraglutide for Low-responders After Bariatric Surgery,Unknown,WITHDRAWN,Liraglutide Pen Injector,DRUG,Other,Zuyderland Medisch Centrum,"['Obesity', 'Obesity, Morbid']",2020-12-21,2021-12-31,https://clinicaltrials.gov/study/NCT04643301
NCT02617654,Liraglutide Effect on Beta-cell Function in C-peptide Positive Type 1 Diabetes,Unknown,COMPLETED,"Liraglutide, Placebo for liraglutide","DRUG, DRUG",Other,Per-Ola Carlsson,['Type 1 Diabetes'],2015-11,2020-09,https://clinicaltrials.gov/study/NCT02617654
NCT01832532,A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 Weeks,Unknown,COMPLETED,liraglutide,DRUG,Other,"Children's Hospital Medical Center, Cincinnati","['Sleep Apnea', 'Sleep Disordered Breathing']",2013-04,2015-12,https://clinicaltrials.gov/study/NCT01832532
NCT02298192,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) in Subjects With Type 2 Diabetes Mellitus Using Two Different Titration Algorithms,Unknown,COMPLETED,insulin degludec/liraglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2014-11-21,2015-12-23,https://clinicaltrials.gov/study/NCT02298192
NCT01785043,Differences in Endothelial Function Amongst Sitagliptin and Liraglutide Users,Unknown,COMPLETED,"Liraglutide, Sitagliptin","DRUG, DRUG",Other,Anna Cruceta,['DIABETES Mellitus Type 2 Not Well Controlled'],2013-03,2014-03,https://clinicaltrials.gov/study/NCT01785043
NCT05965908,Effect of Liraglutide in Obese Women With Polycystic Ovary Syndrome,Unknown,UNKNOWN,"liraglutide, Metformin","DRUG, DRUG",Other,Beni-Suef University,['Polycystic Ovary'],2023-07-30,2023-09-30,https://clinicaltrials.gov/study/NCT05965908
NCT05029076,Human Bioequivalence Test of Liraglutide Injection,Unknown,COMPLETED,"Liraglutide injection, Victoza","DRUG, DRUG",Other,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",['Type 2 Diabetes'],2019-05-21,2019-06-01,https://clinicaltrials.gov/study/NCT05029076
NCT02420262,A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"insulin degludec/liraglutide, insulin glargine, insulin aspart","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2015-07-26,2016-10-05,https://clinicaltrials.gov/study/NCT02420262
NCT03172494,"A Trial Comparing Insulin Degludec/Liraglutide, Insulin Degludec, and Liraglutide in Chinese Subjects With Type 2 Diabetes Inadequately Controlled on Oral Antidiabetic Drugs (OADs)",Unknown,COMPLETED,"Insulin degludec/liraglutide, Insulin degludec, Liraglutide","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2017-05-26,2019-06-14,https://clinicaltrials.gov/study/NCT03172494
NCT05419856,"Safety, Tolerability and Pharmacokinetics of Intraarticular 4P004 Single Dose in Patient With KL 2-4 Osteoarthritic Knee",Unknown,COMPLETED,"4P-004, Placebo","DRUG, DRUG",Other,4Moving Biotech,['Knee Osteoarthritis'],2022-08-09,2023-10-31,https://clinicaltrials.gov/study/NCT05419856
NCT04046822,Effect of Liraglutide on Microbiome in Obesity,Unknown,UNKNOWN,"Liraglutide 6 MG/ML [Saxenda], Placebo","DRUG, DRUG",Other,Federico II University,"['Obesity', 'Weight Loss', 'Microbiome']",2019-01-09,2020-01-09,https://clinicaltrials.gov/study/NCT04046822
NCT02963922,Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal Insulin,Unknown,COMPLETED,"Liraglutide 3.0 mg, Placebo","DRUG, DRUG",Other,Novo Nordisk A/S,"['Metabolism and Nutrition Disorder', 'Obesity']",2017-02-06,2018-09-10,https://clinicaltrials.gov/study/NCT02963922
NCT04683237,Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia,Unknown,WITHDRAWN,"Liraglutide Injection, Megestrol Acetate 160 MG","DRUG, DRUG",Other,Xiaojun Chen,"['Atypical Endometrial Hyperplasia', 'Obese', 'Fertility Issues']",2021-03-20,2025-11-30,https://clinicaltrials.gov/study/NCT04683237
NCT03421119,Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes,Unknown,UNKNOWN,"Liraglutide 6 MG/ML Pen Injector, Metformin, Sulfonylurea/non-sulfonylurea insulin secretagogues","DRUG, DRUG, DRUG",Other,Cinnagen,"['Diabetes Mellitus, Type 2']",2019-06-20,2019-12-01,https://clinicaltrials.gov/study/NCT03421119
NCT02602600,Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis,Unknown,COMPLETED,Liraglutide,DRUG,Other,Eva Prescott,['Microvascular Angina'],2015-11-19,2017-04-18,https://clinicaltrials.gov/study/NCT02602600
NCT05794581,A Study to Assess the Effects of CT-868 Treatment on Glucose Homeostasis in Participants with Type 1 Diabetes,Unknown,COMPLETED,"CT-868, Placebo, Victoza","DRUG, DRUG, DRUG",Other,"Carmot Therapeutics, Inc.",['Type 1 Diabetes'],2023-03-21,2024-03-06,https://clinicaltrials.gov/study/NCT05794581
NCT01937598,Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2D,Unknown,COMPLETED,"Placebo, Mixed meal test, Liraglutide, Sitagliptin","DRUG, OTHER, DRUG, DRUG",Other,Michael A. Nauck,['Type 2 Diabetes'],2013-08,2014-04,https://clinicaltrials.gov/study/NCT01937598
NCT01515553,Bioequivalence of Two Liraglutide Formulations in Healthy Volunteers,Unknown,COMPLETED,liraglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes', 'Healthy']",2007-01,2007-04,https://clinicaltrials.gov/study/NCT01515553
NCT01175473,Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes,Unknown,COMPLETED,"Lixisenatide (AVE0010), Pen auto-injector, Liraglutide, Pre-filled pen injector, Metformin","DRUG, DEVICE, DRUG, DEVICE, DRUG",Other,Sanofi,['Type 2 Diabetes Mellitus'],2010-08,2010-11,https://clinicaltrials.gov/study/NCT01175473
NCT01425580,Liraglutide and Heart Failure in Type 2 Diabetes,Unknown,COMPLETED,"liraglutide, glimepiride, Metformin","DRUG, DRUG, DRUG",Other,Thomas Nystrom,"['Congestive Heart Failure', 'Type 2 Diabetes Mellitus']",2012-01,2016-08,https://clinicaltrials.gov/study/NCT01425580
NCT01270789,LIraglutide and Beta-cell RepAir (LIBRA) Study,Unknown,COMPLETED,"Liraglutide, placebo","DRUG, DRUG",Other,"Mount Sinai Hospital, Canada",['Type 2 Diabetes'],2011-01,2013-12,https://clinicaltrials.gov/study/NCT01270789
NCT03371862,Liraglutide on Decreasing Parenteral Support in Short Bowel Patients (SLIPS),Unknown,WITHDRAWN,Liraglutide Pen Injector [Victoza],DRUG,Other,Imperial College London,['Short Bowel Syndrome'],2017-10-20,2020-08-06,https://clinicaltrials.gov/study/NCT03371862
NCT01336023,"Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes",Unknown,COMPLETED,"insulin degludec/liraglutide, insulin degludec, liraglutide","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2011-05-23,2012-05-24,https://clinicaltrials.gov/study/NCT01336023
NCT02910570,Changes in Skin Autoflouresence Following Weight Loss and Maintenance Using Liraglutide in Knee Osteoarthritis,Unknown,COMPLETED,"Liraglutide 3 mg (Saxenda), Liraglutide 3 mg placebo","DRUG, DRUG",Other,Parker Research Institute,"['Osteoarthritis, Knee']",2016-11,2019-02,https://clinicaltrials.gov/study/NCT02910570
NCT02072096,A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM),Unknown,TERMINATED,"Glimepiride, Metformin, Pioglitazone, Acarbose, Linagliptin, Sitagliptin, Liraglutide, Insulin Glargine, Exenatide once weekly (QW), Exenatide twice daily (BID)","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2014-02,2015-10,https://clinicaltrials.gov/study/NCT02072096
NCT01473953,"Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects",Unknown,COMPLETED,"liraglutide-depot, placebo","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2', 'Healthy']",2011-10,2012-03,https://clinicaltrials.gov/study/NCT01473953
NCT03642600,The Gut Microbiome in Women With Polycystic Ovary Syndrome,Unknown,COMPLETED,"dietary advice plus myo-inositol and folic acid, dietary advice plus Liraglutide Pen Injector","DIETARY_SUPPLEMENT, DRUG",Other,Universitaire Ziekenhuizen KU Leuven,"['PCOS', 'Obesity', 'Metabolic Syndrome']",2019-02-28,2020-02-01,https://clinicaltrials.gov/study/NCT03642600
NCT06976619,The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes,Unknown,RECRUITING,"Liraglutide Pen Injector, Saline Injections","DRUG, OTHER",Other,Mayo Clinic,"['Type 1 Diabetes', 'Type 2 Diabetes']",2025-10-03,2028-10-30,https://clinicaltrials.gov/study/NCT06976619
NCT01403025,Evaluating the Safety and Effectiveness of Liraglutide in Subjects With Type 2 Diabetes,Unknown,COMPLETED,liraglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2011-07-19,2015-12-28,https://clinicaltrials.gov/study/NCT01403025
NCT02527993,Treatment of Hypoglycemia Following Gastric Bypass Surgery,Unknown,COMPLETED,"Glucobay (acarbose), Januvia (sitagliptin), Verapamil HEXAL (verapamil), Victoza (liraglutide), Signifor (pasireotide), Continuous glucose monitoring (CGM), Meal tolerance test (MTT)","DRUG, DRUG, DRUG, DRUG, DRUG, DEVICE, DIETARY_SUPPLEMENT",Other,Zealand University Hospital,"['Hypoglycemia', 'Obesity', 'Surgery']",2015-10,2017-04-08,https://clinicaltrials.gov/study/NCT02527993
NCT02147925,Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects,Unknown,COMPLETED,"Liraglutide combined with metformin, Insulin glargine combined with metformin, Sitagliptin combined with metformin","DRUG, DRUG, DRUG",Other,Sun Yat-sen University,['Non-alcoholic Fatty Liver Disease'],2014-08,2017-04,https://clinicaltrials.gov/study/NCT02147925
NCT01599338,"Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic Patients",Unknown,COMPLETED,Liraglutide,DRUG,Other,Centre Hospitalier Universitaire Dijon,"['Type 2 Diabetes Mellitus', 'Overweight']",2011-01,2011-01,https://clinicaltrials.gov/study/NCT01599338
NCT06201819,Liraglutide Effectiveness in Preoperative Weight-loss for Bariatric-metabolic Surgery,Unknown,COMPLETED,Liraglutide injection,DRUG,Other,Unidad de Cirugia Bariatrica Hospital Civil Dr. Juan I. Menchaca,"['Weight Loss', 'Bariatric Surgery Candidate', 'Obesity, Morbid']",2022-12-18,2023-03-18,https://clinicaltrials.gov/study/NCT06201819
NCT02611232,Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults,Unknown,UNKNOWN,"Victoza®, Placebo","DRUG, DRUG",Other,University of Oulu,['Type 1 Diabetes'],2015-12,2024-06,https://clinicaltrials.gov/study/NCT02611232
NCT02928471,Multi-parametric Imaging of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss,Unknown,COMPLETED,Intensive dietary intervention,DIETARY_SUPPLEMENT,Other,Henrik Gudbergsen,"['Osteoarthritis', 'Obesity']",2016-11,2019-02,https://clinicaltrials.gov/study/NCT02928471
NCT03225209,Medically Reproducing Bariatric Surgery,Unknown,COMPLETED,OPTIFAST,OTHER,Other,Moahad S Dar,['Type 2 Diabetes Mellitus'],2018-01-31,2018-10-23,https://clinicaltrials.gov/study/NCT03225209
NCT02008682,"The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes",Unknown,COMPLETED,"liraglutide, sitagliptin","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2013-12,2014-11,https://clinicaltrials.gov/study/NCT02008682
NCT01117350,Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure,Unknown,COMPLETED,"Insulin glargine, Liraglutide, Metformin","DRUG, DRUG, DRUG",Other,Sanofi,"['Diabetes Mellitus, Type 2']",2010-07,2012-10,https://clinicaltrials.gov/study/NCT01117350
NCT00873223,Examination of the Effects of Liraglutide on the Mode of Action of Insulin Detemir,Unknown,COMPLETED,"liraglutide, insulin detemir","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2009-03,2009-09,https://clinicaltrials.gov/study/NCT00873223
NCT03426085,The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes,Unknown,UNKNOWN,"Liraglutide 6 mg Solution for Injection, Placebo","DRUG, OTHER",Other,Eastern Virginia Medical School,"['Autonomic Nervous System Diseases', 'Sweat Gland Diseases', 'Diabetic Neuropathy With Neurologic Complication']",2016-05,2020-04,https://clinicaltrials.gov/study/NCT03426085
NCT01029886,Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes,Unknown,COMPLETED,"exenatide once weekly, liraglutide","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2010-01,2011-01,https://clinicaltrials.gov/study/NCT01029886
NCT01628445,Study of Liraglutide in Individuals With Type 2 Diabetes Using Insulin,Unknown,TERMINATED,"liraglutide, placebo injection","DRUG, DRUG",Other,University of Manitoba,['Type 2 Diabetes'],2012-08,2015-11,https://clinicaltrials.gov/study/NCT01628445
NCT02036372,"Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus",Unknown,COMPLETED,"Liraglutide, Insulin bolus, GIK infusion","DRUG, DRUG, DRUG",Other,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),['Diabetes Mellitus Type II'],2014-01,2017-01,https://clinicaltrials.gov/study/NCT02036372
NCT03341429,Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response,Unknown,COMPLETED,"Liraglutide Pen Injector [Saxenda], Placebo","DRUG, DRUG",Other,"University College, London",['Obesity'],2018-08-22,2019-11-28,https://clinicaltrials.gov/study/NCT03341429
NCT02483299,Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary Syndrome,Unknown,COMPLETED,"Metformin, Glucophage tablets and Victoza","DRUG, DRUG",Other,University Medical Centre Ljubljana,"['PCOS', 'Obesity']",2014-01,2015-04,https://clinicaltrials.gov/study/NCT02483299
NCT02518945,Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes,Unknown,COMPLETED,"Dapagliflozin, Insulin, Liraglutide, Dapagliflozin placebo","DRUG, DRUG, DRUG, DRUG",Other,University at Buffalo,['Type 1 Diabetes Mellitus'],2015-08,2015-12,https://clinicaltrials.gov/study/NCT02518945
NCT03799198,Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity,Unknown,COMPLETED,"Weight Management Program (WMP), Medication for chronic weight management (Rx)","OTHER, DRUG",Other,Novo Nordisk A/S,['Obesity'],2019-01-07,2020-05-22,https://clinicaltrials.gov/study/NCT03799198
NCT03856047,Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity.,Unknown,COMPLETED,"NNC0174-0833, Placebo (NNC0174-0833), Liraglutide 3.0 mg, Placebo (Liraglutide 3.0 mg)","DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Overweight', 'Obesity']",2019-03-01,2020-03-02,https://clinicaltrials.gov/study/NCT03856047
NCT00700817,"The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus",Unknown,COMPLETED,"liraglutide, sitagliptin, metformin, liraglutide","DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2008-06,2009-06,https://clinicaltrials.gov/study/NCT00700817
NCT05153590,A Research Study About Weight Loss and Treatment Patterns With the Use of Saxenda® in Adults in Real-life Settings in Switzerland,Unknown,COMPLETED,Saxenda®,DRUG,Other,Novo Nordisk A/S,['Obesity or Overweight'],2021-12-03,2022-04-15,https://clinicaltrials.gov/study/NCT05153590
NCT01234649,Combined Liraglutide and Metformin Therapy in Women With Previous Gestational Diabetes Mellitus (GDM),Unknown,COMPLETED,"Metformin XR plus placebo, Metformin XR plus liraglutide","DRUG, DRUG",Other,Woman's,"['Gestational Diabetes Mellitus', 'Type 2 Diabetes Mellitus', 'Metabolic Syndrome', 'Impaired Glucose Tolerance', 'Disorder of Glucose Regulation']",2011-08-11,2019-04-24,https://clinicaltrials.gov/study/NCT01234649
NCT01795248,The Impact of Liraglutide on Glucose Tolerance and the Risk of Type 2 Diabetes in Women With Previous Pregnancy-induced Diabetes,Unknown,COMPLETED,"Liraglutide, Placebo","DRUG, DRUG",Other,Tina Vilsboll,['Gestational Diabetes Mellitus'],2012-07,2019-09,https://clinicaltrials.gov/study/NCT01795248
NCT01954147,Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus,Unknown,UNKNOWN,"GLP-1, SC, Standard Medical Treatment","DRUG, BIOLOGICAL, OTHER",GLP-1 agonist,Diabetes Care Center of Nanjing Military Command,['Type 2 Diabetes'],2013-10,2014-10,https://clinicaltrials.gov/study/NCT01954147
NCT03757130,Multiple Ascending Dose Study of AMG 598 in Adults With Obesity,Unknown,COMPLETED,"AMG 598, Placebo, Liraglutide","DRUG, DRUG, DRUG",Other,Amgen,['Obesity'],2018-11-26,2019-12-16,https://clinicaltrials.gov/study/NCT03757130
NCT01845259,Does a GLP-1 Receptor Agonist Change Glucose Tolerance in Antipsychotic-treated Patients?,Unknown,UNKNOWN,"Liraglutide, Liraglutide Placebo","DRUG, DRUG",Other,Psychiatric Centre Rigshospitalet,['Impaired Glucose Tolerance Associated With Drugs'],2013-04,2016-03,https://clinicaltrials.gov/study/NCT01845259
NCT02973321,A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"SAR425899, Placebo, Liraglutide, Metformin","DRUG, DRUG, DRUG, DRUG",Other,Sanofi,['Type 2 Diabetes Mellitus'],2016-12-02,2017-12-27,https://clinicaltrials.gov/study/NCT02973321
NCT01509755,Comparison of Liraglutide and Glimepiride on Blood Sugar Control in Subjects With Type 2 Diabetes,Unknown,COMPLETED,"placebo, liraglutide, glimepiride","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2000-10,2001-10,https://clinicaltrials.gov/study/NCT01509755
NCT02650206,Effect of Liraglutide (Victoza) on Inflammation in Human Adipose Tissue and Blood,Unknown,COMPLETED,"Victoza (liraglutide) with dietician monitoring, Placebo with dietician monitoring","DRUG, OTHER",Other,Stanford University,"['Diabetes Mellitus, Type 2', 'Diabetes Mellitus, Type II', 'Diabetes Mellitus, Adult-Onset', 'Inflammation']",2015-01,2019-09-27,https://clinicaltrials.gov/study/NCT02650206
NCT01654120,Study of Effectiveness of Liraglutide Added to High Dose Insulin in Type II Diabetics,Unknown,COMPLETED,"Liraglutide, Insulin","DRUG, DRUG",Other,Mountain Diabetes and Endocrine Center,"['Diabetes Mellitus, Type II']",2011-12,2013-11,https://clinicaltrials.gov/study/NCT01654120
NCT05479591,A Research Study Looking at Blood Sugar Control in People With Type 2 Diabetes Previously Treated With Premix Insulin and Initiating Treatment With Insulin Degludec/Liraglutide (IDegLira) in Local Clinical Practice in Croatia,Unknown,WITHDRAWN,IDegLira,DRUG,Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2022-07-30,2023-04-30,https://clinicaltrials.gov/study/NCT05479591
NCT02100475,"A Trial Comparing Sequential Addition of Insulin Aspart Versus Further Dose Increase With Insulin Degludec/Liraglutide in Subjects With Type 2 Diabetes Mellitus, Previously Treated With Insulin Degludec/Liraglutide and Metformin and in Need of Further Intensification",Unknown,COMPLETED,"insulin degludec/liraglutide, insulin aspart","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2014-04,2015-04,https://clinicaltrials.gov/study/NCT02100475
NCT02055014,Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity),Unknown,UNKNOWN,"Liraglutide, Duodenal-jejunal bypass liner - Endobarrier device","DRUG, DEVICE",Other,Sandwell & West Birmingham Hospitals NHS Trust,"['Type 2 Diabetes', 'Obesity', 'Diabesity']",2013-07,2017-03,https://clinicaltrials.gov/study/NCT02055014
NCT02960659,Title: Therapeutic Targets in African-American Youth With Type 2 Diabetes,Unknown,COMPLETED,"Liraglutide, Metformin","DRUG, DRUG",Other,National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK),['Type 2 Diabetes'],2017-05-09,2022-05-20,https://clinicaltrials.gov/study/NCT02960659
NCT07244003,Efficacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabetes With Poor Glycemic Control,Unknown,RECRUITING,"Metformin, Triple Therapy of Other Oral Antidiabetic Drugs, ganagliflozin, liraglutide","DRUG, DRUG, DRUG, DRUG",Triple agonist,"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.",['T2DM (Type 2 Diabetes Mellitus)'],2025-03-29,2027-12-31,https://clinicaltrials.gov/study/NCT07244003
NCT02650596,Effects of GLP-1 on Chronic Heart Failure,Unknown,UNKNOWN,"GLP-1, Placebo","DRUG, DRUG",GLP-1 agonist,Shi Yang,['Heart Failure'],2016-01,2018-02,https://clinicaltrials.gov/study/NCT02650596
NCT01508923,Effect of Liraglutide on Glucose Profiles and Gastric Emptying in Subjects With Type 2 Diabetes,Unknown,COMPLETED,"liraglutide, placebo","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2001-05,2002-02,https://clinicaltrials.gov/study/NCT01508923
NCT02235961,"Investigate Safety, Tolerability and Pharmacokinetics for Single Doses of NNC9204-0530 Alone and in Combination With Liraglutide in Overweight to Obese But Otherwise Healthy Male Subjects",Unknown,COMPLETED,"NNC9204-0530, liraglutide, placebo","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Metabolism and Nutrition Disorder', 'Obesity']",2014-09-04,2016-07-06,https://clinicaltrials.gov/study/NCT02235961
NCT02138045,Treatment of Diabetic Neuropathy With Liraglutide,Unknown,COMPLETED,"Placebo treatment, Liraglutide treatment","DRUG, DRUG",Other,Aalborg University Hospital,"['Diabetes Mellitus, Type 1', 'Type 1 Diabetes Mellitus']",2014-05,2017-02,https://clinicaltrials.gov/study/NCT02138045
NCT03011008,Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus,Unknown,UNKNOWN,"Liraglutide, Insulin","DRUG, DRUG",Other,Second Xiangya Hospital of Central South University,"['Type 1 Diabetes Mellitus', 'Autoimmune Diabetes']",2017-01,2020-12,https://clinicaltrials.gov/study/NCT03011008
NCT03500484,Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.,Phase 1,TERMINATED,Liraglutide,DRUG,Other,Yale University,"['Obesity, Childhood', 'Neural Development']",2018-06-06,2020-06-25,https://clinicaltrials.gov/study/NCT03500484
NCT04417582,Life Style Modification Medical and Surgical Management in Patients With Obesity,Unknown,UNKNOWN,bariatric surgey,PROCEDURE,Other,Marmara University,"['Obesity', 'Weight Change, Body', 'Obesity; Endocrine', 'Obesity, Metabolically Benign']",2020-01-01,2023-12-01,https://clinicaltrials.gov/study/NCT04417582
NCT06449703,A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects,Unknown,RECRUITING,"insulin degludec/liraglutide, Xultophy®","DRUG, DRUG",Other,"Tonghua Dongbao Pharmaceutical Co.,Ltd",['Healthy'],2024-05-06,2024-06-16,https://clinicaltrials.gov/study/NCT06449703
NCT01542242,Liraglutide Use in Prader-Willi Syndrome,Unknown,TERMINATED,Liraglutide,DRUG,Other,Vancouver General Hospital,"['Diabetes Mellitus Type 2', 'Prader Willi Syndrome']",2012-02,2013-03,https://clinicaltrials.gov/study/NCT01542242
NCT02931370,Ultrasound of the Knee in Obese Patients With Knee Osteoarthritis; Weight Loss,Unknown,COMPLETED,Dietary Supplement: Intensive dietary intervention,DIETARY_SUPPLEMENT,Other,Henrik Gudbergsen,"['Osteoarthritis', 'Obesity']",2016-11,2019-02,https://clinicaltrials.gov/study/NCT02931370
NCT01784965,Liraglutide and a Calorie Restricted Diet Augments Weight Loss and Decreases Risk of Type 2 Diabetes and CVD.,Unknown,COMPLETED,"liraglutide, Placebo","DRUG, DRUG",Other,Stanford University,"['Pre-diabetes', 'Older Adults']",2009-12,2012-12,https://clinicaltrials.gov/study/NCT01784965
NCT01541215,"Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 Diabetes",Unknown,COMPLETED,"liraglutide, placebo, metformin","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2012-11-13,2017-11-15,https://clinicaltrials.gov/study/NCT01541215
NCT02754817,A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus,Unknown,COMPLETED,insulin degludec/liraglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2016-04-26,2016-10-20,https://clinicaltrials.gov/study/NCT02754817
NCT01624259,A Study Comparing the Effect of Dulaglutide With Liraglutide in Type 2 Diabetes,Unknown,COMPLETED,"LY2189265, Liraglutide, Metformin","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes'],2012-06,2013-11,https://clinicaltrials.gov/study/NCT01624259
NCT05172999,Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia,Unknown,ACTIVE_NOT_RECRUITING,"levonorgestrel-releasing intrauterine system, Polyethylene Glycol Loxenatide","DEVICE, DRUG",Other,Fudan University,"['Atypical Endometrial Hyperplasia', 'Obesity', 'Fertility Issues']",2022-01-08,2024-12-30,https://clinicaltrials.gov/study/NCT05172999
NCT06720246,Impact of Bariatric Surgery and Liraglutide on Cognitive-Behavioral Markers of Long-Term Weight Loss in Obesity,Unknown,RECRUITING,,,Unknown,I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio,['Obesity and Overweight'],2024-06-26,2027-05-01,https://clinicaltrials.gov/study/NCT06720246
NCT01821846,Investigating the Safety Profile of Liraglutide Under Normal Conditions of Use in Korean Subjects With Type 2 Diabetes Mellitus,Unknown,COMPLETED,liraglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2013-11-20,2017-03-08,https://clinicaltrials.gov/study/NCT01821846
NCT05225974,A Randomized Phase 1 Study of Liralutide Injection in Healthy Chinese Subjects,Unknown,COMPLETED,"Liraglutide injection, Liraglutide injection(Victoza®)","DRUG, DRUG",Other,The Affiliated Hospital of Qingdao University,['Therapeutic Equivalency'],2021-07-16,2021-07-30,https://clinicaltrials.gov/study/NCT05225974
NCT02423824,Cognitive Dysfunction and Glucagon-like Peptide-1 Agonists,Unknown,COMPLETED,Liraglutide,BIOLOGICAL,Other,"University Health Network, Toronto","['Bipolar Disorder', 'Major Depressive Disorder']",2015-05,2016-04,https://clinicaltrials.gov/study/NCT02423824
NCT01451905,GLP-1 Receptors in Normal Skin and Skin From Patients With Psoriasis,Unknown,UNKNOWN,"Liraglutide, Placebo","DRUG, DRUG",Other,"University Hospital, Gentofte, Copenhagen",['Reduction of Psoriasis Following Liraglutide Therapy in Terms of PASI and DLQI'],2011-08,2012-12,https://clinicaltrials.gov/study/NCT01451905
NCT01507311,Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes,Unknown,COMPLETED,"liraglutide, placebo","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",1999-09,1999-12,https://clinicaltrials.gov/study/NCT01507311
NCT01843075,Evaluating Liraglutide in Alzheimer's Disease,Unknown,UNKNOWN,"Liraglutide, Placebo","DRUG, DRUG",Other,Imperial College London,"[""Alzheimer's Disease""]",2014-01,2019-12,https://clinicaltrials.gov/study/NCT01843075
NCT01618162,The Efficacy of Insulin Degludec/Liraglutide as add-on Therapy in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on Sulphonylurea With or Without Metformin Therapy,Unknown,COMPLETED,"insulin degludec/liraglutide, placebo","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2012-08-29,2013-10-23,https://clinicaltrials.gov/study/NCT01618162
NCT01394341,Liraglutide Treatment to Patients With Severe Renal Insufficiency,Unknown,COMPLETED,Liraglutide,DRUG,Other,Bo Feldt-Rasmussen,"['Type 2 Diabetes Mellitus', 'End-stage Renal Disease']",2011-09,2013-10,https://clinicaltrials.gov/study/NCT01394341
NCT05221229,Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF ),Unknown,ACTIVE_NOT_RECRUITING,Liraglutide plus upstream risk factors modification advice and consultation,DRUG,Other,University Hospital Birmingham,"['Atrial Fibrillation', 'Recurrence', 'Overweight and Obesity', 'Liraglutide']",2022-04-17,2025-06-30,https://clinicaltrials.gov/study/NCT05221229
NCT04575194,Study of the Cardiometabolic Effects of Obesity Pharmacotherapy,Unknown,UNKNOWN,"Liraglutide 6 MG/ML [Saxenda], Naltrexone-Bupropion Combination","DRUG, DRUG",Other,National and Kapodistrian University of Athens,"['Obesity', 'Blood Pressure']",2020-09-08,2022-09-30,https://clinicaltrials.gov/study/NCT04575194
NCT07225829,A Trial to Investigate the Safety and Efficacy of Intra-articular 4P004 Injection in Subjects With Knee Synovitis and Osteoarthritis,Unknown,RECRUITING,"4P004, Placebo (NaCl 0.9%)","DRUG, DRUG",Other,4Moving Biotech,"['Knee Osteoarthritis', 'Synovitis of Knee']",2025-06-17,2026-05,https://clinicaltrials.gov/study/NCT07225829
NCT01392898,Liraglutide and Insulin Therapy in Patients With Type 2 Diabetes,Unknown,UNKNOWN,"liraglutide, Insulin","DRUG, DRUG",Other,Radboud University Medical Center,['Type 2 Diabetes Mellitus'],2012-02,2014-05,https://clinicaltrials.gov/study/NCT01392898
NCT01499108,Time Course of the Blood Pressure Lowering Effect of Liraglutide Therapy in Type 2 Diabetes,Unknown,COMPLETED,liraglutide,DRUG,Other,Peter Rossing,['Type 2 Diabetes'],2012-08,2013-07,https://clinicaltrials.gov/study/NCT01499108
NCT01512108,Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone,Unknown,COMPLETED,"liraglutide, oral anti-diabetic drug","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2012-01-10,2013-04-26,https://clinicaltrials.gov/study/NCT01512108
NCT02490176,Effects of Glucagon Like Peptide-1 on Haemodynamic Parameters,Unknown,UNKNOWN,"liraglutide, placebo","DRUG, DRUG",Other,Chinese PLA General Hospital,['Heart Failure'],2015-07,2016-07,https://clinicaltrials.gov/study/NCT02490176
NCT01507389,Safety of Liraglutide in Subjects With Liver Impairment and in Subjects With Normal Liver Function,Unknown,COMPLETED,liraglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2006-03,2006-06,https://clinicaltrials.gov/study/NCT01507389
NCT02443155,A Clinical Proof-of-principle Trial in Adult Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Investigating the Effect of NNC0114-0006 and Liraglutide on Preservation of Beta-cell Function,Unknown,COMPLETED,"NNC0114-0006, liraglutide, placebo","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 1']",2015-11-10,2018-08-31,https://clinicaltrials.gov/study/NCT02443155
NCT01572740,Efficacy and Safety of Liraglutide in Combination With Insulin Therapy Compared to Insulin Alone in Japanese Subjects With Type 2 Diabetes,Unknown,COMPLETED,"liraglutide, placebo, insulin","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2012-04-05,2012-11-01,https://clinicaltrials.gov/study/NCT01572740
NCT03347890,Reward Mechanisms in Obesity,Unknown,COMPLETED,Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml or Placebo,DRUG,Other,Zoltan Pataky,['Obesity'],2018-03-05,2020-03-18,https://clinicaltrials.gov/study/NCT03347890
NCT03888157,"A Research Study Looking at How Victoza® Works in People With Type 2 Diabetes in Iran, Followed in Local Clinical Routine",Unknown,COMPLETED,Liraglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes Mellitus, Type 2']",2019-03-10,2020-10-21,https://clinicaltrials.gov/study/NCT03888157
NCT00620282,The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"liraglutide, placebo, glimepiride","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2008-02,2010-05,https://clinicaltrials.gov/study/NCT00620282
NCT03374956,Individualized Obesity Pharmacotherapy,Unknown,COMPLETED,"Phentermine-Topiramate, Liraglutide, Naltrexone/bupropion, Phentermine","DRUG, DRUG, DRUG, DRUG",Other,Mayo Clinic,['Obesity'],2017-12-11,2022-05-26,https://clinicaltrials.gov/study/NCT03374956
NCT03804411,Prognostic Predictors of Response to Hypoglycemic Therapy,Unknown,UNKNOWN,"Automatic system guided treatment, Standard treatment","DRUG, DRUG",Other,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","['Diabetes Mellitus, Type 2']",2017-08-01,2020-03,https://clinicaltrials.gov/study/NCT03804411
NCT01511692,Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 Diabetes,Unknown,COMPLETED,"liraglutide, placebo, placebo, glimepiride","DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2005-11,2007-09,https://clinicaltrials.gov/study/NCT01511692
NCT04605861,The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients,Unknown,COMPLETED,"Liraglutide, Placebo","DRUG, DRUG",Other,Shanghai Zhongshan Hospital,"['Obese', 'Overweight']",2020-08-18,2022-12-31,https://clinicaltrials.gov/study/NCT04605861
NCT01753362,Liraglutide In Overweight Patients With Type 1 Diabetes,Unknown,COMPLETED,"liraglutide, placebo","DRUG, DRUG",Other,University at Buffalo,['Type 1 Diabetes'],2012-12,2017-12,https://clinicaltrials.gov/study/NCT01753362
NCT02473809,"The Effect of Liraglutide on Bone Turnover, Bone Mass and Bone Cell Function",Unknown,COMPLETED,"Liraglutide, Placebo","DRUG, DRUG",Other,University of Aarhus,"['Diabetes Complications', 'Osteoporosis']",2015-08,2017-10,https://clinicaltrials.gov/study/NCT02473809
NCT02696148,"A Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Liraglutide in Obese Children Aged 7 to 11 Years",Unknown,COMPLETED,"liraglutide, placebo","DRUG, DRUG",Other,Novo Nordisk A/S,"['Metabolism and Nutrition Disorder', 'Obesity']",2016-03-14,2017-04-13,https://clinicaltrials.gov/study/NCT02696148
NCT01513525,Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers,Unknown,COMPLETED,liraglutide,DRUG,Other,Novo Nordisk A/S,"['Diabetes', 'Healthy']",2007-02,2007-05,https://clinicaltrials.gov/study/NCT01513525
NCT06559722,A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes,Unknown,NOT_YET_RECRUITING,"Insulin Degludec/liraglutide Injection, XULTOPHY®","DRUG, DRUG",Other,"Tonghua Dongbao Pharmaceutical Co.,Ltd",['Type 2 Diabetes'],2024-08,2025-10,https://clinicaltrials.gov/study/NCT06559722
NCT03479762,In Market Utilisation of Liraglutide Used for Weight Management in the UK: a Study in the CPRD Primary Care Database,Unknown,COMPLETED,Liraglutide,DRUG,Other,Novo Nordisk A/S,"['Obesity', 'Overweight']",2018-04-20,2022-09-12,https://clinicaltrials.gov/study/NCT03479762
NCT02016846,Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for Diabetes,Unknown,UNKNOWN,"Liraglutide, Placebo","DRUG, DRUG",Other,Rabin Medical Center,['Glucocorticoid Induced Hyperglycemia'],2014-01,2015-01,https://clinicaltrials.gov/study/NCT02016846
NCT03672812,The Use of Liraglutide in Brain Death,Unknown,COMPLETED,Liraglutide,DRUG,Other,Hospital de Clinicas de Porto Alegre,['Brain Death'],2018-09-01,2019-12-10,https://clinicaltrials.gov/study/NCT03672812
NCT04373967,Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes,Unknown,UNKNOWN,"Victoza®., Metformin Hydrochloride, TQZ2451","DRUG, DRUG, DRUG",Other,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",['Type 2 Diabetes'],2020-04-29,2021-12-01,https://clinicaltrials.gov/study/NCT04373967
NCT06438146,LIROH - Liraglutide for Obesity in HIV,Unknown,RECRUITING,Liraglutide,DRUG,Other,Brigham and Women's Hospital,"['Obesity', 'HIV Infections']",2024-05-02,2025-05,https://clinicaltrials.gov/study/NCT06438146
NCT03520062,The Effect of Liraglutide on Pancreatic Hormones and Its Size,Unknown,COMPLETED,Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml,DRUG,Other,Nicolai Jacob Wewer Albrechtsen,['Obesity'],2017-08-15,2019-04-30,https://clinicaltrials.gov/study/NCT03520062
NCT01982630,Study of the Safety and Efficacy of MK-8521 Compared to Placebo and a Diabetes Drug in Participants With Type 2 Diabetes Mellitus (MK-8521-003),Unknown,COMPLETED,"MK-8521, Liraglutide, Placebo","DRUG, DRUG, DRUG",Other,Merck Sharp & Dohme LLC,['Diabetes Mellitus'],2013-11-07,2014-10-03,https://clinicaltrials.gov/study/NCT01982630
NCT01511159,Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male Volunteers,Unknown,COMPLETED,"liraglutide, placebo, liraglutide, liraglutide, insulin human, insulin human, liraglutide","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Healthy']",2001-10,2001-12,https://clinicaltrials.gov/study/NCT01511159
NCT00331851,Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes,Unknown,COMPLETED,"liraglutide, insulin glargine, metformin, glimepiride","DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2006-05,2007-04,https://clinicaltrials.gov/study/NCT00331851
NCT05767255,Risk of Hypoglycemia in the Transition From Inpatient to Outpatient Setting. Comparative Study of Basal-bolus Insulin Versus Basal Insulin Plus GLP-1 Analogue,Unknown,UNKNOWN,"insulin degludec + liraglutide, Insulin Glargine - Insulin Aspart","DRUG, DRUG",Other,Hospital Universitario San Ignacio,"['Diabetes Mellitus, Type 2 Treated With Insulin']",2022-12-01,2023-08-30,https://clinicaltrials.gov/study/NCT05767255
NCT01515592,Safety and Tolerability of Liraglutide in Healthy Japanese Male Volunteers,Unknown,COMPLETED,"liraglutide, liraglutide, liraglutide, placebo","DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2006-01,2006-04,https://clinicaltrials.gov/study/NCT01515592
NCT03948347,Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus,Unknown,UNKNOWN,Liraglutide,DRUG,Other,First Affiliated Hospital of Jinan University,"['Ischemic Stroke', 'Transient Ischemic Attack', 'Type 2 Diabetes Mellitus']",2019-06-25,2023-12,https://clinicaltrials.gov/study/NCT03948347
NCT01916174,"A Trial to Demonstrate Bioequivalence Between Two Insulin Degludec/Liraglutide Formulations, B5 and V2 in Healthy Subjects",Unknown,COMPLETED,"insulin degludec/liraglutide, insulin degludec/liraglutide","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2', 'Healthy']",2013-08,2013-11,https://clinicaltrials.gov/study/NCT01916174
NCT01518166,Effect of Liraglutide on Gastrointestinal Absorption of Several Drugs and Potential Influence of Liraglutide on Intragastric pH,Unknown,COMPLETED,"liraglutide, placebo, atorvastatin, lisinopril, griseofulvin, digoxin","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Healthy']",2006-05,2007-04,https://clinicaltrials.gov/study/NCT01518166
NCT06865365,Preoperative Use of Liraglutide Additionally to Common Dietological Measures as Opposed to Dietological Measures Alone,Unknown,NOT_YET_RECRUITING,"Liraglutide daily (0.6-3.0mg, highest tolerable dose) additional to dietological measures and lifestyle optimization suggestions, Dietologic measures and lifestyle optimization for weight loss","DRUG, BEHAVIORAL",Other,Medical University of Vienna,"['Obesity, Adolescent']",2025-05-01,2027-02-01,https://clinicaltrials.gov/study/NCT06865365
NCT01296412,Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403),Unknown,COMPLETED,"sitagliptin, liraglutide, glimepiride, metformin","DRUG, DRUG, DRUG, DRUG",Other,Merck Sharp & Dohme LLC,"['Diabetes Mellitus, Type 2']",2011-03-11,2012-02-29,https://clinicaltrials.gov/study/NCT01296412
NCT02743598,Liraglutide for HIV-associated Neurocognitive Disorder,Unknown,TERMINATED,Liraglutide,DRUG,Other,Temple University,"['HIV Infection', 'Diabetes Mellitus Type 2', 'Obesity', 'Overweight', 'Metabolic Syndrome']",2016-09,2018-06-01,https://clinicaltrials.gov/study/NCT02743598
NCT06818292,Investigation of the Relationship Between Peripheral and Central Metabolic Changes Induced by GLP-1 Agonists,Unknown,COMPLETED,"Liraglutide, Placebo","BIOLOGICAL, BIOLOGICAL",Other,Nils Opel,['Healthy'],2024-10-21,2024-12-06,https://clinicaltrials.gov/study/NCT06818292
NCT01299012,Liraglutide as Additional Treatment in Patients With Type 1 Diabetes Mellitus,Unknown,COMPLETED,Liraglutide,DRUG,Other,University at Buffalo,['Type 1 Diabetes Mellitus'],2010-10,2013-02,https://clinicaltrials.gov/study/NCT01299012
NCT02089256,Effect of Repeated Administration of Liraglutide on Insulinogenic Indices,Unknown,COMPLETED,Liraglutide,DRUG,Other,University of Tartu,['Healthy'],2014-06,2015-03,https://clinicaltrials.gov/study/NCT02089256
NCT01615978,Safety and Tolerability of Liraglutide in Japanese Subjects With Type 2 Diabetes,Unknown,COMPLETED,"liraglutide, liraglutide, placebo","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2003-12,2004-03,https://clinicaltrials.gov/study/NCT01615978
NCT01232946,Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake,Unknown,COMPLETED,"liraglutide, insulin detemir, liraglutide plus insulin detemir","DRUG, DRUG, DRUG",Other,Indiana University,['Type 2 Diabetes'],2012-01,2017-09-08,https://clinicaltrials.gov/study/NCT01232946
NCT01789086,"A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 Years",Unknown,COMPLETED,"liraglutide, placebo","DRUG, DRUG",Other,Novo Nordisk A/S,"['Metabolism and Nutrition Disorder', 'Obesity']",2013-02,2014-05,https://clinicaltrials.gov/study/NCT01789086
NCT02909933,Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity,Unknown,COMPLETED,"liraglutide, metformin and liraglutide","DRUG, DRUG",Other,University Medical Centre Ljubljana,"['Polycystic Ovary Syndrome', 'Obesity']",2015-07,2015-10,https://clinicaltrials.gov/study/NCT02909933
NCT00614120,Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 Diabetes,Unknown,COMPLETED,"liraglutide, placebo, liraglutide, liraglutide, glimepiride, metformin, placebo","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2008-01,2009-02,https://clinicaltrials.gov/study/NCT00614120
NCT01455441,The Effects of Physical Training and GLP-1 Receptor Agonist Liraglutide Treatment in Patients With Type 2 Diabetes,Unknown,COMPLETED,"Training and liraglutide, Training and placebo","OTHER, OTHER",Other,Tina Vilsboll,['Type 2 Diabetes'],2011-10,2013-06,https://clinicaltrials.gov/study/NCT01455441
NCT01782261,Incretin Effect on the Immunological Phenotype,Unknown,COMPLETED,"Liraglutide, Saxagliptin","DRUG, DRUG",Other,Medical University of Graz,['Type 1 Diabetes'],2012-02,2015-02,https://clinicaltrials.gov/study/NCT01782261
NCT02895672,GLP-1/Basal Insulin Combination Therapy,Unknown,COMPLETED,GLP-1 therapy,DRUG,GLP-1 agonist,Albany College of Pharmacy and Health Sciences,['Type 2 Diabetes Mellitus'],2016-08,2016-11,https://clinicaltrials.gov/study/NCT02895672
NCT05360537,"Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients",Unknown,COMPLETED,"Insulin Degludec / Liraglutide Injectable Product, Insulin Glargine","DRUG, DRUG",Other,University of Palermo,"['Diabetes Mellitus, Type 2']",2021-04-01,2021-12-01,https://clinicaltrials.gov/study/NCT05360537
NCT02488057,Improving Beta Cell Function in Mexican American Women With Prediabetes,Unknown,COMPLETED,"Liraglutide, Weight loss","DRUG, BEHAVIORAL",Other,Ohio State University,['Pre-Diabetes'],2016-05,2019-03,https://clinicaltrials.gov/study/NCT02488057
NCT06439056,Phase 1 Study Assessing the Pharmacokinetics of NEX-22A in Subjects With T2D,Unknown,COMPLETED,"NEX-22A, a prolonged release formulation of liraglutide",DRUG,Other,Nanexa AB,['Type 2 Diabetes'],2024-05-27,2025-07-18,https://clinicaltrials.gov/study/NCT06439056
NCT01511172,"Effect of Liraglutide as add-on to Metformin Compared to Either Liraglutide or Metformin Alone, or to a Combination of Metformin and a SU (Sulphonylurea) Agent in Subjects With Type 2 Diabetes",Unknown,COMPLETED,"liraglutide, metformin, placebo, placebo, glimepiride","DRUG, DRUG, DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2002-08,2002-12,https://clinicaltrials.gov/study/NCT01511172
NCT01191268,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-4),Unknown,COMPLETED,"Insulin Glargine, LY2189265, Insulin Lispro","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2010-11,2012-02,https://clinicaltrials.gov/study/NCT01191268
NCT03824002,"Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables",Unknown,COMPLETED,"Dulaglutide, Aspart insulin, Glargine, Metformin, Repaglinide","DRUG, DRUG, DRUG, DRUG, DRUG",Other,University of Palermo,['Diabetes Mellitus'],2017-04-01,2017-10-01,https://clinicaltrials.gov/study/NCT03824002
NCT01458210,A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants,Unknown,COMPLETED,"Ortho-Cyclen, Dulaglutide","DRUG, BIOLOGICAL",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2011-10,2012-02,https://clinicaltrials.gov/study/NCT01458210
NCT02770885,Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study),Unknown,COMPLETED,"Dulaglutide, Placebo","DRUG, DRUG",Other,"University Hospital, Basel, Switzerland",['Primary Polydipsia'],2016-03,2019-05-17,https://clinicaltrials.gov/study/NCT02770885
NCT05946148,Novel Antidiabetic Medications and Their Effect on Liver Steatosis (NAMELS-18),Unknown,COMPLETED,"Empagliflozin, Dulaglutide, Control Rx","DRUG, DRUG, DRUG",Other,National and Kapodistrian University of Athens,"['Non-Alcoholic Fatty Liver Disease', 'Liver Steatosis']",2018-06-01,2021-05-31,https://clinicaltrials.gov/study/NCT05946148
NCT03204396,Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues,Unknown,COMPLETED,"Dulaglutide, 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])","DRUG, DRUG",Other,"University Hospital, Basel, Switzerland","['Glucagon-like Peptide-1', 'Smoking Cessation', 'Weight Change, Body', 'Craving']",2017-06-26,2022-07-30,https://clinicaltrials.gov/study/NCT03204396
NCT04641312,A Study of LY3457263 in Healthy Participants and Participants With Type 2 Diabetes,Unknown,COMPLETED,"LY3457263, Dulaglutide, Placebo","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Healthy', 'Type 2 Diabetes']",2020-11-25,2021-12-21,https://clinicaltrials.gov/study/NCT04641312
NCT01301092,A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.,Unknown,COMPLETED,LY2189265,BIOLOGICAL,Other,Eli Lilly and Company,"['Diabetes Mellitus, Type II']",2011-02,2011-08,https://clinicaltrials.gov/study/NCT01301092
NCT06331286,The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity,Unknown,UNKNOWN,dulaglutide injection,DRUG,Other,First Affiliated Hospital of Zhejiang University,"['Bipolar Disorder', 'Obesity', 'Cognition']",2023-09-01,2024-12-31,https://clinicaltrials.gov/study/NCT06331286
NCT06739122,A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS),Unknown,RECRUITING,Dulaglutide,DRUG,Other,Eli Lilly and Company,['Type 2 Diabetes'],2025-01-10,2026-06,https://clinicaltrials.gov/study/NCT06739122
NCT05048719,A Study of LY3502970 in Participants With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"LY3502970, Dulaglutide, Placebo, Placebo","DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes'],2021-09-15,2022-09-30,https://clinicaltrials.gov/study/NCT05048719
NCT01468181,A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"LY2189265, Sulfonylureas (SU), Biguanides (BG), alpha-glucosidase inhibitor (a-GI), Thiazolidinedione (TZD), Glinides","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes Mellitus'],2011-11,2013-12,https://clinicaltrials.gov/study/NCT01468181
NCT02963766,A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes,Unknown,COMPLETED,"Dulaglutide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes'],2016-12-29,2021-06-12,https://clinicaltrials.gov/study/NCT02963766
NCT01149421,A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 Diabetes,Unknown,COMPLETED,"LY2189265, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2010-06,2011-09,https://clinicaltrials.gov/study/NCT01149421
NCT04893148,Efficacy and Safety of iGlarLixi Versus Insulin Glargine Plus Dulaglutide in Patients With Type 2 Diabetes,Unknown,UNKNOWN,"IGlarLixi, Dulaglutide","DRUG, DRUG",Other,Chungbuk National University Hospital,"['Type 2 Diabetes Mellitus', 'Glucose, High Blood']",2020-05-26,2021-12-30,https://clinicaltrials.gov/study/NCT04893148
NCT05459285,A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects,Unknown,COMPLETED,"14028 injection, dulaglutide injection","BIOLOGICAL, BIOLOGICAL",Other,"Sunshine Lake Pharma Co., Ltd.",['Type 2 Diabetes'],2022-05-31,2022-07-02,https://clinicaltrials.gov/study/NCT05459285
NCT05254418,Effects of GLP1-RA on Ectopic Fat Deposition in Chronic Kidney Disease,Unknown,COMPLETED,dulaglutide injection,DRUG,Other,Vanderbilt University Medical Center,['Chronic Kidney Diseases'],2022-03-15,2024-05-01,https://clinicaltrials.gov/study/NCT05254418
NCT01126580,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3),Unknown,COMPLETED,"Metformin, LY2189265, Placebo (oral), Placebo (subcutaneous)","DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2010-05,2011-11,https://clinicaltrials.gov/study/NCT01126580
NCT04387201,GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response,Unknown,COMPLETED,"Cyanocobalamin, Dulaglutide","DRUG, DRUG",Other,"The University of Texas Health Science Center, Houston","['Glucose Intolerance', 'Overweight and Obesity', 'Drug Effect', 'Adiposity']",2020-05-15,2023-10-06,https://clinicaltrials.gov/study/NCT04387201
NCT01432938,A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants,Unknown,COMPLETED,"dulaglutide, Warfarin","BIOLOGICAL, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2011-09,2011-12,https://clinicaltrials.gov/study/NCT01432938
NCT03962010,"A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus",Unknown,UNKNOWN,"GX-G6, Control","DRUG, DRUG",Other,"Genexine, Inc.",['Type 2 Diabetes Mellitus'],2019-06-01,2022-06-01,https://clinicaltrials.gov/study/NCT03962010
NCT04876027,GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS),Unknown,COMPLETED,"GLP-1 RAs, calorie restricted diet","DRUG, OTHER",GLP-1 agonist,Shanghai 10th People's Hospital,['Polycystic Ovary Syndrome'],2021-05-15,2022-04-30,https://clinicaltrials.gov/study/NCT04876027
NCT05680129,A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM,Unknown,COMPLETED,"Ecnoglutide high dosage, Ecnoglutide low dosage, Dulaglutide, Metformin","DRUG, DRUG, DRUG, DRUG",Other,"Hangzhou Sciwind Biosciences Co., Ltd.","['T2DM', 'Type 2 Diabetes Mellitus']",2023-01-10,2024-07-03,https://clinicaltrials.gov/study/NCT05680129
NCT02750410,A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes,Unknown,COMPLETED,"Dulaglutide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes'],2016-08,2018-06-18,https://clinicaltrials.gov/study/NCT02750410
NCT06235086,A Study of TG103 Injection Combined With Metformin in Treatment of Type 2 Diabetes Mellitus,Unknown,ACTIVE_NOT_RECRUITING,"TG103, Dulaglutide","DRUG, DRUG",Other,"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.",['Type 2 Diabetes Mellitus'],2024-04-08,2026-03-30,https://clinicaltrials.gov/study/NCT06235086
NCT06257966,A Phase 3 Study to Evaluate the Efficacy of JY09 Compared With Dulaglutide in Combination Therapy Diabetes Mellitus Type 2 Patients With Metformin,Unknown,ACTIVE_NOT_RECRUITING,"Exendin-4 Fc fusion protein injection(1.2mg）, Exendin-4 Fc fusion protein injection（2.4mg）, Dulaglutide, Metformin","DRUG, DRUG, DRUG, DRUG",Other,"Beijing Dongfang Biotech Co., Ltd.",['Type2 Diabetes Mellitus'],2024-07-17,2026-10-01,https://clinicaltrials.gov/study/NCT06257966
NCT05516966,"Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus",Unknown,COMPLETED,"HRS9531, Placebo, Dulaglutide Injection","DRUG, DRUG, DRUG",Other,"Fujian Shengdi Pharmaceutical Co., Ltd.","['Diabetes Mellitus, Type 2']",2022-10-12,2023-05-24,https://clinicaltrials.gov/study/NCT05516966
NCT05478707,Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes,Unknown,RECRUITING,"Dulaglutide, Placebo, exercise training","DRUG, DRUG, BEHAVIORAL",Other,University of Virginia,"['Diabetes Mellitus, Type 1', 'Endothelial Dysfunction']",2023-10-05,2027-06-30,https://clinicaltrials.gov/study/NCT05478707
NCT03724981,A Study Comparing the Dulaglutide Pen and the Semaglutide Pen,Unknown,COMPLETED,"Dulaglutide Pen, Semaglutide Pen","DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2018-10-18,2019-04-12,https://clinicaltrials.gov/study/NCT03724981
NCT05348122,A Study of TG103 Injection in Type 2 Diabetes Subjects,Unknown,UNKNOWN,"TG103,Q2W, TG103,QW, Placebo,Q2W, Placebo,QW, Dulaglutide,QW","DRUG, DRUG, DRUG, DRUG, DRUG",Other,"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.",['Type 2 Diabetes Mellitus'],2022-06-15,2023-11-01,https://clinicaltrials.gov/study/NCT05348122
NCT05606913,A Study of IBI362 in Participants With Type 2 Diabetes,Unknown,COMPLETED,"dulaglutide, IBI362","DRUG, DRUG",Other,Innovent Biologics (Suzhou) Co. Ltd.,['Type 2 Diabetes'],2023-01-06,2024-01-26,https://clinicaltrials.gov/study/NCT05606913
NCT05492305,Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health,Unknown,UNKNOWN,GLP-1 receptor agonist,DRUG,GLP-1 agonist,King's College London,"['Diabetes Mellitus', 'Obesity', 'Mental Health Issue']",2022-09,2023-06,https://clinicaltrials.gov/study/NCT05492305
NCT02152371,A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes,Unknown,COMPLETED,"Dulaglutide, Placebo, Insulin Glargine, Metformin","DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2014-05,2015-10,https://clinicaltrials.gov/study/NCT02152371
NCT05305794,"Effect of Weekly GLP1 Agonist Treatment in ""double Diabetes""",Unknown,RECRUITING,"Insulin + semaglutide treatment, Usual insulin treatment, Biological check-up","DRUG, DRUG, BIOLOGICAL",Other,Centre Hospitalier Universitaire Dijon,['Double Diabetes'],2022-07-12,2026-08,https://clinicaltrials.gov/study/NCT05305794
NCT05005741,The Effects of Glucose Control and Weight Loss Between Beinaglutide and Dulaglutide in Type 2 Diabetes With Overweight or Obesity.,Unknown,UNKNOWN,"Beinaglutide, Dulaglutide","DRUG, DRUG",Other,Second Xiangya Hospital of Central South University,"['Diabetes Mellitus, Type 2', 'Overweight or Obesity']",2021-05-01,2023-12-31,https://clinicaltrials.gov/study/NCT05005741
NCT03141632,Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake,Unknown,COMPLETED,"Dulaglutide, Placebo","DRUG, OTHER",Other,"University Hospital, Basel, Switzerland","['Thirst', 'Water-Electrolyte Imbalance']",2016-10-17,2017-05,https://clinicaltrials.gov/study/NCT03141632
NCT04687514,Effects of Glucagon-Like Peptide-1 Analogs on Sexuality,Unknown,COMPLETED,"Dulaglutide, Placebo","DRUG, DRUG",Other,"University Hospital, Basel, Switzerland",['Sexual Functioning'],2021-05-05,2022-09-05,https://clinicaltrials.gov/study/NCT04687514
NCT06148649,Phase 2 Study of HEC88473 Injection in Subjects With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"HEC88473, Placebo, Dulaglutide",DRUG,Other,"Dongguan HEC Biopharmaceutical R&D Co., Ltd.",['Type 2 Diabetes'],2023-12-10,2025-02-27,https://clinicaltrials.gov/study/NCT06148649
NCT03668470,Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes,Unknown,COMPLETED,"Dulaglutide, Placebo","DRUG, DRUG",Other,Hospices Civils de Lyon,['Adult Subjects With Type1Diabetes and Insulin Microsecretion'],2019-01-31,2021-02-03,https://clinicaltrials.gov/study/NCT03668470
NCT03648554,Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST),Unknown,UNKNOWN,"dulaglutide (TRULICITY®) 1.5 mg, reinforced dietary monitoring","DRUG, OTHER",Other,"Central Hospital, Nancy, France","['Diabetes Mellitus, Type 2', 'NASH - Nonalcoholic Steatohepatitis']",2019-09-01,2023-09-30,https://clinicaltrials.gov/study/NCT03648554
NCT00791479,Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes,Unknown,COMPLETED,"LY2189265 and Lifestyle Measures, Placebo solution and Lifestyle Measures","DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2008-12,2010-01,https://clinicaltrials.gov/study/NCT00791479
NCT04135287,Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients,Unknown,UNKNOWN,GLP-1 receptor agonist,DRUG,GLP-1 agonist,Dasman Diabetes Institute,"['Diabetes Mellitus, Type 2']",2020-03-01,2023-03-01,https://clinicaltrials.gov/study/NCT04135287
NCT05390892,PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes,Unknown,RECRUITING,"SGLT2 inhibitor, GLP-1 receptor agonist","DRUG, DRUG",GLP-1 agonist,Brigham and Women's Hospital,"['Type2Diabetes', 'ASCVD']",2022-09-26,2029-03-01,https://clinicaltrials.gov/study/NCT05390892
NCT02846233,Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?,Unknown,COMPLETED,"GLP1 receptor agonist, basal insulin, SGLT2 inhibitor, Metformin","DRUG, DRUG, DRUG, DRUG",GLP-1 agonist,"University of California, San Francisco",['Type 2 Diabetes Mellitus'],2016-08,2018-12,https://clinicaltrials.gov/study/NCT02846233
NCT02597049,A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"Dulaglutide, Placebo, SGLT2 inhibitor, Metformin","DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes Mellitus'],2015-11,2017-02,https://clinicaltrials.gov/study/NCT02597049
NCT01769378,Study of How Dulaglutide Compares to Placebo in Participants With Type 2 Diabetes Who Are Also on Sulfonylurea Therapy (AWARD-8),Unknown,COMPLETED,"Placebo, Dulaglutide, Glimepiride","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes Mellitus'],2013-01,2014-12,https://clinicaltrials.gov/study/NCT01769378
NCT03444142,Effect of Exenatide LAR or Dulaglutide on the Variability of 24-hour Heart Rate and Blood Pressure in Type 2 Diabetes,Unknown,UNKNOWN,"Exenatide LAR, Dulaglutide","DRUG, DRUG",Other,University of Guadalajara,"['Diabetes Mellitus, Type 2']",2017-11-17,2021-11-30,https://clinicaltrials.gov/study/NCT03444142
NCT04731272,GLP-1 Agonist Therapy in Cystic Fibrosis-Related Glucose Intolerance,Unknown,RECRUITING,Dulaglutide 0.75Mg/0.5Ml Inj Pen,DRUG,Other,University of Pennsylvania,"['Cystic Fibrosis', 'Pancreatic Insufficiency', 'Abnormal Glucose Tolerance', 'Diabetes']",2021-07-16,2026-06-30,https://clinicaltrials.gov/study/NCT04731272
NCT04829903,Dulaglutide Versus Liraglutide in Obese Type 2 Diabetic Adolescents Using Metformin,Unknown,COMPLETED,"Dulaglutide, Liraglutide","DRUG, DRUG",Other,Corporacion Parc Tauli,"['Type 2 Diabetes Treated With Insulin', 'Obesity', 'Adolescent Obesity']",2020-01-02,2021-03-29,https://clinicaltrials.gov/study/NCT04829903
NCT04867785,A Study of LY3437943 in Participants With Type 2 Diabetes,Unknown,COMPLETED,"LY3437943, Dulaglutide, Placebo","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes'],2021-05-13,2022-07-08,https://clinicaltrials.gov/study/NCT04867785
NCT01250834,LY2189265 and Atorvastatin Interaction Study,Unknown,COMPLETED,"Atorvastatin, LY2189265","DRUG, BIOLOGICAL",Other,Eli Lilly and Company,['Healthy Volunteers'],2010-12,2011-03,https://clinicaltrials.gov/study/NCT01250834
NCT04374578,Effect of Dulaglutide on Glycemic Variability in Patients With Type 2 Diabetes,Unknown,COMPLETED,Dulaglutide 1.5 MG/ML,DRUG,Other,Shanghai Zhongshan Hospital,['Type 2 Diabetes'],2020-05-08,2021-01-31,https://clinicaltrials.gov/study/NCT04374578
NCT01667900,A Study of Dulaglutide in Chinese Participants,Unknown,COMPLETED,"Dulaglutide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2', 'Healthy Volunteers']",2012-08,2014-06,https://clinicaltrials.gov/study/NCT01667900
NCT01324388,A Study of the Effect of LY2189265 on Two Blood Pressure Drugs,Unknown,COMPLETED,"LY2189265, Metoprolol, Lisinopril, Placebo","BIOLOGICAL, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2011-03,2011-08,https://clinicaltrials.gov/study/NCT01324388
NCT01436201,A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants,Unknown,COMPLETED,"Digoxin, Dulaglutide","DRUG, BIOLOGICAL",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2011-09,2011-11,https://clinicaltrials.gov/study/NCT01436201
NCT04143802,A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM),Unknown,COMPLETED,"LY3437943, Dulaglutide, Placebo","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2019-12-18,2020-12-28,https://clinicaltrials.gov/study/NCT04143802
NCT05161429,BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes,Unknown,UNKNOWN,"DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU","DRUG, DRUG, DRUG, DRUG, DRUG",GLP-1 agonist,Brigham and Women's Hospital,"['Diabetes Mellitus, Type 2']",2021-07-01,2024-06-30,https://clinicaltrials.gov/study/NCT05161429
NCT03363906,A Study of Dulaglutide in Healthy Participants,Unknown,COMPLETED,"Dulaglutide (Reference), Dulaglutide (Test)","DRUG, DRUG",Other,Eli Lilly and Company,['Healthy'],2017-12-07,2018-06-06,https://clinicaltrials.gov/study/NCT03363906
NCT03495102,A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes,Unknown,COMPLETED,Dulaglutide,DRUG,Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2018-04-05,2019-05-28,https://clinicaltrials.gov/study/NCT03495102
NCT01253304,A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment,Unknown,COMPLETED,LY2189265,DRUG,Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2010-11,2011-11,https://clinicaltrials.gov/study/NCT01253304
NCT01558271,A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"LY2189265, Placebo, Liraglutide","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes Mellitus'],2012-03,2013-10,https://clinicaltrials.gov/study/NCT01558271
NCT02973100,A Study of Investigational Dulaglutide Doses in Participants With Type 2 Diabetes on Metformin Monotherapy,Unknown,COMPLETED,"Dulaglutide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes'],2016-12,2017-07-15,https://clinicaltrials.gov/study/NCT02973100
NCT05407961,A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"LY3532226, Placebo, Dulaglutide","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2022-06-07,2024-01-12,https://clinicaltrials.gov/study/NCT05407961
NCT06324461,GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery,Unknown,RECRUITING,Dulaglutide 0.75mg subcutaneous injection,DRUG,Other,The University of Hong Kong,['Myocardial Injury'],2024-03-20,2028-12-31,https://clinicaltrials.gov/study/NCT06324461
NCT01644500,A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus,Unknown,COMPLETED,"Dulaglutide, Glimepiride, Placebo as Capsules, Placebo as SC Injection","DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes Mellitus'],2012-07,2014-08,https://clinicaltrials.gov/study/NCT01644500
NCT04591626,A Study of Dulaglutide (LY2189265) in Chinese Participants With Type 2 Diabetes,Unknown,COMPLETED,"Dulaglutide, Placebo, Insulin Glargine","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes Mellitus'],2020-12-07,2022-04-28,https://clinicaltrials.gov/study/NCT04591626
NCT07109700,A Study of HDM1005 in Participants With T2DM Not Controlled With Diet/Exercise or Metformin,Unknown,RECRUITING,"HDM1005 1, HDM1005 2, HDM1005 3, HDM1005 4, Placebo, Dulaglutide 1.5 MG","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,"Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.",['Type 2 Diabetes'],2025-04-30,2026-01-31,https://clinicaltrials.gov/study/NCT07109700
NCT00734474,A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin,Unknown,COMPLETED,"LY2189265, Sitagliptin, Placebo solution, Placebo tablet, Metformin","DRUG, DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2008-08,2011-06,https://clinicaltrials.gov/study/NCT00734474
NCT01394952,Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND),Unknown,COMPLETED,"Dulaglutide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Cardiovascular Disease', 'Diabetes Mellitus, Type 2']",2011-07-22,2018-08-21,https://clinicaltrials.gov/study/NCT01394952
NCT01064687,A Study in Participants With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"LY2189265, Exenatide, Placebo, Metformin, Pioglitazone","DRUG, DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2010-02,2011-11,https://clinicaltrials.gov/study/NCT01064687
NCT03590626,Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease,Unknown,COMPLETED,Dulaglutide,DRUG,Other,"Medanta, The Medicity, India","['Non Alcoholic Fatty Liver Disease', 'Type2 Diabetes Mellitus']",2019-01-01,2020-01-14,https://clinicaltrials.gov/study/NCT03590626
NCT03315780,A Study of the Glucodynamic Effects of Dulaglutide (LY2189265) in Japanese Participants With Type 2 Diabetes,Unknown,COMPLETED,"Dulaglutide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes'],2017-10-28,2018-02-28,https://clinicaltrials.gov/study/NCT03315780
NCT02787551,"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period",Unknown,COMPLETED,"Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Sanofi,['Type 2 Diabetes Mellitus'],2016-07-06,2018-05-25,https://clinicaltrials.gov/study/NCT02787551
NCT01621178,A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD),Unknown,COMPLETED,"Dulaglutide, Insulin glargine, Insulin lispro","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Type 2 Diabetes', 'Chronic Kidney Disease']",2012-07,2016-06,https://clinicaltrials.gov/study/NCT01621178
NCT06901648,A Study of HS-20094 in Patients With T2DM,Unknown,COMPLETED,"HS-20094, Dulaglutide, Palcebo","DRUG, DRUG, DRUG",Other,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",['Type 2 Diabetes'],2024-02-06,2025-03-07,https://clinicaltrials.gov/study/NCT06901648
NCT03684642,Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin,Unknown,TERMINATED,"Efpeglenatide, Dulaglutide, Background therapy Metformin","DRUG, DRUG, DRUG",Other,Sanofi,['Type 2 Diabetes Mellitus'],2018-09-26,2020-10-13,https://clinicaltrials.gov/study/NCT03684642
NCT01524770,A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe,Unknown,COMPLETED,Dulaglutide,BIOLOGICAL,Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2012-03,2012-06,https://clinicaltrials.gov/study/NCT01524770
NCT00630825,A Study of Dose Titration of LY2189265 in Overweight Participants With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"LY2189265, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Diabetes Mellitus Type 2'],2008-04,2009-01,https://clinicaltrials.gov/study/NCT00630825
NCT05377333,A Study of LY3457263 Alone and in Combination With Dulaglutide (LY2189265) in Participants With Type 2 Diabetes,Unknown,COMPLETED,"LY3457263, Placebo, Dulaglutide","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2022-06-02,2023-11-22,https://clinicaltrials.gov/study/NCT05377333
NCT06611904,The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria,Unknown,ACTIVE_NOT_RECRUITING,"Dulaglutide, DPP-4 Inhibitors","DRUG, DRUG",Other,Attikon Hospital,"['Urine Albumin (UAlb)', 'Glycocalyx', 'Arterial Stiffness']",2018-02-01,2022-02-05,https://clinicaltrials.gov/study/NCT06611904
NCT04515576,A Study of LY3493269 in Participants With Type 2 Diabetes,Unknown,COMPLETED,"LY3493269, Dulaglutide, Placebo","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2020-08-25,2021-03-09,https://clinicaltrials.gov/study/NCT04515576
NCT05140694,Effect of Empagliflozin and Dulaglutide on MAFLD in Patients With T2D,Unknown,NOT_YET_RECRUITING,"Empagliflozin, Dulaglutide, Empagliflozin and Dulaglutide","DRUG, DRUG, DRUG",Other,Seoul National University Bundang Hospital,"['Metabolic-associated Fatty Liver Disease', 'Type 2 Diabetes']",2023-12-01,2024-06-30,https://clinicaltrials.gov/study/NCT05140694
NCT03959865,GLP-1 REceptor Agonists and Real World EvIdeNce,Unknown,UNKNOWN,"Long-acting GLP-1RA, Short-acting GLP-1RA, Human-based GLP-1RA, Exendin-based GLP-1RA, Fixed ratio BI/GLP-1RA combination, Flexible BI/GLP-1RA combination","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",GLP-1 agonist,University of Padova,['Type 2 Diabetes'],2018-12-19,2019-02-11,https://clinicaltrials.gov/study/NCT03959865
NCT04466904,Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM,Unknown,COMPLETED,"IBI362, Placebo, Dulaglutide","DRUG, DRUG, DRUG",Other,Innovent Biologics (Suzhou) Co. Ltd.,['Type 2 Diabetes'],2020-09-12,2021-05-28,https://clinicaltrials.gov/study/NCT04466904
NCT07156539,A Phase 3 Study of HS-20094 in Patients With T2DM,Unknown,NOT_YET_RECRUITING,"HS-20094 Injection, Dulaglutide Injection","DRUG, DRUG",Other,"Jiangsu Hansoh Pharmaceutical Co., Ltd.",['Type 2 Diabetes'],2025-09-30,2027-03-30,https://clinicaltrials.gov/study/NCT07156539
NCT03015220,Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes,Unknown,COMPLETED,"Semaglutide, Dulaglutide","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2017-01-10,2018-07-12,https://clinicaltrials.gov/study/NCT03015220
NCT03936660,A 12 Month Site Randomized Trial in Adults With Type 2 Diabetes Mellitus and History of Cardiovascular Disease,Unknown,COMPLETED,Intense Education Intervention,OTHER,Other,Duke University,"['Diabetes Mellitus, Type 2', 'Cardiovascular Diseases']",2019-07-25,2022-12-30,https://clinicaltrials.gov/study/NCT03936660
NCT01075282,A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2),Unknown,COMPLETED,"Insulin Glargine, LY2189265, Metformin, Glimepiride","DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2010-02,2012-05,https://clinicaltrials.gov/study/NCT01075282
NCT04184947,Cardiovascular Outcomes SGLT-2 Inhibitors Versus GLP-1 Receptor Agonists,Unknown,COMPLETED,"SGLT2 inhibitor, GLP-1 receptor agonist","DRUG, DRUG",GLP-1 agonist,University of Padova,['Type 2 Diabetes'],2014-03-01,2018-12-31,https://clinicaltrials.gov/study/NCT04184947
NCT06851962,Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes Clinical Trial,Unknown,NOT_YET_RECRUITING,"Metformin, Dulaglutide, Semaglutide 1.0 mg, Empagliflozin (BI 10773), Canagliflozin, Dapagliflozin, pioglitazone, Sitagliptin, Vildagliptin (Galvus), linagliptin","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Fundación para la Investigación del Hospital Clínico de Valencia,['Diabetes Mellitus Type 2'],2025-04,2026-06,https://clinicaltrials.gov/study/NCT06851962
NCT03492580,A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease,Unknown,COMPLETED,"Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Glucagon-like Peptide-1 (GLP-1) Agonist, Anti-hyperglycemic Agents (AHA), Thiazolidinediones (TZD), Sulfonylureas (SU), Insulin","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",GLP-1 agonist,"Janssen Research & Development, LLC","['Diabetes Mellitus, Type 2', 'Cardiovascular Diseases']",2018-02-22,2018-04-06,https://clinicaltrials.gov/study/NCT03492580
NCT01511393,An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC),Unknown,ENROLLING_BY_INVITATION,No treatment given,OTHER,Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2', 'Medullary Thyroid Carcinoma', 'Weight Management']",2012-01,2039-12,https://clinicaltrials.gov/study/NCT01511393
NCT01648582,A Study Comparing the Effects and Safety of Dulaglutide With Insulin Glargine in Type 2 Diabetes Mellitus,Unknown,COMPLETED,"Dulaglutide, Insulin glargine, Metformin, Sulfonylureas","DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes Mellitus'],2012-07,2014-08,https://clinicaltrials.gov/study/NCT01648582
NCT01001104,A Study of LY2189265 in Japanese Patients With Type 2 Diabetes,Unknown,COMPLETED,"LY2189265, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2009-10,2010-12,https://clinicaltrials.gov/study/NCT01001104
NCT04862234,Perioperative Stress Hyperglycemia in General and Vascular Surgery Patients,Unknown,TERMINATED,"Dulaglutide, Placebo, Continuous glucose monitor (CGM), blinded","DRUG, DRUG, DEVICE",Other,Emory University,['Hyperglycemia Stress'],2021-08-06,2023-06-22,https://clinicaltrials.gov/study/NCT04862234
NCT05659537,A Study of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes Mellitus in India,Unknown,COMPLETED,Dulaglutide,DRUG,Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2022-12-29,2024-01-16,https://clinicaltrials.gov/study/NCT05659537
NCT06581120,GLP_1 RA Ultrasound Study,Unknown,ENROLLING_BY_INVITATION,"Glucagon-Like Peptide-1 receptor agonists, Point of Care Gastric Ultrasound","DRUG, DIAGNOSTIC_TEST",Other,"Children's Hospital Medical Center, Cincinnati","['Glucagon Like Peptide-1 (GLP-1', 'Delayed Gastric Emptying', 'Risk of Aspiration', 'Diabetes', 'Morbid Obesity']",2024-07-08,2026-07,https://clinicaltrials.gov/study/NCT06581120
NCT01408888,A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes,Unknown,COMPLETED,"LY2189265, Sitagliptin","BIOLOGICAL, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2011-08,2012-04,https://clinicaltrials.gov/study/NCT01408888
NCT06449235,Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh,Unknown,NOT_YET_RECRUITING,"Omarigliptin, Sulphonylureas, Metformin, Other DPP4-i, Thiazolidinediones, Alpha-Glucosidase Inhibitor, Glucagon-Like Peptide-1, Receptor Agonists (GLP1RA), SGLT2 inhibitors","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",GLP-1 agonist,"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders",['Type2diabetes'],2024-09,2025-04,https://clinicaltrials.gov/study/NCT06449235
NCT05196958,Interest of GLP1 Analogues in Overweight Type 2 Diabetic Patients With Chronic Inflammatory Bowel Disease,Unknown,UNKNOWN,GLP1 analogues,OTHER,GLP-1 agonist,Fondation Hôpital Saint-Joseph,"['Inflammatory Bowel Diseases', 'Diabetes Mellitus, Type 2']",2022-01-25,2024-01-14,https://clinicaltrials.gov/study/NCT05196958
NCT03498001,Effects of GLP-1 Agonists on CArdiac Steatosis Evaluated by Magnetic Resonance Imaging,Unknown,COMPLETED,"GLP-1 agonists, Cardiac MRI, Follow up by phone","DRUG, PROCEDURE, OTHER",GLP-1 agonist,Centre Hospitalier Universitaire Dijon,['Type II Diabetes'],2018-04-16,2023-06-06,https://clinicaltrials.gov/study/NCT03498001
NCT01584232,A Study of Dulaglutide in Japanese Participants With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"LY2189265, Insulin glargine, Sulfonylureas (SU), Biguanide (BG)","DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes Mellitus'],2012-04,2013-07,https://clinicaltrials.gov/study/NCT01584232
NCT03743025,Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients,Unknown,TERMINATED,"Dulaglutide Injection, Saline Injection","DRUG, OTHER",Other,Emory University,['Stress Hyperglycemia'],2019-03-08,2023-05-02,https://clinicaltrials.gov/study/NCT03743025
NCT01300260,Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose,Unknown,COMPLETED,"LY2189265, Placebo, Insulin, Glucose, Glucagon","BIOLOGICAL, DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2011-02,2011-08,https://clinicaltrials.gov/study/NCT01300260
NCT04965506,A Study of IBI362 in Chinese Patients With Type 2 Diabetes,Unknown,COMPLETED,"IBI362, placebo, Dulaglutide","DRUG, OTHER, OTHER",Other,Innovent Biologics (Suzhou) Co. Ltd.,['Type 2 Diabetes'],2021-09-06,2022-04-28,https://clinicaltrials.gov/study/NCT04965506
NCT01215968,A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"LY2189265, Placebo","BIOLOGICAL, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2010-09,2011-07,https://clinicaltrials.gov/study/NCT01215968
NCT04200625,Semaglutide vs Dulaglutide on Epicardial Adipose Tissue,Unknown,COMPLETED,,,Unknown,University of Miami,['Epicardial Fat'],2019-09-24,2019-12-09,https://clinicaltrials.gov/study/NCT04200625
NCT04189848,Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc,Unknown,COMPLETED,"Semaglutide, Dulaglutide","DRUG, DRUG",Other,Novo Nordisk A/S,"['Healthy Volunteers', 'Diabetes Mellitus, Type 2', 'Overweight', 'Obesity']",2019-12-03,2020-01-29,https://clinicaltrials.gov/study/NCT04189848
NCT04809220,A Study of Two Doses of Dulaglutide (LY2189265) in Japanese Patients With Type 2 Diabetes,Unknown,COMPLETED,"Dulaglutide, Oral antihyperglycemics","DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus', 'Diabetes Mellitus, Type 2', 'Glucose Metabolism Disorders', 'Metabolic Disease', 'Endocrine System Diseases', 'Hypoglycemic Agents', 'Type 2 Diabetes Mellitus (T2DM)']",2021-04-13,2022-10-01,https://clinicaltrials.gov/study/NCT04809220
NCT00679042,Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol,Unknown,ACTIVE_NOT_RECRUITING,Islets of Langerhans transplantation,BIOLOGICAL,Other,CellTrans Inc.,['Type 1 Diabetes Mellitus'],2007-09-05,2017-07-19,https://clinicaltrials.gov/study/NCT00679042
NCT01700075,Physical and Chemical Study of Atherosclerosis Mechanisms,Unknown,COMPLETED,"Conventional treatment, Weight loss treatment","DRUG, DIETARY_SUPPLEMENT",Other,Nazarbayev University,"['Myocardial Infarction', 'Coronary Artery Diseases', 'Diabetes Mellitus, Type 2', 'Atherosclerosis of Femoral Artery']",2009-01,2009-12,https://clinicaltrials.gov/study/NCT01700075
NCT05597475,GLP1R-imaging in Post-RYGB Hypoglycemia,Unknown,RECRUITING,GLP-1R PET,DIAGNOSTIC_TEST,GLP-1 agonist,Rijnstate Hospital,"['Obesity', 'Hypoglycemia Post Gastric Bypass Surgery', 'Hyperinsulinemic Hypoglycemia']",2016-11-01,2024-05-30,https://clinicaltrials.gov/study/NCT05597475
NCT01789957,Extension Study for 2993-112,Unknown,COMPLETED,AC2993,DRUG,Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2002-09,2004-06,https://clinicaltrials.gov/study/NCT01789957
NCT00359762,Exenatide Versus Glimepiride in Patients With Type 2 Diabetes,Unknown,COMPLETED,"exenatide, glimepiride","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2006-09,2011-03,https://clinicaltrials.gov/study/NCT00359762
NCT04431713,Exenatide Once-weekly as a Treatment for Multiple System Atrophy,Unknown,COMPLETED,Exenatide Pen Injector [Bydureon],DRUG,Other,"University College, London",['Multiple System Atrophy'],2020-09-16,2024-03-22,https://clinicaltrials.gov/study/NCT04431713
NCT00960661,"A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes",Unknown,COMPLETED,"exenatide, insulin lispro, Metformin, Insulin/ Glargine","DRUG, DRUG, DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2009-09,2012-08,https://clinicaltrials.gov/study/NCT00960661
NCT02917057,Subanalyses of Elderly Type 2 Diabetes Patients or Type 2 Diabetes Patients With Renal Impairment,Unknown,COMPLETED,"exenatide once weekly, basal insulin","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes'],2015-08-01,2015-08-01,https://clinicaltrials.gov/study/NCT02917057
NCT00477581,A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"exenatide, sitagliptin","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2007-05,2007-09,https://clinicaltrials.gov/study/NCT00477581
NCT01969149,Exenatide for Stress Hyperglycemia,Unknown,COMPLETED,"Exenatide, Insulin","DRUG, DRUG",Other,Centre Hospitalier Universitaire de Besancon,['Stress Hyperglycemia'],2015-01,2015-12,https://clinicaltrials.gov/study/NCT01969149
NCT00845182,Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function,Unknown,COMPLETED,"Pioglitazone, Exenatide, Pioglitazone and Exenatide","DRUG, DRUG, DRUG",Other,The University of Texas Health Science Center at San Antonio,"['Type 2 Diabetes', 'Healthy', 'Impaired Glucose Tolerance']",2007-06,2010-07,https://clinicaltrials.gov/study/NCT00845182
NCT00642538,A Study Designed to Determine the Safety and Pharmacological Response ofMKC253 Inhalation Powder in Adults With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"MKC253 Inhalation Powder, Technosphere Inhalation Powder, subcutaneous injection","DRUG, DRUG, DRUG",Other,Mannkind Corporation,"['Diabetes Mellitus, Type 2']",2008-02,2008-09,https://clinicaltrials.gov/study/NCT00642538
NCT00099619,Comparing Exenatide and Insulin Glargine in Type 2 Diabetes Patients for Whom Insulin is the Next Appropriate Therapy,Unknown,COMPLETED,"exenatide/insulin glargine, insulin glargine/exenatide","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2004-09,2005-08,https://clinicaltrials.gov/study/NCT00099619
NCT02404376,COMBinAtion Therapy in Myocardial Infarction: The COMBAT-MI Trial,Unknown,COMPLETED,"Exenatide, Remote Ischemic Conditioning (RIC), Placebo","DRUG, OTHER, DRUG",Other,Hospital Universitari Vall d'Hebron Research Institute,['ST Elevation Acute Myocardial Infarction'],2016-03,2019-08,https://clinicaltrials.gov/study/NCT02404376
NCT00259896,In-patient Study in Patients With Type 2 Diabetes Mellitus,Unknown,COMPLETED,exenatide,DRUG,Other,GlaxoSmithKline,"['Type 2 Diabetes Mellitus', 'Diabetes Mellitus, Type 2']",2005-10,,https://clinicaltrials.gov/study/NCT00259896
NCT02673931,GLP-1 and Hyperoxia for Organ Protection in Heart Surgery,Unknown,ACTIVE_NOT_RECRUITING,"Byetta (Lilly, Exenatide), Conoxia (AGA, oxygen), 20% Human Albumin","DRUG, DRUG, DRUG",Other,"Rigshospitalet, Denmark","['Coronary Disease', 'Shock, Cardiogenic', 'Renal Failure', 'Stroke', 'Brain Injury', 'Aortic Valve Disease']",2016-02,2024-09,https://clinicaltrials.gov/study/NCT02673931
NCT02119819,A Study to Compare a New Drug for Type 2 Diabetes to Placebo and to a Treatment Already Available for Type 2 Diabetes,Unknown,COMPLETED,"LY2944876, Exenatide extended-release, Placebo, Metformin","DRUG, DRUG, DRUG, DRUG",Other,"OPKO Health, Inc.","['Diabetes Mellitus, Type 2']",2014-04,2015-08,https://clinicaltrials.gov/study/NCT02119819
NCT03060980,"Comparison of Efficacy, Safety, and Tolerability of ITCA 650 to Empagliflozin and Glimepiride as add-on Metformin",Unknown,TERMINATED,"ITCA 650 20/60 mcg/day, Empagliflozin (oral), Glimepiride (oral)","DRUG, DRUG, DRUG",Other,Intarcia Therapeutics,"['Diabetes Mellitus, Type 2']",2017-03-03,2018-01-26,https://clinicaltrials.gov/study/NCT03060980
NCT00948168,Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes,Unknown,COMPLETED,exenatide (Byetta),DRUG,Other,Cliniques universitaires Saint-Luc- Université Catholique de Louvain,['Type 2 Diabetes Mellitus'],2008-07,2009-07,https://clinicaltrials.gov/study/NCT00948168
NCT00044668,"Evaluation of the Effect on Glucose Control and Safety of AC2993 in Patients With Type 2 Diabetes Treated With Metformin, Sulfonylurea, or Metformin and Sulfonylurea Combination",Unknown,COMPLETED,AC2993,DRUG,Other,AstraZeneca,"['Diabetes Mellitus, Type 2']",2002-08,2005-09,https://clinicaltrials.gov/study/NCT00044668
NCT02584075,Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function,Unknown,UNKNOWN,"Byetta (Exenatide), Glucophage ( Metformin Hydrochloride)","DRUG, DRUG",Other,Beijing Chao Yang Hospital,['Coronary Endothelial Function'],2015-11,2017-11,https://clinicaltrials.gov/study/NCT02584075
NCT00937079,Whole Body 111In-exendin-4 Imaging Study in Insulinoma Patients,Unknown,COMPLETED,111In-exendin-4 imaging,OTHER,Other,"University Hospital, Basel, Switzerland","['Hyperinsulinism', 'Hypoglycemia', 'Insulinoma']",2007-11,2011-12,https://clinicaltrials.gov/study/NCT00937079
NCT03182231,GLP1-imaging Before and After Bariatric Surgery,Unknown,UNKNOWN,68Ga-NODAGA-exendin-4 PET/CT,RADIATION,Other,Radboud University Medical Center,"['Diabetes Mellitus, Type 2', 'Bariatric Surgery Candidate']",2016-10-07,2023-07-01,https://clinicaltrials.gov/study/NCT03182231
NCT00324363,Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Metformin or Sulfonylureas and Metformin,Unknown,COMPLETED,"exenatide, Placebo","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2006-01,2007-04,https://clinicaltrials.gov/study/NCT00324363
NCT01444898,Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome,Unknown,COMPLETED,Exenatide,DRUG,Other,Children's Hospital Los Angeles,['Prader-Willi Syndrome'],2012-03,2013-05,https://clinicaltrials.gov/study/NCT01444898
NCT00039026,Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea,Unknown,COMPLETED,"AC2993, AC2993, Placebo, Placebo","DRUG, DRUG, DRUG, DRUG",Other,AstraZeneca,"['Diabetes Mellitus, Non-Insulin-Dependent']",2002-02,2003-08,https://clinicaltrials.gov/study/NCT00039026
NCT02432976,Impact of Perioperative Exenatide Infusion on Quality of Life in Cardiac Surgery Patients,Unknown,COMPLETED,"Exenatide, Insulin","DRUG, DRUG",Other,Centre Hospitalier Universitaire de Besancon,['Quality of Life'],2015-05,2017-01,https://clinicaltrials.gov/study/NCT02432976
NCT02442791,GLP-1 Analogs for Neuroprotection After Cardiac Arrest,Unknown,COMPLETED,"Byetta (Lilly, Exenatide), 20% Human Albumin","DRUG, OTHER",Other,Jesper Kjaergaard,"['Cardiac Arrest', 'Coma']",2014-06,2016-06,https://clinicaltrials.gov/study/NCT02442791
NCT04307797,Effect of Glucagon and Glucagon-like Peptide-1 Co-agonism on Cardiac Function and Metabolism in Overweight Participants with Type 2 Diabetes,Unknown,COMPLETED,"0.9% Sodium-chloride, Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min, Glucagon 12.5ng/kg/min and 0.9% saline, 0.9% Sodium-chloride, Exenatide (50ng/min for 30 minutes loading followed by 25ng/min maintenance) and glucagon 12.5ng/kg/min, Glucagon 12.5ng/kg/min","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Cambridge University Hospitals NHS Foundation Trust,"['Type 2 Diabetes', 'Obesity']",2022-01-18,2022-10-07,https://clinicaltrials.gov/study/NCT04307797
NCT03059719,Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"Exenatide injection(Byetta), PB-119 injection","BIOLOGICAL, BIOLOGICAL",Other,"PegBio Co., Ltd.",['Type II Diabetes Mellitus'],2015-04-08,2016-09-30,https://clinicaltrials.gov/study/NCT03059719
NCT00855439,Evaluation of Exenatide in Patients With Diabetic Neuropathy,Unknown,COMPLETED,"Exenatide, Glargine","DRUG, DRUG",Other,University of Michigan,"['Type 2 Diabetes Mellitus', 'Diabetic Peripheral Neuropathy']",2008-06,2014-05,https://clinicaltrials.gov/study/NCT00855439
NCT02288273,Study to Evaluate the Effect of BYDUREON on 24-hour Glucose Control in Metformin Treated Patients With Type 2 Diabetes.,Unknown,COMPLETED,"Bydureon, Placebo","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes'],2014-12,2015-08,https://clinicaltrials.gov/study/NCT02288273
NCT02090673,Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea,Unknown,COMPLETED,Exenatide,DRUG,Other,AstraZeneca,['Diabetes Mellitus Type 2'],2009-02,2014-03,https://clinicaltrials.gov/study/NCT02090673
NCT01342042,"The Safety,Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus",Unknown,UNKNOWN,rExenatide-4,BIOLOGICAL,Other,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",['Type 2 Diabetes'],2011-03,2011-12,https://clinicaltrials.gov/study/NCT01342042
NCT00085969,Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"Placebo 0.04 mL twice daily, Placebo 0.04 mL once daily, Placebo 0.08 mL once daily, B - Exenatide 10 mcg twice daily, C - Exenatide 10 mcg once daily, Exenatide 20 mcg once daily","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,AstraZeneca,"['Diabetes Mellitus, Type 2']",2003-09,2004-01,https://clinicaltrials.gov/study/NCT00085969
NCT04504370,Safety and Efficacy of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects,Unknown,COMPLETED,"GLP-1 receptor agonist, Placebo","DRUG, DRUG",GLP-1 agonist,"PegBio Co., Ltd.",['Type 2 Diabetes Mellitus (T2DM)'],2020-04-27,2022-03-30,https://clinicaltrials.gov/study/NCT04504370
NCT00845559,The Effects of Exenatide on Post-Meal Sugar Peaks and Vascular Health in Obese/Pre-Diabetic Young Adults,Unknown,WITHDRAWN,Exenatide,DRUG,Other,Yale University,"['Obesity', 'Insulin Resistance', 'Impaired Glucose Tolerance', 'Cardiovascular Disease']",2008-08,2010-03,https://clinicaltrials.gov/study/NCT00845559
NCT00560417,Comparison of Two Basal Insulins for Patients With Type 2 Diabetes Taking Oral Diabetes Medicines and Exenatide,Unknown,COMPLETED,"Insulin Lispro Protamine Suspension, Insulin Glargine","DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2007-11,2009-12,https://clinicaltrials.gov/study/NCT00560417
NCT00935532,Study to Evaluate the Efficacy and Safety of Exenatide Once-Weekly Injection Compared to Once-Daily Insulin in Type 2 Diabetes Mellitus,Unknown,COMPLETED,"exenatide once weekly, insulin glargine","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2009-07,2010-09,https://clinicaltrials.gov/study/NCT00935532
NCT00886626,GLP-1 Therapy for Weight Loss and Improved Glucose Tolerance in Obese Children,Unknown,COMPLETED,Exenatide,DRUG,Other,University of Minnesota,"['Obesity, Morbid']",2009-05,2011-02,https://clinicaltrials.gov/study/NCT00886626
NCT01501084,Effects of the GLP-1 Exenatide on Satiety in Lean and Obese Women,Unknown,COMPLETED,"Exenatide, Normal saline .2cc subcutaneous injection","DRUG, DRUG",Other,"University of California, Los Angeles",['Obesity'],2011-12,2012-12,https://clinicaltrials.gov/study/NCT01501084
NCT01855490,Study of the Acute Metabolic Effect of Exenatide in Type 1 Diabetes,Unknown,COMPLETED,Exenatide,DRUG,Other,Yale University,['Type 1 Diabetes'],2012-01,2013-07,https://clinicaltrials.gov/study/NCT01855490
NCT00744224,PREDnisolone-induced Beta-cell Dysfunction Prevented by EXenatide,Unknown,COMPLETED,"Placebo, Prednisolone, Prednisolone and Exenatide","DRUG, DRUG, DRUG",Other,"Amsterdam UMC, location VUmc","['Glucocorticoid-induced Glucometabolic Abnormalities', 'Glucocorticoid-induced Beta-cell Dysfunction']",2009-02,2010-01,https://clinicaltrials.gov/study/NCT00744224
NCT02641990,Study of the Effect of ITCA 650 on the PK/PD of Oral Contraceptive in Healthy Female Subjects,Unknown,COMPLETED,"ITCA 650 20/60 mcg/day, ITCA placebo, ITCA placebo, ITCA 650 20/60 mcg/day","DRUG, DRUG",Other,Intarcia Therapeutics,['Healthy Adult Premenopausal Female Volunteers'],2015-12,2016-02,https://clinicaltrials.gov/study/NCT02641990
NCT01938235,Exenatide for Myocardial Protection During Reperfusion Study,Unknown,UNKNOWN,"Exenatide, Placebo","DRUG, DRUG",Other,"University Health Network, Toronto",['Myocardial Infarction'],2014-02,2017-07,https://clinicaltrials.gov/study/NCT01938235
NCT05610800,Exenatide for Smoking Cessation and Prevention of Weight Gain,Unknown,RECRUITING,"Exenatide 2 milligram (mg) Injection, Placebo, Nicotine patch, Smoking Cessation Counseling","DRUG, DRUG, DRUG, BEHAVIORAL",Other,"The University of Texas Health Science Center, Houston","['Smoking Cessation', 'Weight Gain']",2022-12-07,2026-03,https://clinicaltrials.gov/study/NCT05610800
NCT01473147,Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients,Unknown,COMPLETED,"Exenatide, Normal saline","DRUG, DRUG",Other,Chang Gung Memorial Hospital,['Type 2 Diabetes Mellitus'],2011-10,2013-06,https://clinicaltrials.gov/study/NCT01473147
NCT00835848,Pharmacological Postconditioning to Reduce Infarct Size Following Primary PCI,Unknown,COMPLETED,"Exenatide, Saline","DRUG, DRUG",Other,"Rigshospitalet, Denmark",['Myocardial Infarction'],2009-01,2009-12,https://clinicaltrials.gov/study/NCT00835848
NCT00516048,An Exploratory Study of the Effect of Treatment Interruption on Safety of Exenatide in Patients With Type 2 Diabetes,Unknown,COMPLETED,exenatide,DRUG,Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2007-08,2008-04,https://clinicaltrials.gov/study/NCT00516048
NCT01976858,A Phase I Study of 8-week Continuous Treatment With Polyethylene Glycol Loxenatide in Patients With Type 2 Diabetes,Unknown,COMPLETED,PEX168,DRUG,Other,"Jiangsu HengRui Medicine Co., Ltd.",['Type 2 Diabetes'],2011-06,2011-09,https://clinicaltrials.gov/study/NCT01976858
NCT01237314,The Impact of Food on Blood Sugar in People With Type 2 Diabetes,Unknown,COMPLETED,,,Unknown,HealthPartners Institute,['Type 2 Diabetes'],2010-11,2013-05,https://clinicaltrials.gov/study/NCT01237314
NCT02802514,A Study Comparing the Effect of Albiglutide With Exenatide on Regional Brain Activity Related to Nausea in Healthy Subjects,Unknown,TERMINATED,"Albiglutide 50mg, Albiglutide matching placebo, Exenatide 10microgram, Exenatide placebo (saline)","DRUG, DRUG, DRUG, DRUG",Other,GlaxoSmithKline,['Diabetes Mellitus'],2016-09-20,2017-08-10,https://clinicaltrials.gov/study/NCT02802514
NCT00064714,Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes,Unknown,COMPLETED,"AC2993 (exenatide), daclizumab (immunosuppressive)","DRUG, DRUG",Other,AstraZeneca,['Diabetes Mellitus'],2003-07,2008-03,https://clinicaltrials.gov/study/NCT00064714
NCT01429506,Efficacy of Laparoscopic Sleeve Gastrectomy and Intensive Medical Management in Obese Type 2 Diabetes,Unknown,COMPLETED,"Sleeve gastrectomy, Intensive medical management","PROCEDURE, DRUG",Other,"Post Graduate Institute of Medical Education and Research, Chandigarh","['Diabetes Mellitus', 'Obesity']",2011-01,2012-08,https://clinicaltrials.gov/study/NCT01429506
NCT01364584,Impact of Exenatide on Cardiovascular Exercise Performance in Type 2 Diabetes,Unknown,COMPLETED,"Exenatide, Placebo","DRUG, DRUG",Other,"University of Colorado, Denver",['Type 2 Diabetes'],2010-10,2014-12,https://clinicaltrials.gov/study/NCT01364584
NCT01455896,A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650,Unknown,COMPLETED,"ITCA 650, ITCA placebo","DRUG, OTHER",Other,Intarcia Therapeutics,['Type 2 Diabetes'],2013-03,2016-03,https://clinicaltrials.gov/study/NCT01455896
NCT01255163,A Pilot Clinical Trial of Exendin-4 in Alzheimer's Disease,Unknown,TERMINATED,"Exendin-4 SC, Placebo SC","DRUG, DRUG",Other,National Institute on Aging (NIA),"[""Alzheimer's Disease"", 'Mild Cognitive Impairment']",2010-11-21,2016-11-18,https://clinicaltrials.gov/study/NCT01255163
NCT00572689,Pilot Study of Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes,Unknown,WITHDRAWN,"Exenatide, Buccal/blood Sample Collection","DRUG, GENETIC",Other,Georgetown University,['Gestational Diabetes'],2013-08,2015-08,https://clinicaltrials.gov/study/NCT00572689
NCT02251431,Extended Release Exenatide Versus Placebo In Diabetic Patients With Type 4 Cardiorenal Syndrome,Unknown,COMPLETED,"BYDUREON, Placebo","DRUG, DRUG",Other,Baylor Research Institute,"['Type 2 Diabetes Mellitus', 'Chronic Kidney Disease', 'Left Ventricular Diastolic Dysfunction']",2015-11,2019-12,https://clinicaltrials.gov/study/NCT02251431
NCT02084654,Exenatide and Weight Loss for Diabetes Prevention,Unknown,COMPLETED,"Exenatide 5 and 10 mcg 2 times a day, placebo","DRUG, DRUG",Other,Stanford University,"['Pre Diabetes', 'Insulin Resistance']",2007-11,2012-10,https://clinicaltrials.gov/study/NCT02084654
NCT00529204,"Effects Of Exenatide On Liver Biochemistry, Liver Histology And Lipid Metabolism In Patients With Fatty Liver Disease",Unknown,TERMINATED,exenatide,DRUG,Other,"University of California, Davis","['Diabetes Complications', 'Fatty Liver']",2007-10,2009-07,https://clinicaltrials.gov/study/NCT00529204
NCT02455076,Exenatide Inpatient Trial: A Randomized Controlled Pilot Trial on the Safety and Efficacy of Exenatide (Byetta®) Therapy for the Inpatient Management of Patients With Type 2 Diabetes,Unknown,COMPLETED,"Exenatide, Glargine, Rapid-acting insulin analogs","DRUG, DRUG, DRUG",Other,Emory University,['Type 2 Diabetes'],2015-09,2018-03,https://clinicaltrials.gov/study/NCT02455076
NCT00753896,Safety of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Treated With Thiazolidinedione Alone or Thiazolidinedione in Combination With Metformin,Unknown,COMPLETED,exenatide,DRUG,Other,AstraZeneca,['Type 2 Diabetes'],2008-10,2009-07,https://clinicaltrials.gov/study/NCT00753896
NCT03160261,Effect of Exenatide on Cortisol Secretion,Unknown,COMPLETED,Exenatide Injection,DRUG,Other,University of Tartu,['Healthy'],2017-09-07,2017-12-28,https://clinicaltrials.gov/study/NCT03160261
NCT00877890,"A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)",Unknown,COMPLETED,"exenatide once weekly, exenatide twice daily","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2009-03,2009-10,https://clinicaltrials.gov/study/NCT00877890
NCT03889496,Quantitative GLP-1 Receptor Imaging Correlated to ex Vivo Distribution of In-111-exendin,Unknown,TERMINATED,indium-111-exendin SPECT/CT,RADIATION,Other,Radboud University Medical Center,['Diabetes Mellitus'],2015-11-16,2021-06-14,https://clinicaltrials.gov/study/NCT03889496
NCT01297062,A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects,Unknown,COMPLETED,"Exenatide, Moxifloxacin, Placebo comparator","DRUG, DRUG, DRUG",Other,AstraZeneca,['Healthy Subjects'],2011-02,2011-04,https://clinicaltrials.gov/study/NCT01297062
NCT00375492,Effect on Weight Loss of Exenatide Versus Placebo,Unknown,COMPLETED,"exenatide, placebo","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2006-09,2008-02,https://clinicaltrials.gov/study/NCT00375492
NCT00381342,Safety and Efficacy of Exenatide as Monotherapy,Unknown,COMPLETED,"exenatide, exenatide, placebo","DRUG, DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2006-09,2007-09,https://clinicaltrials.gov/study/NCT00381342
NCT05328843,Study to Evaluate the Pharmacokinetic Characteristics of Pegylated Exenatide Injection (PB-119) in Subjects With Different Degrees of Renal Insufficiency and Matched Subjects With Normal Renal Function,Unknown,UNKNOWN,PB119,DRUG,Other,"PegBio Co., Ltd.",['Type2Diabetes'],2022-05-01,2022-10-01,https://clinicaltrials.gov/study/NCT05328843
NCT04909333,Exenatide-test for Diagnosing Endogenous Hyperinsulinemic Hypoglycemia,Unknown,COMPLETED,"Exenatide, 0.9% saline solution","DRUG, DRUG",Other,"University Hospital, Basel, Switzerland",['Endogenous Hyperinsulinism'],2021-04-29,2024-04-30,https://clinicaltrials.gov/study/NCT04909333
NCT01783717,Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage,Unknown,UNKNOWN,Exenatide,DRUG,Other,Huashan Hospital,"['Hypothalamic Obesity', 'Diabetes Mellitus']",2012-12,2015-01,https://clinicaltrials.gov/study/NCT01783717
NCT01237197,Exenatide in Extreme Pediatric Obesity,Unknown,COMPLETED,"Exenatide, Placebo","DRUG, DRUG",Other,University of Minnesota,['Obesity'],2010-10,2012-05,https://clinicaltrials.gov/study/NCT01237197
NCT00635492,CHOICE: CHanges to Treatment and Outcomes in Patients With Type 2 Diabetes Initiating InjeCtablE Therapy,Unknown,COMPLETED,"exenatide, any human insulin or analog insulin(s) given in any regimen by subcutaneous injection","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2008-01,2011-12,https://clinicaltrials.gov/study/NCT00635492
NCT05418907,Exendin PET/CT for Imaging of Paragangliomas,Unknown,UNKNOWN,68Ga-NODAGA-exendin-4 PET/CT,RADIATION,Other,Radboud University Medical Center,['Paraganglioma'],2022-06-01,2024-12-01,https://clinicaltrials.gov/study/NCT05418907
NCT01003184,Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes,Unknown,COMPLETED,"exenatide once weekly, insulin detemir","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2009-10,2011-07,https://clinicaltrials.gov/study/NCT01003184
NCT04303819,The Effect of Exenatide on Fasting Bile Acids,Unknown,COMPLETED,Exenatide treatment,DRUG,Other,Beijing Chao Yang Hospital,['Type 2 Diabetes Mellitus in Obese'],2020-01-05,2020-01-28,https://clinicaltrials.gov/study/NCT04303819
NCT02104739,Effects of Antidiabetic Medications on the Postprandial State in Prediabetes,Unknown,COMPLETED,"Exenatide, Saxagliptin, Exenatide extended-release (ER), Placebo","DRUG, DRUG, DRUG, OTHER",Other,"The University of Texas Health Science Center, Houston","['Prediabetes', 'Obesity']",2014-04,2017-03,https://clinicaltrials.gov/study/NCT02104739
NCT04354090,"Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of JY09",Unknown,COMPLETED,JY09,DRUG,Other,"Beijing Dongfang Biotech Co., Ltd.","['Diabetes Mellitus, Type 2']",2018-04-26,2018-12-27,https://clinicaltrials.gov/study/NCT04354090
NCT01021527,A Study to Assess the Effects of Exenatide on Insulin Secretion Rates Using a Graded Infusion of Intravenous Glucose (0000-099)(COMPLETED),Unknown,COMPLETED,"Comparator: Treatment A, Comparator: Treatment B, Comparator: Treatment C, Comparator: graded glucose infusion","OTHER, DRUG, DRUG, PROCEDURE",Other,Merck Sharp & Dohme LLC,['Healthy'],2008-02,2008-03,https://clinicaltrials.gov/study/NCT01021527
NCT00344851,Exenatide and Metformin Therapy in Overweight Women With PCOS,Unknown,COMPLETED,"metformin, exenatide or combined (metformin & exenatide )",DRUG,Other,Metabolic Center of Louisiana Research Foundation,['Polycystic Ovary Syndrome'],2006-06,,https://clinicaltrials.gov/study/NCT00344851
NCT02229396,Phase 3 28-Week Study With 24-Week and 52-week Extension Phases to Evaluate Efficacy and Safety of Exenatide Once Weekly and Dapagliflozin Versus Exenatide and Dapagliflozin Matching Placebo,Unknown,COMPLETED,"Exantide with Dapagliflozin, Exentide, Dapagliflozin","DRUG, DRUG, DRUG",Other,AstraZeneca,['Diabetes Mellitus'],2014-09-04,2016-04-26,https://clinicaltrials.gov/study/NCT02229396
NCT00623545,Bioenergetic Alterations After Exenatide Administration,Unknown,COMPLETED,Exenatide,DRUG,Other,"University of Wisconsin, Madison",['Healthy'],2008-01,2010-04,https://clinicaltrials.gov/study/NCT00623545
NCT01093729,A Study of HM11260C in Healthy Male Subject,Unknown,COMPLETED,"HM11260C, HM11260C, HM11260C, HM11260C, HM11260C","DRUG, DRUG, DRUG, DRUG, DRUG",Other,Hanmi Pharmaceutical Company Limited,['Healthy'],2010-02,2010-10,https://clinicaltrials.gov/study/NCT01093729
NCT00508287,"Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes",Unknown,COMPLETED,"BMS-686117, Byetta, Placebo","DRUG, DRUG, DRUG",Other,Bristol-Myers Squibb,['Type 2 Diabetes'],2007-08,2007-11,https://clinicaltrials.gov/study/NCT00508287
NCT02118376,Effects of GLP-1 Receptor Agonist on Fat Redistribution and Inflammatory Status,Unknown,UNKNOWN,Exenatide,DRUG,Other,Shanghai 10th People's Hospital,['Obesity'],2014-08,2014-12,https://clinicaltrials.gov/study/NCT02118376
NCT02496611,Enhancing Weight Loss Maintenance With GLP-1RA (BYDUREON™) in Adolescents With Severe Obesity,Unknown,COMPLETED,"Weight loss with pharmacotherapy, Weight loss without pharmacotherapy","DRUG, DRUG",Other,University of Minnesota,['Severe Obesity'],2015-12,2020-08-14,https://clinicaltrials.gov/study/NCT02496611
NCT03182192,GLP1R-imaging in Hypoglycemia,Unknown,UNKNOWN,68Ga-NODAGA-exendin-4 PET/CT,RADIATION,Other,Radboud University Medical Center,['Hypoglycemia'],2016-04-01,2024-07-01,https://clinicaltrials.gov/study/NCT03182192
NCT04979611,The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma,Unknown,UNKNOWN,68Ga-NOTA-exendin-4,DRUG,Other,First Affiliated Hospital of Fujian Medical University,['Insulinoma'],2020-08-01,2025-08-01,https://clinicaltrials.gov/study/NCT04979611
NCT02971722,a Study of JY09 in Chinese Healthy Subjects,Unknown,UNKNOWN,"JY09, Placebo","DRUG, DRUG",Other,"Beijing Dongfang Biotech Co., Ltd.",['Healthy'],2016-12,2017-05,https://clinicaltrials.gov/study/NCT02971722
NCT00882050,Intravenous Exenatide (Byetta) During Surgery,Unknown,COMPLETED,"Exenatide 0.27 ng/kg/min, Exenatide 0.41 ng/kg/min, Placebo","DRUG, DRUG, DRUG",Other,Thomas Jefferson University,"['Euglycemia', 'Hypoglycemia', 'Hyperglycemia']",2009-03,2016-04,https://clinicaltrials.gov/study/NCT00882050
NCT01432405,Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes,Unknown,COMPLETED,"Exenatide, Pioglitazone","DRUG, DRUG",Other,Baylor College of Medicine,['Type 2 Diabetes Mellitus'],2007-06,2008-07,https://clinicaltrials.gov/study/NCT01432405
NCT00044694,Evaluation of the Effect on Glucose Control and the Safety and Tolerability of AC2993 in Patients With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"Placebo 0.01 mL, Placebo 0.02 mL, Placebo 0.03 mL, Placebo 0.04 mL, AC2993 2.5 mcg, AC2993 5.0 mcg, AC2993 7.5 mcg, AC2993 10.0 mcg","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,AstraZeneca,"['Diabetes Mellitus, Non-Insulin-Dependent']",2002-08,2003-05,https://clinicaltrials.gov/study/NCT00044694
NCT00667732,"How Glargine Insulin, Oral Diabetes Medications and Exenatide May Improve Blood Sugar Control and Weight Gain in Type 2 Diabetics",Unknown,COMPLETED,"exenatide, placebo","DRUG, DRUG",Other,Oregon Health and Science University,['Type 2 Diabetes'],2007-03,2009-10,https://clinicaltrials.gov/study/NCT00667732
NCT03645408,"The Effects of Exenatide, a GLP-1 Agonist, on Alcohol Self-Administration in Heavy Drinkers",Unknown,TERMINATED,"Exenatide, Sham injection","DRUG, OTHER",Other,Boston Medical Center,['Alcohol Use Disorder'],2019-05-02,2021-07-01,https://clinicaltrials.gov/study/NCT03645408
NCT02325960,A Comparison of Exenatide and Insulin Glargine,Unknown,COMPLETED,"exenatide, Insulin glargine","DRUG, DRUG",Other,The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School,['Type 2 Diabetes'],2015-01,2016-07,https://clinicaltrials.gov/study/NCT02325960
NCT00099320,Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using Thiazolidinediones or Thiazolidinediones and Metformin,Unknown,COMPLETED,"exenatide, Placebo","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2004-05,2005-08,https://clinicaltrials.gov/study/NCT00099320
NCT03383068,Research of Intensive Metabolic Intervention Before Pregnancy in PCOS,Unknown,UNKNOWN,"Acarbose 100 MG, Exenatide, Orlistat, Metformin","DRUG, DRUG, DRUG, DRUG",Other,RenJi Hospital,"['PCOS', 'Impaired Glucose Tolerance']",2018-01-01,2018-12-31,https://clinicaltrials.gov/study/NCT03383068
NCT00622323,Post Marketing Surveillance Study of Byetta ™ (Exenatide) Use Among Filipino Patients,Unknown,COMPLETED,,,Unknown,AstraZeneca,['Type 2 Diabetes Mellitus'],2008-02,2009-09,https://clinicaltrials.gov/study/NCT00622323
NCT00717457,"A Study of Taspoglutide Versus Exenatide for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin, Thiazolidinedione or a Combination of Both.",Unknown,COMPLETED,"exenatide, taspoglutide, taspoglutide","DRUG, DRUG, DRUG",Other,Hoffmann-La Roche,['Diabetes Mellitus Type 2'],2008-07,2011-03,https://clinicaltrials.gov/study/NCT00717457
NCT02417142,Exenatide Weekly Injections as an Adjunctive Treatment in Patients With Schizophrenia,Unknown,COMPLETED,"Exenatide, Placebo","DRUG, DRUG",Other,"University of Massachusetts, Worcester","['Schizophrenia', 'Schizoaffective Disorder']",2014-09,2019-07,https://clinicaltrials.gov/study/NCT02417142
NCT02975297,Exenatide Once Weekly for Smoking Cessation,Unknown,COMPLETED,"Exenatide, NRT, Counseling, Placebo","DRUG, DRUG, BEHAVIORAL, DRUG",Other,"The University of Texas Health Science Center, Houston",['Smoking Cessation'],2016-07,2020-01-03,https://clinicaltrials.gov/study/NCT02975297
NCT01951651,Effect of Exenatide on Liver and Heart Fat and Inflammation,Unknown,COMPLETED,"Exenatide, Glipizide","DRUG, DRUG",Other,Baylor College of Medicine,['Type 2 Diabetes Mellitus'],2010-04,2012-10,https://clinicaltrials.gov/study/NCT01951651
NCT01484873,Weight Loss Study for Patients With Obesity Due to Craniopharyngioma or Other Brain Tumor,Unknown,COMPLETED,Exenatide,DRUG,Other,Vanderbilt University Medical Center,"['Obesity', 'Overweight', 'Craniopharyngioma']",2012-06,2015-03,https://clinicaltrials.gov/study/NCT01484873
NCT02981069,Effect of Chronic Exenatide Therapy on Beta Cell Function and Insulin Sensitivity in T2DM,Unknown,COMPLETED,"Dapagliflozin, Exenatide, Placebo","DRUG, DRUG, DRUG",Other,The University of Texas Health Science Center at San Antonio,"['Diabetes Mellitus, Type 2']",2017-12-15,2022-07-14,https://clinicaltrials.gov/study/NCT02981069
NCT04154072,A Clinical Study of NLY01 in Patient's With Early Parkinson's Disease,Unknown,COMPLETED,"NLY01, Vehicle","DRUG, DRUG",Other,"Neuraly, Inc.",['Parkinson Disease'],2020-02-27,2023-02-14,https://clinicaltrials.gov/study/NCT04154072
NCT04232969,Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease,Unknown,ACTIVE_NOT_RECRUITING,Exenatide extended release 2mg (Bydureon),DRUG,Other,"University College, London","[""Parkinson's Disease""]",2020-01-20,2024-02-24,https://clinicaltrials.gov/study/NCT04232969
NCT00845507,Exenatide for the Treatment of Weight Gain Associated With Olanzapine in Obese Adults,Unknown,COMPLETED,"Exenatide, Placebo","DRUG, DRUG",Other,University of Cincinnati,['Weight Gain'],2008-12,2015-07,https://clinicaltrials.gov/study/NCT00845507
NCT00964262,A Study to Evaluate Safety and Pharmacokinetics/Pharmacodynamics of Sustained Release(SR) Exenatide,Unknown,COMPLETED,"SR Exenatide (PT302), Placebo","DRUG, DRUG",Other,"Peptron, Inc.",['Type 2 Diabetes Mellitus'],2009-08,2010-10,https://clinicaltrials.gov/study/NCT00964262
NCT00456300,Role of Exenatide in Type 1 Diabetes,Unknown,COMPLETED,"Exenatide, Insulin","DRUG, DRUG",Other,Montefiore Medical Center,['Type 1 Diabetes'],2007-03,2009-03,https://clinicaltrials.gov/study/NCT00456300
NCT01147627,Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients,Unknown,COMPLETED,"exenatide injection, Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R, Pioglitazone","DRUG, DRUG, DRUG",Other,Sun Yat-sen University,"['Diabetes Mellitus, Type 2', 'Newly Diagnosed']",2010-08,2012-08,https://clinicaltrials.gov/study/NCT01147627
NCT00434954,Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes,Unknown,COMPLETED,"exenatide twice daily (BID), premixed insulin aspart twice daily (BID)","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2007-02,2009-06,https://clinicaltrials.gov/study/NCT00434954
NCT03297879,Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients With Newly Diagnosed Type 2 Diabetes,Unknown,COMPLETED,Exenatide or metformin hydrochloride,DRUG,Other,Beijing Chao Yang Hospital,['Type2 Diabetes'],2013-01-01,2016-02-28,https://clinicaltrials.gov/study/NCT03297879
NCT00313001,Effects of Biphasic Insulin Aspart 70/30 vs. Exenatide in Type 2 Diabetes Patients Not Reaching Blood Glucose Targets on Metformin and a Sulfonylurea.,Unknown,COMPLETED,"biphasic insulin aspart, exenatide","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2006-04,2007-07,https://clinicaltrials.gov/study/NCT00313001
NCT05037045,Effect of Gene Polymorphisms on GLP-1 Receptor Agonists Response in Patients With T2DM,Unknown,COMPLETED,GLP-1 receptor agonist,DRUG,GLP-1 agonist,The Affiliated Hospital of Xuzhou Medical University,['Type 2 Diabetes Mellitus'],2019-01-10,2023-10-01,https://clinicaltrials.gov/study/NCT05037045
NCT00917267,A Study to Examine the Effects of Exenatide Once-Weekly Injection on Glucose Control and Safety in Asian Subjects,Unknown,COMPLETED,"exenatide once weekly, exenatide twice daily","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2009-07,2010-09,https://clinicaltrials.gov/study/NCT00917267
NCT01140893,Effects of Exenatide on Glycemic Control and Weight in Continuous Subcutaneous Insulin Infusion (CSII) Type 2 Treated Patients With Type 2 Diabetes,Unknown,UNKNOWN,"Exenatide, Placebo","DRUG, DRUG",Other,"University Hospital, Caen",['Type 2 Diabetes'],2010-11,2017-05,https://clinicaltrials.gov/study/NCT01140893
NCT00135330,An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"exenatide, rosiglitazone","DRUG, DRUG",Other,AstraZeneca,"['Diabetes Mellitus, Type 2']",2005-10,2008-07,https://clinicaltrials.gov/study/NCT00135330
NCT03672604,A Phase 1 Study to Assess the Safety of NLY01 in Healthy Subjects,Unknown,COMPLETED,NLY01,DRUG,Other,"Neuraly, Inc.",['Safety and Tolerability in Healthy Volunteers'],2018-09-19,2019-07-30,https://clinicaltrials.gov/study/NCT03672604
NCT02194595,Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL),Unknown,COMPLETED,"Basal insulin and exenatide, Basal insulin only, Basal insulin and bolus insulin","DRUG, DRUG, DRUG",Other,"Mount Sinai Hospital, Canada",['Type 2 Diabetes'],2014-09,2021-12,https://clinicaltrials.gov/study/NCT02194595
NCT00872378,The Effects of Exenatide After Gastric Restriction,Unknown,UNKNOWN,"Exenatide, Placebo","DRUG, DRUG",Other,Advanced Specialty Care,['Morbid Obesity'],2009-02,2010-12,https://clinicaltrials.gov/study/NCT00872378
NCT00736229,Intravenous Exenatide in Coronary Intensive Care Unit (ICU) Patients,Unknown,COMPLETED,Exenatide,DRUG,Other,Saint Luke's Health System,"['Hyperglycemia', 'Acute Coronary Syndromes', 'Myocardial Infarction']",2008-08,2011-06,https://clinicaltrials.gov/study/NCT00736229
NCT03199261,A Study of Pharmacokinetic Comparison of Two Recombinant Exendin-4 Formulations in Chinese Healthy Male Subjects,Unknown,COMPLETED,"rE-4 Injection, rE-4 Freeze-dried Powder","DRUG, DRUG",Other,"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.",['Type 2 Diabetes'],2016-12-23,2017-01-21,https://clinicaltrials.gov/study/NCT03199261
NCT00870194,A Comparison of Adding Exenatide With Switching to Exenatide in Patients With Type 2 Diabetes Experiencing Inadequate Glycemic Control With Sitagliptin Plus Metformin,Unknown,COMPLETED,"exenatide and sitagliptin, exenatide and placebo","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2009-03,2010-04,https://clinicaltrials.gov/study/NCT00870194
NCT00500370,"A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients",Unknown,COMPLETED,"exenatide, placebo","DRUG, DRUG",Other,AstraZeneca,['Obesity'],2007-06,2008-02,https://clinicaltrials.gov/study/NCT00500370
NCT05670379,"Assessment of Safety, Tolerability and Drug Levels of Exenatide Implant",Unknown,COMPLETED,"Exenatide Implant, Bydureon BCise (exenatide extended release), Semaglutide, 1.0 mg/mL","COMBINATION_PRODUCT, DRUG, DRUG",Other,"Vivani Medical, Inc","['Overweight and Obesity', 'Type2diabetes']",2024-12-20,2025-08-21,https://clinicaltrials.gov/study/NCT05670379
NCT01302327,GLP Analogs for Diabetes in Wolfram Syndrome Patients,Unknown,WITHDRAWN,Exenatide,DRUG,Other,Hadassah Medical Organization,"['Diabetes Mellitus Associated With Genetic Syndrome', 'Wolfram Syndrome']",2011-03-01,2013-03-01,https://clinicaltrials.gov/study/NCT01302327
NCT04305002,Exenatide Treatment in Parkinson's Disease,Unknown,UNKNOWN,"Exenatide, Placebo","DRUG, DRUG",Other,"Center for Neurology, Stockholm",['Parkinson Disease'],2020-01-21,2023-10-10,https://clinicaltrials.gov/study/NCT04305002
NCT02533453,"A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients.",Unknown,COMPLETED,Bydureon,BIOLOGICAL,Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2016-01-28,2016-12-07,https://clinicaltrials.gov/study/NCT02533453
NCT01507038,Safety and Efficacy of YH14617 in Diabetes Mellitus,Unknown,COMPLETED,"YH14617, YH14617, YH14617, Placebo","DRUG, DRUG, DRUG, DRUG",Other,Yuhan Corporation,['Diabetes Mellitus'],2011-12,2015-01,https://clinicaltrials.gov/study/NCT01507038
NCT01269008,Closed Loop System With Pramlintide Versus Exenatide,Unknown,COMPLETED,Medtronic ePID 2.0,DEVICE,Other,Albert Einstein College of Medicine,['Type 1 Diabetes'],2010-12,2013-01,https://clinicaltrials.gov/study/NCT01269008
NCT02380521,"Exenatide Once Weekly, Cardiovascular Risk and Type-2 Diabetes",Unknown,COMPLETED,Exenatide once weekly (BYDUREON™),DRUG,Other,University of Palermo,['Type 2 Diabetes Mellitus'],2015-01,2016-07,https://clinicaltrials.gov/study/NCT02380521
NCT00603239,Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin,Unknown,COMPLETED,"exenatide, placebo","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2008-01,2009-07,https://clinicaltrials.gov/study/NCT00603239
NCT02475499,Incretin-based Drugs and Pancreatic Cancer,Unknown,COMPLETED,"DPP-4 inhibitors, GLP-1 analogs, Sulfonylureas, Biguanides, Thiazolidinediones, Alpha-glucosidase inhibitors, Meglitinides","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",GLP-1 agonist,"Canadian Network for Observational Drug Effect Studies, CNODES","['Diabetes Mellitus, Type 2']",2014-03,2015-04,https://clinicaltrials.gov/study/NCT02475499
NCT00701935,Effect of Exenatide on Abdominal Fat Distribution in Patients With Type 2 Diabetes Pretreated With Metformin,Unknown,TERMINATED,"placebo, exenatide","DRUG, DRUG",Other,AstraZeneca,['Diabetes Mellitus'],2008-08,2012-01,https://clinicaltrials.gov/study/NCT00701935
NCT05034783,[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients,Phase 1,UNKNOWN,"[68Ga]Ga-HBED-CC-exendin-4, [68Ga]Ga-NOTA-exendin-4","DRUG, DRUG",Other,Peking Union Medical College Hospital,['Insulinoma'],2021-10-01,2022-10-13,https://clinicaltrials.gov/study/NCT05034783
NCT02829502,The Effect of GLP-1 Receptor Agonist on Cerebral Blood Flow Velocity in Stroke,Unknown,UNKNOWN,"Byetta, Normosaline","DRUG, DRUG",Other,Christina Kruuse,['Ischemic Stroke'],2016-08,2023-08,https://clinicaltrials.gov/study/NCT02829502
NCT01988545,GLP-1's Effect on Cardiac Parameters and Mesenteric Blood Flow,Unknown,UNKNOWN,"1,5 nmol/kg,GLP-1 sc injection, 1,5 nmol/kg GLP-1 9-36amide, sc injection, Exendin-4 ;10 ug,sc injection, saline","OTHER, OTHER, OTHER, OTHER",GLP-1 agonist,Zealand University Hospital,['Healthy'],2013-11,2014-06,https://clinicaltrials.gov/study/NCT01988545
NCT03419624,The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients,Unknown,TERMINATED,"Dapagliflozin 10mg, Exenatide 2 mg [Bydureon], Placebo Oral Tablet, Placebo injection, Insulin, Metformin, if taken before","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Universitätsklinikum Hamburg-Eppendorf,"['Obesity', 'Diabetes Mellitus, Type 2']",2018-02-19,2019-04-01,https://clinicaltrials.gov/study/NCT03419624
NCT01254123,Effect of Additional Treatment With EXenatide in Patients With an Acute Myocardial Infarction (the EXAMI Trial),Unknown,UNKNOWN,"Exenatide infusion, Placebo infusion.","DRUG, DRUG",Other,"Amsterdam UMC, location VUmc",['Patients With a First Acute Myocardial Infarction to be Treated With Primary Percutaneous Coronary Intervention (PCI).'],2009-11,,https://clinicaltrials.gov/study/NCT01254123
NCT01455883,A Study to Evaluate ITCA 650 Compared to Glimepiride for the Treatment of Type 2 Diabetes,Unknown,WITHDRAWN,"ITCA 650 60 mcg/day, glimepiride","DRUG, DRUG",Other,Intarcia Therapeutics,['Type 2 Diabetes'],2013-02,2014-07,https://clinicaltrials.gov/study/NCT01455883
NCT02476760,Incretin-based Drugs and Acute Pancreatitis,Unknown,COMPLETED,"DPP-4 inhibitors, GLP-1 analogs, Insulins, Biguanides, Sulfonylureas, Thiazolidinediones, Alpha-glucosidase inhibitors, Meglitinides","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",GLP-1 agonist,"Canadian Network for Observational Drug Effect Studies, CNODES","['Diabetes Mellitus, Type 2']",2014-03,2015-04,https://clinicaltrials.gov/study/NCT02476760
NCT00637273,"A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)",Unknown,COMPLETED,"exenatide once weekly, sitagliptin, pioglitazone, placebo tablet, placebo once weekly","DRUG, DRUG, DRUG, DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2008-01,2009-02,https://clinicaltrials.gov/study/NCT00637273
NCT01046721,"Study Looking at Cardiovascular Effects of Exenatide, Its Blood Pressure Lowering Effect and Its Mechanisms",Unknown,COMPLETED,"Exenatide, Saline","DRUG, DRUG",Other,University of Nottingham,['Type 2 Diabetes'],2009-09,2012-12,https://clinicaltrials.gov/study/NCT01046721
NCT01455909,A Study to Evaluate ITCA 650 Compared to Sitagliptin for the Treatment of Type 2 Diabetes,Unknown,WITHDRAWN,"ITCA 650 60 mcg/day, sitagliptin","DRUG, DRUG",Other,Intarcia Therapeutics,['Type 2 Diabetes'],2013-02,2014-07,https://clinicaltrials.gov/study/NCT01455909
NCT01017302,A Study With RO5095932 in Patients With Type 2 Diabetes on Stable Metformin Therapy.,Unknown,COMPLETED,"Placebo, Placebo, RO5095932, RO5095932","DRUG, DRUG, DRUG, DRUG",Other,Hoffmann-La Roche,['Diabetes Mellitus Type 2'],2009-12,2011-08,https://clinicaltrials.gov/study/NCT01017302
NCT02794402,"Double-blinded, 6 Months Study With Bydureon® or Placebo in Adolescents With Obesity to Explore Changes in BMI",Unknown,COMPLETED,"Exenatide, Placebo","DRUG, BEHAVIORAL",Other,Uppsala University,['Obesity'],2015-09,2016-09,https://clinicaltrials.gov/study/NCT02794402
NCT02847403,Long-acting Exenatide and Cognitive Decline in Dysglycemic Patients,Unknown,UNKNOWN,"Exenatide, placebo","DRUG, OTHER",Other,Azienda Ospedaliero-Universitaria di Parma,"['Dysglycemia', 'Cognitive Deficit']",2016-02,2019-07,https://clinicaltrials.gov/study/NCT02847403
NCT01940770,Specific Clinical Experience Investigation for Long-term Use of Bydureon.,Unknown,COMPLETED,,,Unknown,AstraZeneca,['Type 2 Diabetes'],2013-10-18,2019-11-29,https://clinicaltrials.gov/study/NCT01940770
NCT00974272,Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation,Unknown,COMPLETED,"Exenatide, Normal Saline","DRUG, OTHER",Other,Carl T. Hayden VA Medical Center,"['Type 2 Diabetes Mellitus', 'Impaired Glucose Tolerance']",2006-08,2008-11,https://clinicaltrials.gov/study/NCT00974272
NCT04029272,Metformin vs Metformin Combined With GLP-1RA (Glucagon-like Peptide 1 Receptor Agonist) on Overweight/Obese PCOS Patients,Unknown,UNKNOWN,"Metformin, Exenatide 2 MG","DRUG, DRUG",Other,Peking Union Medical College Hospital,['Polycystic Ovary Syndrome'],2019-07-20,2020-02-28,https://clinicaltrials.gov/study/NCT04029272
NCT04897802,Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study),Unknown,RECRUITING,"Experimental: GLP1-RA (exenatide) administration, Control: Placebo administration","DRUG, DRUG",GLP-1 agonist,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,"['Hypopituitarism', 'Central Diabetes Insipidus', 'Panhypopituitarism', 'Psychological Disorder', 'Social Isolation', 'Hypothalamic Diseases', 'Pituitary Diseases', 'Oxytocin Deficiency']",2021-09-13,2024-04-30,https://clinicaltrials.gov/study/NCT04897802
NCT02157974,Liver and Fat Regulation in Overweight Adolescent Girls,Unknown,COMPLETED,Byetta 5Mcg Pen Injection,DRUG,Other,"University of Colorado, Denver","['Hepatic Steatosis', 'Polycystic Ovarian Syndrome', 'Obesity']",2014-08,2022-12,https://clinicaltrials.gov/study/NCT02157974
NCT06387199,Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide,Unknown,RECRUITING,"Semaglutide with 4 meal strategies, Placebo with 4 meal strategies","DRUG, DRUG",Other,McGill University Health Centre/Research Institute of the McGill University Health Centre,"['Type 1 Diabetes', 'Diabetes Mellitus']",2024-12-01,2027-01,https://clinicaltrials.gov/study/NCT06387199
NCT01270191,The Effects of Short-Term Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients,Unknown,UNKNOWN,"Exenatide, Humulin-N","DRUG, DRUG",Other,"Taipei Veterans General Hospital, Taiwan",['Type 2 Diabetes'],2010-11,2014-12,https://clinicaltrials.gov/study/NCT01270191
NCT00518882,Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes,Unknown,COMPLETED,"liraglutide, exenatide","DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2007-08,2008-04,https://clinicaltrials.gov/study/NCT00518882
NCT00658021,Safety and Efficacy of Exenatide as Monotherapy and Adjunctive Therapy to Oral Antidiabetic Agents in Adolescents With Type 2 Diabetes,Unknown,COMPLETED,"Placebo, Exenatide, Exenatide","DRUG, DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes'],2008-05-30,2019-04-18,https://clinicaltrials.gov/study/NCT00658021
NCT03970044,Effectiveness of Exenatide Plus Dapagliflozin on 24 Hour Glucose Variability Measured by CGM. A Proof of Concept.,Unknown,COMPLETED,"Exenatide 2 MG, Dapagliflozin 10 MG","DRUG, DRUG",Other,"Consano Clinical Research, LLC","['Diabetes Mellitus, Type 2']",2019-07-02,2021-06-01,https://clinicaltrials.gov/study/NCT03970044
NCT00707031,"GLP-1 Receptor Agonist Lixisenatide Versus Exenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin",Unknown,COMPLETED,"Lixisenatide (AVE0010), Pen auto-injector, Exenatide, Prefilled pen injector, Metformin","DRUG, DEVICE, DRUG, DEVICE, DRUG",Other,Sanofi,"['Diabetes Mellitus, Type 2']",2008-06,2010-11,https://clinicaltrials.gov/study/NCT00707031
NCT00729326,Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione,Unknown,COMPLETED,"exenatide, sitagliptin, placebo, placebo","DRUG, DRUG, DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2008-08,2009-10,https://clinicaltrials.gov/study/NCT00729326
NCT02974244,Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins,Unknown,COMPLETED,"exenatide once weekly, basal insulin","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes'],2014-10-28,2014-10-28,https://clinicaltrials.gov/study/NCT02974244
NCT01281228,The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and Diabetes,Unknown,COMPLETED,"exenatide, exenatide + exendin (9-39), placebo","DRUG, DRUG, DRUG",Other,"Amsterdam UMC, location VUmc","['Diabetes Mellitus', 'Diabetes Mellitus, Type 2', 'Obesity']",2011-09,2013-10,https://clinicaltrials.gov/study/NCT01281228
NCT00097500,Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes,Unknown,COMPLETED,"exenatide, Insulin glargine, Metformin","DRUG, DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2004-09,2009-12,https://clinicaltrials.gov/study/NCT00097500
NCT04379856,Proof of Concept Study in Patients With Short Bowel Syndrome,Unknown,UNKNOWN,NM-002,DRUG,Other,"9 Meters Biopharma, Inc.",['Short Bowel Syndrome'],2020-06-23,2020-12-11,https://clinicaltrials.gov/study/NCT04379856
NCT02811484,"Efficacy of Exenatide-LAR and Dapagliflozin in Overweight/Obese, Insulin Treated Patients With Type 2 Diabetes",Unknown,WITHDRAWN,"Exenatide-LAR plus Dapagliflozin placebo, Exenatide-LAR plus Dapagliflozin, Insulin Titration, Behavioral Therapy","DRUG, DRUG, DRUG, BEHAVIORAL",Other,Weill Medical College of Cornell University,"['Diabetes Mellitus, Type 2']",2016-06,2018-06,https://clinicaltrials.gov/study/NCT02811484
NCT05662189,Assessment of Pancreatic Beta Cell Mass and Function by Positron Emission Tomography Imaging in Human Diabetes Mellitus,Unknown,RECRUITING,"68Ga-exendin-4, mixed meal test","DRUG, OTHER",Other,Azienda Ospedaliero-Universitaria di Parma,"['Type1diabetes', 'Type2diabetes', 'Pre Diabetes', 'Hyperinsulinism']",2022-03-15,2025-07,https://clinicaltrials.gov/study/NCT05662189
NCT01144338,Exenatide Study of Cardiovascular Event Lowering Trial (EXSCEL): A Trial To Evaluate Cardiovascular Outcomes After Treatment With Exenatide Once Weekly In Patients With Type 2 Diabetes Mellitus,Unknown,COMPLETED,"Exenatide Once Weekly, Placebo","DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2010-06-18,2017-04-21,https://clinicaltrials.gov/study/NCT01144338
NCT00747968,The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET,Unknown,COMPLETED,"Byetta, Exenatide",DRUG,Other,University of Aarhus,['Type 2 Diabetes'],2010-02,2010-11,https://clinicaltrials.gov/study/NCT00747968
NCT03361098,DECREASE: Dapagliflozin Plus Exenatide on Central REgulation of Appetite in diabeteS typE 2,Unknown,COMPLETED,"Dapagliflozin 10mg, Exenatide, placebo exenatide, placebo dapagliflozin","DRUG, DRUG, OTHER, OTHER",Other,"Amsterdam UMC, location VUmc","['Type 2 Diabetes Mellitus', 'Obesity']",2017-09-18,2019-11-25,https://clinicaltrials.gov/study/NCT03361098
NCT00577824,Efficacy and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Who Are Treated With Oral Antidiabetic(s),Unknown,COMPLETED,"exenatide, exenatide, placebo","DRUG, DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes'],2008-01,2008-11,https://clinicaltrials.gov/study/NCT00577824
NCT05622123,BetaFIT Study: Beta Cell Imaging After Faecal mIcrobiota Transplantation,Unknown,UNKNOWN,68Ga-NODAGA-Exendin-4,DRUG,Other,Radboud University Medical Center,['Type 1 Diabetes'],2023-02-23,2024-02-28,https://clinicaltrials.gov/study/NCT05622123
NCT04504396,Safety and Efficacy of PB-119 in Subjects With Type 2 Diabetes and Not Well-controlled by Metformin Monotherapy,Unknown,COMPLETED,"GLP-1 receptor agonist, Placebo","DRUG, DRUG",GLP-1 agonist,"PegBio Co., Ltd.",['Type 2 Diabetes Mellitus (T2DM)'],2020-06-23,2022-09-15,https://clinicaltrials.gov/study/NCT04504396
NCT03768518,GLP-1 Receptor Expression in CHI,Unknown,UNKNOWN,68Ga-exendin-4 PET/CT,DIAGNOSTIC_TEST,Other,Radboud University Medical Center,['Congenital Hyperinsulinism'],2018-02-07,2019-02-01,https://clinicaltrials.gov/study/NCT03768518
NCT00254800,The Effects of Exenatide on Oral Contraceptive Pharmacokinetics in Healthy Females,Unknown,COMPLETED,"ethinyl estradiol and levonorgestrel; exenatide, ethinyl estradiol and levonorgestrel; exenatide, ethinyl estradiol and levonorgestrel; exenatide","DRUG, DRUG, DRUG",Other,AstraZeneca,['Type 2 Diabetes Mellitus'],2005-11,2006-08,https://clinicaltrials.gov/study/NCT00254800
NCT01676116,The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy,Unknown,COMPLETED,"insulin degludec/liraglutide, liraglutide, exenatide","DRUG, DRUG, DRUG",Other,Novo Nordisk A/S,"['Diabetes', 'Diabetes Mellitus, Type 2']",2012-08-29,2014-03-11,https://clinicaltrials.gov/study/NCT01676116
NCT07203443,Child Cognitive-Affective Resilience Following 13-11 Event : A Pluridisciplinary Study of Intergenerational Transmission of a Traumatic Event,Unknown,RECRUITING,"MRI, Psychological assessment, Cognitive assessment, Cortisol sample","OTHER, OTHER, BEHAVIORAL, OTHER",Other,"Institut National de la Santé Et de la Recherche Médicale, France",['Intergenerational Trauma'],2024-12-17,2027-01-15,https://clinicaltrials.gov/study/NCT07203443
NCT06300164,The Effect of Unripe Carob Fruit in Celiac Patients,Unknown,NOT_YET_RECRUITING,Unripre Carob,DIETARY_SUPPLEMENT,Other,Toros University,['Celiac Disease'],2024-04-01,2024-05-01,https://clinicaltrials.gov/study/NCT06300164
NCT04788797,AN-PEP on Gluten Exposure in Celiacs,Unknown,COMPLETED,"Prolyl Endopeptidase, Placebo","DRUG, OTHER",Other,Dr. C. Bonorino Udaondo Gastroenterology Hospital,['Celiac Disease'],2021-03-17,2022-07-30,https://clinicaltrials.gov/study/NCT04788797
NCT02459535,Immediate and Long-term Induction of Incretin Release by Artificial Sweeteners 1,Unknown,COMPLETED,"oral stimulation glucose, oral stimulation saccharin, oral stimulation aspartame, oral stimulation sucralose","OTHER, OTHER, OTHER, OTHER",Other,German Institute of Human Nutrition,"['Pre-diabetes', 'Diabetes']",2015-03,2017-06,https://clinicaltrials.gov/study/NCT02459535
NCT05578690,Healthy Lifestyle Before and During Pregnancy to Prevent Childhood Obesity - the PRE-STORK-trial,Unknown,RECRUITING,"Diet, Exercise, Mentorship","BEHAVIORAL, BEHAVIORAL, BEHAVIORAL",Other,Steno Diabetes Center Copenhagen,"['Overweight and Obesity', 'Pregnancy Related']",2022-10-26,2029-07,https://clinicaltrials.gov/study/NCT05578690
NCT02773927,Combination of Metformin/Inulin vs Inulin on Adiponectin in Metabolic Syndrome,Unknown,COMPLETED,"Metformin, Agave inulin, Placebo of agave inulin, Metformin placebo","DRUG, DIETARY_SUPPLEMENT, OTHER, OTHER",Other,"Centro Universitario de Ciencias de la Salud, Mexico",['Metabolic Syndrome'],2013-01,2014-01,https://clinicaltrials.gov/study/NCT02773927
NCT02239458,DPP-IV Inhibition Prior to Development of Diabetes in Patients With Cystic Fibrosis,Unknown,UNKNOWN,Saxagliptin,DRUG,Other,Ram Weiss,['Cystic Fibrosis'],2015-06,2016-06,https://clinicaltrials.gov/study/NCT02239458
NCT00847080,Treatment With Sitagliptin for Reactive Hypoglycemia Secondary to Dysinsulinism,Unknown,COMPLETED,"Sitagliptin phosphate, Placebo","DRUG, DRUG",Other,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,['Reactive Hypoglycemia'],2008-12,2010-12,https://clinicaltrials.gov/study/NCT00847080
NCT03806920,Isomaltulose VS Sucrose - Postprandial Effect on Incretin Profile and Second Meal Effect,Unknown,COMPLETED,"Intervention A, Intervention B, Intervention C, Intervention D","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,German Institute of Human Nutrition,"['Diabetes Mellitus, Type 2', 'Metabolic Syndrome']",2016-11-05,2018-09-30,https://clinicaltrials.gov/study/NCT03806920
NCT02569762,Effects of Artificial Sweeteners on Gut Microbiota and Glucose Metabolism,Unknown,COMPLETED,"Sucralose-Aspartame, Aspartame-Sucralose","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Manitoba,['Impaired Glucose Tolerance'],2016-07,2018-01,https://clinicaltrials.gov/study/NCT02569762
NCT03814694,Cut Down on Carbohydrate Usage in the Diet of Type 2 Diabetes. The Hypo-energetic Study,Unknown,COMPLETED,"CRHP Diet, CD Diet","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,Bispebjerg Hospital,"['Diabetes Mellitus, Type 2', 'Overweight and Obesity']",2019-01-29,2020-07-22,https://clinicaltrials.gov/study/NCT03814694
NCT05308381,"Breakfast, Exercise and Metabolic Health in Healthy Women",Unknown,UNKNOWN,"Fasted exercise, High protein breakfast exercise, High carbohydrate breakfast exercise","BEHAVIORAL, BEHAVIORAL, BEHAVIORAL",Other,National Taiwan Normal University,"['Metabolic Health', 'Appetitive Behavior', 'Energy Balance']",2022-03-15,2024-03-01,https://clinicaltrials.gov/study/NCT05308381
NCT06723886,Antidiabetic Effect of Olive Pomace Oil,Unknown,RECRUITING,"Experimental arm: Olive pomace oil, High-oleic acid sunflower oil","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,Instituto de Ciencia y Tecnología de Alimentos y Nutrición,"['Type 2 Diabetes Mellitus', 'Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)', 'Prediabetic State', 'Diabetes', 'Diabetes Mellitus']",2025-01-15,2026-03-30,https://clinicaltrials.gov/study/NCT06723886
NCT06689501,"12-Week Trial Investigating L-carnitine Tartrate, Dihydrocapsiate and Protein Yeast Hydrolysate on Energy Intake and Expenditure in Overweight Adults",Unknown,COMPLETED,"SPICE BLEND CAPSULE, Placebo","COMBINATION_PRODUCT, OTHER",Other,Société des Produits Nestlé (SPN),['Overweight and Obesity'],2024-10-30,2025-06-26,https://clinicaltrials.gov/study/NCT06689501
NCT05011968,Intervention Study on Iodine Biofortification Vegetables ( Nutri-I-Food,Unknown,COMPLETED,"Lettuce with not biofortification, Lettuce biofortificated with Iodine","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Palermo,['Healthy Individuals'],2019-03-01,2019-06-26,https://clinicaltrials.gov/study/NCT05011968
NCT01176760,Intact Vagal Innervation for and Glucagon-like Peptide-1 (GLP-1) Effects,Unknown,UNKNOWN,"Dipeptidyl peptidase 4 (DPP 4) inhibitor, oral glucose","DRUG, OTHER",Other,"University Hospital, Gentofte, Copenhagen","['Vagotomy, Truncal']",2009-08,2011-10,https://clinicaltrials.gov/study/NCT01176760
NCT01642108,Treatment With Sitagliptin in Non-obese Japanese Patients With Type 2 Diabetes Mellitus,Unknown,UNKNOWN,Sitagliptin,DRUG,Other,Niigata Medical Center,['Type 2 Diabetes'],2012-07,2013-05,https://clinicaltrials.gov/study/NCT01642108
NCT05030376,Intraileal Glucose vs. Saline Infusion on Hormone Secretion and Glycemic Excursions,Unknown,COMPLETED,intraileal infusion,DIETARY_SUPPLEMENT,Other,Qilu Hospital of Shandong University,['Incretins'],2021-09-22,2022-03-01,https://clinicaltrials.gov/study/NCT05030376
NCT05167084,Acute Consequences Of Food-induced Glucocorticoid Secretion In Healthy Individuals,Phase 1,COMPLETED,"Metyrapone 250 mg Oral Tablets, Placebo 250 mg Tablets, Hydrocortisone 19,9mg s.c., pulsatile with a flow rate of 10μl/s, Placebo (0,9% NaCl solution)","DRUG, DRUG, DRUG, DRUG",Other,Eleonora Seelig,['Glucocorticoid Effect'],2022-02-08,2023-06-08,https://clinicaltrials.gov/study/NCT05167084
NCT04482738,Study of the Effects of Overfeeding on Glucocorticoids in Lean and Obese Subjects,Unknown,COMPLETED,High-calorie meal,OTHER,Other,Eleonora Seelig,['Overweight and Obesity'],2020-05-14,2021-02-20,https://clinicaltrials.gov/study/NCT04482738
NCT02640118,The Impact of Lixisenatide on Postprandial Glucose Tolerance in Pancreatectomised Subjects,Unknown,COMPLETED,"Lixisenatide, Lixisenatide-Placebo, Standardized liquid meal","DRUG, DRUG, OTHER",Other,"University Hospital, Gentofte, Copenhagen",['Diabetes After Total Pancreatectomy'],2015-08,2016-07,https://clinicaltrials.gov/study/NCT02640118
NCT06094894,Effects of Sucralose in Gut Intestinal Microbiota and Postprandial GLP-1,Unknown,COMPLETED,"sucralose, placebo","OTHER, OTHER",Other,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,"['GLP-1', 'Gut Microbiota', 'Insulin Resistance']",2023-06-01,2024-02-29,https://clinicaltrials.gov/study/NCT06094894
NCT03966261,The Role of Incretins in Bone Remodeling in Humans,Unknown,TERMINATED,blood sample,OTHER,Other,"University Hospital, Angers","['Incretins', 'Osteoporosis', 'Bone Remodeling', 'Healthy']",2020-03-10,2022-05-02,https://clinicaltrials.gov/study/NCT03966261
NCT06897241,"Personalized Metabolic Responses to Rapid, Slow and Resistant Starch",Unknown,RECRUITING,"Resistant starch, Slow digestible starch, Rapid digestible starch","OTHER, OTHER, OTHER",Other,Chalmers University of Technology,['Adults With Overweight and Obesity'],2025-04-08,2026-05-01,https://clinicaltrials.gov/study/NCT06897241
NCT06115460,The Impact of Sitagliptin as an Add on Therapy With Closed Loop Control in Adolescents With Diabetic Nephropathy,Unknown,COMPLETED,oral sitagliptin supplementation,DRUG,Other,Ain Shams University,['Type 1 Diabetic Nephropathy'],2022-03-01,2023-06-01,https://clinicaltrials.gov/study/NCT06115460
NCT02366624,Effect of Bariatric Surgery on Bile Acid Homeostasis,Unknown,COMPLETED,,,Unknown,Pontificia Universidad Catolica de Chile,['Morbid Obesity'],2013-02,2014-03,https://clinicaltrials.gov/study/NCT02366624
NCT03829800,"Formulas for Diabetes With Sucromalt & Isomaltulose on Glycemic Index, Hormones & Subjective Appetite in Type 2 Diabetes",Unknown,COMPLETED,"Ensure® Abbott Nutrition, Glucerna® Abbott Nutrition, Diasip® Nutricia Advanced, Glicolab®","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,Universidad del Zulia,"['Diabetes Mellitus, Type 2']",2016-09-01,2017-09-01,https://clinicaltrials.gov/study/NCT03829800
NCT02747472,GIP Receptor Antagonist Studies in Humans,Unknown,COMPLETED,"GIP-A, GIP(1-42), Saline","DRUG, DRUG, OTHER",GIP agonist,"University Hospital, Gentofte, Copenhagen",['Glucose Metabolism'],2016-04,2016-07,https://clinicaltrials.gov/study/NCT02747472
NCT03585920,The Influence of Fat Perception on Satiety From Consumption of Reduced Fat Snacks,Unknown,COMPLETED,Expanded Corn Snack,BEHAVIORAL,Other,University of Reading,"['Appetitive Behavior', 'Individual Difference', 'Food Sensitivity', 'Food Preferences']",2018-07-02,2019-04-11,https://clinicaltrials.gov/study/NCT03585920
NCT02324010,"Effects of Sitagliptin on Gastric Emptying, Glycaemia and Blood Pressure in Type 2 Diabetes",Unknown,COMPLETED,"Sitagliptin, Placebo","DRUG, DRUG",Other,Royal Adelaide Hospital,"['Gastroparesis', 'Diabetes Mellitus']",2015-07,2017-01,https://clinicaltrials.gov/study/NCT02324010
NCT01559779,Effect of Gastric Bypass Surgery on Pancreatic Islets and Incretin Function,Unknown,COMPLETED,,,Unknown,Hvidovre University Hospital,['Obesity'],2010-11,2012-07,https://clinicaltrials.gov/study/NCT01559779
NCT02585427,"Effects of Co-ingesting a Low/High GI Meal With Different Fat Saturation on Postprandial Glucose, Insulin, and Triacylglycerol Responses in Healthy Participants",Unknown,COMPLETED,"low glycemic index rice, high glycemic index rice, butter, olive oil and grapeseed oil",DIETARY_SUPPLEMENT,Other,Singapore Institute of Food and Biotechnology Innovation,['Healthy'],2014-11,2016-04,https://clinicaltrials.gov/study/NCT02585427
NCT01767441,Bariatric Surgeries and Glucose Homeostasis During a Mixed Meal Test,Unknown,COMPLETED,"Roux-en-Y-gastric bypass, laparoscopic adjustable gastric banding, laparoscopic sleeve gastrectomy, diet treatment","PROCEDURE, PROCEDURE, PROCEDURE, OTHER",Other,Azienda Ospedaliera Universitaria Integrata Verona,['Obesity'],2013-02,2015-12,https://clinicaltrials.gov/study/NCT01767441
NCT06729905,Study of the Effects of Yerba Mate on Cardiometabolic Health,Unknown,COMPLETED,"Yerba mate tea, Control drink","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,Instituto de Ciencia y Tecnología de Alimentos y Nutrición,"['Cardiovascular Risk', 'Hypercholerolemia']",2012-01-10,2013-07-30,https://clinicaltrials.gov/study/NCT06729905
NCT06334172,The Role of Oxytocin in Regulating Blood Glucose,Unknown,RECRUITING,"Oxytocin, Placebo","DRUG, OTHER",Other,"University Hospital, Gentofte, Copenhagen",['Glucose Metabolism Disorders (Including Diabetes Mellitus)'],2024-01-01,2026-12-31,https://clinicaltrials.gov/study/NCT06334172
NCT01436734,"Role of Aprotinin in Glucagon Degradation, Measurement by Radioimmunoactive Method (RIA) I125",Unknown,COMPLETED,"Fasting glycemia, Hypoglycemia","OTHER, OTHER",Other,"University Hospital, Gentofte, Copenhagen",['Hyperglucagonemia'],2011-07,2012-12,https://clinicaltrials.gov/study/NCT01436734
NCT05530070,Cardiovascular Risk Factors in Coeliac Disease: a Series of Studies,Unknown,RECRUITING,"Dietary intervention, Standard of care, Cardiovascular risk-related parameters","OTHER, OTHER, DIAGNOSTIC_TEST",Other,University of Pecs,['Coeliac Disease'],2022-09-01,2026-09,https://clinicaltrials.gov/study/NCT05530070
NCT05391438,Impact of Meal Timing on Glycemic Profile in Latino Adolescents With Obesity,Unknown,COMPLETED,Meal-timing,OTHER,Other,Children's Hospital Los Angeles,"['Pediatric Obesity', 'Meal Timing']",2022-09-01,2023-08-01,https://clinicaltrials.gov/study/NCT05391438
NCT02411825,Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients,Unknown,COMPLETED,"SAR425899, placebo, metformin","DRUG, DRUG, DRUG",Other,Sanofi,['Type 2 Diabetes Mellitus'],2015-03,2016-01,https://clinicaltrials.gov/study/NCT02411825
NCT04065243,Experimental Overfeeding in Humans,Unknown,COMPLETED,"Overfeeding diet, Isocaloric diet","OTHER, OTHER",Other,University of Copenhagen,"['Overfed', 'Obesity']",2019-08-22,2023-01-01,https://clinicaltrials.gov/study/NCT04065243
NCT01231815,Coronary Flow Reserve Evaluation in PET and in MRI Scanner in Heart Transplanted Patients : Comparison With Multi-detectors Scanner,Unknown,UNKNOWN,"15O-H2O PET -, MRI","RADIATION, RADIATION",Other,"University Hospital, Caen",['Heart Disease'],2010-11,2014-12,https://clinicaltrials.gov/study/NCT01231815
NCT02128945,Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies,Unknown,COMPLETED,[18F] - Fludarabine PET/CT,OTHER,Other,"University Hospital, Caen",['Untreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma Patients'],2014-04,2016-04,https://clinicaltrials.gov/study/NCT02128945
NCT01562782,Change of Fructose to Fat in South Asians,Unknown,COMPLETED,Fructose + Glucose Beverage,OTHER,Other,The Rogosin Institute,"['Elevated Triglycerides', 'Diabetes', 'Cardiovascular Disease', 'Dyslipidemia']",2012-04-02,2013-10-10,https://clinicaltrials.gov/study/NCT01562782
NCT06419686,The Glucagonotropic Effects of Glucose-dependent Insulinotropic Polypeptide and Alanine in Healthy Individuals,Unknown,RECRUITING,"Placebo (saline), GIP, Alanine, GIP + alanine","OTHER, DRUG, DRUG, DRUG",GIP agonist,"University Hospital, Gentofte, Copenhagen",['Effect of iv Administration of GIP and Alanine'],2024-01-01,2024-05,https://clinicaltrials.gov/study/NCT06419686
NCT02669524,Dissection of the Gastrointestinal-mediated Glucose Disposal and Incretin Defect in Patients With Type 2 Diabetes,Unknown,COMPLETED,"LY2409021, LY2409021 placebo, OGTT, IIGI, Standardised liquid meal","DRUG, DRUG, PROCEDURE, PROCEDURE, PROCEDURE",Other,"University Hospital, Gentofte, Copenhagen",['Type 2 Diabetes'],2015-10,2016-08,https://clinicaltrials.gov/study/NCT02669524
NCT00434642,"A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma",Unknown,COMPLETED,"Carboplatin, Gemcitabine, Bevacizumab, Placebo","DRUG, DRUG, DRUG, DRUG",Other,"Genentech, Inc.",['Ovarian Cancer'],2007-04,2010-09,https://clinicaltrials.gov/study/NCT00434642
NCT04334161,Evaluation of the Neuro-endocrine Response to Post-prandial Hyperinsulinaemic Hypoglycaemia.,Unknown,COMPLETED,Administration of glucose and controlled induction of hypoglycaemia.,COMBINATION_PRODUCT,Other,Lia Bally,"['Roux-en-y Gastric Bypass', 'Post Prandial Hypoglycemia']",2020-10-02,2021-07-13,https://clinicaltrials.gov/study/NCT04334161
NCT01698502,Physical Training and the Incretin Effect,Unknown,COMPLETED,,,Unknown,University of Copenhagen,['Healthy'],2012-08,2013-02,https://clinicaltrials.gov/study/NCT01698502
NCT02931630,The Effect of Whey Protein and Dietary Fibers on Risk Markers of the Metabolic Syndrome and Bone Health,Unknown,COMPLETED,"Whey protein powder, Maltodextrin powder, High fiber bread, Low fiber bread","OTHER, OTHER, OTHER, OTHER",Other,Aarhus University Hospital,"['Abdominal Obesity', 'Metabolic Syndrome', 'Type 2 Diabetes', 'Cardiovascular Disease']",2016-05,2017-06-29,https://clinicaltrials.gov/study/NCT02931630
NCT02921906,Effect of Food Composition on Postprandial Insulin Secretion in Neonatal Diabetes,Unknown,COMPLETED,"High protein meal, High carbohydrate meal, Paracetamol, Fasting state - sulphonylurea only","OTHER, OTHER, DRUG, OTHER",Other,Royal Devon and Exeter NHS Foundation Trust,['Neonatal Diabetes'],2016-06,2022-06-20,https://clinicaltrials.gov/study/NCT02921906
NCT05349149,IL-6 Regulation of Energy Stores During Recovery From an Acute Exercise Bout,Unknown,COMPLETED,"Tocilizumab/Actemra® (Roche), Saline 9%","DRUG, DRUG",Other,Helga Ellingsgaard,['Glycogen Depletion'],2022-04-20,2022-10-11,https://clinicaltrials.gov/study/NCT05349149
NCT02537314,Role of the Foregut in Nutrient Metabolism in Lean and Obese Humans,Unknown,COMPLETED,"benzocaine, placebo","DRUG, OTHER",Other,Vanderbilt University Medical Center,['Obesity'],2015-09,2022-12-08,https://clinicaltrials.gov/study/NCT02537314
NCT03478098,Meal Glycaemic Index and Exercise After Gastric Bypass,Unknown,COMPLETED,"Low GI mealtest, Low GI mealtest and subsequent exercise, High GI mealtest, High GI mealtest and subsequent exercise","OTHER, OTHER, OTHER, OTHER",Other,Kirstine Nyvold Bojsen-Moeller,"['Roux-en-Y Gastric Bypass', 'Obesity']",2018-03-01,2020-03-01,https://clinicaltrials.gov/study/NCT03478098
NCT04223284,Olfactory Odour Stimulation for Metabolism Control,Unknown,COMPLETED,"D-Limonene, SLVO","OTHER, OTHER",Other,"University Hospital, Basel, Switzerland",['Obesity'],2019-12-10,2022-05-10,https://clinicaltrials.gov/study/NCT04223284
NCT00321321,The Beta Cell Responsiveness to Glucose-dependent Insulinotropic Polypeptide (GIP) With and Without Sulfonylurea in Patients With Type 2 Diabetes,Unknown,COMPLETED,Sulfonylurea,DRUG,Other,"University Hospital, Gentofte, Copenhagen","['Diabetes Mellitus, Type 2']",2006-05,2007-03,https://clinicaltrials.gov/study/NCT00321321
NCT02879955,Carbohydrates and Gut Hormones After Gastric Bypass Surgery,Unknown,COMPLETED,"Glucose + Fructose, Sucrose, Isomaltulose, Sucrose + Acarbose","OTHER, OTHER, OTHER, OTHER",Other,Hvidovre University Hospital,['Overweight'],2016-08,2017-06,https://clinicaltrials.gov/study/NCT02879955
NCT00647023,Incretin Secretion in Women With Polycystic Ovary Syndrome (PCOS),Unknown,TERMINATED,metformin,DRUG,Other,Hvidovre University Hospital,['Polycystic Ovary Syndrome'],2004-02,2006-05,https://clinicaltrials.gov/study/NCT00647023
NCT04182464,Effects of Sucralose in Insulin Sensitivity,Unknown,COMPLETED,"Sucralose, Placebo","OTHER, OTHER",Other,Paloma Almeda-Valdés,['Insulin Sensitivity/Resistance'],2019-11-01,2021-08-30,https://clinicaltrials.gov/study/NCT04182464
NCT05368194,Food Intake and Epigenetic Alteration in the Spermatozoa of Singletons and Twins,Unknown,COMPLETED,"Isocaloric Unprocessed Diet, Isocaloric Processed Diet, Excess Calorie Unprocessed Diet, Excess Calorie Processed Diet","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Copenhagen,"['Fertility Issues', 'Nutrition, Healthy', 'Epigenetic Disorder', 'Overnutrition']",2021-10-20,2022-07-01,https://clinicaltrials.gov/study/NCT05368194
NCT02673554,The Reduced Insulinotropic Effect of a Continuous Infusion Relative to a Bolus Injection of GIP,Unknown,COMPLETED,"GIP Bolus, GIP Clamp, Oral glucose tolerance test (OGTT), hyperglycemic clamp","DRUG, DRUG, PROCEDURE, PROCEDURE",GIP agonist,Diabeteszentrum Bad Lauterberg im Harz,['Type 2 Diabetes'],2004-05,2008-12,https://clinicaltrials.gov/study/NCT02673554
NCT02264951,Fat-induced Release of GLP-1 in Humans,Unknown,COMPLETED,"Tributyrin, C8-diet oil, Olive oil, Carrot","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,"Glostrup University Hospital, Copenhagen",['Type 2 Diabetes'],2013-10,2013-12,https://clinicaltrials.gov/study/NCT02264951
NCT02685345,A Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus Receiving Sitagliptin,Unknown,COMPLETED,"DS-8500a 25 mg, DS-8500a 75 mg, placebo","DRUG, DRUG, DRUG",Other,"Daiichi Sankyo Co., Ltd.",['Type 2 Diabetes Mellitus'],2016-01,2016-09,https://clinicaltrials.gov/study/NCT02685345
NCT00998699,Study of the Effects of XOMA 052 on Insulin Production in Subjects With Well Controlled Type 1 Diabetes,Unknown,COMPLETED,"Xoma 052, Placebo","DRUG, DRUG",Other,XOMA (US) LLC,['Type 1 Diabetes'],2010-02,2013-08,https://clinicaltrials.gov/study/NCT00998699
NCT06789263,"Effect of a Collagen Hydrolysate on Postprandial Blood Glucose Profile, Gastric Emptying and GLP-1 Release in Normoglycemic and Prediabetic Subjects",Unknown,RECRUITING,"Collagen hydrolyzed peptides, Placebo","DIETARY_SUPPLEMENT, OTHER",Other,Rousselot BVBA,"['Prediabetes', 'Normoglycemic']",2025-01-29,2025-12,https://clinicaltrials.gov/study/NCT06789263
NCT07215559,"A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes",Unknown,RECRUITING,"Macupatide, Eloralintide, Macupatide Placebo, Eloralintide Placebo","DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Obesity', 'Overweight', 'Diabetes Mellitus, Type 2']",2025-10-16,2027-03,https://clinicaltrials.gov/study/NCT07215559
NCT01189890,Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251),Unknown,COMPLETED,"sitagliptin phosphate, Glimepiride, Placebo to Sitagliptin, Placebo to Glimepiride","DRUG, DRUG, DRUG, DRUG",Other,Merck Sharp & Dohme LLC,['Type 2 Diabetes Mellitus'],2010-08-16,2012-10-31,https://clinicaltrials.gov/study/NCT01189890
NCT02711397,Quantification of Gluten Peptides in Feces,Unknown,COMPLETED,Observational study,OTHER,Other,Biomedal S.L.,['Celiac Disease'],2012-04,2014-06,https://clinicaltrials.gov/study/NCT02711397
NCT01994135,Effects of Carbohydrase-inhibiting Polyphenols on Glycaemic Response in Vivo,Unknown,COMPLETED,"Reference food, Test food dose 1, Test food dose 2","OTHER, OTHER, OTHER",Other,University of Leeds,['Hyperglycaemia'],2014-08,2015-03,https://clinicaltrials.gov/study/NCT01994135
NCT05654805,"Nutraceutical Improvement of Glucose Metabolism, NAFLD and Insulin Resistance by Oat-fiber Supplementation in Type 2 Diabetes Mellitus Patients",Unknown,UNKNOWN,Drinking powder supplement,DIETARY_SUPPLEMENT,Other,"Charite University, Berlin, Germany","['Type 2 Diabetes', 'NAFLD']",2022-12-15,2024-08,https://clinicaltrials.gov/study/NCT05654805
NCT03522792,Neurotensin - an Important Regulator of Appetite in Humans?,Unknown,UNKNOWN,"Neurotensin, Saline, Ad libitum meal, Liquid meal","OTHER, OTHER, OTHER, OTHER",Other,University of Copenhagen,['Physiology - Regulation of Appetite and Food Intake'],2018-01-05,2019-05-01,https://clinicaltrials.gov/study/NCT03522792
NCT06923839,"Testing the Potential Metabolic Effect of the Human Gut Bacterial Peptide, RUCILP, in Healthy Men",Unknown,ACTIVE_NOT_RECRUITING,"Test bacterial peptide: RUCILP, Placebo","BIOLOGICAL, OTHER",Other,Oluf Pedersen,['Healthy Male Adults'],2025-07-28,2025-08-27,https://clinicaltrials.gov/study/NCT06923839
NCT02518737,Examination of the Postprandial Bone Remodeling in Persons With Reduced GIP-Receptor Activity,Unknown,COMPLETED,Meal Test,OTHER,Other,University of Copenhagen,['Bone Remodeling'],2015-09,2016-06,https://clinicaltrials.gov/study/NCT02518737
NCT05802472,Effect of an Polyphenolic Beverage in Healthy Volunteers,Unknown,ACTIVE_NOT_RECRUITING,Polyphenolic beverage from extract of Vachellia farnesiana,OTHER,Other,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,"['Healthy', 'Safety Issues']",2022-04-06,2025-10-30,https://clinicaltrials.gov/study/NCT05802472
NCT05929144,Optimization of MRI Sequences Used in the Study of Neurodegenerative Diseases,Unknown,RECRUITING,MRI sequences testing,OTHER,Other,"University Hospital, Caen",['Memory Disorders'],2023-05-05,2028-07,https://clinicaltrials.gov/study/NCT05929144
NCT02628392,A Phase 2 Study of DS-8500a in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM),Unknown,COMPLETED,"DS-8500a, Sitagliptin, placebo","DRUG, DRUG, DRUG",Other,"Daiichi Sankyo Co., Ltd.",['Type2 Diabetes Mellitus'],2015-11,2016-09,https://clinicaltrials.gov/study/NCT02628392
NCT03263819,Gastrointestinal Symptoms in Postural Orthostatic Tachycardia Syndrome,Unknown,COMPLETED,Oral glucose tolerance test,DIAGNOSTIC_TEST,Other,Vanderbilt University Medical Center,['Postural Tachycardia Syndrome'],2017-06-20,2020-12-31,https://clinicaltrials.gov/study/NCT03263819
NCT04507685,Asian Indian Prediabetes Study,Unknown,COMPLETED,Lifestyle (Diet and Exercise),OTHER,Other,"Institute for Human Development and Potential (IHDP), Singapore",['Pre Diabetes'],2020-10-19,2023-01-27,https://clinicaltrials.gov/study/NCT04507685
NCT03590158,Time RestrIcted Feeding For Improving Diabetes Risk (TRIFFID),Unknown,COMPLETED,TRF,BEHAVIORAL,Other,University of Adelaide,"['Type2 Diabetes', 'Obesity']",2018-07-17,2019-06-29,https://clinicaltrials.gov/study/NCT03590158
NCT04170010,Long Term Effects of Weight Loss on Post-prandial Gut Hormone Responses and Meal Induced Thermogenesis,Unknown,UNKNOWN,,,Unknown,National and Kapodistrian University of Athens,['Morbid Obesity'],2019-12-09,2022-12-31,https://clinicaltrials.gov/study/NCT04170010
NCT03370484,Calcium and Gut Hormones,Unknown,COMPLETED,"Control, Milk mineral supplement","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Bath,"['Obesity', 'Diabetes']",2017-10-01,2018-01-31,https://clinicaltrials.gov/study/NCT03370484
NCT02589028,The Effects of Premeal Consumption of Protein-enriched Bar on Blood Glucose Level and Secretion of Hormones,Unknown,COMPLETED,"premeal protein-enriched bar intake, breakfast follows by protein bar","DIETARY_SUPPLEMENT, OTHER",Other,Seoul National University Hospital,['Diabetes Mellitus'],2015-10,2016-07,https://clinicaltrials.gov/study/NCT02589028
NCT05456347,Effect of a Low-calorie and High-protein Diet Specially Rich in Animal Protein Compared to a Low-calorie and High-protein Diet Specially Rich in Plant Protein on Glucose Metabolism in Subjects With Prediabetes or Type 2 Diabetes and Overweight or Obesity.,Unknown,COMPLETED,"Low-calorie and high-protein diet with the majority of protein coming from animal sources., Low-calorie and high-protein diet with the majority of protein coming from plant sources.","BEHAVIORAL, BEHAVIORAL",Other,Universidad de Zaragoza,"['Diabetes Mellitus, Type 2', 'Overweight and Obesity', 'PreDiabetes']",2021-07-01,2022-10-01,https://clinicaltrials.gov/study/NCT05456347
NCT02850393,Inhibitory Control of the Mind : Neural Bases and Impact for Obsessive-compulsive Disorders,Unknown,UNKNOWN,"Functional magnetic resonance imaging, behavioral measures, physiological measurements","OTHER, BEHAVIORAL, OTHER",Other,"University Hospital, Caen","['Obsessive Compulsive Disorder', 'Healthy']",2016-07,2019-03,https://clinicaltrials.gov/study/NCT02850393
NCT02089438,"DPP-4 Inhibition, Incretins and Islet Function",Unknown,COMPLETED,"Saxagliptin, Vildagliptin, Sitagliptin","DRUG, DRUG, DRUG",Other,Lund University,['Type 2 Diabetes'],2014-05,2017-06,https://clinicaltrials.gov/study/NCT02089438
NCT02953587,Effect of Ghrelin on Glucose Metabolism After Bariatric Surgery,Unknown,COMPLETED,"Oral Glucose Tolerance Test (OGTT), Human Ghrelin, Saline","PROCEDURE, DRUG, DRUG",Other,Vanderbilt University Medical Center,['Obesity'],2016-09,2019-08-21,https://clinicaltrials.gov/study/NCT02953587
NCT00656864,Pioglitazone Incretin Study,Unknown,COMPLETED,"Pioglitazone, Placebo","DRUG, DRUG",Other,University of Vermont,"['Diabetes Mellitus, Type 2']",2008-05,2010-11,https://clinicaltrials.gov/study/NCT00656864
NCT01638949,Multi-modal Neuroimaging in Alzheimer's Disease,Unknown,COMPLETED,"Memory assessment, Circulating biomarkers measure, ApoE4, Brain imaging examination MRI and PET examinations","BEHAVIORAL, BIOLOGICAL, GENETIC, OTHER",Other,"University Hospital, Caen","[""Alzheimer's Disease""]",2012-05,2020-01-20,https://clinicaltrials.gov/study/NCT01638949
NCT01643811,Effect of Gastrectomy and Anastomosis on Diabetes and Hypertension in Early Gastric Cancer Patients,Unknown,COMPLETED,"gastrectomy, Endoscopic submucosal dissection","PROCEDURE, PROCEDURE",Other,"National Cancer Center, Korea",['Early Gastric Cancer'],2012-04,2016-02,https://clinicaltrials.gov/study/NCT01643811
NCT06208904,The Involvement of the Gut Hormone GIP in the Pathophysiology of Post Prandial Hypotension,Unknown,ENROLLING_BY_INVITATION,"Intravenous infusion of GIPRA, Intravenous infusion of saline","OTHER, OTHER",GIP agonist,"University Hospital, Gentofte, Copenhagen",['PostPrandial Hypotension'],2024-05-15,2025-12-31,https://clinicaltrials.gov/study/NCT06208904
NCT02372526,The Effect of Different Macronutrients on Gastrointestinal Hormone Secretion After Gastric Bypass Operation,Unknown,UNKNOWN,"Mealtest: High protein 200 kcal 200 ml liquid meal consumed during 10 minutes, Mealtest: High fat 200 kcal 200 ml liquid meal consumed during 10 minutes, Mealtest: High carbohydrate 200 kcal 200 ml liquid meal consumed during 10 minutes, Mealtest: High fat 200 kcal 200 ml liquid meal with pancreatic lipase inhibitor consumed during 10 minutes","OTHER, OTHER, OTHER, OTHER",Other,Kirstine Nyvold Bojsen-Moeller,"['Bariatric Surgery (Gastric Bypass)', 'Overweight']",2015-01,2016-08,https://clinicaltrials.gov/study/NCT02372526
NCT06151782,Immunosafe-CeD: Are Partially Hydrolysed Gluten Harmful to Celiac Disease Patients?,Unknown,COMPLETED,"Wheat gluten 1000 mg, Barley gluten 1000 mg, Barley gluten 50 mg, Barley hydrolyzed gluten 50 mg, Placebo slurry","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,Oslo University Hospital,"['Celiac Disease', 'Food Intolerance']",2024-01-01,2025-05-30,https://clinicaltrials.gov/study/NCT06151782
NCT06668935,Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring,Unknown,RECRUITING,To utilize the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) to help prolong the length of time people with diabetes maintain adherence to GLP-1 and dual GIP/GLP-1 agonists,DEVICE,Dual agonist,Abbott Diabetes Care,['Diabetes Mellitus'],2024-10-24,2026-10,https://clinicaltrials.gov/study/NCT06668935
NCT01906359,Effects of Triacylglycerol Structure on Gut Hormones and Haemostatic Markers,Unknown,COMPLETED,"Native palm olein (IV56), Chemically interesterified palm olein (IV56), High oleic sunflower oil","OTHER, OTHER, OTHER",Other,Malaysia Palm Oil Board,['Type 2 Diabetes Mellitus'],2012-09,2013-07,https://clinicaltrials.gov/study/NCT01906359
NCT05099393,Effect of Non-nutritive Sweeteners on Vascular Function in Humans,Unknown,RECRUITING,Non Nutritive Sweeteners,DIETARY_SUPPLEMENT,Other,"University Hospital, Grenoble",['Non Nutritive Sweeteners Consumption'],2022-03-28,2024-10,https://clinicaltrials.gov/study/NCT05099393
NCT02005978,Brain-gut Interaction in Irradiated Patients With Acromegaly,Unknown,UNKNOWN,,,Unknown,"Rigshospitalet, Denmark",['Acromegaly'],2013-04,2017-07,https://clinicaltrials.gov/study/NCT02005978
NCT00612950,Beta-Cell Function After Near-Normalisation of Blood Glucose,Unknown,COMPLETED,"glucagon-like peptide-1,, glucose dependent insulinotropic polypeptide, Saline","DRUG, DRUG, DRUG",Other,Hvidovre University Hospital,['Type 2 Diabetes'],2006-10,2007-02,https://clinicaltrials.gov/study/NCT00612950
NCT01453842,Diet Oil Induced Stimulation of GLP-1,Phase 1,COMPLETED,"Diet oil, Olive oil, Carrot","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Copenhagen,['Type 2 Diabetes Mellitus'],2011-03,2011-12,https://clinicaltrials.gov/study/NCT01453842
NCT02944110,Delineation of the Diabetogenic Role of Extrapancreatic Glucagon in Totally Pancreatectomised Patients Using Glucagon Receptor Antagonism,Unknown,UNKNOWN,"Glucagon receptor antagonist LY2409021, Placebo","DRUG, DRUG",Other,"University Hospital, Gentofte, Copenhagen",['Diabetes After Total Pancreatectomy'],2016-04,2019-11,https://clinicaltrials.gov/study/NCT02944110
NCT06733116,Standardizing Reporting Practices for Isokinetic Testing: a Delphi Study,Unknown,NOT_YET_RECRUITING,Delphi method survey,OTHER,Other,"University Hospital, Caen",['Developing a Consensus Framework to Standardize Isokinetic Testing Data Reporting'],2025-01-01,2025-08-01,https://clinicaltrials.gov/study/NCT06733116
NCT05284344,The Impact of Glucotoxicity on Gastric Emptying in Chinese Patients With Newly Diagnosed Type 2 Diabetes,Unknown,COMPLETED,Anti-Diabetics,DRUG,Other,University of Adelaide,['Type 2 Diabetes'],2021-01-24,2023-12-31,https://clinicaltrials.gov/study/NCT05284344
NCT06743009,Metabolic Effects of the Exercise-metabolite Lac-Phe,Unknown,RECRUITING,"N-lactoyl-phenylalanine, NaCl","OTHER, OTHER",Other,University of Aarhus,['Healthy Overweight/Obese'],2025-05-13,2026-01-01,https://clinicaltrials.gov/study/NCT06743009
NCT07212868,The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery,Unknown,NOT_YET_RECRUITING,"REMD-477 versus Placebo, Exogenous glucagon versus saline infusion","DRUG, OTHER",Other,The University of Texas Health Science Center at San Antonio,['Non-Diabetic'],2025-12-01,2030-05-01,https://clinicaltrials.gov/study/NCT07212868
NCT04271189,Managing DIabetes Remission After Combined Therapy in EarLy Stage of DiabetEs,Unknown,COMPLETED,"Metformin-Sitagliptin-Empaglifozin-Pioglitazone, Standard of care","DRUG, DRUG",Other,Azienda Ospedaliero-Universitaria di Parma,['Newly Diagnosed Type 2 Diabetes'],2020-09-01,2024-08-31,https://clinicaltrials.gov/study/NCT04271189
NCT03414151,Gut Microbiome in AP Naive,Unknown,UNKNOWN,Observation,OTHER,Other,Centre for Addiction and Mental Health,"['Psychotic Disorder', 'Schizophrenia']",2018-02-07,2022-03,https://clinicaltrials.gov/study/NCT03414151
NCT03455049,"The Effect of Andrographis Paniculata to GLP-1, Fasting Insulin, Insulin 2-h Post OGTT, and HOMA-IR",Unknown,COMPLETED,Andrographis Paniculata Ext,OTHER,Other,Indonesia University,['Increased Insulin'],2017-10-17,2018-05-02,https://clinicaltrials.gov/study/NCT03455049
NCT01515059,Analysing Differences in Glycaemic Control Immediately Post Obesity SurgEry (The ADIPOSE Study),Unknown,TERMINATED,,,Unknown,University of Leicester,['Obesity'],2012-09,2015-12,https://clinicaltrials.gov/study/NCT01515059
NCT05885074,Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors,Unknown,WITHDRAWN,"Empagliflozin Arm, Control Arm, Exercise capacity VO2 maximum determination, Exercise Challenge","DRUG, OTHER, OTHER, OTHER",Other,University of Alabama at Birmingham,"['Obesity', 'Weight Loss']",2025-01-30,2026-01-30,https://clinicaltrials.gov/study/NCT05885074
NCT04610203,"Glycaemic Response, Insulinaemic Response, GLP-1 and GIP Testing of Food Product Lines",Unknown,COMPLETED,"25 g Nutralys Pea Protein, 50 g Nutralys S85 Plus., 50 g Glucose","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,Oxford Brookes University,['Healthy'],2018-12-03,2019-07-05,https://clinicaltrials.gov/study/NCT04610203
NCT06925204,Natural Course and Therapeutic Effect of Chronic Pancreatitis,Unknown,RECRUITING,Observation,OTHER,Other,Changhai Hospital,['Chronic Pancreatitis'],2025-04-13,2035-12-01,https://clinicaltrials.gov/study/NCT06925204
NCT02110017,Exploration of Neural Bases in Social Cognition,Unknown,UNKNOWN,fMRI social cognition task,OTHER,Other,"University Hospital, Caen","['Interpersonal Relations', 'Schizophrenia', 'Magnetic Resonance Imaging, Functional']",2013-09,2015-09,https://clinicaltrials.gov/study/NCT02110017
NCT06959043,Therapeutic Strategies for Type 2 Diabetes Based on Lifestyle Changes: Plant-based Diet and Physical Exercise,Unknown,RECRUITING,"Probiotic Supplementation, Placebo Administration","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,Maria Elizabeth Rossi da Silva,"['Type 2 Diabetes Mellitus (T2DM)', 'Insulin Resistance', 'Inflamation', 'Gut Microbiomes']",2022-11-22,2025-08,https://clinicaltrials.gov/study/NCT06959043
NCT02916355,Role of Interleukin (IL)-1 in Postprandial Fatigue - The Chäschüechli 2 Study,Unknown,COMPLETED,"Anakinra, NaCl","DRUG, DRUG",Other,"University Hospital, Basel, Switzerland",['Adiposity'],2016-08,2017-04,https://clinicaltrials.gov/study/NCT02916355
NCT05369585,Mode of Action (MoA) Study of TOTUM-63 in Individuals at Increased Cardio-metabolic Risk,Unknown,COMPLETED,TOTUM-63,DIETARY_SUPPLEMENT,Other,Valbiotis,"['Prediabetic State', 'Dysglycemia', 'Overweight and Obesity']",2022-04-25,2023-04-12,https://clinicaltrials.gov/study/NCT05369585
NCT00411411,Long Term Effects of DPP-IV Inhibitor Treatment in Patients With Type 2 Diabetes,Unknown,COMPLETED,"Januvia, Placebo","DRUG, DRUG",Other,"University Hospital, Gentofte, Copenhagen",['Type 2 Diabetes'],2007-02,2009-02,https://clinicaltrials.gov/study/NCT00411411
NCT02237521,The Effect of the Incretin Hormones on the Endocrine Pancreatic Function During Hyperglycemia in End-stage Renal Disease,Unknown,COMPLETED,"Eu- and hyperglycemic clamp, Arginine test","OTHER, OTHER",Other,Bo Feldt-Rasmussen,['End-stage Renal Disease'],2014-09,2016-04-28,https://clinicaltrials.gov/study/NCT02237521
NCT02849899,Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period,Unknown,UNKNOWN,"Vildagliptin, Placebo","DRUG, DRUG",Other,Centre Hospitalier Universitaire de Besancon,"['Disorder Related to Renal Transplantation', 'Diabetes']",2018-10-26,2024-07,https://clinicaltrials.gov/study/NCT02849899
NCT07149064,Effect of Chronic Exposure to Nextida GC-B on Glycemic Control in Adults With Normoglycemia and Prediabetes,Unknown,NOT_YET_RECRUITING,"Nextida GC-B, Placebo","DIETARY_SUPPLEMENT, OTHER",Other,Rousselot BVBA,"['Normoglycemia', 'Prediabetes', 'Glycemic Control']",2025-11,2026-04,https://clinicaltrials.gov/study/NCT07149064
NCT05798598,Evaluation of Competencies in Scientific Writing and Attendees' Satisfaction After Two Different Types of Training Courses: SCRIU-B Study,Unknown,UNKNOWN,Scientific writing training course,OTHER,Other,Dr. Antoni Esteve Foundation,['Scientific Writing Training Course'],2019-07-05,2023-12-31,https://clinicaltrials.gov/study/NCT05798598
NCT03556098,Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes,Unknown,COMPLETED,"glucose-dependent insulinotropic peptide, Glucose-Dependent Insulin-Releasing Hormone[3-30], Saline Solution","DRUG, DRUG, DRUG",Other,Steno Diabetes Center Copenhagen,"['Diabetes Mellitus, Type 1']",2019-02-22,2020-02-11,https://clinicaltrials.gov/study/NCT03556098
NCT01391884,Elimination of Incretin Hormones in Patients With Severe Kidney Failure,Unknown,COMPLETED,,,Unknown,Bo Feldt-Rasmussen,['Uremia'],2011-06,2012-06,https://clinicaltrials.gov/study/NCT01391884
NCT01914133,Acarbose and Older Adults With Postprandial Hypotension,Unknown,COMPLETED,"Acarbose, Placebo","DRUG, DRUG",Other,Kenneth Madden,"['Other Specified Hypotension', 'Syncope']",2014-01,2021-05,https://clinicaltrials.gov/study/NCT01914133
NCT04581447,Extending Time Without Diabetes After Bariatric Surgery: a Trial Comparing the Metformin Addition or Not to Standard Care,Unknown,RECRUITING,"Metformin, Standard Care, Standardized meal","DRUG, OTHER, DIETARY_SUPPLEMENT",Other,Assistance Publique - Hôpitaux de Paris,"['Diabetes', 'Bariatric Surgery', 'Metformin']",2021-01-07,2026-07,https://clinicaltrials.gov/study/NCT04581447
NCT04219813,Urinary Gluten Immunogenic Peptides Detection in Non-celiac Gluten/Wheat Sensitivity,Unknown,RECRUITING,Urinary test,OTHER,Other,University of Palermo,['Non-celiac Gluten/Wheat Sensitivity'],2021-01-01,2025-12-31,https://clinicaltrials.gov/study/NCT04219813
NCT03370497,Calcium-protein Co-ingestion and Gut Hormones,Unknown,COMPLETED,"Milk Mineral Supplement, Whey Protein Hydrolysate","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Bath,"['Obesity', 'Diabetes']",2017-10-01,2018-01-31,https://clinicaltrials.gov/study/NCT03370497
NCT01173978,Insulinotropic Effect of GIP and GLP-1 Before and After Reduced Glucose Tolerance,Unknown,COMPLETED,"Steroid hormone, No intervention","BEHAVIORAL, OTHER",Other,"Glostrup University Hospital, Copenhagen","['Insulin Resistance', 'Deteriorated Glucose Homeostasis', 'Inactivity']",2010-04,2010-07,https://clinicaltrials.gov/study/NCT01173978
NCT05361148,Long-term Health After Severe Acute Malnutrition in Children and Adults: the Role of the Pancreas,Unknown,COMPLETED,no interventions will be used,OTHER,Other,London School of Hygiene and Tropical Medicine,"['Pancreas Atrophy', 'Diabetes', 'Malnutrition']",2021-01-12,2023-08-30,https://clinicaltrials.gov/study/NCT05361148
NCT02548585,"A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus",Unknown,COMPLETED,"MEDI0382, Placebo","DRUG, DRUG",Other,MedImmune LLC,['Type 2 Diabetes Mellitus'],2015-12-09,2017-02-24,https://clinicaltrials.gov/study/NCT02548585
NCT04646746,Acute Studies on the Glycemic Index After Intake of Different Sorts of Barley in Subjects With Type 2 Diabetes,Unknown,COMPLETED,"100% wheat, 50% nude barley and 50% wheat, 75% nude barley and 25% wheat, 50% gene-modified high-amylose barley and 50% wheat","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Aarhus,['Type 2 Diabetes'],2021-02-08,2021-10-29,https://clinicaltrials.gov/study/NCT04646746
NCT00501657,Effects of Sitagliptin on Gastric Emptying in Healthy Subjects,Unknown,COMPLETED,"Sitagliptin, Placebo","DRUG, DRUG",Other,Royal Adelaide Hospital,"['Gastroparesis', 'Diabetes Mellitus']",2007-07,2008-06,https://clinicaltrials.gov/study/NCT00501657
NCT05597904,Background of Different Phenotypes of Coeliac Disease,Unknown,RECRUITING,Genetic predisposition,GENETIC,Other,Tampere University Hospital,"['Celiac Disease', 'Dermatitis Herpetiformis']",2022-11-08,2027-12-31,https://clinicaltrials.gov/study/NCT05597904
NCT04905589,Medium Chain Triglycerides (MCT) and Whey Protein Isolate (WPI) for Type 2 Diabetes Patients (Combine),Unknown,COMPLETED,"BetaQuik™, WheyBasics, Iso-voluminous water","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, OTHER",Other,Société des Produits Nestlé (SPN),['Type 2 Diabetes'],2021-04-30,2022-08-01,https://clinicaltrials.gov/study/NCT04905589
NCT05768958,Hedonic and Homeostatic Appetite Control in Obesity and Type 2 Diabetes in the Context of Meal and Exercise Timing,Unknown,ACTIVE_NOT_RECRUITING,"Exercise, Control","OTHER, OTHER",Other,Steno Diabetes Center Copenhagen,"['Overweight and Obesity', 'Type 2 Diabetes']",2023-03-22,2024-08-21,https://clinicaltrials.gov/study/NCT05768958
NCT01020617,"The Effect of Probiotics on Low-grade Inflammation, Microbiota and Risk Factors for Metabolic Syndrome in Obese Children",Unknown,COMPLETED,Ls-33,DIETARY_SUPPLEMENT,Other,University of Copenhagen,"['Metabolic Syndrome', 'Inflammation', 'Obesity']",2009-04,2010-08,https://clinicaltrials.gov/study/NCT01020617
NCT04194424,A Multidisciplinary Weight Loss Program at AUB-MC,Unknown,ACTIVE_NOT_RECRUITING,"Multidisciplinary weight loss program, Standard Care, Metformin Hcl 850Mg Tab","OTHER, OTHER, DRUG",Other,American University of Beirut Medical Center,"['Obesity', 'Weight Loss']",2023-08-15,2026-09-15,https://clinicaltrials.gov/study/NCT04194424
NCT04767880,Acute Metabolic Effects of Pre-meal Consumption of Whey in Women at Risk of Gestational Diabetes Mellitus,Unknown,COMPLETED,"Whey, Placebo","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Aarhus,['Gestational Diabetes Mellitus in Pregnancy'],2021-04-26,2023-09-29,https://clinicaltrials.gov/study/NCT04767880
NCT06589856,Does Oral Lactate Affect Gut Hormone Secretion in a Dose-response Relationship?,Unknown,NOT_YET_RECRUITING,"Placebo, LAC5, LAC10, LAC20","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Aarhus,['Metabolic Syndrome'],2024-10,2025-01,https://clinicaltrials.gov/study/NCT06589856
NCT06391320,Obesity Queue Database,Unknown,RECRUITING,other,OTHER,Other,RenJi Hospital,['Obesity'],2023-09-01,2028-12-31,https://clinicaltrials.gov/study/NCT06391320
NCT06398340,Identifying Wearable Biomarkers to Monitor Dietary Intake,Unknown,RECRUITING,"High Calorie Meal Intervention, Low Calorie Meal Intervention","OTHER, OTHER",Other,Imperial College London,"['Energy Intake', 'Metabolism', 'Digestion', 'Wearables', 'Dietary Intake Assessment', 'Healthy Volunteers', 'Blood Glucose']",2024-08-19,2025-06-30,https://clinicaltrials.gov/study/NCT06398340
NCT02152124,"Growth Hormone, IGF-1 and Medical Treatment in Acromegaly: Are There Effects on Gut Hormone Physiology and Postprandial Substrate Metabolism?",Unknown,COMPLETED,,,Unknown,"University Hospital, Ghent",['Acromegaly'],2014-06-01,2017-08-31,https://clinicaltrials.gov/study/NCT02152124
NCT02180620,Pre-dinner vs. Post-dinner Exercise on Glycemic Control,Unknown,COMPLETED,"No exercise, Meal then exercise, exercise then meal","OTHER, OTHER, OTHER",Other,University of Missouri-Columbia,['Type 2 Diabetes'],2013-09,2014-04,https://clinicaltrials.gov/study/NCT02180620
NCT02775513,Metabolism of Patients With Genetically Caused Cardiac Arrhythmia,Unknown,UNKNOWN,,,Unknown,University of Copenhagen,['Long QT Syndrome'],2010-09,2016-05,https://clinicaltrials.gov/study/NCT02775513
NCT02697305,Incretin Effects of Branched Chain Amino Acids,Unknown,COMPLETED,"IV BCAA, ORAL BCAA, ORAL Placebo","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT, OTHER",Other,"Charles University, Czech Republic",['Glucose Metabolism Disorders'],2014-09,2015-05,https://clinicaltrials.gov/study/NCT02697305
NCT00716170,"GIP, GLP-1 and GLP-2 in Type 2 Diabetic Hyperglucagonemia",Unknown,COMPLETED,"Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)",BIOLOGICAL,Dual agonist,Herlev Hospital,['Type 2 Diabetes Mellitus'],2008-07,2009-07,https://clinicaltrials.gov/study/NCT00716170
NCT05263401,Keto Drinks as a Meal Primer in Patients With Type 2 Diabetes,Unknown,COMPLETED,3-hydroxybutyrate,DIETARY_SUPPLEMENT,Other,University of Aarhus,"['Type 2 Diabetes', 'Ketoses, Metabolic']",2022-01-01,2022-09-30,https://clinicaltrials.gov/study/NCT05263401
NCT03337971,Nutritional Supplement and Bone Health in Post-Menopausal Women,Unknown,COMPLETED,"PLACEBO, MBPM","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Limerick,"['Bone and Bones', 'Osteoporosis Risk', 'Osteoporosis, Postmenopausal']",2017-10-03,2018-12-28,https://clinicaltrials.gov/study/NCT03337971
NCT02218333,Health Effects of Milk Proteins in Elderly Subjects,Unknown,COMPLETED,"Milk, Placebo","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,University of Oslo,['Healthy'],2014-08,2015-09,https://clinicaltrials.gov/study/NCT02218333
NCT01257464,Sitagliptin in Cystic Fibrosis-Related Diabetes,Unknown,TERMINATED,"Sitagliptin, Placebo","DRUG, DRUG",Other,University of British Columbia,['Cystic Fibrosis'],2010-09,2012-06,https://clinicaltrials.gov/study/NCT01257464
NCT01048268,Glucose-dependent Insulinotropic Polypeptide - New Role as Blood Glucose Stabilizer?,Unknown,COMPLETED,"glucose-dependent insulinotropic polypeptide, Placebo","DRUG, DRUG",Other,"University Hospital, Gentofte, Copenhagen",['Diabetes Mellitus'],2009-12,2014-04,https://clinicaltrials.gov/study/NCT01048268
NCT02203240,Cocoa and Metabolic Health in Prediabetes,Unknown,COMPLETED,"Cocoa, Placebo","OTHER, OTHER",Other,Virginia Polytechnic Institute and State University,['Prediabetes'],2014-06,2015-12,https://clinicaltrials.gov/study/NCT02203240
NCT02464514,Macronutrient Regulation of Ghrelin and Peptide YY,Unknown,COMPLETED,"High carbohydrate meal, High fat meal","OTHER, OTHER",Other,Duke University,"['Obesity', 'Prader Willi Syndrome']",2004-01,2005-12,https://clinicaltrials.gov/study/NCT02464514
NCT02235584,Insulinotropic Effect of GLP-1 and GIP After Dexamethasone,Unknown,COMPLETED,Dexamethasone,DRUG,Other,Hvidovre University Hospital,['Type 2 Diabetes'],2009-07,2014-06,https://clinicaltrials.gov/study/NCT02235584
NCT06728787,Robot-assisted Walking Treatment in Hereditary Spastic Paraplegia (HSP),Unknown,RECRUITING,Robot-Assisted Gait Training,DEVICE,Other,IRCCS Eugenio Medea,['Hereditary Spastic Paraplegia'],2012-01-01,2026-12-31,https://clinicaltrials.gov/study/NCT06728787
NCT01303315,TANTALUS Therapy in Type 2 Diabetic Patients Intolerant or Inadequately Responsive to GLP-1 Receptor Agonist Therapy,Unknown,TERMINATED,TANTALUS System,DEVICE,Other,"MetaCure (USA), Inc.","['Diabetes Mellitus, Type 2']",2011-01,2011-07,https://clinicaltrials.gov/study/NCT01303315
NCT02876484,Effects of Bile Acids and Bile Acid Sequestrants on GLP-1 Secretion After Roux-en-Y Gastric Bypass,Unknown,COMPLETED,"Colesevelam, Chenodeoxycholic Acid, Water","DRUG, DRUG, OTHER",Other,Hvidovre University Hospital,['Severe Obesity'],2016-06,2017-06,https://clinicaltrials.gov/study/NCT02876484
NCT03027336,Efficacy and Tolerability of the Nutraceutical Formulation Coleosoma in Dyslipidemic Subjects,Unknown,COMPLETED,"Coleosoma, Placebo","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,Azienda Ospedaliero-Universitaria di Parma,['Dyslipidemias'],2016-01,2016-08,https://clinicaltrials.gov/study/NCT03027336
NCT00858312,Dairy Foods and Weight Loss,Unknown,COMPLETED,"high dairy diet, Low Dairy","OTHER, OTHER",Other,"USDA, Western Human Nutrition Research Center",['Overweight and Obesity'],2006-10,2009-08,https://clinicaltrials.gov/study/NCT00858312
NCT00674817,An Investigation Of The Interaction Of GSK961081 With Inhaled Beta-Agonist And Anti-Muscarinic Drugs.,Unknown,COMPLETED,"400 microgrammes GSK961081, 1200 microgrammes GSK961081","DRUG, DRUG",Other,Theravance Biopharma,"['Pulmonary Disease, Chronic Obstructive']",2008-04-01,2008-10-01,https://clinicaltrials.gov/study/NCT00674817
NCT00092989,"Investigation of Intravenous (IV) Administration of an Approved Drug (MK-0476, Montelukast Sodium) for Acute Asthma (MK-0476-288)",Unknown,COMPLETED,"montelukast sodium, placebo","DRUG, DRUG",Other,Organon and Co,['Asthma'],2004-07,2007-03,https://clinicaltrials.gov/study/NCT00092989
NCT01493882,Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled Asthma,Unknown,WITHDRAWN,"Placebo, JNJ-39758979 30 mg/d, JNJ-39758979 100 mg/d, JNJ-39758979 300 mg/d","DRUG, DRUG, DRUG, DRUG",Other,"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",['Asthma'],2012-03,2015-06,https://clinicaltrials.gov/study/NCT01493882
NCT02279160,Safety and Efficacy of APD811 in Pulmonary Arterial Hypertension,Unknown,COMPLETED,"APD811, Placebo","DRUG, DRUG",Other,United Therapeutics,['Pulmonary Arterial Hypertension'],2014-12,2017-06,https://clinicaltrials.gov/study/NCT02279160
NCT01714713,A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy,Unknown,COMPLETED,EVP-6124,DRUG,Other,FORUM Pharmaceuticals Inc,"['Schizophrenia', 'Impaired Cognition']",2013-06,2015-10,https://clinicaltrials.gov/study/NCT01714713
NCT05477108,"Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant",Unknown,COMPLETED,"Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal)","DRUG, DRUG",Other,AstraZeneca,['Chronic Obstructive Pulmonary Disease'],2022-07-29,2023-04-11,https://clinicaltrials.gov/study/NCT05477108
NCT04163458,Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART),Unknown,COMPLETED,"MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL, MENOPUR powder and solvent for solution for injection, 75 IU, Placebo (for MENOPUR solution for injection in pre-filled pen), Placebo (for MENOPUR powder and solvent for solution for injection)","DRUG, DRUG, OTHER, OTHER",Other,Ferring Pharmaceuticals,['Infertility'],2019-10-25,2021-05-28,https://clinicaltrials.gov/study/NCT04163458
NCT00391820,Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial),Unknown,COMPLETED,TD-5108,DRUG,Other,Alfasigma S.p.A.,['Chronic Constipation'],2006-10,,https://clinicaltrials.gov/study/NCT00391820
NCT00813917,Varenicline for the Treatment of Smokeless Tobacco,Unknown,COMPLETED,"varenicline, placebo","DRUG, DRUG",Other,Mayo Clinic,['Nicotine Dependence'],2009-02,2010-10,https://clinicaltrials.gov/study/NCT00813917
NCT01218984,ALK21-004: Single-dose Opiate Challenge of Medisorb® Naltrexone (VIVITROL®) in Adults Who Use Opioids,Unknown,COMPLETED,"Medisorb naltrexone 75 mg, Medisorb naltrexone 150 mg, Medisorb naltrexone 300 mg, Hydromorphone (10 mg/mL), Naloxone Challenge and Oral Naltrexone Tolerability Testing","DRUG, DRUG, DRUG, DRUG, DRUG",Other,"Alkermes, Inc.",['Opiate Dependence'],2002-03,2003-05,https://clinicaltrials.gov/study/NCT01218984
NCT00821691,Action of Amantadine on Post-Stroke Aphasic Patients,Unknown,COMPLETED,"Amantadin, Placebo","DRUG, DRUG",Other,Centre Hospitalier Universitaire de Nice,['Cerebral Infarction'],2009-03,2013-04,https://clinicaltrials.gov/study/NCT00821691
NCT01459029,High Dose D-Serine as Adjuvant Treatment for Recent Onset Schizophrenia,Unknown,UNKNOWN,D-serine,DRUG,Other,Hadassah Medical Organization,['Schizophrenia'],2011-11,2013-10,https://clinicaltrials.gov/study/NCT01459029
NCT03078257,Different Platelet Activities Between Intracoronary and Peripheral Blood in Coronary Artery Disease Patients,Unknown,UNKNOWN,"tirofiban in PV, tirofiban in IC, antiplatelet thrombolysin, placebo, Clopidogrel, Aspirin, Clopidogrel","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,The First Affiliated Hospital with Nanjing Medical University,['Coronary Artery Disease'],2016-01-01,2017-11,https://clinicaltrials.gov/study/NCT03078257
NCT04686994,Study to Evaluate the Safety and Efficacy of ASC41 in Overweight and Obese Subjects,Unknown,COMPLETED,"ASC 41, ASC 41 Placebo","DRUG, DRUG",Other,"Gannex Pharma Co., Ltd.","['Overweight and Obesity', 'NAFLD', 'Hyperlipidemia']",2020-12-22,2021-01-19,https://clinicaltrials.gov/study/NCT04686994
NCT06611930,CK-0045 Proof-of-concept Study in Participants With Overweight / Obesity and Type 2 Diabetes,Unknown,ACTIVE_NOT_RECRUITING,"CK-0045, Placebo","DRUG, DRUG",Other,Cytoki Pharma,"['Type 2 Diabetes Mellitus (T2DM)', 'Obesity and Overweight']",2024-09-16,2025-11-18,https://clinicaltrials.gov/study/NCT06611930
NCT02048215,Effect on Energy Metabolism at Cellular Level of Diet Plus Treatment With Ephedrine and Caffeine in Obesity,Unknown,COMPLETED,"Caffeine, Placebo, Ephedrine, Hypocaloric diet","DRUG, DRUG, DRUG, OTHER",Other,Istituto Auxologico Italiano,['Obesity'],2000-02,2001-01,https://clinicaltrials.gov/study/NCT02048215
NCT05527704,the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial),Unknown,ACTIVE_NOT_RECRUITING,"Salbutamol, 0,9% Chloride Sodium","DRUG, DRUG",Other,Medical University of Warsaw,"['TTN', 'Respiratory Failure', 'PPHN']",2021-12-31,2025-11-30,https://clinicaltrials.gov/study/NCT05527704
NCT01387425,Efficacy And Safety Of Smoking Cessation With Varenicline Tartrate In Diabetic Smokers: (DIASMOKE),Unknown,COMPLETED,"varenicline, placebo tablet is made of lactose","DRUG, DRUG",Other,Universita degli Studi di Catania,"['Smoking Cessation', 'Diabetes']",2011-06,2015-12,https://clinicaltrials.gov/study/NCT01387425
NCT00394914,Effects of Pleconaril Nasal Spray on Common Cold Symptoms and Asthma Exacerbations Following Rhinovirus Exposure (Study P04295),Unknown,COMPLETED,"Pleconaril, Placebo to Pleconaril","DRUG, DRUG",Other,Merck Sharp & Dohme LLC,"['Asthma', 'Common Cold', 'Picornavirus Infection', 'Rhinovirus']",2006-08,2007-04,https://clinicaltrials.gov/study/NCT00394914
NCT05252949,OEA for Targeting Lipid Metabolism in GWI,Unknown,COMPLETED,"Oleoylethanolamide (OEA), Placebo","DIETARY_SUPPLEMENT, DIETARY_SUPPLEMENT",Other,Roskamp Institute Inc.,['Gulf War Illness'],2021-06-10,2024-09-30,https://clinicaltrials.gov/study/NCT05252949
NCT01007149,Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma,Unknown,COMPLETED,"omalizumab, Placebo","DRUG, DRUG",Other,Novartis Pharmaceuticals,['Asthma'],2009-09,2011-02,https://clinicaltrials.gov/study/NCT01007149
NCT00317577,Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma,Unknown,COMPLETED,"brimonidine, timolol",DRUG,Other,Chicago Center for Vision Research,"['Glaucoma, Open Angle']",1998-12,,https://clinicaltrials.gov/study/NCT00317577
NCT06251375,Early Sedation With Dexmedetomidine vs. Placebo in Older Ventilated Critically Ill Patients,Unknown,NOT_YET_RECRUITING,"Dexmedetomidine, Placebo","DRUG, OTHER",Other,St. Joseph's Healthcare Hamilton,['Respiratory Insufficiency'],2025-09-07,2027-12-31,https://clinicaltrials.gov/study/NCT06251375
NCT03622112,A Study to Assess the Efficacy and Safety of Multiple Dose Levels of AZD7594 Administered Once Daily by Inhalation in Asthmatic Subjects,Unknown,COMPLETED,"AZD7594 DPI 55μg/50μg., AZD7594 DPI 99 µg/90 µg, AZD7594 DPI 198 µg/180 µg, AZD7594 DPI 396 µg/360 µg once daily., AZD7594 DPI 792 µg/720 µg, Placebo for AZD7594 once daily., FF 100 µg once daily (open-label)","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,AstraZeneca,['Asthma'],2019-01-02,2019-09-30,https://clinicaltrials.gov/study/NCT03622112
NCT01248975,Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for Asthma,Unknown,COMPLETED,"FP/SAL 250/50mcg BID, GSK2190915 200mg QD (AM), GSK2190915 100mg QD (AM), Montelukast 10mg QD (PM), Placebo tablets (2) (AM), Placebo capsule (PM)","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,GlaxoSmithKline,['Asthma'],2010-12,2011-10,https://clinicaltrials.gov/study/NCT01248975
NCT05778071,Evaluation of the Safety and Efficacy of Eneboparatide (AZP-3601) in Patients With Chronic Hypoparathyroidism,Unknown,ACTIVE_NOT_RECRUITING,"eneboparatide, Placebo","COMBINATION_PRODUCT, COMBINATION_PRODUCT",Other,"Alexion Pharmaceuticals, Inc.","['Chronic Hypoparathyroidism', 'Endocrine System Diseases', 'Parathyroid Diseases']",2023-06-07,2024-11-15,https://clinicaltrials.gov/study/NCT05778071
NCT06568367,"Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)",Unknown,RECRUITING,"Solriamfetol 150 mg, Solriamfetol 300 mg, Placebo","DRUG, DRUG, DRUG",Other,"Axsome Therapeutics, Inc.","['Excessive Sleepiness', 'Shift-work Disorder']",2024-08-01,2026-12,https://clinicaltrials.gov/study/NCT06568367
NCT00665600,Efficacy and Safety of Levalbuterol in Chronic Obstructive Pulmonary Disease (COPD),Unknown,COMPLETED,"Levalbuterol HCl, Levalbuterol HCl, Albuterol Sulfate, Placebo","DRUG, DRUG, DRUG, DRUG",Other,"Sumitomo Pharma America, Inc.",['Chronic Obstructive Pulmonary Disease (COPD)'],2002-02,2003-03,https://clinicaltrials.gov/study/NCT00665600
NCT02552147,Nicotinic Cholinergic Modulation as a Novel Treatment Strategy for Aggression Associated With Autism,Unknown,COMPLETED,"Transdermal nicotine, Transdermal placebo","DRUG, OTHER",Other,Yale University,"['Autism Spectrum Disorder', 'Aggression', 'Irritability']",2015-09,2017-11-17,https://clinicaltrials.gov/study/NCT02552147
NCT03902106,Physiological Response to Salbutamol and Exercise,Unknown,UNKNOWN,"salbutamol, exercise","DRUG, OTHER",Other,University of Copenhagen,['Healthy'],2019-03-28,2021-06-30,https://clinicaltrials.gov/study/NCT03902106
NCT00349245,Dexmedetomidine vs. Remifentanil for Sedation During AFI,Unknown,COMPLETED,"Remifentanil, Dexmedetomidine","DRUG, DRUG",Other,"The University of Texas Health Science Center, Houston","['Intubation, Endotracheal']",2006-06,2007-08,https://clinicaltrials.gov/study/NCT00349245
NCT03096834,A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies,Unknown,COMPLETED,"AMG334 (70 mg) Pre-Filled Syringe (PFS), Placebo Pre-Filled Syringe (PFS)","BIOLOGICAL, BIOLOGICAL",Other,Novartis Pharmaceuticals,['Episodic Migraine'],2017-03-20,2018-01-18,https://clinicaltrials.gov/study/NCT03096834
NCT06715098,Comparison of Robot Assisted Gait Training and Body Weight Supported Treadmill Training Using Gait Analysis and SEMG Measurements,Unknown,COMPLETED,"RoboGait, RehaWalk, Conventional","DEVICE, DEVICE, OTHER",Other,Pamukkale University,"['Stroke, Ischemic']",2023-12-14,2024-08-31,https://clinicaltrials.gov/study/NCT06715098
NCT04917315,To Evaluate the Efficacy and Safety of JLP-2002 on Symptoms of Overactive Bladder,Unknown,COMPLETED,"JLP-2002 A mg, Placebo","DRUG, DRUG",Other,"Jeil Pharmaceutical Co., Ltd.",['Overactive Bladder'],2020-05-21,2021-08-18,https://clinicaltrials.gov/study/NCT04917315
NCT00964249,Phase I Study of GW642444M in Healthy Japanese Male Subjects,Unknown,COMPLETED,"GW642444, Placebo","DRUG, DRUG",Other,GlaxoSmithKline,"['Pulmonary Disease, Chronic Obstructive']",2008-09-20,2008-12-01,https://clinicaltrials.gov/study/NCT00964249
NCT06194552,A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07,Unknown,COMPLETED,"NTRX-07, Placebo","DRUG, DRUG",Other,"NeuroTherapia, Inc.",['Alzheimer Disease'],2022-09-06,2023-05-31,https://clinicaltrials.gov/study/NCT06194552
NCT04783090,MT1013 Clinical TRIAL In Healthy Subject,Unknown,COMPLETED,MT1013,DRUG,Other,"Shaanxi Micot Pharmaceutical Technology Co., Ltd.",['Healthy Volunteer'],2021-06-28,2021-12-31,https://clinicaltrials.gov/study/NCT04783090
NCT01526161,Management of Asthma in School-age Children on Therapy,Unknown,COMPLETED,"inhaled fluticasone propionate, salmeterol, Montelukast","DRUG, DRUG, DRUG",Other,Professor Warren Lenney,['Asthma'],2009-04,2010-06,https://clinicaltrials.gov/study/NCT01526161
NCT02152670,Understanding Dopamine Mechanisms in Cocaine Addiction Using AMPT and Methylphenidate With [11C]RAC/[11C]PHNO PET,Unknown,TERMINATED,"Methylphenidate, Alpha Methyl Para Tyrosine (AMPT), [11C]PHNO, [11C]raclopride","DRUG, DRUG, OTHER, OTHER",Other,Yale University,['Cocaine Dependence'],2014-05,2014-06-09,https://clinicaltrials.gov/study/NCT02152670
NCT00209508,2 Year Study to Evaluate the Effects of GPI 1485 on [123I]b-CIT/SPECTScanning and Clinical Efficacy in Patients With PD,Unknown,COMPLETED,GPI 1485,DRUG,Other,Eisai Inc.,"[""Parkinson's Disease""]",2002-11,,https://clinicaltrials.gov/study/NCT00209508
NCT04612517,"A Multiple Ascending Dose Trial Assessing Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP7570",Phase 1,COMPLETED,"ZP7570, Placebo","DRUG, DRUG",Other,Zealand Pharma,['Healthy'],2020-10-26,2021-08-30,https://clinicaltrials.gov/study/NCT04612517
NCT01863186,"Efficacy, Safety and Dose-Response Study Followed by Open-Label Study of Lofexidine Treatment of Opioid Withdrawal",Unknown,COMPLETED,"Lofexidine HCl, Placebo, Open Label Lofexidine HCL","DRUG, DRUG, DRUG",Other,"USWM, LLC (dba US WorldMeds)","['Opioid Dependence', 'Acute Opioid Withdrawal Syndrome']",2013-06,2014-11,https://clinicaltrials.gov/study/NCT01863186
NCT03660813,Follicle Size and Oocyte Development,Unknown,COMPLETED,"Follicle measurment, Ovitrelle ( Hcg 250 mcg), Decapeptyl ( GnRH Agonist 0.1 mg*2 )","DIAGNOSTIC_TEST, DRUG, DRUG",Other,Sheba Medical Center,['IVF Treatment'],2018-07-01,2021-08-01,https://clinicaltrials.gov/study/NCT03660813
NCT04251182,Clinical Study Evaluating Efficacy and Safety of T3D-959 in Mild-to-moderate AD Subjects,Unknown,COMPLETED,"15mg T3D-959, 30 mg T3D-959, 45 mg T3D-959, Placebos","DRUG, DRUG, DRUG, DRUG",Other,"T3D Therapeutics, Inc.",['Alzheimer Disease'],2021-03-01,2023-01-20,https://clinicaltrials.gov/study/NCT04251182
NCT05328258,Use of GnRHa During Chemotherapy for Fertility Protection,Unknown,RECRUITING,"Triptorelin Embonate, Sodium Chloride solution 0.9%","DRUG, DRUG",Other,Kenny Rodriguez-Wallberg,"['Breast Cancer Female', 'Acute Leukemia', 'Lymphoma', 'Osteosarcoma', 'Soft Tissue Sarcoma', 'Ewing Sarcoma']",2023-03-31,2028-01-01,https://clinicaltrials.gov/study/NCT05328258
NCT01500317,Comparison of the Effects of Tapentadol and Oxycodone on Gastrointestinal and Colonic Transit in Humans,Unknown,COMPLETED,"Tapentadol, Oxycodone, Placebo","DRUG, DRUG, DRUG",Other,Mayo Clinic,['Effects of 2 Mu-opiates on Gastrointestinal Transit'],2011-05,2011-10,https://clinicaltrials.gov/study/NCT01500317
NCT01471340,A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241),Unknown,COMPLETED,"Mometasone Furoate/Formoterol MDI 100/5 mcg, Mometasone Furoate/Formoterol MDI 200/5 mcg, Mometasone Furoate MDI 100 mcg, Mometasone Furoate MDI 200 mcg, Albuterol 90 mcg /salbutamol 100 mcg HFA MDI, Prednisone/prednisolone","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Organon and Co,['Asthma'],2012-01-09,2016-11-30,https://clinicaltrials.gov/study/NCT01471340
NCT00755079,Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury,Unknown,COMPLETED,"extended release beta-2 adrenergic agonist, placebo","DRUG, DRUG",Other,US Department of Veterans Affairs,['Spinal Cord Injury'],2007-04,2012-08,https://clinicaltrials.gov/study/NCT00755079
NCT07229495,Tegileridine for Postoperative Pain After Adolescent Scoliosis Surgery,Unknown,NOT_YET_RECRUITING,"Tegileridine, morphine","DRUG, DRUG",Other,Peking Union Medical College Hospital,"['Scoliosis; Adolescence', 'Pain After Surgery', 'Analgesia, Patient-controlled']",2026-01-01,2027-06-30,https://clinicaltrials.gov/study/NCT07229495
NCT02041195,Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients,Unknown,COMPLETED,"Setmelanotide, Placebo","DRUG, DRUG",Other,"Rhythm Pharmaceuticals, Inc.",['Overweight and Obesity'],2014-01,2014-08,https://clinicaltrials.gov/study/NCT02041195
NCT01716754,Efficacy and Safety of QGE031versus Placebo and Omalizumab in Patients Aged 18-75 Years With Asthma,Unknown,COMPLETED,"QGE031, Omalizumab, Placebo","DRUG, DRUG, DRUG",Other,Novartis Pharmaceuticals,['Asthma'],2012-12,2016-01,https://clinicaltrials.gov/study/NCT01716754
NCT01444430,A 6 Month Safety Study Comparing Symbicort With Inhaled Corticosteroid Only in Asthmatic Adults and Adolescents,Unknown,COMPLETED,"Symbicort pMDI, budesonide pMDI","DRUG, DRUG",Other,AstraZeneca,['Asthma'],2011-12,2015-10,https://clinicaltrials.gov/study/NCT01444430
NCT07135141,Mazdutide as Adjuvant Therapy Following Sleeve Gastrectomy in Severe Obesity,Unknown,NOT_YET_RECRUITING,"Sleeve gastrectomy plus early mazdutide initiation, Sleeve gastrectomy followed with early mazdutide placebo initation","DRUG, DRUG",Other,Beijing Friendship Hospital,['Severe Obesity'],2025-09-30,2027-09-30,https://clinicaltrials.gov/study/NCT07135141
NCT07061886,Drug Effects on Mood and Behavior - Expectancy,Phase 1,RECRUITING,"LSD, Placebo","DRUG, DRUG",Other,University of Chicago,['LSD'],2025-06-26,2026-06-05,https://clinicaltrials.gov/study/NCT07061886
NCT00529529,Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma,Unknown,COMPLETED,"Indacaterol 300 μg, Salmeterol 50 μg, Placebo to indacaterol, Placebo to salmeterol","DRUG, DRUG, DRUG, DRUG",Other,Novartis Pharmaceuticals,['Asthma'],2007-09,2008-08,https://clinicaltrials.gov/study/NCT00529529
NCT02813239,Dual Triggering in Patients With a High Immature Oocyte Rate,Unknown,COMPLETED,"hCG, hCG + GnRH agonist","OTHER, OTHER",Other,IVI Madrid,['INFERTILITY'],2014-11,2014-11,https://clinicaltrials.gov/study/NCT02813239
NCT03406078,Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma,Unknown,COMPLETED,"Tezepelumab, Placebo","BIOLOGICAL, OTHER",Other,AstraZeneca,['Asthma'],2018-03-05,2020-09-25,https://clinicaltrials.gov/study/NCT03406078
NCT04658849,Insulin Resistance Following ADT for Prostate CA,Phase 1,WITHDRAWN,"Pioglitazone 30 Mg Oral Tablet, Pioglitazone placebo tablet","DRUG, DRUG",Other,St. Louis University,"['Insulin Resistance', 'Prostate Cancer']",2020-12-02,2023-03-29,https://clinicaltrials.gov/study/NCT04658849
NCT00299858,Theophylline in Chronic Obstructive Pulmonary Disease,Unknown,COMPLETED,Theophylline,DRUG,Other,Ottawa Hospital Research Institute,['COPD'],2006-10,2010-05,https://clinicaltrials.gov/study/NCT00299858
NCT03572790,Effects of Seven Day Prucalopride Administration in Healthy Volunteers,Unknown,COMPLETED,"Prucalopride, Placebo","DRUG, OTHER",Other,University of Oxford,"['Molecular Mechanisms of Pharmacological Action', 'Depression', 'Depressive Disorder', 'Mood Disorders', 'Mental Disorders', 'Antidepressive Agents', 'Cognition']",2018-06-11,2019-05-17,https://clinicaltrials.gov/study/NCT03572790
NCT02452190,Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils,Unknown,COMPLETED,"Reslizumab, Placebo","DRUG, DRUG",Other,"Teva Branded Pharmaceutical Products R&D, Inc.",['Asthma'],2015-09-28,2017-12-04,https://clinicaltrials.gov/study/NCT02452190
NCT03813160,Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis,Unknown,COMPLETED,"Lenabasum 20 mg, Lenabasum 5 mg, Placebo","DRUG, DRUG, DRUG",Other,Corbus Pharmaceuticals Inc.,['Dermatomyositis'],2018-12-17,2021-03-31,https://clinicaltrials.gov/study/NCT03813160
NCT01443546,Study of Dual Trigger Ovulation in Oocyte Donors,Unknown,TERMINATED,"HCG, Lupron Trigger, Dual Trigger","DRUG, DRUG, DRUG",Dual agonist,Weill Medical College of Cornell University,['Infertility'],2013-01,2016-06,https://clinicaltrials.gov/study/NCT01443546
NCT04401475,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC Vs. Placebo + SOC in Adult Hospitalized Patients with COVID-19",Unknown,SUSPENDED,"SOC plus 15mg/kg EB05 IV, SOC plus Placebo IV","BIOLOGICAL, OTHER",Other,Edesa Biotech Inc.,"['COVID-19', 'ARDS']",2020-11-25,2024-12,https://clinicaltrials.gov/study/NCT04401475
NCT00736489,Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199,Unknown,COMPLETED,"AZD3199, Formoterol, Placebo","DRUG, DRUG, DRUG",Other,AstraZeneca,"['Asthma', 'Airway Obstruction']",2008-08,2008-12,https://clinicaltrials.gov/study/NCT00736489
NCT07058259,Acupuncture for Persistent Dyspnea Despite Medical Treatment in COPD,Unknown,ACTIVE_NOT_RECRUITING,"Acupuncture, Standard COPD Pharmacological Therapy (LAMA + LABA or LAMA + LABA + ICS)","BEHAVIORAL, DRUG",Other,Istanbul Medeniyet University,"['COPD (Chronic Obstructive Pulmonary Disease)', 'Acupuncture']",2024-11-15,2025-06-30,https://clinicaltrials.gov/study/NCT07058259
NCT03738618,Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2),Unknown,COMPLETED,"Follitropin delta, Placebo","DRUG, DRUG",Other,Ferring Pharmaceuticals,"['Infertility, Female']",2018-10-29,2020-12-21,https://clinicaltrials.gov/study/NCT03738618
NCT00550225,Succinate Salt Version of GSK961081 for Healthy Volunteers,Unknown,COMPLETED,"GSK961081, GSK961081 matching placebo","DRUG, DRUG",Other,Theravance Biopharma,"['Pulmonary Disease, Chronic Obstructive']",2007-11-29,2008-01-08,https://clinicaltrials.gov/study/NCT00550225
NCT07223216,Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants,Unknown,RECRUITING,BMF-650,DRUG,Other,Biomea Fusion Inc.,['Obesity'],2025-10-23,2026-05,https://clinicaltrials.gov/study/NCT07223216
NCT01215279,AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD),Unknown,COMPLETED,"AZD2423, Placebo to AZD2423","DRUG, DRUG",Other,AstraZeneca,"['Chronic Obstructive Pulmonary Disease', 'Lung Disease']",2010-10,2011-03,https://clinicaltrials.gov/study/NCT01215279
NCT02573870,Batefenterol/Fluticasone Furoate in Treatment of Chronic Obstructive Pulmonary Disease,Unknown,COMPLETED,"Batefenterol + Fluticasone Furoate, Placebo, Albuterol","DRUG, DRUG, DRUG",Other,GlaxoSmithKline,"['Pulmonary Disease, Chronic Obstructive']",2015-12-01,2016-07-05,https://clinicaltrials.gov/study/NCT02573870
NCT03181841,Effects of PF-06412562 on Value-based Decision-making in Healthy Individuals,Unknown,COMPLETED,"PF-06412562, Placebo","DRUG, DRUG",Other,University of Zurich,['Decision Making'],2017-05-08,2017-12-20,https://clinicaltrials.gov/study/NCT03181841
NCT04446845,Double Stimulation Followed by a Fresh Embryo Transfer,Unknown,COMPLETED,"Double Stimulation (Elonva+rFSH) in luteal /follicular phase, Conventional Stimulation (Elonva+rFSH) in follicular phase","DRUG, DRUG",Other,Fundación Santiago Dexeus Font,['Infertility'],2020-10-30,2023-01-15,https://clinicaltrials.gov/study/NCT04446845
NCT05606341,Innate Immunity Stimulation Via TLR9 in Early AD,Unknown,RECRUITING,"CpG1018, CpG1018, CpG1018, Placebo","DRUG, DRUG, DRUG, DRUG",Other,NYU Langone Health,"['Mild Cognitive Impairment', 'Alzheimer Dementia']",2023-03-13,2025-11,https://clinicaltrials.gov/study/NCT05606341
NCT01641692,A 3-period Crossover Study With GSK573719 as Monotherapy in Adult Subjects With Asthma,Unknown,COMPLETED,"GSK573719 Active treatment or Placebo, GSK573719 (Sub-group cohort), Salbutamol/Albuterol","DRUG, PROCEDURE, DRUG",Other,GlaxoSmithKline,['Asthma'],2012-05,2013-02,https://clinicaltrials.gov/study/NCT01641692
NCT03767244,"A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy",Unknown,ACTIVE_NOT_RECRUITING,"Apalutamide, Androgen Deprivation Therapy (ADT), Placebo","DRUG, DRUG, DRUG",Other,"Janssen Research & Development, LLC",['Prostatic Neoplasms'],2019-06-11,2026-02-10,https://clinicaltrials.gov/study/NCT03767244
NCT03740737,Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-1),Unknown,COMPLETED,"Follitropin delta, Placebo","DRUG, OTHER",Other,Ferring Pharmaceuticals,['Infertility'],2018-10-26,2020-11-11,https://clinicaltrials.gov/study/NCT03740737
NCT02304666,Study of Inflammatory Markers (VNN1) in Crohn Disease and Ulcerative Colitis.,Unknown,UNKNOWN,Colonoscopy for biopsies samples,PROCEDURE,Other,Assistance Publique Hopitaux De Marseille,"[""Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)""]",2014-11,2017-10,https://clinicaltrials.gov/study/NCT02304666
NCT04203381,Skeletal Health and Bone Marrow Composition Among Youth,Unknown,ACTIVE_NOT_RECRUITING,GnRH Agonist,DEVICE,Other,"Amy DiVasta, MD","['Gender Dysphoria in Children', 'Puberty', 'Bone Development']",2020-09-15,2025-12-30,https://clinicaltrials.gov/study/NCT04203381
NCT06307665,Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma,Unknown,RECRUITING,"BDA MDI, AS MDI","COMBINATION_PRODUCT, COMBINATION_PRODUCT",Other,AstraZeneca,['Asthma'],2024-05-20,2027-10-13,https://clinicaltrials.gov/study/NCT06307665
NCT01208090,ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis,Unknown,COMPLETED,"ACT-128800, Placebo","DRUG, DRUG",Other,Actelion,['Psoriasis'],2010-10-31,2012-10-31,https://clinicaltrials.gov/study/NCT01208090
NCT02703584,Co Administration of GnRH Agonist and hCG for Final Oocyte Maturation,Unknown,COMPLETED,"Buseralin, Placebo, pregnyl","DRUG, OTHER, DRUG",Other,"Mount Sinai Hospital, Canada",['Infertility'],2016-03,2018-09,https://clinicaltrials.gov/study/NCT02703584
NCT00567476,Omalizumab Use and Asthma-Related Quality of Life in Patients With Severe Persistent Allergic Asthma,Unknown,COMPLETED,"Omalizumab, Inhaled corticosteroids (ICS), Long-acting beta 2-adrenergic agonist (LABA), Short-acting beta 2-adrenergic agonist (SABA)","DRUG, DRUG, DRUG, DRUG",Other,Novartis,['Asthma'],2007-11,2010-04,https://clinicaltrials.gov/study/NCT00567476
NCT05997576,A Study of TG103 Injection in Non-diabetic Overweight or Obesity,Unknown,COMPLETED,"TG103 22.5 mg, Placebo","DRUG, DRUG",Other,"CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.",['Overweight or Obesity'],2023-11-22,2025-02-17,https://clinicaltrials.gov/study/NCT05997576
NCT01624974,Study to Evaluate the Effectiveness and Safety of MK-1029 in the Treatment of Persistent Asthma That is Not Controlled With Montelukast (ML) in Adults (MK-1029-011),Unknown,COMPLETED,"MK-1029, Placebo, Montelukast (ML)","DRUG, DRUG, DRUG",Other,Merck Sharp & Dohme LLC,['Asthma'],2012-08-09,2014-05-05,https://clinicaltrials.gov/study/NCT01624974
NCT06854952,"A Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of TERN-601 in Adults With Overweight or Obesity",Unknown,COMPLETED,"TERN-601, Matching Placebo","DRUG, OTHER",Other,"Terns, Inc.",['Overweight or Obesity'],2025-03-07,2025-08-19,https://clinicaltrials.gov/study/NCT06854952
NCT05848505,Opioid-sparing Effect of Intranasal Dexmedetomidine,Unknown,COMPLETED,Dexmedetomidine,DRUG,Other,Pierre-Yves P Lequeux,['Tonsillar Hypertrophy'],2022-02-25,2022-12-20,https://clinicaltrials.gov/study/NCT05848505
NCT04876937,Low-Dose Dexmedetomidine for Delirium Prevention in Mechanically Ventilated Septic Patients,Unknown,TERMINATED,"Dexmedetomidine, Placebo (normal saline)","DRUG, DRUG",Other,Peking University First Hospital,"['Adult', 'Intensive Care Unit', 'Sepsis', 'Mechanical Ventilation', 'Delirium', 'Dexmedetomidine']",2021-05-28,2024-02-02,https://clinicaltrials.gov/study/NCT04876937
NCT02786212,The Effects of Dexmedetomidine on Microcirculation and Surgical Outcomes After Cardiac Surgeries,Unknown,COMPLETED,"Dexmedetomidine, Normal Saline","DRUG, DRUG",Other,National Taiwan University Hospital,['Cardiac Surgical Procedure'],2016-09,2019-05,https://clinicaltrials.gov/study/NCT02786212
NCT00731770,Comparing Fluticasone-salmeterol in Chronic Obstructive Pulmonary Disease (COPD) and Sleep,Unknown,COMPLETED,"Advair 250, Placebo- matched, Placebo, Advair 250 - matched","DRUG, DRUG, DRUG, DRUG",Other,Milton S. Hershey Medical Center,['COPD'],2009-01,2010-04,https://clinicaltrials.gov/study/NCT00731770
NCT02299375,Safety and Efficacy Study of Losmapimod (GW856553) in Frequently Exacerbating Participants With Chronic Obstructive Pulmonary Disease (COPD),Unknown,COMPLETED,"Losmapimod tablets, Placebo tablets, Salbutamol MDI","DRUG, DRUG, DRUG",Other,GlaxoSmithKline,"['Pulmonary Disease, Chronic Obstructive']",2014-12-09,2016-06-30,https://clinicaltrials.gov/study/NCT02299375
NCT02545127,Merotocin in Mothers With Inadequate Milk Production and Infants Delivered Prematurely,Unknown,TERMINATED,"Merotocin, Placebo","DRUG, DRUG",Other,Ferring Pharmaceuticals,"['Preterm Delivery', 'Inadequate Milk Production']",2021-05-28,2022-11-11,https://clinicaltrials.gov/study/NCT02545127
NCT03943251,"The Study of a Selective Serotonin Partial Agonist and Reuptake Inhibitors, HEC113995PA•H2O,in Healthy Subjects",Unknown,COMPLETED,"HEC113995PA•H2O tablet, Placebo tablet","DRUG, DRUG",Other,"Sunshine Lake Pharma Co., Ltd.",['Healthy'],2019-07-04,2019-12-11,https://clinicaltrials.gov/study/NCT03943251
NCT00443482,Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer),Unknown,COMPLETED,formoterol,DRUG,Other,Novartis,['Asthma'],2007-02,2007-05,https://clinicaltrials.gov/study/NCT00443482
NCT00404313,The Effect of MK0633 in Patients With Chronic Asthma (0633-007),Unknown,TERMINATED,"MK0633, Comparator: placebo","DRUG, DRUG",Other,Merck Sharp & Dohme LLC,['Asthma'],2008-01,2009-06,https://clinicaltrials.gov/study/NCT00404313
NCT00394186,A Study To Investigate GW427353 In Subjects With Irritable Bowel Syndrome (IBS),Unknown,COMPLETED,"GW427353, Placebo","DRUG, DRUG",Other,GlaxoSmithKline,['Irritable Bowel Syndrome (IBS)'],2006-08,,https://clinicaltrials.gov/study/NCT00394186
NCT01366560,Effect of GSK962040 on Oesophageal Function,Unknown,COMPLETED,"Active, Placebo","DRUG, DRUG",Other,GlaxoSmithKline,['Gastrointestinal Motility'],2010-08-31,2010-10-22,https://clinicaltrials.gov/study/NCT01366560
NCT02157818,A Comparison of Sedative Drugs for Conscious Sedation During Ultrasound Guided Transbronchial Needle Aspiration,Unknown,COMPLETED,"midazolam, Dexmedetomidine","DRUG, DRUG",Other,Seoul National University Hospital,['Endobronchial Ultrasound Guided Transbronchial Needle Aspiration'],2014-06,2015-07,https://clinicaltrials.gov/study/NCT02157818
NCT02084797,V2 Receptor Effects on Fluid Regulation and Performance,Unknown,COMPLETED,V2R (Vasopressin 2 receptor),DRUG,Other,Oakland University,"['Electrolyte Imbalance', 'Hyponatremia', 'Hypernatremia']",2011-06,2011-10,https://clinicaltrials.gov/study/NCT02084797
NCT05466890,Phase 2a to Evaluate PL-8177 in Subjects with Active Ulcerative Colitis (UC),Unknown,ACTIVE_NOT_RECRUITING,"PL8177 Placebo, PL8177","DRUG, DRUG",Other,"Palatin Technologies, Inc","['Ulcerative Colitis', 'Ulcerative Colitis Acute', 'Ulcerative', 'Ulcerative Colitis Flare']",2022-09-15,2025-02-10,https://clinicaltrials.gov/study/NCT05466890
NCT04197479,A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients,Unknown,COMPLETED,"Placebo, Resmetirom","DRUG, DRUG",Other,"Madrigal Pharmaceuticals, Inc.",['Non-Alcoholic Fatty Liver Disease'],2019-12-16,2023-01-06,https://clinicaltrials.gov/study/NCT04197479
NCT00140946,A Study to Assess the Effect of Montelukast Sodium With Concomitant Administration of Inhaled Budesonide in Asthmatic Patients (0476-075),Unknown,COMPLETED,"MK0476; montelukast sodium/Duration of Treatment: 16 weeks, Comparator: placebo / Duration of Treatment: 16 weeks","DRUG, DRUG",Other,Organon and Co,['Asthma'],1998-03,2000-10,https://clinicaltrials.gov/study/NCT00140946
NCT05348980,Intramuscular Phenylephrine HCL for Prevention of Spinal Anesthesia Induced Hypotension,Unknown,COMPLETED,"Phenylephrine Hydrochloride 4 mg, Phenylephrine Hydrochloride 8 mg","DRUG, DRUG",Other,Rehman Medical Institute - RMI,"['Hypotension', 'Anesthesia']",2020-01-01,2020-07-31,https://clinicaltrials.gov/study/NCT05348980
NCT03902080,"Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men With Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH)",Unknown,COMPLETED,"Vibegron, Placebo","DRUG, DRUG",Other,Urovant Sciences GmbH,['Overactive Bladder'],2019-03-26,2023-06-15,https://clinicaltrials.gov/study/NCT03902080
NCT04008966,Comparative Study Between Single Versus Dual Trigger for Poor Responders in GnRH-antagonist ICSI Cycles,Unknown,COMPLETED,"combined oral contaraceptive pills, recombinant FSH, Urinaru gonadotropin, GnRH antagonist, Human chorionic gonadotropin, GnRH agonist, Ovum pick up, Embryo transfer, natural Progesterone","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, PROCEDURE, PROCEDURE, DRUG",Other,Cairo University,['Assisted Reproduction'],2016-07-20,2019-06-02,https://clinicaltrials.gov/study/NCT04008966
NCT03863366,Effects of Acute Prucalopride Administration in Healthy Volunteers,Unknown,COMPLETED,"Prucalopride, Placebo","DRUG, OTHER",Other,University of Oxford,"['Molecular Mechanisms of Pharmacological Action', 'Depression', 'Depressive Disorder', 'Mood Disorders', 'Mental Disorder', 'Antidepressive Agents', 'Cognition']",2017-02-07,2017-08-08,https://clinicaltrials.gov/study/NCT03863366
NCT00284856,Montelukast Asthmatic Smoker Study (0476-332)(COMPLETED),Unknown,COMPLETED,"montelukast sodium, Comparator: Placebo, Comparator: fluticasone, Comparator: Placebo","DRUG, DRUG, DRUG, DRUG",Other,Organon and Co,['Asthma'],2006-05,2010-04,https://clinicaltrials.gov/study/NCT00284856
NCT00418613,A Research Study of MK0633 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0633-009)(COMPLETED),Unknown,COMPLETED,"MK633, Comparator: Placebo (unspecified)","DRUG, DRUG",Other,Merck Sharp & Dohme LLC,['Chronic Obstructive Pulmonary Disease (COPD)'],2008-01,2009-03,https://clinicaltrials.gov/study/NCT00418613
NCT01366053,Hormone Sensitive Prostate Cancer Patients Switched to Degarelix Therapy After Failing on GnRH Agonists,Unknown,COMPLETED,,,Unknown,CMX Research,['Prostate Cancer'],2011-03,2015-07,https://clinicaltrials.gov/study/NCT01366053
NCT03847896,A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma,Unknown,COMPLETED,"Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose), Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose), Budesonide metered dose inhaler / BD MDI 160 µg, Albuterol sulfate metered dose inhaler / AS MDI 180 μg, Placebo metered-dose inhaler / Placebo MDI","COMBINATION_PRODUCT, COMBINATION_PRODUCT, DRUG, DRUG, OTHER",Other,Bond Avillion 2 Development LP,['Asthma'],2019-03-20,2021-07-20,https://clinicaltrials.gov/study/NCT03847896
NCT00749411,Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD,Unknown,COMPLETED,"Placebo, GSK233705/GW642444","DRUG, DRUG",Other,GlaxoSmithKline,"['Pulmonary Disease, Chronic Obstructive']",2008-11-13,2009-02-12,https://clinicaltrials.gov/study/NCT00749411
NCT02220400,Ketamine Prevent POCD,Unknown,UNKNOWN,Ketamine,DRUG,Other,RenJi Hospital,"['Necrosis of Femoral Head', 'Knee Osteoarthritis']",2014-09,2016-09,https://clinicaltrials.gov/study/NCT02220400
NCT03815695,"A SAD/MAD to Assess the Safety, PK/PD of FT-4202 in Healthy Volunteers and Sickle Cell Disease Patients",Unknown,COMPLETED,FT-4202/Placebo,DRUG,Other,"Forma Therapeutics, Inc.","['Healthy Volunteers', 'Sickle Cell Disease']",2018-12-11,2021-12-17,https://clinicaltrials.gov/study/NCT03815695
NCT03325972,Study on the Effects of Intravenous Dexmedetomidine on Pain in Patients Undergoing Elective Spinal Surgery,Unknown,COMPLETED,"Dexmedetomidine, Placebo Saline","DRUG, OTHER",Other,NYU Langone Health,['Chronic Pain'],2016-09-14,2022-02-22,https://clinicaltrials.gov/study/NCT03325972
NCT02005900,Effect of DHA on Lipid and Carbohydrate Metabolism Alterations and Body Fat Distribution in HIV Patients Under HAART.,Unknown,COMPLETED,Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART,DRUG,Other,Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,"['HIV-associated Hypertriglyceridemia', 'HIV-associated Hypercholesterolemia', 'HIV-associated Inflammatory State']",2011-06,2013-06,https://clinicaltrials.gov/study/NCT02005900
NCT03747211,Asthma Severity in Women: The Influence of Training and Menopause,Unknown,TERMINATED,Aerobic exercise,BEHAVIORAL,Other,"Rigshospitalet, Denmark",['Late-Onset Asthma'],2019-02-12,2021-05-01,https://clinicaltrials.gov/study/NCT03747211
NCT05630781,Orexin s Role in the Neurobiology of Substance Use Disorder,Unknown,RECRUITING,"Belsomra, Placebo, Methylphenidate","DRUG, DRUG, DRUG",Other,National Institute on Drug Abuse (NIDA),['Nicotine Dependence'],2023-02-15,2027-12-31,https://clinicaltrials.gov/study/NCT05630781
NCT01192178,Fall Epidemic Viral Pediatric Study,Unknown,COMPLETED,"FLOVENT™ DISKUS™ 100 mcg BID, ADVAIR™ DISKUS™ 100/50 mcg BID","DRUG, DRUG",Other,GlaxoSmithKline,['Asthma'],2010-08,2010-12,https://clinicaltrials.gov/study/NCT01192178
NCT01082848,ARIpiprazole in Anorexia NErvosa,Unknown,UNKNOWN,"aripiprazole, placebo","DRUG, DRUG",Other,Juan A. Arnaiz,['Anorexia Nervosa'],2010-03,2013-03,https://clinicaltrials.gov/study/NCT01082848
NCT02715336,Efficacy and Safety of Medication Used to Stimulate Ovulation,Unknown,UNKNOWN,Ovulation induction with hCG and Lupron (GnRH agonist),DRUG,Other,Create Fertility Center,"['IVF Cycle', 'Ovarian Stimulation', 'Egg Retrieval', 'Pregnancy', 'Miscarriages', 'Ovarian Hyperstimulation']",2015-10,2020-09,https://clinicaltrials.gov/study/NCT02715336
NCT05201404,Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis,Unknown,RECRUITING,"Namodenoson, Placebo","DRUG, DRUG",Other,Can-Fite BioPharma,"['Hepatocellular Carcinoma', 'Cirrhosis']",2023-03-15,2026-02,https://clinicaltrials.gov/study/NCT05201404
NCT02014480,"A Cross-Over Study to Evaluate Lung Function Response After Treatment With Umeclidinium (UMEC) 62.5 Micrograms (mcg), Vilanterol (VI) 25 mcg, and Umeclidinium/Vilanterol (UMEC/VI) 62.5/25 mcg Once-Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",Unknown,COMPLETED,"Umeclidinium 62.5 mcg, Vilanterol 25 mcg, Umeclidinium/Vilanterol 62.5/25 mcg","DEVICE, DEVICE, DEVICE",Other,GlaxoSmithKline,"['Pulmonary Disease, Chronic Obstructive']",2013-02-01,2013-06-01,https://clinicaltrials.gov/study/NCT02014480
NCT01520909,"Study of a New Medication for Childhood Chronic Immune Thrombocytopenia (ITP), a Blood Disorder of Low Platelet Counts That Can Lead to Bruising Easily, Bleeding Gums, and/or Bleeding Inside the Body.",Unknown,COMPLETED,"Eltrombopag, Placebo","DRUG, DRUG",Other,GlaxoSmithKline,['Idiopathic Thrombocytopenic Purpura'],2012-03,2014-01,https://clinicaltrials.gov/study/NCT01520909
NCT07014644,"A Randomized, Double-Blind, Single-Center Clinical Study on the Efficacy of Naltrexone Implant in Antagonizing Opioid Agonist Hydromorphone",Unknown,COMPLETED,"0.9g Naltrexone Implant + 0.6g Naltrexone Implant Placebo, 1.5g Naltrexone Implant","DRUG, DRUG",Other,"Shenzhen Sciencare Medical Industries Co., Ltd.",['Opioid Dependence'],2018-08-07,2020-05-13,https://clinicaltrials.gov/study/NCT07014644
NCT06237309,REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction,Unknown,ACTIVE_NOT_RECRUITING,"REGN5381, Placebo","DRUG, DRUG",Other,Regeneron Pharmaceuticals,['Heart Failure'],2024-04-11,2025-09-17,https://clinicaltrials.gov/study/NCT06237309
NCT07042516,Safety and Efficacy of Asimadoline (TP0052) in Patients With Vasomotor Symptoms (VMS).,Unknown,RECRUITING,Asimadoline,DRUG,Other,Tioga Pharmaceuticals,['Vasomotor Symptoms'],2025-08-13,2026-12-31,https://clinicaltrials.gov/study/NCT07042516
NCT04956328,Study of Obeticholic Acid（OCA） Combination With Ursodeoxycholic Acid (UDCA) in Patients With Primay Biliary Cirrhosis (PBC),Unknown,UNKNOWN,"Obeticholic Acid Tablets, UDCA, Placebo","DRUG, DRUG, DRUG",Other,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",['Primary Biliary Cirrhosis'],2021-07-22,2023-09-20,https://clinicaltrials.gov/study/NCT04956328
NCT03062592,"FFAR Agonist on Incretins, Insulin, Lipids and Inflammation",Unknown,COMPLETED,Pine nut oil,DIETARY_SUPPLEMENT,Other,Odense University Hospital,"['Type2 Diabetes Mellitus', 'Obesity']",2016-02,2016-04,https://clinicaltrials.gov/study/NCT03062592
NCT01079741,Safety Study of Adjuvant Vaccine to Treat Melanoma Patients,Unknown,COMPLETED,NY-ESO-1 protein; Poly-ICLC; Montanide,BIOLOGICAL,Other,Nina Bhardwaj,['Melanoma'],2010-09,2013-03-11,https://clinicaltrials.gov/study/NCT01079741
NCT00715624,"GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin",Unknown,COMPLETED,"Lixisenatide (AVE0010), Placebo, Basal Insulin, Metformin, Pen auto-injector","DRUG, DRUG, DRUG, DRUG, DEVICE",Other,Sanofi,"['Diabetes Mellitus, Type 2']",2008-07,2011-02,https://clinicaltrials.gov/study/NCT00715624
NCT02540070,Evaluation of Motor Sparing Knee Block to Infiltration Analgesia for Pain Following Knee Arthroplasty,Unknown,UNKNOWN,"Periarticular, Motor free, Motor free with dex, Ropivacaine, epinephrine, morphine, Ketorolac, Dexmedetomidine, saline","PROCEDURE, PROCEDURE, PROCEDURE, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's,"['Osteoarthritis', 'Knee Arthroplasty', 'Pain Management']",2014-08,2017-12,https://clinicaltrials.gov/study/NCT02540070
NCT06159673,ACP-204 in Adults With Alzheimer's Disease Psychosis,Unknown,RECRUITING,"ACP-204, Placebo","DRUG, DRUG",Other,ACADIA Pharmaceuticals Inc.,"[""Alzheimer's Disease Psychosis""]",2023-11-14,2028-01,https://clinicaltrials.gov/study/NCT06159673
NCT01762761,Eltrombopag Phase III Study In Chinese Chronic ITP Patients,Unknown,COMPLETED,"eltrombopag, placebo","DRUG, DRUG",Other,Novartis Pharmaceuticals,"['Purpura, Thrombocytopenic, Idiopathic and Hepatitis C']",2013-02-18,2014-06-05,https://clinicaltrials.gov/study/NCT01762761
NCT01219738,Acute Airway Vascular Smooth Muscle Effects of Inhaled Budesonide,Unknown,COMPLETED,"Budesonide 360ug, Budesonide 720ug, Budesonide 1440ug, Budesonide720ug 4 times, Placebo","DRUG, DRUG, DRUG, DRUG, DRUG",Other,University of Miami,['Asthma'],2008-07,2012-08,https://clinicaltrials.gov/study/NCT01219738
NCT00861809,The Effect of Single Doses of the Motilin Receptor Agonist GSK962040 in Type I Diabetic Patients With Gastroparesis,Unknown,COMPLETED,"GSK962040 25 mg, Placebo, GSK962040 50 mg, GSK962040 1250 mg","DRUG, DRUG, DRUG, DRUG",Other,GlaxoSmithKline,['Gastroparesis'],2009-06,2010-11,https://clinicaltrials.gov/study/NCT00861809
NCT06639087,A Phase Ib Study of AZD5462 on Top of Dapagliflozin in Participants With Heart Failure and Moderate Renal Impairment,Unknown,TERMINATED,"AZD5462, Dapagliflozin, Placebo","DRUG, DRUG, OTHER",Other,AstraZeneca,"['Renal Impairment', 'Heart Failure']",2024-09-27,2025-05-29,https://clinicaltrials.gov/study/NCT06639087
NCT06566248,A Clinical Trial to Evaluate the Efficacy and Safety of TQA3810 Tablets in Combination/Non Combination With Nucleoside (Acid) Analogues in Patients With Primary/Treated Chronic Hepatitis B,Unknown,RECRUITING,"TQA3810 tablets+NUC, Placebo+NUC","DRUG, DRUG",Other,"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.",['Chronic Hepatitis B'],2024-03-20,2024-09,https://clinicaltrials.gov/study/NCT06566248
NCT01262898,Dose Response of 28 Days of Dosing of GSK962040 in Type I and II Diabetic Male and Female Subjects With Gastroparesis,Unknown,COMPLETED,"GSK962040 (5 mg tablet), GSK962040 (25 mg tablet), GSK962040 (125 mg tablet), Placebo","DRUG, DRUG, DRUG, DRUG",Other,GlaxoSmithKline,['Gastroparesis'],2011-05-03,2013-02-26,https://clinicaltrials.gov/study/NCT01262898
NCT02040233,Multiple Dose Study in Heart Failure of BAY 1067197,Unknown,COMPLETED,"BAY1067197 (10 mg), BAY1067197, Placebo (10 mg), Placebo","DRUG, DRUG, DRUG, DRUG",Other,Bayer,['Heart Failure'],2014-01-28,2015-01-29,https://clinicaltrials.gov/study/NCT02040233
NCT02814643,Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma,Unknown,COMPLETED,"Benralizumab, Benralizumab Placebo, Seasonal influenza virus vaccine","DRUG, DRUG, DRUG",Other,AstraZeneca,['Asthma'],2016-07-01,2017-01-24,https://clinicaltrials.gov/study/NCT02814643
NCT06175832,PPOS (Progestin Primed Ovarian Stimulation) and Corifollitropin Alfa (CFA) Cross-over Study,Unknown,NOT_YET_RECRUITING,"Elonva®, Puregon®, Orgalutran®, Gonapeptyl®, Cerazette®","DRUG, DRUG, DRUG, DRUG, DRUG",Other,"University Hospital, Ghent","['Ovarian Stimulation', 'Quality of Life', 'Preimplantation Genetic Testing', 'Fertility Preservation']",2025-01-14,2025-05-10,https://clinicaltrials.gov/study/NCT06175832
NCT02275052,A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD),Unknown,COMPLETED,"UMEC/VI DPI, Placebo DPI, Albuterol/salbutamol MDI","DRUG, DRUG, DRUG",Other,GlaxoSmithKline,"['Pulmonary Disease, Chronic Obstructive']",2015-01-23,2016-06-02,https://clinicaltrials.gov/study/NCT02275052
NCT01928771,Efficacy and Safety Study of Benralizumab Added to High-dose Inhaled Corticosteroid Plus LABA in Patients With Uncontrolled Asthma,Unknown,COMPLETED,"Benralizumab, Placebo","BIOLOGICAL, BIOLOGICAL",Other,AstraZeneca,['Asthma'],2013-09-19,2016-04-05,https://clinicaltrials.gov/study/NCT01928771
NCT01270464,A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma,Unknown,COMPLETED,"Reslizumab, Placebo","DRUG, DRUG",Other,"Teva Branded Pharmaceutical Products R&D, Inc.",['Eosinophilic Asthma'],2011-02,2013-09,https://clinicaltrials.gov/study/NCT01270464
NCT01517932,Effects of Dexmedetomidine on Stress Response and Postoperative Analgesia,Unknown,COMPLETED,"dexmedetomidine, saline placebo","DRUG, DRUG",Other,Fang Luo,"['Restlessness', 'Pain']",2011-06,2011-12,https://clinicaltrials.gov/study/NCT01517932
NCT01609478,"Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma",Unknown,COMPLETED,"indacaterol, placebo, mometasone furoate","DRUG, DRUG, DRUG",Other,Novartis Pharmaceuticals,['Asthma'],2012-08,2013-07,https://clinicaltrials.gov/study/NCT01609478
NCT02127697,Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma,Unknown,WITHDRAWN,"NVA237, Placebo to NVA237, salbutamol/ albuterol","DRUG, DRUG, DRUG",Other,Novartis Pharmaceuticals,['Asthma'],2015-03,2017-05,https://clinicaltrials.gov/study/NCT02127697
NCT00687700,A Study to Investigate the Pharmacology of a Dual Pharmacophore in Healthy Volunteers,Unknown,COMPLETED,"GSK961081, GSK961081 matching placebo, Propranolol, Propranolol matching placebo","DRUG, DRUG, DRUG, DRUG",Other,Theravance Biopharma,"['Pulmonary Disease, Chronic Obstructive']",2008-03-10,2008-05-27,https://clinicaltrials.gov/study/NCT00687700
NCT07087054,Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen,Unknown,RECRUITING,"Paltusotine, Placebo","DRUG, DRUG",Other,Crinetics Pharmaceuticals Inc.,"['Carcinoid Syndrome', 'Carcinoid', 'Carcinoid Tumor', 'Carcinoid Tumor of Ileum', 'Carcinoid Tumor of Cecum', 'Carcinoid Tumor of Liver', 'Carcinoid Tumor of Pancreas', 'Carcinoid Syndrome Diarrhea', 'Carcinoid Intestine Tumor']",2025-11-19,2027-08,https://clinicaltrials.gov/study/NCT07087054
NCT02429765,Effect of Aclidinium/Formoterol on Nighttime Lung Function and Morning Symptoms in Chronic Obstructive Pulmonary Disease,Unknown,COMPLETED,"ACL/FOR, Placebo","DRUG, DRUG",Other,Queen's University,['COPD'],2015-10,2018-08,https://clinicaltrials.gov/study/NCT02429765
NCT03110757,"A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults",Unknown,COMPLETED,"GLA-AF, Hepatitis B Virus Vaccine (Recombinant), Sm-TSP-2/Alhydrogel","BIOLOGICAL, BIOLOGICAL, BIOLOGICAL",Other,National Institute of Allergy and Infectious Diseases (NIAID),['Schistosomiasis'],2018-05-20,2019-11-14,https://clinicaltrials.gov/study/NCT03110757
NCT01147744,Dose Ranging Study Evaluating the Efficacy and Safety of GSK2190915 Administered Once Daily,Unknown,COMPLETED,"Fluticasone Propionate 100mcg via ACCUHALER/DISKUS, GSK2190915 100mg, GSK2190915 10mg, GSK2190915 300mg, GSK2190915 30mg, Montelukast 10mg, Placebo GSK2190915 one tablet, Placebo montelukast, Placebo fluticasone propionate via ACCUHALER/DISKUS, Placebo GSK2190915 two tablets","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,GlaxoSmithKline,['Asthma'],2010-06-28,2011-10-06,https://clinicaltrials.gov/study/NCT01147744
NCT05026398,Fenfluramine and Cognition,Unknown,COMPLETED,"Fenfluramine, Placebo","DRUG, OTHER",Other,University of Oxford,['Cognitive Function'],2021-04-12,2022-06-22,https://clinicaltrials.gov/study/NCT05026398
NCT05677763,OM-85 in Paediatric Recurrent Respiratory Tract Infections With Wheezing Lower Respiratory Illness,Unknown,ACTIVE_NOT_RECRUITING,"OM-85, Placebo","DRUG, DRUG",Other,OM Pharma SA,"['Respiratory Tract Infections', 'Wheezing Lower Respiratory Illness']",2022-12-12,2026-03-23,https://clinicaltrials.gov/study/NCT05677763
NCT00523445,The Effects of Varenicline on Cognitive Function in Patients With Schizophrenia,Unknown,COMPLETED,"Varenicline(Chantix), Placebo","DRUG, DRUG",Other,Inje University,['Schizophrenia'],2007-09,2009-06,https://clinicaltrials.gov/study/NCT00523445
NCT01018550,AMG 853 Phase 2 Study in Subjects With Inadequately Controlled Asthma,Unknown,COMPLETED,"AMG 853, AMG 853, AMG 853, AMG 853, Placebo","DRUG, DRUG, DRUG, DRUG, DRUG",Other,Amgen,['Asthma'],2009-10,2010-12,https://clinicaltrials.gov/study/NCT01018550
NCT04762836,"Pain, Learning, and Nocebo",Unknown,COMPLETED,"D-cycloserine, Conditioning, Extinction, fMRI, Placebo","DRUG, BEHAVIORAL, BEHAVIORAL, OTHER, DRUG",Other,Leiden University Medical Center,"['Chronic Pain', 'Pain Syndrome']",2021-02-28,2021-08-20,https://clinicaltrials.gov/study/NCT04762836
NCT03038308,Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole,Unknown,COMPLETED,Ropinirole,DRUG,Other,Columbia University,"['Hyperprolactinemia', 'Prolactinoma']",2016-09-16,2020-11-05,https://clinicaltrials.gov/study/NCT03038308
NCT04912115,"Randomized, Double-Blind, Active Placebo-Controlled Study of Ketamine to Treat Levodopa-Induced Dyskinesia",Unknown,SUSPENDED,"Ketamine, Midazolam","DRUG, DRUG",Other,PharmaTher Inc.,"['Dyskinesias', 'Movement Disorders', 'Central Nervous System Diseases', 'Nervous System Diseases', 'Neurologic Manifestations']",2021-10-05,2023-12-30,https://clinicaltrials.gov/study/NCT04912115
NCT04607525,Dexmedetomidine Infusion Effect on Hemodynamic Variables During Craniotomy,Unknown,COMPLETED,"Dexmedetomidine, normal saline","DRUG, DRUG",Other,Ain Shams University,"['Hemodynamic Instability', 'Supratentorial Neoplasms']",2020-11-21,2021-01-20,https://clinicaltrials.gov/study/NCT04607525
NCT03272009,Evaluation of the Safety and Pharmacology of EYP001 in HBV Subjects,Unknown,COMPLETED,"EYP001a, Placebo, Entecavir, peg-interferon alfa-2a","DRUG, DRUG, DRUG, DRUG",Other,Enyo Pharma,"['Hepatitis B, Chronic']",2017-09-21,2018-07-30,https://clinicaltrials.gov/study/NCT03272009
NCT00452699,A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma,Unknown,COMPLETED,"Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID, Fluticasone propionate 250 mcg BID","DRUG, DRUG",Other,GlaxoSmithKline,['Asthma'],2007-05,2009-05,https://clinicaltrials.gov/study/NCT00452699
NCT01316887,"A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",Unknown,COMPLETED,"125/25 mcg once-daily GSK573719/GW642444, 125mcg once-daily GSK573719, Placebo once-daily","DRUG, DRUG, DRUG",Other,GlaxoSmithKline,"['Pulmonary Disease, Chronic Obstructive']",2011-01-01,2012-07-01,https://clinicaltrials.gov/study/NCT01316887
NCT00993863,Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction,Unknown,COMPLETED,"Placebo, ADL5859 30 mg, ADL5859 100 mg, ADL5859 200 mg, ibuprofen 400 mg","DRUG, DRUG, DRUG, DRUG, DRUG",Other,"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",['Acute Pain'],2007-06,2007-09,https://clinicaltrials.gov/study/NCT00993863
NCT06940674,Adjunctive Cannabidiol for Recovery From Opioid Study,Unknown,RECRUITING,"Cannabidiol, Placebo","DRUG, DRUG",Other,Icahn School of Medicine at Mount Sinai,['Opioid Use Disorder (OUD)'],2025-06-13,2027-07-15,https://clinicaltrials.gov/study/NCT06940674
NCT00420290,"Inflammation, Proteolysis and IL-1 Beta Receptor Inhibition in Chronic Hemodialysis Patients",Unknown,COMPLETED,"kineret, placebo","DRUG, DRUG",Other,Vanderbilt University,['End Stage Renal Disease'],2008-01,2010-05,https://clinicaltrials.gov/study/NCT00420290
NCT06958718,Ultrasound vs. Surgical ESP Block With Bupivacaine-Dexmedetomidine in Lumbar Fusion Surgery,Unknown,COMPLETED,"Ultrasound Guided erector spinae plane block (UB), Surgical erector spinae plane block (SB), Dexmedetomidine, Bupivacaine Hcl 0.5% Inj","PROCEDURE, PROCEDURE, DRUG, DRUG",Other,Fayoum University Hospital,['Post Operative Pain'],2025-05-06,2025-08-31,https://clinicaltrials.gov/study/NCT06958718
NCT06245213,A Study of ANAVEX3-71 in Adults With Schizophrenia,Unknown,ACTIVE_NOT_RECRUITING,"ANAVEX3-71 oral capsules, Placebo oral capsules","DRUG, DRUG",Other,Anavex Life Sciences Corp.,['Schizophrenia'],2024-03-15,2025-06-30,https://clinicaltrials.gov/study/NCT06245213
NCT03515096,Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT,Unknown,COMPLETED,"Eltrombopag, rhTPO","DRUG, DRUG",Other,Shenzhen Second People's Hospital,"['Eltrombopag', 'Hematopoietic Stem Cell Transplantation', 'Thrombocytopenia']",2018-07-01,2021-08-02,https://clinicaltrials.gov/study/NCT03515096
NCT00622635,A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD),Unknown,COMPLETED,"Indacaterol 300 μg, Placebo to indacaterol, Salmeterol 50 μg","DRUG, DRUG, DRUG",Other,Novartis Pharmaceuticals,['Chronic Obstructive Pulmonary Disease'],2008-01,2008-07,https://clinicaltrials.gov/study/NCT00622635
NCT02531516,An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS,Unknown,ACTIVE_NOT_RECRUITING,"Apalutamide, Bicalutamide, Bicalutamide Placebo, Apalutamide Placebo, GnRH (agonist), 74-80 Grays (units of radiation)","DRUG, DRUG, DRUG, DRUG, DRUG, RADIATION",Other,"Aragon Pharmaceuticals, Inc.",['Prostatic Neoplasms'],2015-11-19,2026-06-30,https://clinicaltrials.gov/study/NCT02531516
NCT06567977,"TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients",Unknown,RECRUITING,Trimbow,OTHER,Other,Chiesi Poland Sp. z o.o.,['Asthma'],2024-08,2025-03-01,https://clinicaltrials.gov/study/NCT06567977
NCT03840057,"Metoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy",Unknown,UNKNOWN,"Azithromycin Injection, Metoclopramide Injectable Solution, Sodium chloride 0.9%","DRUG, DRUG, DRUG",Other,Waihong Chung,"['Gastro Intestinal Bleeding', 'Upper Gastrointestinal Bleeding']",2020-07-01,2021-06,https://clinicaltrials.gov/study/NCT03840057
NCT04651777,Evaluation of Triple Therapy Using Magnetic Resonance Imaging in Asthma,Unknown,ACTIVE_NOT_RECRUITING,FF/UMEC/VI,DRUG,Other,Dr. Grace Parraga,['Asthma'],2022-08-08,2023-08-25,https://clinicaltrials.gov/study/NCT04651777
NCT05213611,REported Outcomes in COPD With Trixeo in Real worlD,Unknown,COMPLETED,,,Unknown,AstraZeneca,['Chronic Obstructive Pulmonary Disease'],2022-08-11,2024-07-08,https://clinicaltrials.gov/study/NCT05213611
NCT06071767,"Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1",Unknown,RECRUITING,"ChAdOx1.tHIVconsv1, ChAdOx1.HIVconsv62, MVA.tHIVconsv3, MVA.tHIVconsv4, Vesatolimod (VES), GS-5423, GS-2872, MVA.tHIVconsv4, Placebo","BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG, BIOLOGICAL, BIOLOGICAL",Other,National Institute of Allergy and Infectious Diseases (NIAID),['HIV-1-infection'],2024-04-01,2028-04-29,https://clinicaltrials.gov/study/NCT06071767
NCT04814940,Retrospective Analysis of Real-world Data From Medical Records on the Use of MENOPUR for Infertility Treatment,Unknown,WITHDRAWN,MENOPUR Cohort,OTHER,Other,Ferring Pharmaceuticals,"['Infertility, Female']",2022-09-01,2023-09-01,https://clinicaltrials.gov/study/NCT04814940
NCT06688279,Effects of Plyometric Exercises in Female Fast Bowlers,Unknown,RECRUITING,"Plyometric Exercise, Standard exercises protocol","OTHER, OTHER",Other,Sehat Medical Complex,"['Plyometric Exercises', 'Strength', 'Dynamic Balance', 'Power']",2024-11-30,2025-05-25,https://clinicaltrials.gov/study/NCT06688279
NCT02554812,A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley),Unknown,TERMINATED,"Avelumab, Utomilumab, PF-04518600, PD 0360324, CMP-001","DRUG, DRUG, DRUG, DRUG, DRUG",Other,Pfizer,['Advanced Cancer'],2015-11-09,2023-03-23,https://clinicaltrials.gov/study/NCT02554812
NCT04460456,A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors,Unknown,UNKNOWN,"SBT6050, pembrolizumab, Cemiplimab","DRUG, DRUG, DRUG",Other,Silverback Therapeutics,['HER2 Positive Solid Tumors'],2020-07-27,2022-12,https://clinicaltrials.gov/study/NCT04460456
NCT04828226,Clonidine to Prevent Delirium After Electroconvulsive Therapy.,Unknown,RECRUITING,"Clonidine, Placebo","DRUG, DRUG",Other,"Insel Gruppe AG, University Hospital Bern","['Major Depressive Disorder', 'Catatonia', 'Bipolar Disorder', 'Delirium Postseizure']",2021-04-27,2026-07-27,https://clinicaltrials.gov/study/NCT04828226
NCT03954132,Spiolto® Respimat® (Tiotropium/Olodaterol) Versus Triple Combination Therapy in Everyday Clinical Treatment Practice for Chronic Obstructive Pulmonary Disease (EVELUT®),Unknown,COMPLETED,"Spiolto® Respimat®, Triple-Therapy (LAMA/LABA/ICS)","DRUG, DRUG",Triple agonist,Boehringer Ingelheim,"['Pulmonary Disease, Chronic Obstructive']",2019-06-07,2021-06-30,https://clinicaltrials.gov/study/NCT03954132
NCT04184297,Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to Triple Therapy,Unknown,COMPLETED,"Tiotropium and Olodaterol (Tio+Olo), Long-acting beta2-agonist and Inhaled corticosteroids (LABA and ICS)","DRUG, DRUG",Other,Boehringer Ingelheim,"['Pulmonary Disease, Chronic Obstructive']",2019-11-01,2019-11-04,https://clinicaltrials.gov/study/NCT04184297
NCT02630290,Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Block (ADRIB Trial),Unknown,COMPLETED,"Ropivacaine, Ropivacaine + Dexmedetomidine","DRUG, DRUG",Other,Guangzhou First People's Hospital,"['Radius Fractures', 'Ulna Fractures', 'Hand Injuries', 'Wrist Injuries', 'Forearm Injuries']",2015-12,2016-06,https://clinicaltrials.gov/study/NCT02630290
NCT02567708,"A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma",Unknown,COMPLETED,"GSK2269557 DPI, Placebo DPI","DRUG, DRUG",Other,GlaxoSmithKline,"['Pulmonary Disease, Chronic Obstructive']",2015-10-01,2016-09-21,https://clinicaltrials.gov/study/NCT02567708
NCT03554109,QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine,Unknown,WITHDRAWN,"Leucovorin, 5-Fluorouracil, Aldoxorubicin HCl, nab-Paclitaxel, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, Avelumab, ALT-803, haNK, Cyclophosphamide, Doxorubicin HCL, paclitaxel","DRUG, DRUG, DRUG, DRUG, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, DRUG, BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG",Other,"ImmunityBio, Inc.",['Triple Negative Breast Cancer (TNBC)'],2018-09,2020-06,https://clinicaltrials.gov/study/NCT03554109
NCT04138758,Comparative Effectiveness and Safety of Tiotropium and Olodaterol in Comparison to LABA/ICS,Unknown,COMPLETED,"Tiotropium bromide + Olodaterol, LABA/ICS","DRUG, DRUG",Other,Boehringer Ingelheim,['COPD'],2019-11-01,2019-11-04,https://clinicaltrials.gov/study/NCT04138758
NCT06351358,Evaluation of the Effects of a Biostimulator and Dermal Fillers for Cheek Augmentation and Contour Deficiencies,Unknown,ACTIVE_NOT_RECRUITING,"Sculptra treatment, Restylane Treatment","DEVICE, DEVICE",Other,Galderma R&D,"['Photoaging', 'Weight Loss', 'Skin Laxity', 'Photodamaged Skin', 'Volume Deficiency of the Midface']",2024-02-19,2025-05-31,https://clinicaltrials.gov/study/NCT06351358
NCT00909779,Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects,Unknown,COMPLETED,"Arformoterol, Placebo","DRUG, DRUG",Other,"Sumitomo Pharma America, Inc.",['Chronic Obstructive Pulmonary Disease'],2009-06,2012-06,https://clinicaltrials.gov/study/NCT00909779
NCT04249310,Early Intervention Efficacy in COPD,Unknown,COMPLETED,"Tiotropium/Olodaterol, Tiotropium","DRUG, DRUG",Other,Boehringer Ingelheim,"['Pulmonary Disease, Chronic Obstructive']",2020-03-27,2020-08-12,https://clinicaltrials.gov/study/NCT04249310
NCT02345161,A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Unknown,COMPLETED,"Triple FF/UMEC/VI, Placebo to match FF/UMEC/VI, Budesonide/Formoterol, Placebo to match Budesonide/Formoterol combination, Albuterol/salbutamol","DRUG, DRUG, DRUG, DRUG, DRUG",Triple agonist,GlaxoSmithKline,"['Pulmonary Disease, Chronic Obstructive']",2015-01-23,2016-04-01,https://clinicaltrials.gov/study/NCT02345161
NCT02794519,A Phase 2a Study to Evaluate the Effects of Sirukumab in Subjects With Severe Poorly Controlled Asthma,Unknown,WITHDRAWN,"Sirukumab, Placebo, Rescue medication","DRUG, DRUG, DRUG",Other,GlaxoSmithKline,['Asthma'],2016-09-23,2016-10-04,https://clinicaltrials.gov/study/NCT02794519
NCT04172701,A Study in South Korea Using Medical Records to Look at Different Treatments for Chronic Obstructive Airway Disease (COPD),Unknown,COMPLETED,"Long-acting Muscarinic Antagonists (LAMA), Inhaled corticosteroid (ICS)/Long-acting Beta Agonists (LABA)","DRUG, DRUG",Other,Boehringer Ingelheim,"['Pulmonary Disease, Chronic Obstructive']",2020-04-15,2020-12-31,https://clinicaltrials.gov/study/NCT04172701
NCT03387085,QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.,Unknown,TERMINATED,"Aldoxorubicin HCl, N-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK for Infusion, avelumab, bevacizumab, Capecitabine, Cisplatin, Cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-Paclitaxel, SBRT","DRUG, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, PROCEDURE",Other,"ImmunityBio, Inc.",['Triple Negative Breast Cancer'],2018-03-19,2020-09-11,https://clinicaltrials.gov/study/NCT03387085
NCT02488590,Systematic Approach for the Diagnosis and Treatment of Obstructive Lung Diseases,Unknown,UNKNOWN,"LABA + LAMA, ICS, LABA + LAMA + ICS, LABA + ICS, other","DRUG, DRUG, DRUG, DRUG, DRUG",Other,KU Leuven,"['Chronic Obstructive Pulmonary Disease', 'Asthma', 'Overlap Syndrome']",2015-07,2020-04,https://clinicaltrials.gov/study/NCT02488590
NCT02164513,"A Study Comparing the Efficacy, Safety and Tolerability of Fixed Dose Combination (FDC) of FF/UMEC/VI With the FDC of FF/VI and UMEC/VI; Administered Once-daily Via a Dry Powder Inhaler (DPI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",Unknown,COMPLETED,"fluticasone furoate (FF), vilanterol (VI), umeclidinium bromide (UMEC)","DRUG, DRUG, DRUG",Other,GlaxoSmithKline,"['Pulmonary Disease, Chronic Obstructive']",2014-06-30,2017-07-17,https://clinicaltrials.gov/study/NCT02164513
NCT02661100,"A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients",Unknown,WITHDRAWN,"Pembrolizumab, CDX-1401, Poly-ICLC","DRUG, BIOLOGICAL, BIOLOGICAL",Other,Case Comprehensive Cancer Center,"['Non Small Cell Lung Cancer', 'Advanced Triple Negative Breast Cancer', 'Small Cell Lung Cancer', 'Urothelial Cancer', 'Mesothelioma', 'Malignant Melanoma']",2017-01,2018-07,https://clinicaltrials.gov/study/NCT02661100
NCT03175666,QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy,Unknown,WITHDRAWN,"avelumab, bevacizumab, capecitabine, cisplatin, cyclophosphamide, 5-Fluorouracil, Leucovorin, nab-paclitaxel, Lovaza, Stereotactic Body Radiation Therapy, ALT-803, ETBX-011, ETBX-051, ETBX-061, GI-4000, GI-6207, GI-6301, haNK","BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, RADIATION, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, BIOLOGICAL",Other,"ImmunityBio, Inc.",['Triple Negative Breast Cancer'],2017-12,2019-01,https://clinicaltrials.gov/study/NCT03175666
NCT04876677,Functional Respiratory Imaging Study,Unknown,COMPLETED,Beclomethasone dipropionate/Formoterol Fumarate/Glycopyrronium,DRUG,Other,Chiesi Farmaceutici S.p.A.,['Chronic Obstructive Pulmonary Disease'],2021-05-25,2022-01-03,https://clinicaltrials.gov/study/NCT04876677
NCT02924688,"A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma",Unknown,COMPLETED,"FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/VI (100/25) mcg, FF/VI (200/25) mcg, Fluticasone/salmeterol (FSC), Albuterol/salbutamol, ELLIPTA DPI, DISKUS DPI, METERED-DOSE INHALER (MDI)","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DEVICE, DEVICE, DEVICE",Other,GlaxoSmithKline,['Asthma'],2016-10-13,2019-02-22,https://clinicaltrials.gov/study/NCT02924688
NCT03899402,Triple Therapy in T1DM,Unknown,ACTIVE_NOT_RECRUITING,"Insulin, Semaglutide, Dapagliflozin, Placebo to Dapagliflozin","DRUG, DRUG, DRUG, DRUG",Other,State University of New York at Buffalo,['Type 1 Diabetes Mellitus'],2019-05-01,2026-01-31,https://clinicaltrials.gov/study/NCT03899402
NCT03265145,Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE],Unknown,COMPLETED,"Stiolto Respimat, ICS (Inhaled Corticosteroid) (Triple therapy), LABA (Long-Acting Beta Agonist) (Triple therapy), LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)","DRUG, DRUG, DRUG, DRUG",Triple agonist,Boehringer Ingelheim,"['Pulmonary Disease, Chronic Obstructive']",2017-09-20,2020-09-30,https://clinicaltrials.gov/study/NCT03265145
NCT04097223,A Study Based on Health Insurance Data About the Treatment of Patients Who Have Been Newly Diagnosed With Chronic Obstructive Pulmonary Disease (COPD),Unknown,COMPLETED,,,Unknown,Boehringer Ingelheim,"['Pulmonary Disease, Chronic Obstructive']",2019-11-20,2020-07-01,https://clinicaltrials.gov/study/NCT04097223
NCT06353997,Neoadjuvant INBRX-106 (Hexavalent OX40 Agonist) in Combination With Pembrolizumab as a Chemotherapy-sparing Regimen for Stage II TNBC (Triple Negative Breast Cancer) Patients,Unknown,RECRUITING,"Pembrolizumab, INBRX-106","DRUG, DRUG",Other,Providence Health & Services,['Triple Negative Breast Cancer'],2024-09-05,2027-06,https://clinicaltrials.gov/study/NCT06353997
NCT02520869,Diagnostic Value of Sperm DNA Fragmentation and Sperm Morphology for Assisted Reproduction Treatment,Unknown,WITHDRAWN,"swim-up technique, zeta test technique","PROCEDURE, PROCEDURE",Other,khalid abd aziz mohamed,['Assisted Reproductive Technology'],2014-04,2016-04,https://clinicaltrials.gov/study/NCT02520869
NCT03963167,Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL),Unknown,COMPLETED,BDP/FF/G fixed combination,DRUG,Other,Chiesi Italia,['COPD'],2019-08-21,2022-03-04,https://clinicaltrials.gov/study/NCT03963167
NCT04657211,Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) Participants,Unknown,COMPLETED,Prospective observational cohort study,OTHER,Other,GlaxoSmithKline,"['Pulmonary Disease, Chronic Obstructive']",2021-01-14,2024-07-01,https://clinicaltrials.gov/study/NCT04657211
NCT03474081,A Comparative Study Between Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy Versus Tiotropium Monotherapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD),Unknown,COMPLETED,"FF/UMEC/VI, Tiotropium, Albuterol/salbutamol, Placebo to match FF/UMEC/VI, Placebo to match tiotropium, ELLIPTA inhaler, HANDIHALER, MDI","DRUG, DRUG, DRUG, DRUG, DRUG, DEVICE, DEVICE, DEVICE",Other,GlaxoSmithKline,"['Pulmonary Disease, Chronic Obstructive']",2018-03-29,2019-07-17,https://clinicaltrials.gov/study/NCT03474081
NCT05311306,REported Outcomes in COPD With Trixeo in Real worlD in Germany,Unknown,COMPLETED,,,Unknown,AstraZeneca,['Chronic Obstructive Pulmonary Disease'],2022-03-15,2024-07-16,https://clinicaltrials.gov/study/NCT05311306
NCT02889809,"Effects of a Orally Inhaled Fluticasone Furoate on Growth Velocity in Prepubertal, Paediatric Subjects With Asthma Over a Year",Unknown,COMPLETED,"Fluticasone furoate, Placebo, Montelukast, Short Acting Beta 2 Agonist","DRUG, DRUG, DRUG, DRUG",Other,GlaxoSmithKline,['Asthma'],2017-07-10,2021-04-09,https://clinicaltrials.gov/study/NCT02889809
NCT02338921,Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination Therapy,Unknown,COMPLETED,"Sitagliptin, Dapagliflozin, Lobeglitazone, Glimepirde, Metformin","DRUG, DRUG, DRUG, DRUG, DRUG",Other,Seoul National University Bundang Hospital,['Type 2 Diabetes'],2015-01,2021-11-30,https://clinicaltrials.gov/study/NCT02338921
NCT04011475,A Study in Taiwan Based on Medical Records That Looks at the Occurrence of Flare-ups in Patients With Chronic Obstructive Pulmonary Disease (COPD) Who Started LABA/LAMA or LAMA Treatment,Unknown,COMPLETED,"Tiotropium + Olodaterol, Other LABA/LAMA, LAMA","DRUG, DRUG, DRUG",Other,Boehringer Ingelheim,"['Pulmonary Disease, Chronic Obstructive']",2019-12-29,2020-10-31,https://clinicaltrials.gov/study/NCT04011475
NCT03219866,Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD),Unknown,TERMINATED,"Nebulizers, Dry Powder Inhaler, Brovana, Pulmicort, Atrovent, Advair Diskus, Spiriva HandiHaler","DEVICE, DEVICE, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Wake Forest University Health Sciences,"['COPD', 'COPD Exacerbation']",2017-10-03,2020-04-01,https://clinicaltrials.gov/study/NCT03219866
NCT06753981,"Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study",Unknown,RECRUITING,Endothelin receptor antagonist (ERA) combined with PDE5i/sGC agonist dual therapy prostacyclin drugs,DRUG,Dual agonist,Qianfoshan Hospital,['Arterial Pulmonary Hypertension (PAH)'],2024-12-10,2026-11-14,https://clinicaltrials.gov/study/NCT06753981
NCT01206283,A Study Comparing Modified Lund Concept and Cerebral Perfusion Pressure-targeted Therapy in Secondary Brain Ischaemia.,Unknown,COMPLETED,"Modified Lund concept, Cerebral perfusion pressure-targeted therapy","PROCEDURE, PROCEDURE",Other,University of Sarajevo,"['Brain Injuries', 'Subarachnoid Hemorrhage']",2006-01,2008-06,https://clinicaltrials.gov/study/NCT01206283
NCT01112241,Bronchodilator Responsiveness in Obliterative Bronchiolitis,Unknown,COMPLETED,albuterol plus tiotropium,DRUG,Other,"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy",['Obliterative Bronchiolitis'],2010-04,2010-05,https://clinicaltrials.gov/study/NCT01112241
NCT05231122,Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer,Unknown,RECRUITING,"Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Bevacizumab, Pembrolizumab, Quality-of-Life Assessment, Questionnaire Administration","BIOLOGICAL, BIOLOGICAL, BIOLOGICAL, OTHER, OTHER",Other,Roswell Park Cancer Institute,"['Ovarian Clear Cell Adenocarcinoma', 'Platinum-Sensitive Ovarian Carcinoma', 'Recurrent Endometrial Serous Adenocarcinoma', 'Recurrent Fallopian Tube Carcinoma', 'Recurrent Fallopian Tube Endometrioid Adenocarcinoma', 'Recurrent Fallopian Tube Serous Adenocarcinoma', 'Recurrent Ovarian Carcinoma', 'Recurrent Ovarian Clear Cell Adenocarcinoma', 'Recurrent Ovarian Endometrioid Adenocarcinoma', 'Recurrent Ovarian Serous Adenocarcinoma', 'Recurrent Platinum-Resistant Ovarian Carcinoma', 'Recurrent Primary Peritoneal Carcinoma', 'Recurrent Primary Peritoneal Clear Cell Adenocarcinoma', 'Recurrent Primary Peritoneal Endometrioid Adenocarcinoma', 'Recurrent Primary Peritoneal Serous Adenocarcinoma']",2024-03-12,2026-12-30,https://clinicaltrials.gov/study/NCT05231122
NCT03858348,"A Retrospective rEal-life daTa Study to Assess the exaceRbations and Lung functIon in Chronic Obstructive Pulmonary Disease ( COPD ) patiEnts receiVing Fluticasone/Salmeterol Comparing to Those Εscalating in Open-triple Fluticasone/Salmeterol, Long Acting Muscarinic Antagonist (LAMA) Combination",Unknown,COMPLETED,,,Unknown,Elpen Pharmaceutical Co. Inc.,"['COPD', 'COPD Exacerbation']",2019-05-01,2019-12-31,https://clinicaltrials.gov/study/NCT03858348
NCT03627858,Fixed Dose Triple Therapy in Severe Chronic Obstructive Pulmonary Disease in a Real World Setting,Unknown,COMPLETED,beclomethasone / formoterol / glycopyrronium,DRUG,Other,Chiesi SA/NV,['Chronic Obstructive Pulmonary Disease'],2018-08-01,2020-08-03,https://clinicaltrials.gov/study/NCT03627858
NCT05816655,"Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer",Unknown,RECRUITING,"Fulvestrant plus AI plus ribociclib, AI plus ribociclib","DRUG, DRUG",Other,Korea University Guro Hospital,['Metastatic Breast Cancer'],2023-05-31,2028-12-31,https://clinicaltrials.gov/study/NCT05816655
NCT06274333,Adding Dexmedetomidine or Tramadol to Paracetamol- An Effort to Attenuate Catheter Related Bladder Discomfort,Unknown,RECRUITING,"Dexmedetomidine 0.5 mic/kg, Tramadol 1mg/kg, Paracetamol 10mg/kg","DRUG, DRUG, DRUG",Other,Al-Azhar University,['Percutaneous Nephrolithotripsy (PCNL)'],2024-02-28,2024-11-30,https://clinicaltrials.gov/study/NCT06274333
NCT05919394,Triple vs High Dose Inhaled CORticosteroids,Unknown,WITHDRAWN,To compare in both treatment arms the percentage of patients controlled at week 52.,DRUG,Other,Galaxia Empírica,['Asthma'],2023-06-01,2024-09-30,https://clinicaltrials.gov/study/NCT05919394
NCT02256215,Vitamin D in the Treatment of Primary Restless Legs Syndrome,Unknown,UNKNOWN,Vitamin D,DRUG,Other,King Abdulaziz University,['Restless Legs Syndrome'],2015-12,2017-12,https://clinicaltrials.gov/study/NCT02256215
NCT06552364,Air Pollution and Inhaled Corticosteroids in COPD,Unknown,NOT_YET_RECRUITING,"LABA+LAMA, LABA+LAMA+ICS, Filtered Air, Diesel Exhaust","DRUG, DRUG, OTHER, OTHER",Other,University of British Columbia,['COPD'],2025-04-01,2026-12-31,https://clinicaltrials.gov/study/NCT06552364
NCT00239499,Pilot Study Comparing Tiotropium (Spiriva) to Salmeterol (Serevent) Plus Fluticasone (Flixotide) in Chronic Obstructive Pulmonary Disease (COPD),Unknown,COMPLETED,"Tiotropium, Salmeterol plus Fluticasone","DRUG, DRUG",Other,Boehringer Ingelheim,"['Pulmonary Disease, Chronic Obstructive']",2003-09,2004-08,https://clinicaltrials.gov/study/NCT00239499
NCT06060587,Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone,Unknown,WITHDRAWN,"Docetaxel, ADT, Abiraterone","DRUG, DRUG, DRUG",Other,Northwestern University,['Prostate Cancer'],2023-10-19,2024-05-03,https://clinicaltrials.gov/study/NCT06060587
NCT02837380,A Phase I Pharmacokinetic Study of Fluticasone Furoate /Umeclidinium Bromide/Vilanterol (100/62.5/25 Microgram [mcg]) After Single and Repeat Dose Administration From a Dry Powder Inhaler in Healthy Chinese Subjects,Unknown,COMPLETED,"FF, VI/UMEC","DRUG, DRUG",Other,GlaxoSmithKline,"['Pulmonary Disease, Chronic Obstructive']",2016-09,2016-11,https://clinicaltrials.gov/study/NCT02837380
NCT05402020,Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan,Unknown,COMPLETED,"Tiotropium (Tio), Inhaled corticosteroids (ICS), Olodaterol (Olo), Long-acting β2-agonists (LABA)","DRUG, DRUG, DRUG, DRUG",Other,Boehringer Ingelheim,"['Pulmonary Disease, Chronic Obstructive']",2022-09-30,2023-02-13,https://clinicaltrials.gov/study/NCT05402020
NCT00425061,Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma,Unknown,COMPLETED,"IMA-638, IMA-638, placebo","BIOLOGICAL, BIOLOGICAL, OTHER",Other,Pfizer,['Asthma'],2007-02,2008-08,https://clinicaltrials.gov/study/NCT00425061
NCT06038279,Trial of INI-2004 in Healthy Volunteers and Participants With Allergic Rhinitis.,Unknown,UNKNOWN,"INI-2004, Placebo","DRUG, DRUG",Other,Inimmune Corporation,"['Allergic Rhinitis Due to Weed Pollen', 'Allergic Rhinitis']",2023-07-04,2024-11-01,https://clinicaltrials.gov/study/NCT06038279
NCT07192016,129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation,Unknown,NOT_YET_RECRUITING,fluticasone furoate(FF)/umeclidinium (UMEC)/vilanterol(VI) (100/62.5/25) mcg,DRUG,Other,"Western University, Canada",['Chronic Obstructive Pulmonary Disease (COPD)'],2026-03,2027-09,https://clinicaltrials.gov/study/NCT07192016
NCT06225284,Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients,Unknown,RECRUITING,Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg,DRUG,Other,National Taiwan University Hospital,"['Triple Negative Breast Cancer', 'Premenopausal Breast Cancer']",2024-08-22,2026-12,https://clinicaltrials.gov/study/NCT06225284
NCT06291064,Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer,Unknown,NOT_YET_RECRUITING,"Cyclophosphamide, Epirubicin, Docetaxel, Carboplatin, Breast Surgery, Capecitabine","DRUG, DRUG, DRUG, DRUG, PROCEDURE, DRUG",Other,University of Chicago,['Triple Negative Breast Cancer'],2025-11,2029-06,https://clinicaltrials.gov/study/NCT06291064
NCT01656395,A Dose-Ranging Study of MK-1029 in Adults With Persistent Asthma (MK-1029-012),Unknown,TERMINATED,"MK-1029, Montelukast 10 mg, Placebo","DRUG, DRUG, DRUG",Other,Merck Sharp & Dohme LLC,['Asthma'],2012-08-23,2014-06-10,https://clinicaltrials.gov/study/NCT01656395
NCT03093402,JBT-101 in Systemic Lupus Erythematosus (SLE),Unknown,COMPLETED,"JBT-101, Placebo","DRUG, DRUG",Other,National Institute of Allergy and Infectious Diseases (NIAID),"['Systemic Lupus Erythematosus', 'SLE', 'Lupus']",2017-12-21,2021-07-28,https://clinicaltrials.gov/study/NCT03093402
NCT02352025,S-equol in Women With Triple Negative Breast Cancer,Phase 1,COMPLETED,S-equol,DRUG,Other,The University of Texas Health Science Center at San Antonio,['Breast Cancer'],2015-04-15,2019-04-10,https://clinicaltrials.gov/study/NCT02352025
NCT03250689,Randomized Study Evaluating the Effect of Danirixin on Neutrophil Extracellular Traps (NETs) in Chronic Obstructive Pulmonary Disease (COPD),Unknown,TERMINATED,"Danirixin, Placebo, Rescue medication, Inhaled COPD maintenance medication","DRUG, DRUG, DRUG, DRUG",Other,GlaxoSmithKline,"['Pulmonary Disease, Chronic Obstructive']",2017-11-15,2018-10-08,https://clinicaltrials.gov/study/NCT03250689
NCT03287310,"First Time in Human (FTIH) Study to Evaluate Safety, Tolerability, Immunogenicity, Pharmacokinetics (PK) and Pharmacodynamics (PD) of GSK3511294 Administered Subcutaneously (SC) in Subjects With Mild to Moderate Asthma",Unknown,COMPLETED,"GSK3511294, Placebo, Salbutamol/albuterol","DRUG, DRUG, DRUG",Other,GlaxoSmithKline,['Asthma'],2017-10-17,2019-07-31,https://clinicaltrials.gov/study/NCT03287310
NCT04206761,Investigating the Effects of QVM149 on MRI Ventilation Defects,Unknown,WITHDRAWN,"QVM149, High Dose Dual Therapy (ICS/LABA)","DRUG, DRUG",Dual agonist,Dr. Grace Parraga,['Asthma'],2021-12-01,2022-07-01,https://clinicaltrials.gov/study/NCT04206761
NCT04853238,Chronic Obstructive Pulmonary Disease (COPD) Maintenance Treatment Patterns in China,Unknown,COMPLETED,Prospective observational cohort study,OTHER,Other,GlaxoSmithKline,"['Pulmonary Disease, Chronic Obstructive']",2021-04-27,2022-11-03,https://clinicaltrials.gov/study/NCT04853238
NCT07030881,Effect of Spacer Use on Exacerbation Risk in High-Risk Older Adults With Chronic Airway Diseases Receiving Triple Therapy,Unknown,NOT_YET_RECRUITING,"pMDI Triple Inhaler and Spacer, pMDI Triple Inhaler Only","DRUG, DRUG",Triple agonist,First Affiliated Hospital of Ningbo University,"['Asthma, COPD']",2025-06-20,2026-04-20,https://clinicaltrials.gov/study/NCT07030881
NCT03519178,A Study of PF-06873600 in People With Cancer,Unknown,TERMINATED,"PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2","DRUG, DRUG, DRUG",Other,Pfizer,"['HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer']",2018-03-07,2023-04-05,https://clinicaltrials.gov/study/NCT03519178
NCT06135714,Metastasis-directed Therapy for Oligometastases of Breast Cancer,Unknown,RECRUITING,"Systemic therapy for 12 weeks after primary registration, Radiation therapy (SBRT/conventional RT), Surgery, Same systemic therapy after secondary registration","DRUG, PROCEDURE, PROCEDURE, DRUG",Other,Tokyo Medical and Dental University,"['Breast Cancer', 'Oligometastasis', 'Metastatic Breast Cancer']",2023-11-08,2026-11-08,https://clinicaltrials.gov/study/NCT06135714
NCT01823835,A Study of GDC-0810 Single Agent or in Combination With Palbociclib and/or a Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Women With Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer,Unknown,TERMINATED,"GDC-0810, LHRH Agonist, Palbociclib","DRUG, DRUG, DRUG",Other,"Genentech, Inc.",['Breast Cancer'],2014-12-29,2020-03-13,https://clinicaltrials.gov/study/NCT01823835
NCT06841354,"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)",Unknown,RECRUITING,"Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Paclitaxel, Nab-paclitaxel, Gemcitabine, Carboplatin","BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Merck Sharp & Dohme LLC,['Triple Negative Breast Neoplasms'],2025-03-16,2030-05-18,https://clinicaltrials.gov/study/NCT06841354
NCT03436511,Burden of Disease Among Subjects With Eosinophilic Chronic Obstructive Pulmonary Disease (COPD),Unknown,COMPLETED,,,Unknown,GlaxoSmithKline,"['Pulmonary Disease, Chronic Obstructive']",2017-12-05,2018-10-31,https://clinicaltrials.gov/study/NCT03436511
NCT00441441,A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma,Unknown,COMPLETED,"fluticasone propionate, fluticasone propionate/salmeterol","DRUG, DRUG",Other,GlaxoSmithKline,['Asthma'],2007-02,2008-01,https://clinicaltrials.gov/study/NCT00441441
NCT07205432,Phase I Study of XTL6001 Injection in Healthy and Obese Subjects,Unknown,RECRUITING,"XTL6001, Placebo","DRUG, DRUG",Other,"Shanghai Xitaili Biomedicine Technology co., Ltd.",['Weight Management in Adult Patients With Obesity or Overweight'],2025-06-13,2026-04,https://clinicaltrials.gov/study/NCT07205432
NCT06665919,The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models,Unknown,COMPLETED,"CYP2C19 Genotype-Guided Clopidogrel Treatment, CYP2C19 Genotype Guided Antiplatelet Treatment Alternative to Clopidogrel, The Conventional Clopidogrel Treatment","OTHER, OTHER, OTHER",Other,Vistamedi Ltd.,"['Coronary Artery Disease', 'Clopidogrel Resistance', 'Coronary Thrombosis', 'Adverse Cardiac Events', 'Bleeding', 'Hospitalisations', 'Death', 'Death From Cardiovascular Disease']",2023-06-15,2025-05-15,https://clinicaltrials.gov/study/NCT06665919
NCT03724877,Effectiveness of Triple Therapy in COPD,Unknown,COMPLETED,"Long-acting beta2-agonist-long-acting muscarinic antagonists-inhaled corticosteroids(LABA-LAMA-ICS), Long-acting beta2-agonist-inhaled corticosteroids-long-acting muscarinic antagonists (LABA-LAMA)","DRUG, DRUG",Other,Boehringer Ingelheim,"['Pulmonary Disease, Chronic Obstructive']",2018-11-10,2018-11-12,https://clinicaltrials.gov/study/NCT03724877
NCT01567540,A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients,Unknown,TERMINATED,Sitagliptin,DRUG,Other,"Institut National de la Santé Et de la Recherche Médicale, France",['Hepatitis C'],2013-03,2014-01,https://clinicaltrials.gov/study/NCT01567540
NCT06302426,Trial of INI-4001 in Patients With Advanced Solid Tumours,Unknown,NOT_YET_RECRUITING,"INI-4001, Nivolumab, Pembrolizumab, Cemiplimab, Avelumab, Atezolizumab, Durvalumab","DRUG, COMBINATION_PRODUCT, COMBINATION_PRODUCT, COMBINATION_PRODUCT, COMBINATION_PRODUCT, COMBINATION_PRODUCT, COMBINATION_PRODUCT",Other,Inimmune Corporation,['Advanced Solid Tumor'],2024-03-29,2024-08-01,https://clinicaltrials.gov/study/NCT06302426
NCT04456205,Inhaled Corticosteroid Withdrawal in Chronic Obstructive Pulmonary Disease (COPD),Unknown,UNKNOWN,,,Unknown,National Taiwan University Hospital,"['COPD', 'Inhaled Corticosteroid']",2019-10-01,2021-10,https://clinicaltrials.gov/study/NCT04456205
NCT04855383,Intramuscular Injection of Human Chorionic Gonadotropin in Frozen Embryo Transfer Cycles,Unknown,COMPLETED,The effect of intramuscular injection of triple doses of human chorionic gonadotropin in frozen embryo transfer cycles,DRUG,Triple agonist,Royan Institute,['Embryo Implantation'],2020-07-01,2022-08-22,https://clinicaltrials.gov/study/NCT04855383
NCT03527927,sTep dOWn Inhalers in the reAl woRlD,Unknown,COMPLETED,Any LABA/LAMA,DRUG,Other,Hywel Dda Health Board,['Chronic Obstructive Pulmonary Disease'],2017-05-17,2019-08-26,https://clinicaltrials.gov/study/NCT03527927
NCT06966700,"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)",Unknown,RECRUITING,"Sacituzumab tirumotecan, Pembrolizumab, Rescue Medication, Carboplatin, Paclitaxel, Doxorubicin, Epirubicin, Cyclophosphamide, Capecitabine, Olaparib","BIOLOGICAL, BIOLOGICAL, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Merck Sharp & Dohme LLC,"['Breast Neoplasms', 'Triple Negative Breast Neoplasms', 'HR Low-Positive/HER2-Negative Breast Neoplasms']",2025-06-30,2033-03-23,https://clinicaltrials.gov/study/NCT06966700
NCT05029999,"CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer",Unknown,RECRUITING,"PLD Chemotherapy, CDX-1140, CDX-301","DRUG, DRUG, DRUG",Other,University of Texas Southwestern Medical Center,"['HER2-negative Breast Cancer', 'Metastatic Breast Cancer']",2022-04-20,2026-04-20,https://clinicaltrials.gov/study/NCT05029999
NCT00911547,The Clinical Effect of MK0476 With Concomitant Administration of and Removal of Inhaled Beclomethasone in Asthmatic Patients (0476-029),Unknown,COMPLETED,"montelukast sodium, beclomethasone, Placebo inhaler, placebo tablet","DRUG, DRUG, DRUG, DRUG",Other,Organon and Co,['Asthma'],1995-03,1996-04,https://clinicaltrials.gov/study/NCT00911547
NCT04099277,A Study of LY3435151 in Participants With Solid Tumors,Unknown,TERMINATED,"LY3435151, Pembrolizumab","DRUG, DRUG",Other,Eli Lilly and Company,"['Solid Tumor', 'Triple-negative Breast Cancer', 'Gastric Adenocarcinoma', 'Head and Neck Squamous Cell Carcinoma', 'Cervical Carcinoma', 'High Grade Serous Ovarian Carcinoma', 'Hepatocellular Carcinoma', 'Undifferentiated Pleomorphic Sarcoma', 'Leiomyosarcoma']",2019-10-28,2020-03-05,https://clinicaltrials.gov/study/NCT04099277
NCT02558231,The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension,Unknown,COMPLETED,"Macitentan, Tadalafil, Selexipag","DRUG, DRUG, DRUG",Other,Actelion,['Pulmonary Arterial Hypertension'],2016-05-01,2019-08-29,https://clinicaltrials.gov/study/NCT02558231
NCT00812929,A Clinical Trial to Test a Study Drug in Volunteers Who Develop Asthma Following Exercise,Unknown,COMPLETED,"Placebo, GSK2190915","DRUG, DRUG",Other,GlaxoSmithKline,['Asthma'],2008-12-01,2009-06-01,https://clinicaltrials.gov/study/NCT00812929
NCT06712563,Pooled Analysis of Single-arm Studies of Budesonide/Glycopyrronium/Formoterol (BGF) in Routine Care Setting,Unknown,RECRUITING,Budesonide/glycopyrrolate/formoterol fumarate,DRUG,Other,AstraZeneca,"['Pulmonary Disease, Chronic Obstructive']",2025-04-17,2026-09-04,https://clinicaltrials.gov/study/NCT06712563
NCT02221999,Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients,Unknown,ACTIVE_NOT_RECRUITING,"Paclitaxel, Cisplatin, Gonadotropin-releasing hormone agonist, Letrozole","DRUG, DRUG, DRUG, DRUG",Other,RenJi Hospital,"['Tubular Breast Cancer', 'Mucinous Breast Cancer', 'Invasive Ductal Breast Cancer', 'Inflammatory Breast Cancer']",2013-09,2019-01,https://clinicaltrials.gov/study/NCT02221999
NCT06052852,Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies,Unknown,TERMINATED,"BDC-3042, Cemiplimab","DRUG, DRUG",Other,"Bolt Biotherapeutics, Inc.","['Triple Negative Breast Cancer', 'Clear Cell Renal Cell Carcinoma', 'Ovarian Cancer', 'Head and Neck Cancer', 'Colorectal Cancer', 'Non-small Cell Lung Cancer', 'Melanoma']",2023-10-11,2025-08-01,https://clinicaltrials.gov/study/NCT06052852
NCT05326412,Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD,Unknown,COMPLETED,Itepekimab SAR440340,DRUG,Other,Sanofi,['Chronic Obstructive Pulmonary Disease'],2022-05-19,2025-03-05,https://clinicaltrials.gov/study/NCT05326412
NCT06606730,Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer,Unknown,RECRUITING,"Pembrolizumab, Deescalation","DRUG, OTHER",Other,UNICANCER,"['Breast Cancers', 'Triple Negative Breast Cancer (TNBC)']",2025-07-23,2033-01-01,https://clinicaltrials.gov/study/NCT06606730
NCT00669617,Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD),Unknown,COMPLETED,"Indacaterol, Salmeterol/fluticasone (50/500 μg), Salbutamol (200 µg), Placebo to Indacaterol, Placebo to Salmeterol/fluticasone, Placebo to salbutamol","DRUG, DRUG, DRUG, DRUG, DRUG, DRUG",Other,Novartis,['Chronic Obstructive Pulmonary Disease'],2008-04,2008-08,https://clinicaltrials.gov/study/NCT00669617
NCT04853225,Investigation of Chronic Obstructive Pulmonary Disease (COPD) Phenotypes and Endotypes in China,Unknown,COMPLETED,Prospective observational cohort study,OTHER,Other,GlaxoSmithKline,"['Pulmonary Disease, Chronic Obstructive']",2020-04-22,2024-06-25,https://clinicaltrials.gov/study/NCT04853225
NCT05916560,A Study of LY3437943 in Participants With Impaired and Normal Liver Function,Unknown,COMPLETED,LY3437943,DRUG,Other,Eli Lilly and Company,"['Healthy', 'Hepatic Insufficiency']",2023-07-13,2025-03-02,https://clinicaltrials.gov/study/NCT05916560
NCT05936151,A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes,Unknown,COMPLETED,"Retatrutide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Overweight or Obesity', 'CKD', 'Type 2 Diabetes']",2023-07-20,2025-10-01,https://clinicaltrials.gov/study/NCT05936151
NCT06003465,A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices,Unknown,COMPLETED,"LY3437943, Test, Reference","DRUG, DEVICE, DEVICE",Other,Eli Lilly and Company,['Healthy'],2023-08-29,2024-02-08,https://clinicaltrials.gov/study/NCT06003465
NCT06313528,A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943,Unknown,COMPLETED,"LY3437943, Placebo","DRUG, OTHER",Other,Eli Lilly and Company,['Obesity'],2024-03-20,2025-08-26,https://clinicaltrials.gov/study/NCT06313528
NCT05929079,A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight,Unknown,ACTIVE_NOT_RECRUITING,"Retatrutide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Type 2 Diabetes', 'Obesity', 'Overweight', 'Obstructive Sleep Apnea']",2023-07-11,2026-05,https://clinicaltrials.gov/study/NCT05929079
NCT05929066,A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight,Unknown,ACTIVE_NOT_RECRUITING,"Retatrutide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Obesity', 'Overweight', 'Osteoarthritis, Knee', 'Obstructive Sleep Apnea']",2023-07-10,2026-04,https://clinicaltrials.gov/study/NCT05929066
NCT06297603,"Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)",Unknown,ACTIVE_NOT_RECRUITING,"Retatrutide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes'],2024-03-15,2026-10,https://clinicaltrials.gov/study/NCT06297603
NCT03841630,A Safety Study of LY3437943 Given as a Single Injection in Healthy Participants,Unknown,COMPLETED,"LY3437943, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Healthy'],2019-03-13,2019-07-25,https://clinicaltrials.gov/study/NCT03841630
NCT07035093,A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain,Unknown,RECRUITING,"Retatrutide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Obesity', 'Overweight', 'Chronic Low Back Pain (CLBP)']",2025-05-29,2027-09,https://clinicaltrials.gov/study/NCT07035093
NCT06260722,Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2),Unknown,ACTIVE_NOT_RECRUITING,"Retatrutide, Semaglutide","DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2024-02-21,2026-08,https://clinicaltrials.gov/study/NCT06260722
NCT06808802,To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants,Unknown,COMPLETED,"Retatrutide, Metoprolol","DRUG, DRUG",Other,Eli Lilly and Company,['Healthy'],2025-02-03,2025-04-15,https://clinicaltrials.gov/study/NCT06808802
NCT05931367,A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee,Unknown,ACTIVE_NOT_RECRUITING,"Retatrutide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Obesity', 'Overweight', 'Osteo Arthritis Knee']",2023-08-01,2025-12,https://clinicaltrials.gov/study/NCT05931367
NCT05611957,A Study of LY3437943 in Healthy Participants and Participants With Impaired Renal Function,Unknown,COMPLETED,LY3437943,DRUG,Other,Eli Lilly and Company,"['Healthy', 'Renal Insufficiency']",2022-11-16,2023-09-05,https://clinicaltrials.gov/study/NCT05611957
NCT06982846,A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia,Unknown,RECRUITING,"Retatrutide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Type 2 Diabetes Mellitus'],2025-06-06,2026-05,https://clinicaltrials.gov/study/NCT06982846
NCT05959096,A Study of LY3437943 in Healthy Participants With a High Body Mass Index,Unknown,COMPLETED,"LY3437943, LY3437943","DRUG, DRUG",Other,Eli Lilly and Company,['Healthy'],2023-07-18,2024-07-25,https://clinicaltrials.gov/study/NCT05959096
NCT06383390,The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes),Unknown,RECRUITING,"Retatrutide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Atherosclerotic Cardiovascular Disease (ASCVD)', 'Chronic Kidney Disease (CKD)']",2024-04-30,2029-02,https://clinicaltrials.gov/study/NCT06383390
NCT04823208,A Study of LY3437943 in Japanese Participants With Type 2 Diabetes Mellitus (T2DM),Unknown,COMPLETED,"LY3437943, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus, Type 2']",2021-05-24,2022-06-23,https://clinicaltrials.gov/study/NCT04823208
NCT05882045,A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease,Unknown,ACTIVE_NOT_RECRUITING,"Retatrutide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Obesity', 'Cardiovascular Diseases']",2023-05-30,2026-04,https://clinicaltrials.gov/study/NCT05882045
NCT06859268,A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity,Unknown,ACTIVE_NOT_RECRUITING,"Retatrutide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Obesity'],2025-03-05,2028-04,https://clinicaltrials.gov/study/NCT06859268
NCT04881760,A Study of LY3437943 in Participants Who Have Obesity or Are Overweight,Unknown,COMPLETED,"LY3437943, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Obesity', 'Overweight']",2021-05-20,2022-05-16,https://clinicaltrials.gov/study/NCT04881760
NCT06354660,Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1),Unknown,ACTIVE_NOT_RECRUITING,"Retatrutide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,['Diabetes Type 2'],2024-04-10,2026-01,https://clinicaltrials.gov/study/NCT06354660
NCT06982859,A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus,Unknown,RECRUITING,"Retatrutide, Semaglutide, Placebo","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,"['Diabetes Mellitus', 'Insulin Sensitivity']",2025-06-02,2026-11,https://clinicaltrials.gov/study/NCT06982859
NCT05548231,A Study of LY3437943 in Chinese Participants With Obesity Or Overweight,Unknown,COMPLETED,"LY3437943, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Overweight', 'Obesity']",2022-10-24,2023-07-27,https://clinicaltrials.gov/study/NCT05548231
NCT05445232,A Drug-Drug Interaction (DDI) Study of LY3437943 in Obese Participants,Unknown,COMPLETED,"LY3437943, Midazolam, Warfarin, Caffeine","DRUG, DRUG, DRUG, DRUG",Other,Eli Lilly and Company,['Obesity'],2022-07-08,2023-02-24,https://clinicaltrials.gov/study/NCT05445232
NCT07232719,A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight,Unknown,NOT_YET_RECRUITING,"Retatrutide, Placebo","DRUG, DRUG",Other,Eli Lilly and Company,"['Obesity', 'Overweight']",2025-12,2027-07,https://clinicaltrials.gov/study/NCT07232719
NCT06039826,A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese,Unknown,COMPLETED,"LY3437943, Ethinyl Estradiol, Drospirenone","DRUG, DRUG, DRUG",Other,Eli Lilly and Company,['Overweight'],2023-09-12,2024-07-11,https://clinicaltrials.gov/study/NCT06039826
